SEARCH
Search DetailsHasegawa Hideki
| Institute for Integrated Innovations Institute for Vaccine Research and Development | Specially Appointed Professor |
Researcher basic information
■ Degree■ URL
researchmap URL■ Various IDs
J-Global ID■ Research Keywords and Fields
Research KeywordResearch Field
Career
■ CareerCareer
- Sep. 2025 - Present
Hokkaido University, ワクチン研究開発拠点, 特任教授 - Apr. 2025 - Present
国立健康危機管理研究機構, 国立感染症研究所インフルエンザ研究センター, センター長 - Apr. 2021 - Mar. 2025
国立感染症研究所 インフルエンザ・呼吸器系ウイルス研究センター - Apr. 2019 - Mar. 2021
国立感染症研究所, インフルエンザウイルス研究センター - Oct. 1997 - Mar. 2019
国立感染症研究所, 感染病理部 - Jun. 1996 - Sep. 1997
ユニバーシティーカレッジダブリン, Ireland - May 1995 - May 1996
米国ロックフェラー大学, United States
Research activity information
■ Papers- A novel candidate vaccine virus derived from Japan's first mammalian case of clade 2.3.4.4b A/H5N1 highly pathogenic avian influenza virus.
Yasushi Suzuki; Tomoko Arita; Masayuki Shirakura; Noriko Kishida; Kaori Sano; Shinji Watanabe; Noriyo Nagata; Yusuke Sakai; Naoko Iwata-Yoshikawa; Tadaki Suzuki; Hideki Hasegawa; Hideki Asanuma
Vaccine, 91, 129048, 129048, 03 Oct. 2026, [International Magazine]
English, Scientific journal, The development of candidate vaccine viruses (CVVs) for pre-pandemic preparedness requires attenuation of pathogenicity while maintaining immunogenicity. In this study, we developed and characterized NIID-002, a reassortant virus derived from A/Ezo red fox/Hokkaido/1/2022 (H5N1; clade 2.3.4.4b), to evaluate its suitability as a candidate vaccine. NIID-002 exhibited markedly reduced pathogenicity compared with its parental strain, while retaining broad antigenic reactivity and protein yield comparable to other clade 2.3.4.4b CVVs. In mammalian models, NIID-002 demonstrated strong attenuation, causing no lethal infection in mice and only minimal weight loss with limited viral replication in ferrets. Antisera raised against NIID-002 reacted broadly with recent wild-type H5N1 isolates, suggesting potential broad protection. Protein yield analysis confirmed a production efficiency comparable to that of other CVVs within the same clade, supporting its feasibility for large-scale vaccine manufacturing. Overall, NIID-002 fulfills the key requirements for the pandemic preparedness of CVV, combining reduced pathogenicity, broad antigenic reactivity, and adequate production efficiency. These findings highlight its potential as a candidate H5N1 vaccine and underscore the continued need for surveillance and refinement of influenza vaccine strategies to address evolving viral threats. - Anti‐idiotypic antibodies as molecular mimics of conserved influenza hemagglutinin epitopes
Hiroshi Itou; Kaori Sano; Akira Ainai; Kazushige Otsuki; Toshikazu Inoue; Takuya Hemmi; Hideki Hasegawa; Tadaki Suzuki
Protein Science, 35, 10, e70795, Oct. 2026, [Peer-reviewed], [International Magazine]
English, Scientific journal, Broadly neutralizing antibodies (bNAbs) provide insights for developing universal influenza vaccines through their ability to neutralize diverse viral strains. However, designing antigens that reliably elicit bNAb responses remains challenging due to the difficulty in targeting conserved epitopes with a single antigen. We developed a method using anti-idiotypic antibodies (IDs) to generate antigens that induce cross-reactive antibodies against diverse influenza A and B hemagglutinins. Our approach leverages IDs that mimic the conformational epitopes targeted by bNAbs. Structural analysis reveals conformational similarity between bNAb-ID and bNAb-HA-binding interfaces, providing mechanistic insight into molecular mimicry. These epitope-mimicking IDs function as effective immunogens, inducing highly cross-reactive antibodies. This study demonstrates the feasibility and structural basis of molecular mimicry-based antigen design for targeting conserved conformational epitopes. Although these findings establish proof of concept, vaccine applicability requires further investigation. - Persistent SARS-CoV-2 infection in SCID rats reflects immune vulnerability of the upper airway and trachea.
Kaya Miyazaki; Nozomi Shiwa-Sudo; Naoko Iwata-Yoshikawa; Yusuke Sakai; Kazuto Yoshimi; Tomoji Mashimo; Tadaki Suzuki; Eiichi N Kodama; Hideki Hasegawa; Noriyo Nagata
Microbiology spectrum, e0410525, 01 Oct. 2026, [International Magazine]
English, Scientific journal, UNLABELLED: In immunocompromised patients, persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection carries the risk of prolonged viral shedding and emergence of new variants. To reproduce the key features of persistent SARS-CoV-2 infection and evaluate its transmissibility, mouse-passaged SARS-CoV-2 was administered intranasally to severe combined immunodeficiency (SCID) rats deficient in Rag2 and Il2rg genes. The virus replicated in SCID rats for at least 6 weeks without causing severe symptoms. The main replication sites were the nasal cavity and trachea, and replicating viruses were barely detectable in the lungs. Infected areas within the nasal cavity and trachea showed minimal infiltration of neutrophils and M2 macrophages; however, a strong inflammatory response was observed in the lungs. Serial sequencing of the viral genome revealed accumulation of persistent mutations, predominantly in regions encoding nonstructural proteins. The persistently shed virus retained its infectivity, enabling its transmission to uninfected SCID rats. This model provides new insights into the immunological and tissue-associated features of persistent SARS-CoV-2 infection and offers a practical research platform for developing therapeutic interventions. IMPORTANCE: Persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in immunocompromised individuals promotes viral evolution and ongoing transmission, yet mechanistic studies have been limited by the absence of appropriate animal models. Existing mouse systems do not support longitudinal sampling or evaluate transmission, leaving critical questions unanswered. We established an SCID rat model that enables repeated noninvasive sampling from the same individuals, allowing longitudinal analysis of viral dynamics during prolonged infection. This approach revealed the emergence, disappearance, and fixation of viral mutations over time. Persistently infected rats also retained infectious and transmitted virus to naïve SCID rats, providing experimental evidence that prolonged infection preserves the transmission potential in this model. Persistent viral replication localized to the nasal cavity and trachea may be relevant to the upper-airway persistence reported in some immunocompromised patients. By capturing selected features of persistent SARS-CoV-2 infection under profoundly immunodeficient conditions, this model provides a valuable platform for investigating viral persistence, evolution, and transmission. - Alarmin cues and regulated cell death calibrate mucosal immunoglobulin A responses and virologic control after intranasal whole-virion inactivated influenza vaccination.
Eita Sasaki; Hideki Asanuma; Yoshimasa Takahashi; Hideki Hasegawa
International immunology, 14 May 2026, [International Magazine]
English, Scientific journal, How tissue damage cues and regulated cell death programs instruct antigen-specific mucosal IgA after vaccination remains incompletely defined. Using a mouse model of intranasal whole-virion inactivated influenza vaccination, we identify two proximal inputs that shape antibody output and virologic control: epithelial necroptosis-associated interleukin-33 release and a macrophage death-program switch that unmasks interleukin-1α. Immunization was accompanied by lung cell death, interleukin-33 release, and the induction of antigen-specific mucosal immunoglobulin A. In alveolar macrophages, vaccine uptake required phagocytosis and was associated with lysosomal destabilization and cathepsin B activity, which were linked to interleukin-1α release under conditions that favored regulated necrotic cell death. Consistent with this, pharmacologic inhibition of caspases shifted the dominant death program in alveolar macrophages and was associated with enhanced B cell activation in the cervical lymph nodes and increased immunoglobulin A-producing cell-like populations. At the functional level, caspase inhibition augmented vaccine-elicited protection, including reduced lung viral titers and attenuated pathology after homologous challenge and improved control of a within-subtype drift influenza A virus challenge strain; these enhancements were partly dependent on interleukin-1α. Together, these data support a model in which alarmin cues and regulated cell death pathways in the lung modulate the magnitude of mucosal immunoglobulin A responses and contribute to virologic control after intranasal whole-virion inactivated influenza vaccination. Limitations include reliance on pharmacologic pathway modulation and a mouse intranasal whole-virion inactivated influenza vaccine model; thus, mechanistic generalization beyond this context should be made cautiously. - Immunogenicity of influenza split vaccine for 2025/26 season in Japan using a mouse model.
Ryuichi Sugiyama; Kayoko Sato; Toru Takenaga; Hiyori Okura; Yusuke Nakai; Keiko Murano; Edna Sze Wai Lui; Emi Ito; Hideki Asanuma; Eita Sasaki; Seiichiro Fujisaki; Miki Akimoto; Aya Sato; Noriko Kishida; Shinji Watanabe; Hideki Hasegawa; Shigeyuki Itamura; Yuichi Harada; Noriko Shimasaki
Japanese journal of infectious diseases, 30 Apr. 2026, [Domestic magazines]
English, Scientific journal, Seasonal influenza viruses continuously evolve, and the composition of the seasonal influenza vaccine is reviewed by the World Health Organization twice a year due to antigenic drift in the viral hemagglutinin (HA) protein. A timely assessment of how well vaccine-induced antibodies react to circulating viruses remains warranted. Here, immunogenicity of reference split vaccines for the 2025/26 season in Japan was analyzed in a mouse model using a microneutralization (MN) antibody assay against circulating A(H1N1)pdm09, A(H3N2), and B/Victoria-lineage viruses. In Japan, the vaccine used in the 2025/26 season consisted of three virus strains: A/Victoria/4897/2022 (IVR-238) (H1N1)pdm09, A/Perth/722/2024 (IVR-262) (H3N2), and B/Austria/1359417/2021 (BVR- 26). Reduced MN reactivity was observed against the tested circulating viruses, including A/Tokyo/EIS11-980/2025 (H1N1)pdm09 (HA subclade D.3.1), A/Tokyo/EIS13-029/2025 (H3N2) (HA subclade J.2.3), A/Tokyo/EIS13-355/2025 (H3N2) (HA subclade K), and B/Kanagawa/AC2414/2025 (B/Victoria lineage, HA subclade C3.1), with MN titers at least four-fold lower than those for the corresponding vaccine strains. These isolates had several amino acid substitutions at the antigenic or glycosylation sites in HA compared to the vaccine strains. These findings provide early laboratory indication of decreased immunogenicity of the vaccine against specific circulating viruses during the 2025/26 season in Japan. - Potent efficacy of an NA-targeting antibody against a broad spectrum of H5N1 influenza viruses.
Saya Moriyama; Julia di Iulio; Fabrizia Zatta; Kevin Hauser; Hideki Asanuma; Hector E Muñoz; John M Errico; Yu Adachi; Ha V Dang; Nadine Czudnochowski; Eita Sasaki; Alex Chen; Yi-Pei Chen; Ryutaro Kotaki; Alessia Peter; Eneida Vetti; Taishi Onodera; M Cyrus Maher; Laura E Rosen; Masayuki Shirakura; Gyorgy Snell; Hideki Hasegawa; Yoshimasa Takahashi; Davide Corti; Matteo Samuele Pizzuto
Nature communications, 02 Mar. 2026, [International Magazine]
English, Scientific journal, For nearly 30 years, Goose/Guangdong-derived highly pathogenic avian influenza H5N1 viruses have posed significant risks to economic stability, food security, and public health. Virus evolution has resulted in various clades, including the panzootic subclade 2.3.4.4b, recognized for its pandemic potential. Here we present the potent in vitro activity of FNI9, a pan-influenza NA-inhibiting monoclonal antibody, against a range of pseudoparticles with NA spanning decades of H5N1 virus evolution. FNI9 also shows strong prophylactic protection in female mice against lethal challenges with H5N1 from clade 1 and 2.3.4.4b. Cryo-EM and molecular dynamics analysis reveal that FNI9 binds to 7 highly conserved H5N1 NA residues (R118, E119, D151, E228, E278, R293, and R368). In silico evolutionary escape profiling and machine learning predict low escapability, high fitness costs, and minimal spread likelihood for viral mutations that evade FNI9 binding. These findings support FNI9 broad protection and underscore the NA role in future influenza vaccine design. - Immune response and IgG subclass dynamics following repeated SARS-CoV-2 mRNA vaccination in Japanese healthcare workers.
Kaori Sano; Hideaki Kato; Akihide Ryo; Hideki Hasegawa; Kei Miyakawa
Vaccine, 77, 128396, 128396, 26 Feb. 2026, [International Magazine]
English, Scientific journal, In Japan, many healthcare workers received up to seven doses of SARS-CoV-2 mRNA vaccines by April 2024. While repeated vaccination aims to strengthen immunity, concerns about immune imprinting and IgG subclass switching, particularly to IgG4, have arisen. This study examined 19 healthcare workers who completed seven doses. Serum and PBMCs collected at five or three time points respectively to measure were analyzed for IgG subclasses, neutralizing antibodies and cellular responses. IgG1-3 levels declined after the second dose but recovered after the third, whereas IgG4 increased post-second dose and remained stable. Neutralizing antibodies against Omicron XBB.1.5 were undetectable after two doses but appeared after the third, despite all being Wuhan strain vaccines, and rose further after the sixth and seventh doses with updated formulations. Cellular immunity remained stable throughout. These findings indicate repeated mRNA vaccination enhances humoral immunity without progressive IgG4 elevation or additional cellular response boosts. - Applications of Pseudoviruses Bearing Glycoproteins of SARS-CoV-2 and Influenza Virus.
Makoto Ota; Kaori Sano; Kenji Yoshihara; Shinji Watanabe; Hideki Hasegawa; Kei Miyakawa
Advances in experimental medicine and biology, 1491, 361, 372, 2026, [International Magazine]
English, Scientific journal, This review discusses pseudoviruses, which are chimeric viral particles constructed by replacing the envelope glycoproteins of viruses such as human immunodeficiency virus (HIV) or vesicular stomatitis virus (VSV) with those of target viruses, and their advantages in the study of highly pathogenic respiratory viruses. These systems serve as valuable tools for elucidating viral entry mechanisms, screening antiviral drugs, quantitatively assessing virus-neutralizing antibodies, and evaluating vaccine efficacy, while reducing the safety risks associated with live viruses. Despite limitations such as applicability primarily to enveloped viruses, ongoing technological advances continue to improve pseudovirus systems, increasing their utility in vaccine development, antiviral research, and rapid response to emerging infectious diseases. - USP45-mediated deubiquitination of HIV-1 Tat regulates viral transcription and latency.
Kei Miyakawa; Hiyori Okura; Yasuyoshi Hatayama; Mayuko Nishi; Hirokazu Kimura; Hiroyuki Yamamoto; Hideki Hasegawa; Tetsuro Matano; Akihide Ryo
Frontiers in microbiology, 17, 1656512, 1656512, 2026, [International Magazine]
English, Scientific journal, The HIV-1 Tat protein is regulated by post-translational modifications, particularly ubiquitination, but the full spectrum of deubiquitinating enzymes (DUBs) controlling HIV-1 transcription remains incompletely understood. We developed a NanoBRET-based screening system using a library of 120 DUB expression vectors and identified USP45 as a novel Tat-interacting DUB. Functional characterization revealed that USP45 specifically deubiquitinates Tat at lysine 19, targeting both K48-linked and K63-linked ubiquitin chains. Notably, USP45 overexpression suppressed Tat-dependent transcriptional activation and HIV-1 viral particle production, while USP45 knockdown enhanced both processes. Transcriptional profiling in latently infected J-Lat 8.4 cells using digital PCR revealed that USP45 primarily inhibits the initial stages of viral transcription, thereby contributing to the maintenance of the latent state by restricting downstream transcriptional processes. Furthermore, USP45 expression is induced by interferons, identifying it as an interferon-stimulated gene. These findings establish that USP45 functions as a host restriction factor that negatively regulates HIV-1 transcription by promoting Tat deubiquitination at lysine 19, representing a promising therapeutic target for controlling HIV-1 latency. - Paramyxovirus matrix protein redirects METTL3 for dual regulation of viral replication and immune evasion.
Takashi Okura; Yusuke Nakai; Taichi Kameya; Fuminori Mizukoshi; Hiyori Okura; Masatoshi Kakizaki; Fumihiro Kato; Yusuke Matsumoto; Yuichiro Nakatsu; Kaoru Takeuchi; Hirokazu Kimura; Makoto Takeda; Noriyuki Otsuki; Kazuya Shirato; Hideki Hasegawa; Akihide Ryo
PLoS pathogens, 21, 12, e1013755, Dec. 2025, [International Magazine]
English, Scientific journal, N6-methyladenosine (m6A) epitranscriptomic modifications play crucial roles in regulating both host and viral gene expression. Here, we revealed a novel mechanism by which paramyxoviruses exploit host m6A machinery to simultaneously enhance viral replication and suppress host immunity. Our results demonstrated that the viral matrix protein (M) of bovine parainfluenza virus type 3 (BPIV3) binds to the methyltransferase domain of METTL3 in the nucleus and facilitates its translocation to the cytoplasm through an exportin-1-dependent pathway. This mechanism is conserved across multiple paramyxoviruses, including human parainfluenza virus type 3, Sendai virus, Nipah virus, and measles virus, suggesting an evolutionarily conserved viral strategy. The relocated METTL3 catalyzes m6A modification at specific sites within viral nucleocapsid protein (N) mRNA, significantly enhancing its stability and protein expression. Using reverse genetics, we generated recombinant viruses harbouring mutations at these m6A acceptor sites, which exhibited markedly attenuated viral replication, confirming the critical role of these epitranscriptomic marks in the viral life cycle. Rescue experiments demonstrated that the expression of exogenous N protein partially restored the viral titer and concomitant genome/antigenome synthesis in m6A site mutant, indicating that reduced N protein abundance represents a key mechanism underlying impaired viral replication. Furthermore, M protein-mediated depletion of nuclear METTL3 significantly reduces m6A modification of host IFN-β mRNA, resulting in diminished interferon expression and compromised antiviral responses. Supporting this mechanism, infection with viruses bearing nuclear export signal mutations that prevent METTL3 cytoplasmic translocation, maintained IFN-β mRNA m6A modification and resulted in significantly elevated IFN-β expression. These findings provide direct mechanistic evidence that paramyxoviruses utilize M-driven METTL3 relocalization as a sophisticated immune evasion strategy. Our study illuminates how paramyxoviruses strategically manipulate epitranscriptomic regulation to create an environment conducive to viral propagation, thereby advancing our understanding of virus-host interactions and identifying potential targets for antiviral therapeutics. - バロキサビルの臨床使用開始から7シーズンにおけるインフルエンザウイルスの感受性
高下 恵美; 藤崎 誠一郎; 森田 博子; 永田 志保; 三浦 秀佳; 岸田 典子; 中村 一哉; 白倉 雅之; 佐藤 彩; 秋元 未来; 菅原 裕美; 三田村 敬子; 安倍 隆; 市川 正孝; 山崎 雅彦; 渡邉 真治; 小田切 孝人; 長谷川 秀樹
日本小児感染症学会総会・学術集会プログラム・抄録集, 57回, 237, 237, (一社)日本小児感染症学会, Nov. 2025
Japanese - SARS-CoV-2 spike-specific IgG4 class switching associates with clinical recovery in Long COVID.
Kaori Sano; Yayoi Kimura; Koichi Hirahata; Hideaki Kato; Hideki Hasegawa; Hidenori Akutsu; Akihide Ryo; Atsushi Goto; Kei Miyakawa
The Journal of infection, 91, 5, 106641, 106641, Nov. 2025, [International Magazine]
English - Long COVIDにおけるS-IgG4クラススイッチングと症状改善の関連性
宮川 敬; 佐野 芳; 木村 弥生; 平畑 光一; 加藤 英明; 長谷川 秀樹; 梁 明秀; 後藤 温
臨床とウイルス, 53, 3, 189, 189, 日本臨床ウイルス学会, Sep. 2025
Japanese - SARS-CoV-2 mRNAワクチンの頻回接種によるIgGサブクラス動態 初期変化とその長期安定性
佐野 芳; 加藤 英明; 梁 明秀; 長谷川 秀樹; 宮川 敬
臨床とウイルス, 53, 3, 234, 234, 日本臨床ウイルス学会, Sep. 2025
Japanese - 発光性ウイルス様粒子を用いた高病原性鳥インフルエンザ中和抗体の迅速評価系の開発
太田 真; 佐野 芳; 百瀬 文隆; 岸田 典子; 有田 知子; 鈴木 康司; 白倉 雅之; 浅沼 秀樹; 渡邉 真治; 長谷川 秀樹; 宮川 敬
臨床とウイルス, 53, 3, 237, 237, 日本臨床ウイルス学会, Sep. 2025
Japanese - Neutralizing antibody evasion of SARS-CoV-2 JN.1 derivatives KP.3, KP.3.1.1, LB.1, and XEC.
Kaori Sano; Kei Miyakawa; Hideaki Kato; Yayoi Kimura; Atsushi Goto; Akihide Ryo; Shinji Watanabe; Hideki Hasegawa
Vaccine, 62, 127472, 127472, 30 Aug. 2025, [International Magazine]
English, Scientific journal, The emergence of SARS-CoV-2 variants poses ongoing challenges to vaccine efficacy. We evaluated neutralizing antibody responses against JN.1 and its derivatives (KP.3, KP.3.1.1, LB.1, and XEC) in healthcare workers who received seven doses of BNT162b2, including the XBB.1.5 monovalent vaccine. In COVID-19-naïve individuals, KP.3.1.1 and LB.1 showed substantial immune escape, whereas previously infected individuals maintained neutralization activity against all variants. We also demonstrated that JN.1-based immunization induces robust cross-neutralizing activity against emerging variants. A single amino acid deletion at position 31 in the spike protein may be associated with enhanced immune evasion. These findings support the potential effectiveness of JN.1-based vaccines while highlighting the need for continued surveillance and vaccine optimization. - Impact of the polymerase acidic protein E199K substitution in influenza A viruses on baloxavir susceptibility
Emi Takashita; Yoshihiro Yasui; Asaka Ikegaya; Kyohei Saka; Noriyuki Maeshiro; Hiroko Morita; Shiho Nagata; Seiichiro Fujisaki; Hideka Miura; Noriko Kishida; Kazuya Nakamura; Masayuki Shirakura; Shinji Watanabe; Hideki Hasegawa; Kazuya Mitsuhashi; Asami Ohnishi; Tomoko Takahashi; Yuko Suzuki; Minako Ato; Youko Fujiya; Naomi Ogawa; Nozomi Saito; Miyako Kon; Ayari Ikeda; Asaka Okubo; Yuki Wakabayashi; Akira Wakatsuki; Rina Kubota; Yoshiyuki Makino; Yasuo Kaburagi; Hitomi Yahata; Tomofumi Seno; Mami Nagashima; Kohei Shimizu; Chie Akaboshi; Yumiko Nagasawa; Kaori Imura; Miho Kitazume; Michiko Takeuchi; Erina Miyajima; Isako Onoda; Hirosato Ehara; Ryota Akaike; Takahisa Shimada; Nao Kobashi; Nobushige Sakai; Masahiro Nishioka; Yusuke Sato; Masakazu Suzuki; Takuya Yano; Asa Tanino; Kazuko Nakagawa; Saeko Morikawa; Hideki Mizutani; Tomohiro Oshibe; Ai Mori; Saya Yamamoto; Shiho Nagase; Yutaka Ueda; Yurie Kanba; Manabu Ishii; Yukie Shimazu; Yasutsugu Kawahara; Mitsuhiro Kameyama; Mizuki Yamamoto; Yukari Tsuchida; Sayako Yoshida; Wataru Satou; Yuri Kondo; Michihiko Miyamoto; Sonoko Izumida; Ukyo Osoegawa; Yumika Takaki; Mayumi Kadoguchi; Minoru Ikeda; Nami Tsuru
Antiviral Research, Jul. 2025
Scientific journal - PHD3-VHL axis controls HIV-2 infection through oxygen-dependent hydroxylation and degradation of Vpx.
Kei Miyakawa; Kiho Tanaka; Yoko Ino; Yayoi Kimura; Taichi Kameya; Fuminori Mizukoshi; Mayuko Nishi; Masaru Yokoyam; Jun Nakabayashi; Masako Nomaguchi; Hironori Sato; Hirokazu Kimura; Hirofumi Akari; Tomoyuki Miura; Akinori Takaoka; Hideki Hasegawa; Tetsuro Matano; Yoji Andrew Minamishima; Akihide Ryo
PLoS pathogens, 21, 6, e1013241, 16 Jun. 2025, [International Magazine]
English, Scientific journal, HIV-2 viral protein X (Vpx) plays a pivotal role in antagonizing the host restriction factors, including SAMHD1 and components of the HUSH complex, to facilitate viral replication. However, the regulatory mechanisms controlling Vpx stability remain unclear. In this study, we identify the von Hippel-Lindau (VHL) tumor suppressor as a novel E3 ubiquitin ligase that specifically targets Vpx for proteasomal degradation. Mechanistically, we demonstrate that VHL-mediated degradation depends on the oxygen-dependent hydroxylation of Vpx at proline residue 41 (Pro41), a modification catalyzed by prolyl hydroxylase domain-containing protein 3 (PHD3). Using an integrated approach combining crosslinking mass spectrometry and molecular modeling analyses, we elucidate the structural architecture of the PHD3-Vpx complex, revealing the spatial orientation of the catalytic domain of PHD3 required for Pro41 hydroxylation. Furthermore, we establish the physiological significance of this pathway in human macrophages, where pharmacological inhibition or genetic ablation of VHL or PHD3 enhances HIV-2 infection by facilitating Vpx-mediated SAMHD1 degradation. Collectively, our findings unveil a previously unrecognized oxygen-sensitive regulatory mechanism influencing HIV-2 infection and suggest novel therapeutic strategies targeting Vpx stability through modulation of its prolyl hydroxylation status. - Iguratimod, a promising therapeutic agent for COVID-19 that attenuates excessive inflammation in mouse models
Seiya Oba; Tadashi Hosoya; Daisuke Kawata; Yoji Komiya; Hideyuki Iwai; Ryuji Koike; Sho Miyamoto; Takayuki Kanno; Akira Ainai; Tadaki Suzuki; Hideki Hasegawa; Shinsuke Yasuda
European Journal of Pharmacology, 996, 177537, 177537, Elsevier BV, Jun. 2025
Scientific journal - Histomorphological variations in progressive multifocal leukoencephalopathy correlated with JCV replication in brain lesions: insights from 91 patients
Kenta Takahashi; Yuko Sato; Hideki Hasegawa; Harutaka Katano; Tadaki Suzuki
Acta Neuropathologica Communications, 19 May 2025
Scientific journal - Establishment of a novel adjuvant screening system for the development of intranasal vaccine adjuvants.
Eita Sasaki; Isao Hamaguchi; Hideki Hasegawa; Yoshimasa Takahashi
Vaccine, 58, 127267, 127267, 17 May 2025, [International Magazine]
English, Scientific journal, Vaccine adjuvants play a pivotal role in enhancing the immunogenicity of vaccines. Some vaccine modalities, such as subunit vaccines and split vaccines, are inherently poorly immunogenic and benefit greatly from combination with adjuvants. Notable examples, such as the herpes zoster glycoprotein E subunit vaccine and the Novavax COVID-19 (NVX-CoV2373) vaccine, underscore the importance of adjuvants in vaccination. Mucosal vaccines, and intranasal vaccines in particular, are gaining increasing attention for their potential to combat respiratory viral infections more effectively than subcutaneous and intramuscular vaccines. This is because mucosal vaccines can induce immunoglobulin (Ig)A production at mucosal surfaces to prevent the transmission of respiratory viruses such as influenza and severe acute respiratory syndrome coronavirus 2. However, few adjuvanted mucosal vaccines have been approved to date. To address this gap, we developed an adjuvant screening system to identify adjuvants suitable for use in combination with intranasal vaccines from a list of existing approved drugs or pharmaceutical additives. By analyzing biomarker gene expression levels, our screening system was able to predict the adjuvanticity and toxicity of a given adjuvant candidate in a short time. Using this screening system, we have to date identified some pharmaceutical additives, which induced a robust antigen-specific IgA antibody response following a single intranasal administration, without significant leukopenic toxicity or type I interferon inducibility. In this review, we discuss the development of our novel adjuvant evaluation system and its potential to enhance the efficacy of mucosal vaccines. - Emergence of Antigenic Variants in Bovine H5N1 Influenza Viruses.
Kei Miyakawa; Makoto Ota; Kaori Sano; Fumitaka Momose; Noriko Kishida; Tomoko Arita; Yasushi Suzuki; Masayuki Shirakura; Hideki Asanuma; Shinji Watanabe; Hideki Hasegawa
Journal of medical virology, 97, 5, e70394, May 2025, [International Magazine]
English, Scientific journal, The recent emergence of the H5N1 influenza virus in dairy cattle has raised significant public health concerns. Using a previously established pseudovirus-based neutralization assay, we evaluated the impact of emerging hemagglutinin (HA) mutations on the efficacy of current candidate vaccine viruses (CVVs). Neutralization analysis revealed that the cow-derived H5N1 virus showed up to a 2.2-fold reduction in sensitivity compared to the CVV homologous neutralization titers. Among the 1,453 HA sequences analyzed from cow-derived H5N1 viruses, we identified four major mutations (E2K, D104G, V147M, and S336N) that emerged after the initial isolation, with 134 isolates (9.22%) harboring all four mutations. These multi-mutation variants exhibited up to a 3.3-fold reduction compared with the CVV homologous neutralization titers. Single-mutation analysis demonstrated that the D104G mutation, present in 47.8% of sequences, markedly contributed to antibody escape. Our findings highlight the importance of continued surveillance and antigenic evaluation of emerging variants for pandemic preparedness strategies. - Impact of COVID-19 on Respiratory Virus Infections in Children, Japan, 2018-2023.
Emi Takashita; Kohei Shimizu; Chiharu Kawakami; Tomoko Momoki; Miwako Saikusa; Hiroki Ozawa; Makoto Kumazaki; Shuzo Usuku; Nobuko Tanaka; Ryuichi Senda; Ichiro Okubo; Seiichiro Fujisaki; Shiho Nagata; Hiroko Morita; Hideka Miura; Kayo Watanabe; Mina Nakauchi; Yoko Matsuzaki; Shinji Watanabe; Hideki Hasegawa; Yoshihiro Kawaoka
Immunity, inflammation and disease, 13, 3, e70176, Mar. 2025, [International Magazine]
English, Scientific journal, BACKGROUND: COVID-19, caused by SARS-CoV-2, was first documented in Japan in January 2020. We previously reported an increased risk of rhinovirus infections among children during the early phase of the COVID-19 pandemic. Here, we assessed the impact of COVID-19 on respiratory virus infections after SARS-CoV-2 spread nationwide. METHODS: We analyzed clinical specimens from 4012 patients with respiratory infections in Yokohama, Japan from January 2018 to April 2023. RESULTS: Among 15 representative respiratory viruses we detected (influenza virus, rhinovirus, coxsackievirus, echovirus, enterovirus, human coronavirus 229E, HKU1, NL63, and OC43, human metapneumovirus, human parainfluenza virus, human parechovirus, RSV, human adenovirus, human bocavirus, human parvovirus B19, herpes simplex virus type 1, and varicella-zoster virus), influenza was most affected by the COVID-19 pandemic, with no influenza viruses detected for nearly 3 years. CONCLUSIONS: The decrease in influenza infections following the emergence of SARS-CoV-2 may have contributed to the previously reported increase in rhinovirus infections. The rhinovirus outbreak, rather than SARS-CoV-2, may have contributed to the decrease in enveloped virus infections (RSV, parainfluenza viruses, metapneumovirus, and coronavirus 229E, HKU1, NL63, and OC43), possibly due to negative virus-virus interactions. - Calboxyvinyl polymer adjuvant enhances respiratory iga responses through mucosal and systemic administration.
Eita Sasaki; Hideki Asanuma; Haruka Momose; Jun-Ichi Maeyama; Saya Moriyama; Noriyo Nagata; Tadaki Suzuki; Isao Hamaguchi; Hideki Hasegawa; Yoshimasa Takahashi
NPJ vaccines, 10, 1, 28, 28, 11 Feb. 2025, [International Magazine]
English, Scientific journal, Adjuvants play a crucial role in enhancing vaccine efficacy. Although several adjuvants have been approved, there remains a demand for safer and more effective adjuvants for nasal vaccines. Here, we identified calboxyvinyl polymer (CVP) as a superior mucosal vaccine adjuvant from pharmaceutical base materials using our screening systems; single nasal vaccination of the CVP-combined influenza split vaccine-induced antigen-specific IgA and IgG antibodies and provided protection against lethal influenza virus infection. Furthermore, nasal vaccination with CVP-combined severe acute respiratory syndrome coronavirus 2 antigen protected against the virus and stimulated the production of highly cross-reactive IgG antibodies against variants XBB1.5 and JN.1. Intriguingly, intramuscular vaccination of the CVP-combined vaccine also elicited the production of IgA antibodies in both nasal wash and bronchoalveolar lavage fluid in mice and cynomolgus monkeys. CVP therefore offers superior adjuvanticity to existing adjuvants and is anticipated to be a safe and effective adjuvant for mucosal vaccines. - Performance of Ultrasensitive Polymerase Chain Reaction Testing for JC Polyomavirus in Cerebrospinal Fluid Compared with Pathological Diagnosis of Progressive Multifocal Leukoencephalopathy
Kenta Takahashi; Kazuo Nakamichi; Yuko Sato; Harutaka Katano; Hideki Hasegawa; Masayuki Saijo; Tadaki Suzuki
Viruses, 16, 12, 1950, 1950, MDPI AG, 19 Dec. 2024
Scientific journal, Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease caused by the JC polyomavirus (JCPyV). Based on the clinical criteria, PML is diagnosed via polymerase chain reaction (PCR) detection of JCPyV DNA in cerebrospinal fluid (CSF) in combination with neurological and imaging findings. Although the utility of CSF JCPyV testing using ultrasensitive PCR assays has been suggested, its potential requires further evaluation. This study retrospectively analyzed the detection performance of ultrasensitive PCR for CSF JCPyV in patients who underwent brain tissue examination based on the pathological diagnostic criteria for PML. Of the 110 patients with pathologically confirmed definite PML or not PML, standard and ultrasensitive CSF testing was performed for 36 and 74 patients, respectively. The sensitivity of ultrasensitive CSF JCPyV testing of the initial specimens was 85%. With the addition of the follow-up testing, this figure increased to 95%. The specificity and false-positive rate of ultrasensitive CSF JCPyV testing, including follow-up, were 100% and 0%, respectively. No statistically significant correlation was observed between CSF and brain JCPyV levels. The results of this study demonstrate the high sensitivity and accuracy of ultrasensitive CSF JCPyV testing and provide essential information for the clinical diagnosis of PML. - An outbreak of influenza A(H1N1)pdm09 antigenic variants exhibiting cross-resistance to oseltamivir and peramivir in an elementary school in Japan, September 2024.
Emi Takashita; Kohei Shimizu; Shuzo Usuku; Ryuichi Senda; Ichiro Okubo; Hiroko Morita; Shiho Nagata; Seiichiro Fujisaki; Hideka Miura; Noriko Kishida; Kazuya Nakamura; Masayuki Shirakura; Masataka Ichikawa; Yoko Matsuzaki; Shinji Watanabe; Yoshimasa Takahashi; Hideki Hasegawa
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 29, 50, Dec. 2024, [International Magazine]
English, Scientific journal, An outbreak of influenza A(H1N1)pdm09 viruses exhibiting cross-resistance to oseltamivir and peramivir occurred in Yokohama, Japan, in September 2024. Among 24 students in a class, 11 were diagnosed with influenza or influenza-like illness, and viruses harbouring the NA H275Y and HA Q210H substitutions were isolated from four. Deep sequencing analysis confirmed the clonal spread of these mutants. Antigenic analysis revealed differences from the vaccine strain. Continued monitoring is crucial to assess the potential for further spread of these mutant viruses. - Rapid and Safe Neutralization Assay for Circulating H5N1 Influenza Virus in Dairy Cows.
Kei Miyakawa; Makoto Ota; Kaori Sano; Fumitaka Momose; Takashi Okura; Noriko Kishida; Tomoko Arita; Yasushi Suzuki; Masayuki Shirakura; Hideki Asanuma; Shinji Watanabe; Akihide Ryo; Hideki Hasegawa
Influenza and other respiratory viruses, 18, 12, e70048, Dec. 2024, [International Magazine]
English, Scientific journal, Rapid and safe neutralization assays are required for highly pathogenic avian influenza viruses, including a clade 2.3.4.4b H5N1 subtype recently found in cows. Here, we report a neutralization assay using luminescent virus-like particles. This assay has lower biosafety requirements and provides a larger dynamic range than conventional methods. We applied this technique to evaluate the cross-reactivity of neutralizing antibodies induced by clade 2.3.4.4b candidate vaccine viruses (CVVs) with the cow-derived H5N1 virus. Our findings indicate that these CVVs share antigenic characteristics with the cow-derived H5N1 virus, suggesting the potential efficacy of vaccines developed using these CVVs. - A Mouse Model of Ovalbumin-Induced Airway Allergy Exhibits Altered Localization of SARS-CoV-2-Susceptible Cells in the Lungs, Which Reflects Omicron BA.5 Infection Dynamics, Viral Mutations, and Immunopathology.
Takao Iketani; Kaya Miyazaki; Naoko Iwata-Yoshikawa; Yusuke Sakai; Nozomi Shiwa-Sudo; Seiya Ozono; Hideki Asanuma; Hideki Hasegawa; Tadaki Suzuki; Noriyo Nagata
Microbiology and immunology, 21 Nov. 2024, [International Magazine]
English, Scientific journal, Asthma, an allergic disease of the airways, is a risk factor for severity of common respiratory viral infections; however, the relationship between asthma and severity in COVID-19 remains unclear. Here, we examined the effects of SARS-CoV-2 (Omicron BA.5 strain) infection in a mouse model of airway allergy. First, stimulation of allergic mice with OVA resulted in the appearance of ACE2-negative mucus-secreting goblet cells in the bronchiolar region, and an increase in the number of ACE2-expressing cells in the alveoli. As a result, ACE2-expressing cells, which are susceptible to SARS-CoV-2, were limited to the distal portion of the bronchioles while they increased in the alveolar area. After viral infection, the peak infectious viral load in the OVA group was 100-fold lower than that in the phosphate buffered saline (PBS) group; however, clearance of viral RNA from the upper/lower airways was delayed. There were notable differences in acquisition of nsp5 and nsp6 mutations by the Omicron BA.5 strain recovered from BALF samples obtained from the OVA and PBS groups. Immune responses associated with viral clearance were essentially the same, but expression of granulocyte-associated chemokines was higher, M2 macrophage responses were predominant, and the higher spike-specific IgG1/IgG2a ratio in the OVA group post-infection. Infection localized in the alveolar region earlier in the OVA group, resulting in more severe alveolar damage than in the PBS group. These data suggest a Th2-shifted immune background and altered localization of SARS-CoV-2 susceptible cells in mice with OVA-induced airway allergy, which reflect Omicron BA.5 infection dynamics, viral mutations, and immunopathology. - 2023/24シーズンのインフルエンザ分離株の解析
岸田 典子; 中村 一哉; 藤崎 誠一郎; 高下 恵美; 佐藤 彩; 秋元 未来; 三浦 秀佳; 森田 博子; 永田 志保; 白倉 雅之; 菅原 裕美; 渡邉 真治; 長谷川 秀樹; インフルエンザ株サーベイランスグループ
病原微生物検出情報月報, 45, 11, 182, 186, 国立健康危機管理研究機構国立感染症研究所感染症サーベイランス研究部, Nov. 2024
Japanese - 2023/24シーズンにおける抗インフルエンザ薬耐性ウイルスの検出
高下 恵美; 藤崎 誠一郎; 岸田 典子; 白倉 雅之; 中村 一哉; 安倍 隆; 市川 正孝; 山崎 雅彦; 三田村 敬子; 渡邉 真治; 長谷川 秀樹
日本小児感染症学会総会・学術集会プログラム・抄録集, 56回, 219, 219, (一社)日本小児感染症学会, Nov. 2024
Japanese - Cellular and humoral immunity and IgG subclass distribution after omicron XBB.1.5 monovalent vaccination in Japan.
Kaori Sano; Takayuki Kurosawa; Kazuo Horikawa; Yayoi Kimura; Atsushi Goto; Akihide Ryo; Hideki Hasegawa; Hideaki Kato; Kei Miyakawa
Vaccine, 42, 26, 126452, 126452, 16 Oct. 2024, [Peer-reviewed], [International Magazine]
English, Scientific journal, BACKGROUND: Up to seven doses of coronavirus disease 2019 (COVID-19) mRNA vaccines (BNT162b2) were administered to Japanese healthcare workers, until February 2024. The monovalent Omicron XBB.1.5 vaccine (hereafter called XBB.1.5 vaccine) was used for dose 7. OBJECTIVE: Although the XBB.1.5 vaccine has been reported to induce a robust increase in neutralizing antibodies against the currently circulating Omicron variant BA.2.86, little is known about its serological effects in Japan, where the BNT162b2 mRNA vaccine is the most frequently administered in the world. STUDY DESIGN: Twenty-five recipients of the XBB.1.5 vaccine, categorized as seronegative (n = 18) or seropositive (n = 7) based on their recent history of COVID-19, were analyzed. Neutralizing antibody titers against Omicron subvariants, receptor binding domain (RBD) IgG levels, IgG subclass distribution, and T-cell responses were assessed. RESULTS: We found a significant increase in neutralizing antibody titers against XBB.1.5 and BA.2.86 variants following XBB.1.5 vaccination, particularly in seropositive individuals. No significant change in total RBD IgG levels was observed, indicating efficient induction of antibodies targeting regions outside the RBD by XBB.1.5 vaccination. IgG subclass analysis demonstrated no significant subclass switching after vaccination. T-cell responses against the virus were comparable between seropositive and seronegative groups. CONCLUSIONS: The study suggests that XBB.1.5 vaccination enhances humoral immunity against Omicron variants without significant IgG subclass switching. However, some individuals with low pre-vaccination IgG titers did not exhibit increased antibody levels post-vaccination, raising concerns about potential immune tolerance. - 日本人医療従事者におけるOmicron XBB.1.5ワクチン接種後の免疫応答の解析
佐野 芳; 加藤 英明; 長谷川 秀樹; 宮川 敬
臨床とウイルス, 52, 3, 172, 172, 日本臨床ウイルス学会, Oct. 2024
Japanese - The comparison of pathogenicity among SARS-CoV-2 variants in domestic cats.
Eun-Sil Park; Yudai Kuroda; Akihiko Uda; Yoshihiro Kaku; Akiko Okutani; Akitoyo Hotta; Kango Tatemoto; Keita Ishijima; Yusuke Inoue; Michiko Harada; Yasushi Ami; Masayuki Shirakura; Shinji Watanabe; Yasushi Suzuki; Toshihiko Harada; Akira Ainai; Nozomi Shiwa; Yusuke Sakai; Naoko Iwata-Yoshikawa; Noriyo Nagata; Tadaki Suzuki; Hideki Hasegawa; Ken Maeda
Scientific reports, 14, 1, 21815, 21815, 18 Sep. 2024, [International Magazine]
English, Scientific journal, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been detected or isolated from domestic cats. It is unclear whether cats play an important role in the SARS-CoV-2 transmission cycle. In this study, we examined the susceptibility of cats to SARS-CoV-2, including wild type and variants, by animal experiments. Cats inoculated with wild type, gamma, and delta variants secreted a large amount of SARS-CoV-2 for 1 week after the inoculation from nasal, oropharyngeal, and rectal routes. Only 100 TCID50 of virus could infect cats and replicate well without severe clinical symptoms. In addition, one cat inoculated with wild type showed persistent virus secretion in feces for over 28 days post-inoculation (dpi). The titer of virus-neutralizing (VN) antibodies against SARS-CoV-2 increased from 11 dpi, reaching a peak at 14 dpi. However, the omicron variant could not replicate well in cat tissues and induced a lower titer of VN antibodies. It is concluded that cats were highly susceptible to SARS-CoV-2 infection, but not to the Omicron Variant, which caused the attenuated pathogenicity. - Necroptosis in alveolar epithelial cells drives lung inflammation and injury caused by SARS-CoV-2 infection.
Yoji Komiya; Mari Kamiya; Seiya Oba; Daisuke Kawata; Hideyuki Iwai; Hiroshi Shintaku; Yoshio Suzuki; Sho Miyamoto; Minoru Tobiume; Takayuki Kanno; Akira Ainai; Tadaki Suzuki; Hideki Hasegawa; Tadashi Hosoya; Shinsuke Yasuda
Biochimica et biophysica acta. Molecular basis of disease, 167472, 167472, 16 Aug. 2024, [International Magazine]
English, Scientific journal, COVID-19, caused by SARS-CoV-2 infection, results in irreversible or fatal lung injury. We assumed that necroptosis of virus-infected alveolar epithelial cells (AEC) could promote local inflammation and further lung injury in COVID-19. Since CD8+ lymphocytes induced AEC cell death via cytotoxic molecules such as FAS ligands, we examined the involvement of FAS-mediated cell death in COVID-19 patients and murine COVID-19 model. We identified the occurrence of necroptosis and subsequent release of HMGB1 in the admitted patients with COVID-19. In the mouse model of COVID-19, lung inflammation and injury were attenuated in Fas-deficient mice compared to Fas-intact mice. The infection enhanced Type I interferon-inducible genes in both groups, while inflammasome-associated genes were specifically upregulated in Fas-intact mice. The treatment with necroptosis inhibitor, Nec1s, improved survival rate, lung injury, and systemic inflammation. SARS-CoV-2 induced necroptosis causes cytokine induction and lung damage, and its inhibition could be a novel therapeutic strategy for COVID-19. - 新型コロナウイルスのゲノムサーベイランス(検疫検体:入国者検疫検体を含む)について
太田 雅之; 高橋 健一郎; 斎藤 益満; 吉田 初佳; 野尻 直未; 村上 耕介; 瀬崎 貴子; 吉見 逸郎; 竹前 喜洋; 東良 俊孝; 影山 努; 齋藤 智也; 高山 郁代; 冨田 有里子; 松山 州徳; 渡邉 真治; 長谷川 秀樹
病原微生物検出情報月報, 45, 6, 87, 88, 国立感染症研究所, Jun. 2024
Japanese - Monitoring Influenza C and D Viruses in Patients With Respiratory Diseases in Japan, January 2018 to March 2023.
Kohei Shimizu; Chiharu Kawakami; Yoko Matsuzaki; Seiichiro Fujisaki; Shiho Nagata; Hiroko Morita; Kayo Watanabe; Hideka Miura; Tomoko Momoki; Miwako Saikusa; Hiroki Ozawa; Makoto Kumazaki; Shuzo Usuku; Nobuko Tanaka; Ryuichi Senda; Ichiro Okubo; Shinji Watanabe; Hideki Hasegawa; Yoshihiro Kawaoka; Emi Takashita
Influenza and other respiratory viruses, 18, 6, e13345, Jun. 2024, [International Magazine]
English, Scientific journal, BACKGROUND: Influenza viruses can cause zoonotic infections that pose public health risks. Surveillance of influenza A and B viruses is conducted globally; however, information on influenza C and D viruses is limited. Longitudinal monitoring of influenza C virus in humans has been conducted in several countries, but there has been no long-term monitoring of influenza D virus in humans. The public health risks associated with the influenza D virus therefore remain unknown. METHODS: We established a duplex real-time RT-PCR to detect influenza C and D viruses and analyzed respiratory specimens collected from 2144 patients in Japan with respiratory diseases between January 2018 and March 2023. We isolated viruses and conducted hemagglutination inhibition tests to examine antigenicity and focus reduction assays to determine susceptibility to the cap-dependent endonuclease inhibitor baloxavir marboxil. RESULTS: We detected three influenza C viruses belonging to the C/Kanagawa- or C/Sao Paulo-lineages, which recently circulated globally. None of the specimens was positive for the influenza D virus. The C/Yokohama/1/2022 strain, isolated from the specimen with the highest viral RNA load and belonging to the C/Kanagawa-lineage, showed similar antigenicity to the reference C/Kanagawa-lineage strain and was susceptible to baloxavir. CONCLUSIONS: Our duplex real-time RT-PCR is useful for the simultaneous detection of influenza C and D viruses from the same specimen. Adding the influenza D virus to the monitoring of the influenza C virus would help in assessing the public health risks posed by this virus. - Prophylactic vaccination inducing anti-Env antibodies can result in protection against HTLV-1 challenge in macaques.
Midori Nakamura-Hoshi; Hiroshi Ishii; Takushi Nomura; Masako Nishizawa; Trang Thi Thu Hau; Nozomi Kuse; Midori Okazaki; Akira Ainai; Tadaki Suzuki; Hideki Hasegawa; Takeshi Yoshida; Kenzo Yonemitsu; Yuriko Suzaki; Yasushi Ami; Hiroyuki Yamamoto; Tetsuro Matano
Molecular therapy : the journal of the American Society of Gene Therapy, 11 May 2024, [International Magazine]
English, Scientific journal, Human T cell leukemia/T-lymphotropic virus type 1 (HTLV-1) infection occurs by cell-to-cell transmission and can induce fatal adult T cell leukemia. Vaccine development is critical for the control of HTLV-1 transmission. However, determining whether vaccine-induced anti-Env antibodies can prevent cell-to-cell HTLV-1 transmission is challenging. Here, we examined the protective efficacy of a vaccine inducing anti-Env antibodies against HTLV-1 challenge in cynomolgus macaques. Eight of 10 vaccinated macaques produced anti-HTLV-1 neutralizing antibodies (NAbs) and were protected from an intravenous challenge with 108 HTLV-1-producing cells. In contrast, the 2 vaccinated macaques without NAb induction and 10 unvaccinated controls showed HTLV-1 infection with detectable proviral load after challenge. Five of the eight protected macaques were administered with an anti-CD8 monoclonal antibody, but proviruses remained undetectable and no increase in anti-HTLV-1 antibodies was observed even after CD8+ cell depletion in three of them. Analysis of Env-specific T cell responses did not suggest involvement of vaccine-induced Env-specific T cell responses in the protection. These results indicate that anti-Env antibody induction by vaccination can result in functionally sterile HTLV-1 protection, implying the rationale for strategies aimed at anti-Env antibody induction in prophylactic HTLV-1 vaccine development. - Attenuation of A(H7N9) influenza virus infection in mice exposed to cigarette smoke
Satoshi Fukuyama; Jason E. Shoemaker; Dongming Zhao; Noriko Nagajima; Yuriko Tomita; Tadashi Maemura; Tiago Jose da Silva Lopes; Tokiko Watanabe; Seiya Yamayoshi; Hideki Hasegawa; Yoshihiro Kawaoka
npj Viruses, 2, 1, Springer Science and Business Media LLC, 25 Mar. 2024
Scientific journal, Abstract
Influenza A(H7N9) virus showed high pathogenicity in humans when it emerged in 2013. Cigarette smoke (CS) causes pulmonary diseases including bronchitis, emphysema, and lung cancer. Although habitual smoking is thought to increase the risk of severe seasonal influenza virus infection, its effect on A(H7N9) virus infection is poorly understood. Here, we employed a mouse model of long-term exposure to CS to investigate the effect of CS on the pathogenicity of A(H7N9) virus infection. Unexpectedly, body weight loss for mice exposed to CS was milder than that for mock-treated mice upon A(H7N9) virus infection. CS exposure improved the survival rate of A(H7N9) virus-infected mice even though virus titers and pathological changes in the lungs were not significantly different between CS-exposed and control mice. Microarray analysis showed that CS-exposure activates cytokine/chemokine activity, immune response, and cell cycle activities that resemble reactivities against A(H7N9) virus infection. Therefore, under conditions where cytokine and chemokine expression in the lungs is already high due to CS exposure, the enhanced expression of cytokines and chemokines caused by A(H7N9) virus infection might be less harmful to the organs compared to the rapid increase in cytokine and chemokine expression in the air-exposed mice due to the infection. CS may thus induce immunoregulatory effects that attenuate severe pulmonary disease during A(H7N9) virus infection. However, these findings do not support CS exposure due to its many other proven negative health effects. - Replication Efficiency of SARS-CoV-2 Omicron Subvariants BA.2.75, BA.5, and XBB.1 in Human Mini-Gut Organoids.
Kei Miyakawa; Masakazu Machida; Tomoyuki Kawasaki; Masatoshi Kakizaki; Yayoi Kimura; Masaya Sugiyama; Hideki Hasegawa; Akihiro Umezawa; Hidenori Akutsu; Akihide Ryo
Cellular and molecular gastroenterology and hepatology, 15 Mar. 2024, [International Magazine]
English, Scientific journal - Characterization of antibodies targeting severe fever with thrombocytopenia syndrome virus glycoprotein Gc
Kaori Sano; Miyuki Kimura; Akiko Sataka; Hideki Hasegawa; Hideki Tani; Tadaki Suzuki
Archives of Virology, Mar. 2024
Scientific journal - 奈良県におけるバロキサビル耐性変異インフルエンザウイルスのcommunity cluster
高下 恵美; 藤崎 誠一郎; 森田 博子; 永田 志保; 三浦 秀佳; 岸田 典子; 中村 一哉; 白倉 雅之; 菅原 裕美; 佐藤 彩; 秋元 未来; 渡邉 真治; 長谷川 秀樹; 松浦 侑輝; 山本 紗也; 千葉 翔子; 井上 ゆみ子; 美並 衣織; 吉川 采也加; 山崎 聖子
病原微生物検出情報月報, 45, 2, 31, 32, 国立感染症研究所, Feb. 2024
Japanese - Author Correction: Immune response and protective efficacy of the SARS-CoV-2 recombinant spike protein vaccine S-268019-b in mice.
Tomoyuki Homma; Noriyo Nagata; Masayuki Hashimoto; Naoko Iwata-Yoshikawa; Naomi M Seki; Nozomi Shiwa-Sudo; Akira Ainai; Keiji Dohi; Eiji Nikaido; Akiko Mukai; Yuuta Ukai; Takayuki Nakagawa; Yusuke Shimo; Hiroki Maeda; Seiki Shirai; Miwa Aoki; Takuhiro Sonoyama; Mamoru Sato; Masataka Fumoto; Morio Nagira; Fumihisa Nakata; Takao Hashiguchi; Tadaki Suzuki; Shinya Omoto; Hideki Hasegawa
Scientific reports, 14, 1, 2599, 2599, 31 Jan. 2024, [International Magazine]
English - Establishment of reference reagents for single-radial-immunodiffusion assay on the 2022/23 seasonal influenza vaccine in Japan and their quality validation.
Noriko Shimasaki; Tomoko Kuwahara; Haruna Nishijima; Kazuya Nakamura; Kayoko Sato; Keiko Murano; Shigeyuki Itamura; Yukiko Akahori; Emi Takashita; Noriko Kishida; Tomoko Arita; Mina Nakauchi; Makoto Takeda; Hideki Hasegawa; Akihide Ryo; Yuichi Harada
Japanese journal of infectious diseases, 30 Nov. 2023, [Domestic magazines]
English, Scientific journal, Potency test of influenza vaccine is currently performed using a single-radial-immunodiffusion (SRID) assay, which requires a reference antigen and anti-hemagglutinin (HA) serum as reference reagents. The reagents must be newly prepared each time the strain used for vaccine production is changed. Establishing reference reagents with consistent quality is, therefore, crucial to accurately and precisely conduct vaccine potency tests. Here, we established the reference reagents for the SRID assay to conduct lot release tests of quadrivalent influenza vaccines in Japan for the 2022/23 influenza season. The potency stability during storage of some reference antigens was confirmed. Furthermore, we evaluated the cross-reactivity of each antiserum raised against the HA protein of two lineages of influenza B virus toward the different lineage of influenza B virus antigen to select a suitable procedure of SRID assay for accurate measurement. Finally, the intra-laboratory reproducibility of the SRID assay using the established reference reagents was validated, and then the SRID reagents had sufficiently consistent quality comparable to that of the reagents used for testing vaccines in past influenza seasons. Our study could contribute to the quality control of influenza vaccines. - 2022/23インフルエンザシーズンにおける薬剤未投与例からのバロキサビル耐性変異ウイルスの検出
高下 恵美; 藤崎 誠一郎; 岸田 典子; 白倉 雅之; 中村 一哉; 安倍 隆; 市川 正孝; 山崎 雅彦; 三田村 敬子; 渡邉 真治; 長谷川 秀樹
日本小児感染症学会総会・学術集会プログラム・抄録集, 55回, 158, 158, (一社)日本小児感染症学会, Nov. 2023
Japanese - 2022/23シーズンのインフルエンザ分離株の解析
岸田 典子; 中村 一哉; 藤崎 誠一郎; 高下 恵美; 佐藤 彩; 秋元 未来; 三浦 秀佳; 森田 博子; 永田 志保; 白倉 雅之; 菅原 裕美; 渡邉 真治; 長谷川 秀樹
病原微生物検出情報月報, 44, 11, 171, 176, 国立感染症研究所, Nov. 2023
Japanese - A community cluster of influenza A(H3N2) virus infection with reduced susceptibility to baloxavir due to a PA E199G substitution in Japan, February to March 2023
Emi Takashita; Seiichiro Fujisaki; Hiroko Morita; Shiho Nagata; Hideka Miura; Yuki Matsuura; Saya Yamamoto; Shoko Chiba; Yumiko Inoue; Iori Minami; Sayaka Yoshikawa; Seiko Yamazaki; Noriko Kishida; Kazuya Nakamura; Masayuki Shirakura; Shinji Watanabe; Hideki Hasegawa
Eurosurveillance, 28 Sep. 2023
Scientific journal - 新型コロナワクチンおよびインフルエンザワクチン接種後の抗体応答とブレイクスルー感染に関する研究
嶋崎 典子; 板村 繁之; 浜本 いつき; 藤崎 誠一郎; 長谷川 秀樹; 竹田 誠; 石井 淳子; 若杉 安希乃; 関根 麻理子; 遠藤 真理; 森 裕紀子
臨床とウイルス, 51, 3, 136, 136, 日本臨床ウイルス学会, Sep. 2023
Japanese - Assessment of the frequency of SARS-CoV-2 Omicron variant escape from RNA-dependent RNA polymerase inhibitors and 3C-like protease inhibitors.
Emi Takashita; Seiichiro Fujisaki; Hiroko Morita; Shiho Nagata; Hideka Miura; Mami Nagashima; Shinji Watanabe; Makoto Takeda; Yoshihiro Kawaoka; Hideki Hasegawa
Antiviral research, 216, 105671, 105671, Aug. 2023, [International Magazine]
English, Scientific journal, The emergence and spread of antiviral-resistant SARS-CoV-2 is of great concern. In this study, we evaluated the propensity of Omicron variants to escape from RNA-dependent RNA polymerase (RdRP) inhibitors and 3C-like protease (3CLpro) inhibitors. SARS-CoV-2 Delta and Omicron variants were serially passaged in vitro in the presence of RdRP inhibitors (remdesivir and molnupiravir) and 3CLpro inhibitors (nirmatrelvir and lufotrelvir) to detect SARS-CoV-2 escape mutants. After five passages with 3CLpro inhibitors, mutant viruses that escaped from 3CLpro inhibitors emerged; however, in the presence of RdRP inhibitors all variants disappeared within 2-4 passages. Our findings suggest that the frequency of SARS-CoV-2 mutant escape from RdRP inhibitors is lower than that from 3CLpro inhibitors. We also found that Delta variants were more likely to acquire amino acid substitutions associated with resistance to 3CLpro inhibitors under the selective pressure of this drug compared with Omicron variants. - Apple-shaped obesity: A risky soil for cytokine-accelerated severity in COVID-19
Tadashi Hosoya; Seiya Oba; Yoji Komiya; Daisuke Kawata; Mari Kamiya; Hideyuki Iwai; Sho Miyamoto; Michiyo Kataoka; Minoru Tobiume; Takayuki Kanno; Akira Ainai; Hiroyuki Sato; Akihiro Hirakawa; Yuichi Mitsui; Takashi Satoh; Kenji Wakabayashi; Tetsuya Yamada; Yasuhiro Otomo; Yasunari Miyazaki; Hideki Hasegawa; Tadaki Suzuki; Shinsuke Yasuda
Proceedings of the National Academy of Sciences, 120, 22, Proceedings of the National Academy of Sciences, 22 May 2023
Scientific journal, Obesity has been recognized as one of the most significant risk factors for the deterioration and mortality associated with COVID-19, but the significance of obesity itself differs among ethnicity. Multifactored analysis of our single institute–based retrospective cohort revealed that high visceral adipose tissue (VAT) burden, but not other obesity-associated markers, was related to accelerated inflammatory responses and the mortality of Japanese COVID-19 patients. To elucidate the mechanisms how VAT-dominant obesity induces severe inflammation after severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection, we infected two different strains of obese mice, C57BL/6JHamSlc-ob/ob (ob/ob), C57BLKS/J-db/db (db/db), genetically impaired in the leptin ligand and receptor, respectively, and control C57BL/6 mice with mouse-adapted SARS-CoV-2. Here, we revealed that VAT-dominant ob/ob mice were extremely more vulnerable to SARS-CoV-2 due to excessive inflammatory responses when compared to SAT-dominant db/db mice. In fact, SARS-CoV-2 genome and proteins were more abundant in the lungs of ob/ob mice, engulfed in macrophages, resulting in increased cytokine production including interleukin (IL)-6. Both an anti-IL-6 receptor antibody treatment and the prevention of obesity by leptin replenishment improved the survival of SARS-CoV-2-infected ob/ob mice by reducing the viral protein burden and excessive immune responses. Our results have proposed unique insights and clues on how obesity increases the risk of cytokine storm and death in patients with COVID-19. Moreover, earlier administration of antiinflammatory therapeutics including anti-IL-6R antibody to VAT-dominant patients might improve clinical outcome and stratification of the treatment for COVID-19, at least in Japanese patients. - Saturation time of exposure interval for cross-neutralization response to SARS-CoV-2: implications for vaccine dose interval
Sho Miyamoto; Yudai Kuroda; Takayuki Kanno; Akira Ueno; Nozomi Shiwa-Sudo; Naoko Iwata-Yoshikawa; Yusuke Sakai; Noriyo Nagata; Takeshi Arashiro; Akira Ainai; Saya Moriyama; Noriko Kishida; Shinji Watanabe; Kiyoko Nojima; Yohei Seki; Takuo Mizukami; Hideki Hasegawa; Hideki Ebihara; Shuetsu Fukushi; Yoshimasa Takahashi; Maeda Ken; Tadaki Suzuki
iScience, 106694, 106694, Elsevier BV, Apr. 2023
Scientific journal - Estimating serum cross-neutralizing responses to SARS-CoV-2 Omicron sub-lineages elicited by pre-Omicron or Omicron breakthrough infection with exposure interval compensation modeling
Sho Miyamoto; Yudai Kuroda; Takayuki Kanno; Akira Ueno; Nozomi Shiwa-Sudo; Naoko Iwata-Yoshikawa; Yusuke Sakai; Noriyo Nagata; Takeshi Arashiro; Akira Ainai; Saya Moriyama; Noriko Kishida; Shinji Watanabe; Kiyoko Nojima; Yohei Seki; Takuo Mizukami; Hideki Hasegawa; Hideki Ebihara; Shuetsu Fukushi; Yoshimasa Takahashi; Ken Maeda; Tadaki Suzuki
Cold Spring Harbor Laboratory, 10 Feb. 2023
Abstract
Understanding the differences in serum cross-neutralizing responses against SARS-CoV-2 variants, including Omicron sub-lineages BA.5, BA.2.75, and BQ.1.1, elicited by exposure to distinct antigens is essential for developing COVID-19 booster vaccines with enhanced cross-protection against antigenically distinct variants. However, fairly comparing the impact of breakthrough infection on serum neutralizing responses to several variants with distinct epidemic timing is challenging because responses after breakthrough infection are affected by the exposure interval between vaccination and infection. We assessed serum cross-neutralizing responses to SARS-CoV-2 variants, including Omicron sub-lineages, in individuals with breakthrough infections before or during the Omicron BA.1 epidemic. To understand the differences in serum cross-neutralizing responses after pre-Omicron or Omicron breakthrough infection, we used Bayesian hierarchical modeling to correct the cross-neutralizing responses for the exposure interval between vaccination and breakthrough infection. The exposure interval required to generate saturated cross-neutralizing potency against each variant differed by variant, with variants more antigenically distant from the ancestral strain requiring a longer interval. Additionally, Omicron breakthrough infection was estimated to have higher impact than booster vaccination and pre-Omicron breakthrough infection on inducing serum neutralizing responses to the ancestral strain and Omicron sub-lineages. However, the breadth of cross-neutralizing responses to Omicron sub-lineages, including BQ.1.1, after Omicron or pre-Omicron breakthrough infection with the ideal exposure interval were estimated to be comparable. Our results highlight the importance of optimizing the interval between vaccine doses for maximizing the breadth of cross-neutralizing activity elicited by booster vaccines with or without Omicron antigen.
Significance Statement
SARS-CoV-2 infections after vaccination with COVID-19 mRNA vaccines with the ancestral spike antigen induce high serum neutralizing responses against Omicron sub-lineages, which are antigenically distant from the ancestral antigen. In individuals with breakthrough infections, the exposure interval from vaccination to infection is critical for the induction of serum cross-neutralizing activity. We used statistical modeling to estimate the serum neutralizing response to Omicron sub-lineages corrected for the influence of different exposure intervals between vaccination and breakthrough infection in individuals with pre-Omicron and Omicron breakthrough infections. This enabled us to assess fairly the effects of exposure to distinct antigens on inducing serum cross-neutralizing responses with the ideal exposure interval, and revealed the clinical significance of optimizing the dose interval in COVID-19 booster vaccination. - Use of the particle agglutination/particle agglutination inhibition test for antigenic analysis of SARS-CoV-2
Jun Kobayashi; Shutoku Matsuyama; Masayuki Shirakura; Tomoko Arita; Yasushi Suzuki; Hideki Asanuma; Shinji Watanabe; Hideki Hasegawa; Kazuya Nakamura
INFLUENZA AND OTHER RESPIRATORY VIRUSES, 17, 2, Feb. 2023
English, Scientific journal - Antiviral Susceptibilities of Distinct Lineages of Influenza C and D Viruses.
Emi Takashita; Shin Murakami; Yoko Matsuzaki; Seiichiro Fujisaki; Hiroko Morita; Shiho Nagata; Misa Katayama; Katsumi Mizuta; Hidekazu Nishimura; Shinji Watanabe; Taisuke Horimoto; Hideki Hasegawa
Viruses, 15, 1, 15 Jan. 2023, [International Magazine]
English, Scientific journal, The emergence and spread of antiviral-resistant influenza viruses are of great concern. To minimize the public health risk, it is important to monitor antiviral susceptibilities of influenza viruses. Analyses of the antiviral susceptibilities of influenza A and B viruses have been conducted globally; however, those of influenza C and D viruses are limited. Here, we determined the susceptibilities of influenza C viruses representing all six lineages (C/Taylor, C/Yamagata, C/Sao Paulo, C/Aichi, C/Kanagawa, and C/Mississippi) and influenza D viruses representing four lineages (D/OK, D/660, D/Yama2016, and D/Yama2019) to RNA polymerase inhibitors (baloxavir and favipiravir) by using a focus reduction assay. All viruses tested were susceptible to both drugs. We then performed a genetic analysis to check for amino acid substitutions associated with baloxavir and favipiravir resistance and found that none of the viruses tested possessed these substitutions. Use of the focus reduction assay with the genotypic assay has proven valuable for monitoring the antiviral susceptibilities of influenza C and D viruses as well as influenza A and B viruses. Antiviral susceptibility monitoring of all influenza virus types should continue in order to assess the public health risks posed by these viruses. - Impact of Reinfection with SARS-CoV-2 Omicron Variants in Previously Infected Hamsters.
Nozomi Shiwa-Sudo; Yusuke Sakai; Naoko Iwata-Yoshikawa; Shinji Watanabe; Souichi Yamada; Yudai Kuroda; Tsukasa Yamamoto; Masayuki Shirakura; Seiichiro Fujisaki; Kaya Miyazaki; Hideka Miura; Shiho Nagata; Shuetsu Fukushi; Ken Maeda; Hideki Hasegawa; Tadaki Suzuki; Noriyo Nagata
Journal of virology, 97, 1, e0136622, 12 Jan. 2023, [Peer-reviewed], [International Magazine]
English, Scientific journal, The diversity of SARS-CoV-2 mutations raises the possibility of reinfection of individuals previously infected with earlier variants, and this risk is further increased by the emergence of the B.1.1.529 Omicron variant. In this study, we used an in vivo, hamster infection model to assess the potential for individuals previously infected with SARS-CoV-2 to be reinfected with Omicron variant and we also investigated the pathology associated with such infections. Initially, Syrian hamsters were inoculated with a lineage A, B.1.1.7, B.1.351, B.1.617.2 or a subvariant of Omicron, BA.1 strain and then reinfected with the BA.1 strain 5 weeks later. Subsequently, the impact of reinfection with Omicron subvariants (BA.1 and BA.2) in individuals previously infected with the BA.1 strain was examined. Although viral infection and replication were suppressed in both the upper and lower airways, following reinfection, virus-associated RNA was detected in the airways of most hamsters. Viral replication was more strongly suppressed in the lower respiratory tract than in the upper respiratory tract. Consistent amino acid substitutions were observed in the upper respiratory tract of infected hamsters after primary infection with variant BA.1, whereas diverse mutations appeared in hamsters reinfected with the same variant. Histopathology showed no acute pneumonia or disease enhancement in any of the reinfection groups and, in addition, the expression of inflammatory cytokines and chemokines in the airways of reinfected animals was only mildly elevated. These findings are important for understanding the risk of reinfection with new variants of SARS-CoV-2. IMPORTANCE The emergence of SARS-CoV-2 variants and the widespread use of COVID-19 vaccines has resulted in individual differences in immune status against SARS-CoV-2. A decay in immunity over time and the emergence of variants that partially evade the immune response can also lead to reinfection. In this study, we demonstrated that, in hamsters, immunity acquired following primary infection with previous SARS-CoV-2 variants was effective in preventing the onset of pneumonia after reinfection with the Omicron variant. However, viral infection and multiplication in the upper respiratory tract were still observed after reinfection. We also showed that more diverse nonsynonymous mutations appeared in the upper respiratory tract of reinfected hamsters that had acquired immunity from primary infection. This hamster model reveals the within-host evolution of SARS-CoV-2 and its pathology after reinfection, and provides important information for countermeasures against diversifying SARS-CoV-2 variants. - A bivalent outer membrane vesicle-based intranasal vaccine to prevent infection of periodontopathic bacteria
Nakao R; Hirayama S; Yamaguchi T; Senpuku H; Hasegawa H; Suzuki T; Akeda Y; Ohnishi M; equal contribution
Vaccine. in press, 41, 30, 4369, 4383, 2023, [Peer-reviewed], [International Magazine]
English, Scientific journal, Periodontal disease has become a serious public health problem, not only causing tooth loss, but also inducing chronic disorders of extra-oral organs. The present study assessed an intranasal vaccine strategy to prevent periodontal disease using outer membrane vesicles (OMVs) of two major periodontopathic bacteria, Porphyromonas gingivalis (Pg) and Aggregatibacter actinomycetemcomitans (Aa). We compared the morphology, composition, and immune activity between OMVs of Pg strain ATCC 33277 and Aa strain Y4. Aa OMVs had a smoother surface and stronger lipid A activity compared to Pg OMVs. The in vitro immune activity elicited by Aa OMVs in macrophage-like cells was remarkably stronger than that of Pg OMVs. Intranasal immunization of mice with Aa OMVs alone resulted in robust, humoral immune responses in blood and saliva. Despites the intrinsically low mucosal immunogenicity of Pg OMVs alone, using Aa OMVs as a mucosal adjuvant strongly enhanced Pg-specific immune responses, resulting in both serum IgG and salivary IgA, both of which aggregated Pg and Aa cells. Furthermore, Aa OMVs were found to be a more potent mucosal adjuvant than Poly(I:C) in the context of enhancing the production of Pg-specific IgG (especially IgG2a) and IgA. In addition, in a randomized, blinded study, mice oral challenged with Pg and Aa after intranasal immunization with Pg OMVs and Aa OMVs had significantly decreased numbers of both microorganisms compared to mock-immunized mice. Furthermore, in an intracerebral injection mouse model, there were no serious adverse effects on the brain even after administrating a dose of OMVs as same as that used for intranasal administration. Taken together, the bivalent OMV intranasal vaccine may be effective in preventing colonization of periodontopathic bacteria in the oral cavity and related systemic disorders associated with periodontal diseases. - Are twindemics occurring?
Emi Takashita; Shinji Watanabe; Hideki Hasegawa; Yoshihiro Kawaoka
Influenza and Other Respiratory Viruses, 17, 1, Wiley, 25 Dec. 2022
Scientific journal - Results from a preclinical study in rodents and a Phase 1/2, randomized, double-blind, placebo-controlled, parallel-group study of COVID-19 vaccine S-268019-a in Japanese adults.
Takuhiro Sonoyama; Satoshi Iwata; Masaharu Shinkai; Naoko Iwata-Yoshikawa; Nozomi Shiwa-Sudo; Takuya Hemmi; Akira Ainai; Noriyo Nagata; Nobuaki Matsunaga; Yukio Tada; Tomoyuki Homma; Shinya Omoto; Risa Yokokawa Shibata; Kenji Igarashi; Tadaki Suzuki; Hideki Hasegawa; Mari Ariyasu
Vaccine, 41, 11, 1834, 1847, 16 Dec. 2022, [International Magazine]
English, Scientific journal, BACKGROUND: In early 2020, developing vaccines was an urgent need for preventing COVID-19 from a contingency perspective. METHODS: S-268019-a is a recombinant protein-based vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), comprising a modified recombinant spike protein antigen adjuvanted with agatolimod sodium, a Toll-like receptor-9 agonist. In the preclinical phase, it was administered intramuscularly twice at a 2-week interval in 7-week-old mice. Immunogenicity was assessed, and the mice were challenged intranasally with mouse-adapted SARS-CoV-2 at 2 and 8 weeks, respectively, after the second immunization. After confirming the preclinical effect, a Phase 1/2, randomized, parallel-group clinical study was conducted in healthy adults (aged 20-64 years). All participants received 2 intramuscular injections at various combinations of the antigen and the adjuvant (S-910823/agatolimod sodium, in μg: 12.5/250, 25/250, 50/250, 25/500, 50/500, 100/500, 10/500, 100/100, 200/1000) or placebo (saline) in an equivalent volume at a 3-week interval and were followed up until Day 50 in this interim analysis. RESULTS: In the preclinical studies, S-268019-a was safe and elicited robust immunoglobulin G (IgG) and neutralizing antibody responses in mice. When challenged with SARS-CoV-2, all S-268019-a-treated mice survived and maintained weight until 10 days, whereas all placebo- or adjuvant-treated (without antigen) mice died within 6 days. In the Phase 1/2 trial, although S-268019-a was well tolerated in adult participants, was safe up to Day 50, and elicited robust anti-spike protein IgG antibodies, it did not elicit sufficient neutralizing antibody levels. CONCLUSIONS: The S-268019-a vaccine was not sufficiently immunogenic in Japanese adults despite robust immunogenicity and efficacy in mice. Our results exemplify the innate challenges in translating preclinical data in animals to clinical trials, and highlight the need for continued research to overcome such barriers. (jRCT2051200092). - Immune response and protective efficacy of the SARS-CoV-2 recombinant spike protein vaccine S-268019-b in mice.
Tomoyuki Homma; Noriyo Nagata; Masayuki Hashimoto; Naoko Iwata-Yoshikawa; Naomi M Seki; Nozomi Shiwa-Sudo; Akira Ainai; Keiji Dohi; Eiji Nikaido; Akiko Mukai; Yuuta Ukai; Takayuki Nakagawa; Yusuke Shimo; Hiroki Maeda; Seiki Shirai; Miwa Aoki; Takuhiro Sonoyama; Mamoru Sato; Masataka Fumoto; Morio Nagira; Fumihisa Nakata; Takao Hashiguchi; Tadaki Suzuki; Shinya Omoto; Hideki Hasegawa
Scientific reports, 12, 1, 20861, 20861, 02 Dec. 2022, [International Magazine]
English, Scientific journal, Vaccines that efficiently target severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent for coronavirus disease (COVID-19), are the best means for controlling viral spread. This study evaluated the efficacy of the COVID-19 vaccine S-268019-b, which comprises the recombinant full-length SARS-CoV-2 spike protein S-910823 (antigen) and A-910823 (adjuvant). In addition to eliciting both Th1-type and Th2-type cellular immune responses, two doses of S-910823 plus A-910823 induced anti-spike protein IgG antibodies and neutralizing antibodies against SARS-CoV-2. In a SARS-CoV-2 challenge test, S-910823 plus A-910823 mitigated SARS-CoV-2 infection-induced weight loss and death and inhibited viral replication in mouse lungs. S-910823 plus A-910823 promoted cytokine and chemokine at the injection site and immune cell accumulation in the draining lymph nodes. This led to the formation of germinal centers and the induction of memory B cells, antibody-secreting cells, and memory T cells. These findings provide fundamental property of S-268019-b, especially importance of A-910823 to elicit humoral and cellular immune responses. - 国立感染症研究所における新型コロナウイルス(SARS-CoV-2)変異株のモニタリングと評価
齋藤 智也; 横田 栄一; 吉見 逸郎; 太田 雅之; 加藤 美生; 山本 朋範; 小林 望; 吉松 芙美; 齋藤 益満; 高橋 健一郎; 濱田 優一; 影山 努; 竹前 喜洋; 久場 由真仁; 島田 智恵; 山岸 拓也; 土橋 酉紀; 福住 宗久; 池上 千晶; 錦 信吾; 高橋 賢亮; 小林 美保; 田畑 早季子; 砂川 富正; 小林 祐介; 有馬 雄三; 神垣 太郎; 新井 智; 新城 雄士; 多屋 馨子; 鈴木 基; 黒田 誠; 関塚 剛史; 佐々木 直文; 鈴木 忠樹; 永田 典代; 飯田 俊; 宮本 翔; 志 和希; 峰 宗太郎; 平田 雄一郎; 高橋 宜聖; 森山 彩野; 竹下 望; 石原 朋子; 森重 優子; 高橋 宏瑞; 内木場 紗奈; 島谷 倫次; 七松 優; 桝永 萌; 江原 玲欧奈; 日尾野 宏美; 北野 泰斗; 佐々木 秀悟; 小川 憲人; 長谷川 秀樹; 渡邉 真治; 松山 州徳; 冨田 有里子; 高山 郁代; 宮崎 かや
病原微生物検出情報月報, 43, 12, 276, 278, 国立感染症研究所, Dec. 2022
Japanese - 国立感染症研究所における新型コロナウイルス(SARS-CoV-2)変異株のモニタリングと評価
齋藤 智也; 横田 栄一; 吉見 逸郎; 太田 雅之; 加藤 美生; 山本 朋範; 小林 望; 吉松 芙美; 齋藤 益満; 高橋 健一郎; 濱田 優一; 影山 努; 竹前 喜洋; 久場 由真仁; 島田 智恵; 山岸 拓也; 土橋 酉紀; 福住 宗久; 池上 千晶; 錦 信吾; 高橋 賢亮; 小林 美保; 田畑 早季子; 砂川 富正; 小林 祐介; 有馬 雄三; 神垣 太郎; 新井 智; 新城 雄士; 多屋 馨子; 鈴木 基; 黒田 誠; 関塚 剛史; 佐々木 直文; 鈴木 忠樹; 永田 典代; 飯田 俊; 宮本 翔; 志 和希; 峰 宗太郎; 平田 雄一郎; 高橋 宜聖; 森山 彩野; 竹下 望; 石原 朋子; 森重 優子; 高橋 宏瑞; 内木場 紗奈; 島谷 倫次; 七松 優; 桝永 萌; 江原 玲欧奈; 日尾野 宏美; 北野 泰斗; 佐々木 秀悟; 小川 憲人; 長谷川 秀樹; 渡邉 真治; 松山 州徳; 冨田 有里子; 高山 郁代; 宮崎 かや
病原微生物検出情報月報, 43, 12, 276, 278, 国立感染症研究所, Dec. 2022
Japanese - In Vitro Efficacy of Antiviral Agents against Omicron Subvariant BA.4.6.
Emi Takashita; Seiya Yamayoshi; Peter Halfmann; Nancy Wilson; Hunter Ries; Alex Richardson; Max Bobholz; William Vuyk; Robert Maddox; David A Baker; Thomas C Friedrich; David H O'Connor; Ryuta Uraki; Mutsumi Ito; Yuko Sakai-Tagawa; Eisuke Adachi; Makoto Saito; Michiko Koga; Takeya Tsutsumi; Kiyoko Iwatsuki-Horimoto; Maki Kiso; Hiroshi Yotsuyanagi; Shinji Watanabe; Hideki Hasegawa; Masaki Imai; Yoshihiro Kawaoka
The New England journal of medicine, 387, 22, 2094, 2097, 01 Dec. 2022, [International Magazine]
English - 2021/22シーズンのインフルエンザ分離株の解析
岸田 典子; 中村 一哉; 藤崎 誠一郎; 高下 恵美; 佐藤 彩; 秋元 未来; 三浦 秀佳; 森田 博子; 永田 志保; 白倉 雅之; 菅原 裕美; 渡邉 真治; 長谷川 秀樹
病原微生物検出情報月報, 43, 11, 247, 252, 国立感染症研究所, Nov. 2022
Japanese - 2021年度感染症流行予測調査におけるインフルエンザ予防接種状況および抗体保有状況
林 愛; 菊池 風花; 新井 智; 北本 理恵; 神谷 元; 鈴木 基; 渡邉 真治; 長谷川 秀樹
病原微生物検出情報月報, 43, 11, 252, 255, 国立感染症研究所, Nov. 2022
Japanese - Histological characteristics of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinases-1 in asthmatic murine model during A(H1N1)pdm09 infection.
Sasagu Kimura; Hiroki Yasudo; Atsunori Oga; Reiji Fukano; Takeshi Matsushige; Hiroki Hamano; Hideki Hasegawa; Noriko Nakajima; Akira Ainai; Hiroshi Itoh; Komei Shirabe; Shoichi Toda; Ryo Atsuta; Shunji Hasegawa
Pathology international, 72, 10, 506, 518, Oct. 2022, [International Magazine]
English, Scientific journal, Pandemic influenza virus A(H1N1)pdm09 infection occurred in healthy children and young adults, but asthmatic patients presented more rapid progression of respiratory distress and plastic bronchitis. To investigate the pathogenesis of worsening respiratory symptoms after A(H1N1)pdm09 infection, we focused on matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinases-1 (TIMP-1). MMP-9 and TIMP-1 levels in bronchoalveolar lavage fluid and serum from mice with and without asthma were evaluated after A(H1N1)pdm09 or seasonal A(H1N1) infection. MMP-9 levels were more elevated in Asthma/A(H1N1)pdm09-infected mice than in non-Asthma/A(H1N1)pdm09-infected mice on both 3 and 7 days post-infection. Immunohistochemical findings in this pneumonia model showed that MMP-9 and TIMP-1 positive cells were observed in blood vessels and bronchus of lung tissue in severe pathological findings of pneumonia with asthma. Microscopically, shedding cells and secretions were conspicuous in the trachea on days 3 and 7 post-infection, in the A(H1N1)pdm09-infected mice with asthma. Our results suggest that MMP-9 and TIMP-1 expressions are related to severe pneumonia in the A(H1N1)pdm09 infection with asthma, leading to cause epithelial cell shedding. - Development of a Monoclonal Antibody Targeting HTLV-1 Envelope gp46 Glycoprotein and Its Application to Near-Infrared Photoimmuno-Antimicrobial Strategy
Yasuyoshi Hatayama; Yutaro Yamaoka; Takeshi Morita; Sundararaj Stanleyraj Jeremiah; Kei Miyakawa; Mayuko Nishi; Yayoi Kimura; Makoto Mitsunaga; Tadayuki Iwase; Hirokazu Kimura; Naoki Yamamoto; Akifumi Takaori-Kondo; Hideki Hasegawa; Akihide Ryo
Viruses, 14, 10, 2153, 2153, MDPI AG, 29 Sep. 2022
Scientific journal, Human T-cell leukemia virus type 1 (HTLV-1), a retrovirus, causes adult T-cell leukemia-lymphoma, HTLV-1 associated myelopathy/tropical spastic paraparesis, and HTLV-1 uveitis. Currently, no antiretroviral therapies or vaccines are available for HTLV-1 infection. This study aimed to develop an antibody against the HTLV-1 envelope protein (Env) and apply it to a near-infrared photoimmuno-antimicrobial strategy (NIR-PIAS) to eliminate HTLV-1 infected cells. We established mouse monoclonal antibodies (mAbs) against HTLV-1 Env by immunization with a complex of liposome and the recombinant protein. Detailed epitope mapping revealed that one of the mAbs bound to the proline-rich region of gp46 and exhibited no obvious neutralizing activity to inhibit viral infection. Instead, the mAb was rarely internalized intracellularly and remained on the cell surface of HTLV-1-infected cells. The antibody conjugated to the photosensitive dye IRDye700Dx recognized HTLV-1 infected cells and killed them following NIR irradiation. These results suggest that the novel mAb and NIR-PIAS could be developed as a new targeted therapeutic tool against HTLV-1 infected cells. - Efficacy of Antiviral Agents against the Omicron Subvariant BA.2.75.
Emi Takashita; Seiya Yamayoshi; Shuetsu Fukushi; Tadaki Suzuki; Ken Maeda; Yuko Sakai-Tagawa; Mutsumi Ito; Ryuta Uraki; Peter Halfmann; Shinji Watanabe; Makoto Takeda; Hideki Hasegawa; Masaki Imai; Yoshihiro Kawaoka
The New England journal of medicine, 387, 13, 1236, 1238, 29 Sep. 2022, [International Magazine]
English - Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathology
Takuya Hemmi; Akira Ainai; Takao Hashiguchi; Minoru Tobiume; Takayuki Kanno; Naoko Iwata-Yoshikawa; Shun Iida; Yuko Sato; Sho Miyamoto; Akira Ueno; Kaori Sano; Shinji Saito; Nozomi Shiwa-Sudo; Noriyo Nagata; Koji Tamura; Ryosuke Suzuki; Hideki Hasegawa; Tadaki Suzuki
Vaccine, Elsevier BV, Aug. 2022
Scientific journal - Immunogenicity and protective efficacy of SARS-CoV-2 recombinant S-protein vaccine S-268019-b in cynomolgus monkeys.
Masayuki Hashimoto; Noriyo Nagata; Tomoyuki Homma; Hiroki Maeda; Keiji Dohi; Naomi M Seki; Ken Yoshihara; Naoko Iwata-Yoshikawa; Nozomi Shiwa-Sudo; Yusuke Sakai; Masayuki Shirakura; Noriko Kishida; Tomoko Arita; Yasushi Suzuki; Shinji Watanabe; Hideki Asanuma; Takuhiro Sonoyama; Tadaki Suzuki; Shinya Omoto; Hideki Hasegawa
Vaccine, 40, 31, 4231, 4241, 29 Jul. 2022, [International Magazine]
English, Scientific journal, The vaccine S-268019-b is a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S)-protein vaccine consisting of full-length recombinant SARS-CoV-2 S-protein (S-910823) as antigen, mixed with the squalene-based adjuvant A-910823. The current study evaluated the immunogenicity of S-268019-b using various doses of S-910823 and its vaccine efficacy against SARS-CoV-2 challenge in cynomolgus monkeys. The different doses of S-910823 combined with A-910823 were intramuscularly administered twice at a 3-week interval. Two weeks after the second dosing, dose-dependent humoral immune responses were observed with neutralizing antibody titers being comparable to that of human convalescent plasma. Pseudoviruses harboring S proteins from Beta and Gamma SARS-CoV-2 variants displayed approximately 3- to 4-fold reduced sensitivity to neutralizing antibodies induced after two vaccine doses compared with that against ancestral viruses, whereas neutralizing antibody titers were reduced >14-fold against the Omicron variant. Cellular immunity was also induced with a relative Th1 polarized response. No adverse clinical signs or weight loss associated with the vaccine were observed, suggesting safety of the vaccine in cynomolgus monkeys. Immunization with 10 µg of S-910823 with A-910823 demonstrated protective efficacy against SARS-CoV-2 challenge according to genomic and subgenomic viral RNA transcript levels in nasopharyngeal, throat, and rectal swab specimens. Pathological analysis revealed no detectable vaccine-dependent enhancement of disease in the lungs of challenged vaccinated monkeys. The current findings provide fundamental information regarding vaccine doses for human trials and support the development of S-268019-b as a safe and effective vaccine for controlling the current pandemic, as well as general protection against SARS-CoV-2 moving forward. - Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants.
Emi Takashita; Seiya Yamayoshi; Viviana Simon; Harm van Bakel; Emilia M Sordillo; Andrew Pekosz; Shuetsu Fukushi; Tadaki Suzuki; Ken Maeda; Peter Halfmann; Yuko Sakai-Tagawa; Mutsumi Ito; Shinji Watanabe; Masaki Imai; Hideki Hasegawa; Yoshihiro Kawaoka
The New England journal of medicine, 387, 5, 468, 470, 20 Jul. 2022, [International Magazine]
English - Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2.
Hirofumi Ohashi; Takayuki Hishiki; Daisuke Akazawa; Kwang Su Kim; Joohyeon Woo; Kaho Shionoya; Kana Tsuchimoto; Shoya Iwanami; Saya Moriyama; Hitomi Kinoshita; Souichi Yamada; Yudai Kuroda; Tsukasa Yamamoto; Noriko Kishida; Shinji Watanabe; Hideki Hasegawa; Hideki Ebihara; Tadaki Suzuki; Maeda Ken; Shuetsu Fukushi; Yoshimasa Takahashi; Shingo Iwami; Koichi Watashi
Antiviral research, 205, 105372, 105372, 04 Jul. 2022, [International Magazine]
English, Scientific journal, The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariant BA.2 has spread in many countries, replacing the earlier Omicron subvariant BA.1 and other variants. Here, using a cell culture infection assay, we quantified the intrinsic sensitivity of BA.2 and BA.1 compared with other variants of concern, Alpha, Gamma, and Delta, to five approved-neutralizing antibodies and antiviral drugs. Our assay revealed the diverse sensitivities of these variants to antibodies, including the loss of response of both BA.1 and BA.2 to casirivimab and of BA.1 to imdevimab. In contrast, EIDD-1931 and nirmatrelvir showed a more conserved activities to these variants. The viral response profile combined with mathematical analysis estimated differences in antiviral effects among variants in the clinical concentrations. These analyses provide essential evidence that gives insight into variant emergence's impact on choosing optimal drug treatment. - Suitability of NIID-MDCK cells as a substrate for cell-based influenza vaccine development from the perspective of adventitious virus susceptibility.
Itsuki Hamamoto; Hitoshi Takahashi; Noriko Shimasaki; Kazuya Nakamura; Katsumi Mizuta; Ko Sato; Hidekazu Nishimura; Norio Yamamoto; Hideki Hasegawa; Takato Odagiri; Masato Tashiro; Eri Nobusawa
Microbiology and immunology, 66, 7, 361, 370, Jul. 2022, [International Magazine]
English, Scientific journal, The practical use of cell-based seasonal influenza vaccines is currently being considered in Japan. From the perspective of adventitious virus contamination, we assessed the suitability of NIID-MDCK cells (NIID-MDCK-Cs) as a safe substrate for the isolation of influenza viruses from clinical specimens. We first established a sensitive multiplex real-time PCR system to screen for 27 respiratory viruses and used it on 34 virus samples that were isolated by passaging influenza-positive clinical specimens in NIID-MDCK-Cs. Incidentally, the limit of detection (LOD) of the system was 100 or fewer genome copies per reaction. In addition to influenza viruses, human enterovirus 68 (HEV-D68) genomes were detected in two samples after two or three passages in NIID-MDCK-Cs. To further investigate the susceptibility of NIID-MDCK-Cs to adventitious viruses, eight common respiratory viruses were subjected to passages in NIID-MDCK-Cs. The genome copy numbers of seven viruses other than parainfluenza 3 decreased below the LOD by passage 4. By passaging in NIID-MDCK-Cs, the genome numbers of the input HEV-D68, 1 × 108 copies, declined to 102 at passage 3 and to under the LOD at passage 4, whereas those of the other six viruses were under the LOD by passage 3. These results implied that during the process of isolating influenza viruses with NIID-MDCK-Cs, contaminating viruses other than parainfluenza 3 can be efficiently removed by passages in NIID-MDCK-Cs. NIID-MDCK-Cs could be a safe substrate for isolating influenza viruses that can be used to develop cell-based influenza vaccine candidate viruses. - Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2.
Ryuta Uraki; Maki Kiso; Shun Iida; Masaki Imai; Emi Takashita; Makoto Kuroda; Peter J Halfmann; Samantha Loeber; Tadashi Maemura; Seiya Yamayoshi; Seiichiro Fujisaki; Zhongde Wang; Mutsumi Ito; Michiko Ujie; Kiyoko Iwatsuki-Horimoto; Yuri Furusawa; Ryan Wright; Zhenlu Chong; Seiya Ozono; Atsuhiro Yasuhara; Hiroshi Ueki; Yuko Sakai-Tagawa; Rong Li; Yanan Liu; Deanna Larson; Michiko Koga; Takeya Tsutsumi; Eisuke Adachi; Makoto Saito; Shinya Yamamoto; Masao Hagihara; Keiko Mitamura; Tetsuro Sato; Masayuki Hojo; Shin-Ichiro Hattori; Kenji Maeda; Riccardo Valdez; Moe Okuda; Jurika Murakami; Calvin Duong; Sucheta Godbole; Daniel C Douek; Ken Maeda; Shinji Watanabe; Aubree Gordon; Norio Ohmagari; Hiroshi Yotsuyanagi; Michael S Diamond; Hideki Hasegawa; Hiroaki Mitsuya; Tadaki Suzuki; Yoshihiro Kawaoka
Nature, 607, 7917, 119, 127, Jul. 2022, [International Magazine]
English, Scientific journal, The recent emergence of SARS-CoV-2 Omicron (B.1.1.529 lineage) variants possessing numerous mutations has raised concerns of decreased effectiveness of current vaccines, therapeutic monoclonal antibodies and antiviral drugs for COVID-19 against these variants1,2. The original Omicron lineage, BA.1, prevailed in many countries, but more recently, BA.2 has become dominant in at least 68 countries3. Here we evaluated the replicative ability and pathogenicity of authentic infectious BA.2 isolates in immunocompetent and human ACE2-expressing mice and hamsters. In contrast to recent data with chimeric, recombinant SARS-CoV-2 strains expressing the spike proteins of BA.1 and BA.2 on an ancestral WK-521 backbone4, we observed similar infectivity and pathogenicity in mice and hamsters for BA.2 and BA.1, and less pathogenicity compared with early SARS-CoV-2 strains. We also observed a marked and significant reduction in the neutralizing activity of plasma from individuals who had recovered from COVID-19 and vaccine recipients against BA.2 compared to ancestral and Delta variant strains. In addition, we found that some therapeutic monoclonal antibodies (REGN10987 plus REGN10933, COV2-2196 plus COV2-2130, and S309) and antiviral drugs (molnupiravir, nirmatrelvir and S-217622) can restrict viral infection in the respiratory organs of BA.2-infected hamsters. These findings suggest that the replication and pathogenicity of BA.2 is similar to that of BA.1 in rodents and that several therapeutic monoclonal antibodies and antiviral compounds are effective against Omicron BA.2 variants. - Therapeutic efficacy of monoclonal antibodies and antivirals against SARS-CoV-2 Omicron BA.1 in Syrian hamsters.
Ryuta Uraki; Maki Kiso; Masaki Imai; Seiya Yamayoshi; Mutsumi Ito; Seiichiro Fujisaki; Emi Takashita; Michiko Ujie; Yuri Furusawa; Atsuhiro Yasuhara; Kiyoko Iwatsuki-Horimoto; Yuko Sakai-Tagawa; Shinji Watanabe; Hideki Hasegawa; Yoshihiro Kawaoka
Nature microbiology, 7, 8, 1252, 1258, 15 Jun. 2022, [International Magazine]
English, Scientific journal, The spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the major antigen stimulating the host's protective immune response. Here we assessed the efficacy of therapeutic monoclonal antibodies (mAbs) against Omicron variant (B.1.1.529) sublineage BA.1 variants in Syrian hamsters. Of the FDA-approved therapeutic mAbs tested (that is, REGN10987/REGN10933, COV2-2196/COV2-2130 and S309), only COV2-2196/COV2-2130 efficiently inhibited BA.1 replication in the lungs of hamsters, and this effect was diminished against a BA.1.1 variant possessing the S-R346K substitution. In addition, treatment of BA.1-infected hamsters with molnupiravir (a SARS-CoV-2 RNA-dependent RNA polymerase inhibitor) or S-217622 (a SARS-CoV-2 protease inhibitor) strongly reduced virus replication in the lungs. These findings suggest that the use of therapeutic mAbs in Omicron-infected patients should be carefully considered due to mutations that affect efficacy, and demonstrate that the antiviral compounds molnupiravir and S-217622 are effective against Omicron BA.1 variants. - Prophylactic Vaccine Targeting TLR3 on Dendritic Cells Ameliorates Eosinophilic Pneumonia in a Mouse SARS-CoV Infection Model.
Naoko Iwata-Yoshikawa; Noriyo Nagata; Hiromi Takaki; Misako Matsumoto; Tadaki Suzuki; Hideki Hasegawa; Tsukasa Seya
ImmunoHorizons, 6, 4, 275, 282, 27 Apr. 2022, [International Magazine]
English, Scientific journal, Putative subcomponent vaccines of severe acute respiratory syndrome coronavirus spike protein and ARNAX (TLR3-specific adjuvant for priming dendritic cells) were examined and compared with spike protein + Alum in a mouse BALB/c model. Survival, body weight, virus-neutralizing Ab titer in the blood, and viral titer in the lung were evaluated for prognosis markers. The infiltration degrees of eosinophils in the lung were histopathologically monitored at 10 d postinfection. The results were: (1) adjuvant was essential in vaccines to achieve a complete recovery from infection, (2) ARNAX displayed optimal body weight recovery compared with Alum, (3) ARNAX was optimal for the amelioration of eosinophilic pneumonia, and (4) the eosinophil infiltration score was not associated with the neutralizing Ab titer in the blood or viral titer in the lung. Although the pathological link between the TLR3 vaccine and lung eosinophil infiltration remains unclear, severe acute respiratory syndrome-mediated eosinophilic pneumonia can be blocked by the prior induction of dendritic cell priming by ARNAX. - Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2.
Emi Takashita; Noriko Kinoshita; Seiya Yamayoshi; Yuko Sakai-Tagawa; Seiichiro Fujisaki; Mutsumi Ito; Kiyoko Iwatsuki-Horimoto; Peter Halfmann; Shinji Watanabe; Kenji Maeda; Masaki Imai; Hiroaki Mitsuya; Norio Ohmagari; Makoto Takeda; Hideki Hasegawa; Yoshihiro Kawaoka
The New England journal of medicine, 386, 15, 1475, 1477, 14 Apr. 2022, [International Magazine]
English - Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant.
Emi Takashita; Noriko Kinoshita; Seiya Yamayoshi; Yuko Sakai-Tagawa; Seiichiro Fujisaki; Mutsumi Ito; Kiyoko Iwatsuki-Horimoto; Shiho Chiba; Peter Halfmann; Hiroyuki Nagai; Makoto Saito; Eisuke Adachi; David Sullivan; Andrew Pekosz; Shinji Watanabe; Kenji Maeda; Masaki Imai; Hiroshi Yotsuyanagi; Hiroaki Mitsuya; Norio Ohmagari; Makoto Takeda; Hideki Hasegawa; Yoshihiro Kawaoka
The New England journal of medicine, 386, 10, 995, 998, 10 Mar. 2022, [International Magazine]
English - Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants.
Sho Miyamoto; Takeshi Arashiro; Yu Adachi; Saya Moriyama; Hitomi Kinoshita; Takayuki Kanno; Shinji Saito; Harutaka Katano; Shun Iida; Akira Ainai; Ryutaro Kotaki; Souichi Yamada; Yudai Kuroda; Tsukasa Yamamoto; Keita Ishijima; Eun-Sil Park; Yusuke Inoue; Yoshihiro Kaku; Minoru Tobiume; Naoko Iwata-Yoshikawa; Nozomi Shiwa-Sudo; Kenzo Tokunaga; Seiya Ozono; Takuya Hemmi; Akira Ueno; Noriko Kishida; Shinji Watanabe; Kiyoko Nojima; Yohei Seki; Takuo Mizukami; Hideki Hasegawa; Hideki Ebihara; Maeda Ken; Shuetsu Fukushi; Yoshimasa Takahashi; Tadaki Suzuki
Med (New York, N.Y.), 3, 4, 249, 261, 04 Mar. 2022, [Peer-reviewed], [International Magazine]
English, Scientific journal, Background: The immune profile against SARS-CoV-2 has dramatically diversified due to a complex combination of exposure to vaccines and infection by various lineages/variants, likely generating a heterogeneity in protective immunity in a given population. To further complicate this, the Omicron variant, with numerous spike mutations, has emerged. These circumstances have created the need to assess the potential of immune evasion by the Omicron in individuals with various immune histories. Methods: The neutralization susceptibility of the variants including the Omicron and their ancestor was comparably assessed using a panel of plasma/serum derived from individuals with divergent immune histories. Blood samples were collected from either mRNA vaccinees or from those who suffered from breakthrough infections by the Alpha/Delta with multiple time intervals following vaccination. Findings: The Omicron was highly resistant to neutralization in fully vaccinated individuals without a history of breakthrough infections. In contrast, robust cross-neutralization against the Omicron were induced in vaccinees that experienced breakthrough infections. The time interval between vaccination and infection, rather than the variant types of infection, was significantly correlated with the magnitude and potency of Omicron-neutralizing antibodies. Conclusions: Immune histories with breakthrough infections can overcome the resistance to infection by the Omicron, with the vaccination-infection interval being the key determinant of the magnitude and breadth of neutralization. The diverse exposure history in each individual warrants a tailored and cautious approach to understanding population immunity against the Omicron and future variants. Funding: This study was supported by grants from the Japan Agency for Medical Research and Development (AMED). - Genome Recombination between Delta and Alpha Variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Tsuyoshi Sekizuka; Kentaro Itokawa; Masumichi Saito; Michitsugu Shimatani; Shutoku Matsuyama; Hideki Hasegawa; Tomoya Saito; Makoto Kuroda
Japanese journal of infectious diseases, 75, 4, 415, 418, 28 Feb. 2022, [Domestic magazines]
English, Scientific journal, Prominent genomic recombination has been observed between the Delta and Alpha variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) isolated from clinical specimens in Japan. Interestingly, the recombination variant detected in this study carries a spike protein identical to the one in the domestic Delta variant, thereby suggesting that further risks would not be concerned with infectivity and immune escape. The recombinant has been classified as XC lineage in the PANGOLIN database. It is necessary to intensively study such marked genetic variations and characterize the emerging variants after careful verification of their lineage and clade assignment. - Characterization and antiviral susceptibility of SARS-CoV-2 Omicron/BA.2.
Yoshihiro Kawaoka; Ryuta Uraki; Maki Kiso; Shun Iida; Masaki Imai; Emi Takashita; Makoto Kuroda; Peter Halfmann; Samantha Loeber; Tadashi Maemura; Seiya Yamayoshi; Seiichiro Fujisaki; Zhongde Wang; Mutsumi Ito; Michiko Ujie; Kiyoko Iwatsuki-Horimoto; Yuri Furusawa; Ryan Wright; Zhenlu Chong; Seiya Ozono; Atsuhiro Yasuhara; Hiroshi Ueki; Yuko Sakai; Rong Li; Yanan Liu; Deanna Larson; Michiko Koga; Takeya Tsutsumi; Eisuke Adachi; Makoto Saito; Shinya Yamamoto; Shohei Matsubara; Masao Hagihara; Keiko Mitamura; Tetsuro Sato; Masayuki Hojo; Shin-Ichiro Hattori; Kenji Maeda; Moe Okuda; Jurika Murakami; Calvin Duong; Sucheta Godbole; Daniel Douek; Shinji Watanabe; Norio Ohmagari; Hiroshi Yotsuyanagi; Michael Diamond; Hideki Hasegawa; Hiroaki Mitsuya; Tadaki Suzuki
Research square, 24 Feb. 2022, [International Magazine]
English, The recent emergence of SARS-CoV-2 Omicron variants possessing large numbers of mutations has raised concerns of decreased effectiveness of current vaccines, therapeutic monoclonal antibodies, and antiviral drugs for COVID-19 against these variants1,2. While the original Omicron lineage, BA.1, has become dominant in many countries, BA.2 has been detected in at least 67 countries and has become dominant in the Philippines, India, and Denmark. Here, we evaluated the replicative ability and pathogenicity of an authentic infectious BA.2 isolate in immunocompetent and human ACE2 (hACE2)-expressing mice and hamsters. In contrast to recent data with chimeric, recombinant SARS-CoV-2 strains expressing the spike proteins of BA.1 and BA.2 on an ancestral WK-521 backbone3, we observed similar infectivity and pathogenicity in mice and hamsters between BA.2 and BA.1, and less pathogenicity compared to early SARS-CoV-2 strains. We also observed a marked and significant reduction in the neutralizing activity of plasma from COVID-19 convalescent individuals and vaccine recipients against BA.2 compared to ancestral and Delta variant strains. In addition, we found that some therapeutic monoclonal antibodies (REGN10987/REGN10933, COV2-2196/COV2-2130, and S309) and antiviral drugs (molnupiravir, nirmatrelvir, and S-217622) can restrict viral infection in the respiratory organs of hamsters infected with BA.2. These findings suggest that the replication and pathogenicity of BA.2 is comparable to that of BA.1 in rodents and that several therapeutic monoclonal antibodies and antiviral compounds are effective against Omicron/BA.2 variants. - COVID-19流行下における他の流行性疾患の疫学変化 COVID-19流行下における小児のライノウイルス感染リスクの上昇
高下 恵美; 川上 千春; 百木 智子; 七種 美和子; 清水 耕平; 小澤 広規; 熊崎 真琴; 宇宿 秀三; 田中 伸子; 大久保 一郎; 森田 博子; 永田 志保; 渡邉 真治; 長谷川 秀樹; 河岡 義裕
日本小児科学会雑誌, 126, 2, 211, 211, (公社)日本小児科学会, Feb. 2022
Japanese - Epidemiology and Genetic Analysis of SARS-CoV-2 in Myanmar during the Community Outbreaks in 2020.
Wint Wint Phyu; Reiko Saito; Keita Wagatsuma; Takashi Abe; Htay Htay Tin; Eh Htoo Pe; Su Mon Kyaw Win; Nay Chi Win; Lasham Di Ja; Sekizuka Tsuyoshi; Kuroda Makoto; Yadanar Kyaw; Irina Chon; Shinji Watanabe; Hideki Hasegawa; Hisami Watanabe
Viruses, 14, 2, 27 Jan. 2022, [International Magazine]
English, Scientific journal, We aimed to analyze the situation of the first two epidemic waves in Myanmar using the publicly available daily situation of COVID-19 and whole-genome sequencing data of SARS-CoV-2. From March 23 to December 31, 2020, there were 33,917 confirmed cases and 741 deaths in Myanmar (case fatality rate of 2.18%). The first wave in Myanmar from March to July was linked to overseas travel, and then a second wave started from Rakhine State, a western border state, leading to the second wave spreading countrywide in Myanmar from August to December 2020. The estimated effective reproductive number (Rt) nationwide reached 6-8 at the beginning of each wave and gradually decreased as the epidemic spread to the community. The whole-genome analysis of 10 Myanmar SARS-CoV-2 strains together with 31 previously registered strains showed that the first wave was caused by GISAID clade O or PANGOLIN lineage B.6 and the second wave was changed to clade GH or lineage B.1.36.16 with a close genetic relationship with other South Asian strains. Constant monitoring of epidemiological situations combined with SARS-CoV-2 genome analysis is important for adjusting public health measures to mitigate the community transmissions of COVID-19. - A lethal mouse model for evaluating vaccine-associated enhanced respiratory disease during SARS-CoV-2 infection.
Naoko Iwata-Yoshikawa; Nozomi Shiwa; Tsuyoshi Sekizuka; Kaori Sano; Akira Ainai; Takuya Hemmi; Michiyo Kataoka; Makoto Kuroda; Hideki Hasegawa; Tadaki Suzuki; Noriyo Nagata
Science advances, 8, 1, eabh3827, 07 Jan. 2022, [International Magazine]
English, Scientific journal, [Figure: see text]. - Dry loop-mediated isothermal amplification assay for detection of SARS-CoV-2 from clinical specimens
Higashimoto Yuki; Ihira Masaru; Kawamura Yoshiki; Inaba Masato; Shirato Kazuya; Suzuki Tadaki; Hasegawa Hideki; Kageyama Tsutomu; Doi Yohei; Hata Tadayoshi; Yoshikawa Tetsushi
Fujita Medical Journal, advpub, Fujita Medical Society, 2022
English, Objectives: To establish a point-of-care test for coronavirus disease 2019 (COVID-19), we developed a dry loop-mediated isothermal amplification (LAMP) method to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA.
Methods: We carried out reverse transcription (RT)-LAMP using the Loopamp SARS-CoV-2 Detection kit (Eiken Chemical, Tokyo, Japan). The entire mixture, except for the primers, is dried and immobilized inside the tube lid.
Results: To determine the specificity of the kit, 22 viruses associated with respiratory infections, including SARS-CoV-2, were tested. The sensitivity of this assay, determined by either a real-time turbidity assay or colorimetric change of the reaction mixture, as evaluated by the naked eye or under illumination with ultraviolet light, was 10 copies/reaction. No LAMP product was detected in reactions performed with RNA from any pathogens other than SARS-CoV-2. After completing an initial validation analysis, we analyzed 24 nasopharyngeal swab specimens collected from patients suspected to have COVID-19. Of the 24 samples, 19 (79.2%) were determined by real-time RT-PCR analysis as being positive for SARS-CoV-2 RNA. Using the Loopamp SARS-CoV-2 Detection kit, we detected SARS-CoV-2 RNA in 15 (62.5%) of the 24 samples. Thus, the sensitivity, specificity, positive predictive value, and negative predictive values of the Loopamp 2019-CoV-2 detection reagent kit were 78.9%, 100%, 100%, and 55.6%, respectively.
Conclusions: The dry LAMP method for detecting SARS-CoV-2 RNA is fast and easy to use, and its reagents can be stored at 4°C, solving the cold chain problem; thus, it represents a promising tool for COVID-19 diagnosis in developing countries. - Antiviral susceptibilities of avian influenza A(H5), A(H7), and A(H9) viruses isolated in Japan.
Emi Takashita; Hiroko Morita; Shiho Nagata; Masayuki Shirakura; Seiichiro Fujisaki; Hideka Miura; Ikuyo Takayama; Tomoko Arita; Yasushi Suzuki; Masaoki Yamaoka; Taichiro Tanikawa; Ryota Tsunekuni; Junki Mine; Saki Sakuma; Yuko Uchida; Akihiro Shibata; Mari Iwanaka; Noriko Kishida; Kazuya Nakamura; Tsutomu Kageyama; Shinji Watanabe; Hideki Hasegawa
Japanese journal of infectious diseases, 75, 4, 398, 402, 28 Dec. 2021, [Domestic magazines]
English, Scientific journal, Circulation of avian influenza A viruses in poultry is a public health concern because these viruses may cause severe disease in humans and have the potential to become more transmissible among humans. Monitoring the susceptibility of these viruses to antivirals is important for influenza pandemic preparedness. However, information about their antiviral susceptibility is limited. Here, we determined the susceptibilities of avian influenza A(H5N1), A(H5N2), A(H5N8), A(H7N7), A(H7N9), A(H9N1), and A(H9N2) viruses isolated in Japan to the antivirals approved for use there: the M2 inhibitor amantadine; the neuraminidase inhibitors oseltamivir, peramivir, zanamivir, and laninamivir; and the RNA polymerase inhibitors baloxavir and favipiravir. Genotypic methods that detect amino acid substitutions associated with antiviral resistance and phenotypic methods that assess viral susceptibility to drugs revealed that these avian influenza A viruses are susceptible to neuraminidase inhibitors and RNA polymerase inhibitors. These results suggest that the neuraminidase inhibitors and the RNA polymerase inhibitors currently approved in Japan could be a treatment option against influenza A virus infections in humans. - 2020/21シーズンのインフルエンザ分離株の解析
岸田 典子; 中村 一哉; 藤崎 誠一郎; 高下 恵美; 佐藤 彩; 秋元 未来; 三浦 秀佳; 森田 博子; 永田 志保; 桑原 朋子; 白倉 雅之; 菅原 裕美; 渡邉 真治; 長谷川 秀樹
病原微生物検出情報月報, 42, 11, 247, 252, 国立感染症研究所, Nov. 2021
Japanese - M-Sec induced by HTLV-1 mediates an efficient viral transmission.
Masateru Hiyoshi; Naofumi Takahashi; Youssef M Eltalkhawy; Osamu Noyori; Sameh Lotfi; Jutatip Panaampon; Seiji Okada; Yuetsu Tanaka; Takaharu Ueno; Jun-Ichi Fujisawa; Yuko Sato; Tadaki Suzuki; Hideki Hasegawa; Masahito Tokunaga; Yorifumi Satou; Jun-Ichirou Yasunaga; Masao Matsuoka; Atae Utsunomiya; Shinya Suzu
PLoS pathogens, 17, 11, e1010126, Nov. 2021, [International Magazine]
English, Scientific journal, Human T-cell leukemia virus type 1 (HTLV-1) infects target cells primarily through cell-to-cell routes. Here, we provide evidence that cellular protein M-Sec plays a critical role in this process. When purified and briefly cultured, CD4+ T cells of HTLV-1 carriers, but not of HTLV-1- individuals, expressed M-Sec. The viral protein Tax was revealed to mediate M-Sec induction. Knockdown or pharmacological inhibition of M-Sec reduced viral infection in multiple co-culture conditions. Furthermore, M-Sec knockdown reduced the number of proviral copies in the tissues of a mouse model of HTLV-1 infection. Phenotypically, M-Sec knockdown or inhibition reduced not only plasma membrane protrusions and migratory activity of cells, but also large clusters of Gag, a viral structural protein required for the formation of viral particles. Taken together, these results suggest that M-Sec induced by Tax mediates an efficient cell-to-cell viral infection, which is likely due to enhanced membrane protrusions, cell migration, and the clustering of Gag. - Identification of serum prognostic biomarkers of severe COVID-19 using a quantitative proteomic approach.
Yayoi Kimura; Yusuke Nakai; Jihye Shin; Miyui Hara; Yuriko Takeda; Sousuke Kubo; Sundararaj Stanleyraj Jeremiah; Yoko Ino; Tomoko Akiyama; Kayano Moriyama; Kazuya Sakai; Ryo Saji; Mototsugu Nishii; Hideya Kitamura; Kota Murohashi; Kouji Yamamoto; Takeshi Kaneko; Ichiro Takeuchi; Eri Hagiwara; Takashi Ogura; Hideki Hasegawa; Tomohiko Tamura; Takeharu Yamanaka; Akihide Ryo
Scientific reports, 11, 1, 20638, 20638, 19 Oct. 2021, [International Magazine]
English, Scientific journal, The COVID-19 pandemic is an unprecedented threat to humanity that has provoked global health concerns. Since the etiopathogenesis of this illness is not fully characterized, the prognostic factors enabling treatment decisions have not been well documented. Accurately predicting the progression of the disease would aid in appropriate patient categorization and thus help determine the best treatment option. Here, we have introduced a proteomic approach utilizing data-independent acquisition mass spectrometry (DIA-MS) to identify the serum proteins that are closely associated with COVID-19 prognosis. Twenty-seven proteins were differentially expressed between severely ill COVID-19 patients with an adverse or favorable prognosis. Ingenuity Pathway Analysis revealed that 15 of the 27 proteins might be regulated by cytokine signaling relevant to interleukin (IL)-1β, IL-6, and tumor necrosis factor (TNF), and their differential expression was implicated in the systemic inflammatory response and in cardiovascular disorders. We further evaluated practical predictors of the clinical prognosis of severe COVID-19 patients. Subsequent ELISA assays revealed that CHI3L1 and IGFALS may serve as highly sensitive prognostic markers. Our findings can help formulate a diagnostic approach for accurately identifying COVID-19 patients with severe disease and for providing appropriate treatment based on their predicted prognosis. - Identification and characterization of a novel Enterococcus bacteriophage with potential to ameliorate murine colitis.
Junko Nishio; Hideo Negishi; Mika Yasui-Kato; Shoji Miki; Kazuhiko Miyanaga; Kotaro Aoki; Takuma Mizusawa; Masami Ueno; Akira Ainai; Masafumi Muratani; Sho Hangai; Hideyuki Yanai; Hideki Hasegawa; Yoshikazu Ishii; Yasunori Tanji; Tadatsugu Taniguchi
Scientific reports, 11, 1, 20231, 20231, 12 Oct. 2021, [International Magazine]
English, Scientific journal, Increase of the enteric bacteriophages (phage), components of the enteric virome, has been associated with the development of inflammatory bowel diseases. However, little is known about how a given phage contributes to the regulation of intestinal inflammation. In this study, we isolated a new phage associated with Enterococcus gallinarum, named phiEG37k, the level of which was increased in C57BL/6 mice with colitis development. We found that, irrespective of the state of inflammation, over 95% of the E. gallinarum population in the mice contained phiEG37k prophage within their genome and the phiEG37k titers were proportional to that of E. gallinarum in the gut. To explore whether phiEG37k impacts intestinal homeostasis and/or inflammation, we generated mice colonized either with E. gallinarum with or without the prophage phiEG37k. We found that the mice colonized with the bacteria with phiEG37k produced more Mucin 2 (MUC2) that serves to protect the intestinal epithelium, as compared to those colonized with the phage-free bacteria. Consistently, the former mice were less sensitive to experimental colitis than the latter mice. These results suggest that the newly isolated phage has the potential to protect the host by strengthening mucosal integrity. Our study may have clinical implication in further understanding of how bacteriophages contribute to the gut homeostasis and pathogenesis. - SARS-CoV-2感染に対するネコの感受性の検証
朴 ウンシル; 黒田 雄大; 宇田 晶彦; 加来 義浩; 立本 完吾; 石嶋 慧多; 網 康至; 白倉 雅之; 鈴木 康司; 原田 俊彦; 志和 希; 岩田 奈織子; 永田 典代; 長谷川 秀樹
日本獣医学会学術集会講演要旨集, 164回, [DVO, 53], (公社)日本獣医学会, Sep. 2021
Japanese - Structure-Guided Creation of an Anti-HA Stalk Antibody F11 Derivative That Neutralizes Both F11-Sensitive and -Resistant Influenza A(H1N1)pdm09 Viruses
Osamu Kotani; Yasushi Suzuki; Shinji Saito; Akira Ainai; Akira Ueno; Takuya Hemmi; Kaori Sano; Koshiro Tabata; Masaru Yokoyama; Tadaki Suzuki; Hideki Hasegawa; Hironori Sato
Viruses, 13, 9, 1733, 1733, MDPI AG, 31 Aug. 2021
Scientific journal, The stalk domain of influenza virus envelope glycoprotein hemagglutinin (HA) constitutes the axis connecting the head and transmembrane domains, and plays pivotal roles in conformational rearrangements of HA for virus infection. Here we characterized molecular interactions between the anti-HA stalk neutralization antibody F11 and influenza A(H1N1)pdm09 HA to understand the structural basis of the actions and modifications of this antibody. In silico structural analyses using a model of the trimeric HA ectodomain indicated that the F11 Fab fragment has physicochemical properties, allowing it to crosslink two HA monomers by binding to a region near the proteolytic cleavage site of the stalk domain. Interestingly, the F11 binding allosterically caused a marked suppression of the structural dynamics of the HA cleavage loop and flanking regions. Structure-guided mutagenesis of the F11 antibody revealed a critical residue in the F11 light chain for the F11-mediated neutralization. Finally, the mutagenesis led to identification of a unique F11 derivative that can neutralize both F11-sensitive and F11-resistant A(H1N1)pdm09 viruses. These results raise the possibility that F11 sterically and physically disturbs proteolytic cleavage of HA for the ordered conformational rearrangements and suggest that in silico guiding experiments can be useful to create anti-HA stalk antibodies with new phenotypes. - Plasma Exchange did not Reduce Viral Load in a Recovered Case of Severe Fever with Thrombocytopenia Syndrome.
Rie Utsunomiya Nishimizu; Seiji Shiota; Toshihiro Ishii; Kaori Sano; Tadaki Suzuki; Hideki Hasegawa; Eishi Miyazaki
Internal medicine (Tokyo, Japan), 61, 2, 253, 256, 30 Jul. 2021, [Domestic magazines]
English, Scientific journal, Severe fever with thrombocytopenia syndrome (SFTS) is an emerging tick-borne infectious disease caused by the SFTS virus (SFTSV). There is no specific treatment for SFTS, although several reports have indicated that plasma exchange (PE) can be an effective therapy for severe SFTS. However, whether or not PE can reduce the viral load is unclear. We herein report a woman with SFTS who had her SFTSV viral load measured just before and after PE. While the patient recovered, there was no significant difference in the SFTSV viral load after PE. Our results confirmed that PE itself does not reduce the SFTSV viral load. - Development of Corona-virus-disease-19 Vaccines.
Hideki Hasegawa
JMA journal, 4, 3, 187, 190, 15 Jul. 2021, [Domestic magazines]
English, Scientific journal, The year 2020 opened with news of an epidemic of pneumonia caused by a new coronavirus similar to the SARS coronavirus in Wuhan, China, and subsequently caused a worldwide pandemic. In Japan, the first infected person was found in January, and later, more than 700 passengers and crew members of the Diamond Princess, a large cruise ship that called at Yokohama port, were found to be infected, and the ship was forced to respond to the outbreak. The causative virus was quickly identified as a beta coronavirus similar to the severe acute respiratory syndrome (SARS) coronavirus of 2003 and was named SARS coronavirus 2 (SARS-CoV-2). The disease was named COVID-19. SARS-CoV-2, like SARS-CoV and MERS-CoV, infects the epithelial cells of the lungs and causes viral pneumonia. As of March 7, 2021, more than 116 million people have been infected and more than 2.5 million people have died worldwide. As a result of the global pandemic, regional blockades have been imposed around the world, and the development of vaccines and therapeutic agents has become an urgent necessity in order to restore normal social activities. In this review, the experience of the development of SARS-CoV-2 vaccine is described. - Propagation of activated B cells by in vitro SFTSV infection of human peripheral blood mononuclear cells.
Yuji Wada; Sho Miyamoto; Shun Iida; Kaori Sano; Yuko Sato; Akira Ainai; Kumpei Saito; Harutaka Katano; Hideki Hasegawa; Tadaki Suzuki
The Journal of infectious diseases, 225, 2, 269, 281, 05 Jul. 2021, [International Magazine]
English, Scientific journal, Severe fever with thrombocytopenia syndrome (SFTS) is an emerging, life-threatening tick-borne viral hemorrhagic fever (VHF) caused by SFTS virus (SFTSV). Transient appearance of plasmablastic lymphocytes in the peripheral blood of SFTS cases has been reported; however, the pathological significance of this transient burst in peripheral blood plasmablastic lymphocytes is unclear. Here, we show that SFTSV infection of human peripheral blood mononuclear cells (PBMCs) in vitro induced propagation of atypical lymphocytes. These atypical lymphocytes were activated B cells, which were induced by secretory factors other than viral particles; these factors were secreted by SFTSV-infected B cells. Activated B cells shared morphological and immunophenotypic characteristics with B cells of plasmablast lineage observed in peripheral blood and autopsy tissues of SFTS cases. This suggests that SFTSV-infected B cells secrete factors that induce B cell differentiation to plasmablasts, which may play an important role in pathogenesis of SFTS through the SFTSV-B cell axis. - Increased risk of rhinovirus infection in children during the coronavirus disease-19 pandemic.
Emi Takashita; Chiharu Kawakami; Tomoko Momoki; Miwako Saikusa; Kouhei Shimizu; Hiroki Ozawa; Makoto Kumazaki; Shuzo Usuku; Nobuko Tanaka; Ichiro Okubo; Hiroko Morita; Shiho Nagata; Shinji Watanabe; Hideki Hasegawa; Yoshihiro Kawaoka
Influenza and other respiratory viruses, 15, 4, 488, 494, Jul. 2021, [International Magazine]
English, Scientific journal, BACKGROUND: Coronavirus disease (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first detected in Japan in January 2020 and has spread throughout the country. Previous studies have reported that viral interference among influenza virus, rhinovirus, and other respiratory viruses can affect viral infections at the host and population level. METHODS: To investigate the impact of COVID-19 on influenza and other respiratory virus infections, we analyzed clinical specimens collected from 2244 patients in Japan with respiratory diseases between January 2018 and September 2020. RESULTS: The frequency of influenza and other respiratory viruses (coxsackievirus A and B; echovirus; enterovirus; human coronavirus 229E, HKU1, NL63, and OC43; human metapneumovirus; human parainfluenza virus 1, 2, 3, and 4; human parechovirus; human respiratory syncytial virus; human adenovirus; human bocavirus; human parvovirus B19; herpes simplex virus type 1; and varicella-zoster virus) was appreciably reduced among all patients during the COVID-19 pandemic except for that of rhinovirus in children younger than 10 years, which was appreciably increased. COVID-19 has not spread among this age group, suggesting an increased risk of rhinovirus infection in children. CONCLUSIONS: Rhinovirus infections should be continuously monitored to understand their increased risk during the COVID-19 pandemic and viral interference with SARS-CoV-2. - Development of highly sensitive and rapid antigen detection assay for diagnosis of COVID-19 utilizing optical waveguide immunosensor.
Rikako Funabashi; Kei Miyakawa; Yutaro Yamaoka; Seiko Yoshimura; Satoshi Yamane; Sundararaj Stanleyraj Jeremiah; Kohei Shimizu; Hiroki Ozawa; Chiharu Kawakami; Shuzo Usuku; Nobuko Tanaka; Etsuko Yamazaki; Hirokazu Kimura; Hideki Hasegawa; Akihide Ryo
Journal of molecular cell biology, 13, 10, 763, 766, 24 Jun. 2021, [International Magazine]
English, Scientific journal - Influenza virus infection expands the breadth of antibody responses through IL-4 signalling in B cells.
Kosuke Miyauchi; Yu Adachi; Keisuke Tonouchi; Taiki Yajima; Yasuyo Harada; Hidehiro Fukuyama; Senka Deno; Yoichiro Iwakura; Akihiko Yoshimura; Hideki Hasegawa; Katsuyuki Yugi; Shin-Ichiro Fujii; Osamu Ohara; Yoshimasa Takahashi; Masato Kubo
Nature communications, 12, 1, 3789, 3789, 18 Jun. 2021, [International Magazine]
English, Scientific journal, Influenza viruses are a major public health problem. Vaccines are the best available countermeasure to induce effective immunity against infection with seasonal influenza viruses; however, the breadth of antibody responses in infection versus vaccination is quite different. Here, we show that nasal infection controls two sequential processes to induce neutralizing IgG antibodies recognizing the hemagglutinin (HA) of heterotypic strains. The first is viral replication in the lung, which facilitates exposure of shared epitopes that are otherwise hidden from the immune system. The second process is the germinal center (GC) response, in particular, IL-4 derived from follicular helper T cells has an essential role in the expansion of rare GC-B cells recognizing the shared epitopes. Therefore, the combination of exposure of the shared epitopes and efficient proliferation of GC-B cells is critical for generating broadly-protective antibodies. These observations provide insight into mechanisms promoting broad protection from virus infection. - Enhanced airway hyperresponsiveness in asthmatic children and mice with A(H1N1)pdm09 infection.
Taira Ariyoshi; Junichiro Tezuka; Hiroki Yasudo; Yasufumi Sakata; Tamaki Nakamura; Takeshi Matsushige; Hideki Hasegawa; Noriko Nakajima; Akira Ainai; Atsunori Oga; Hiroshi Itoh; Komei Shirabe; Shoichi Toda; Ryo Atsuta; Shouichi Ohga; Shunji Hasegawa
Immunity, inflammation and disease, 9, 2, 457, 465, Jun. 2021, [International Magazine]
English, Scientific journal, BACKGROUND: Severe asthma exacerbation is an important comorbidity of the 2009 HIN1 pandemic (A(H1N1)pdm09) in asthmatic patients. However, the mechanisms underlying severe asthma exacerbation remain unknown. In this study, airway hyperresponsiveness (AHR) was measured in pediatric asthma patients infected with A(H1N1)pdm09. We also evaluated AHR in asthmatic mice with A(H1N1)pdm09 infection and those with seasonal influenza for comparison. METHODS: AHRs in asthmatic children were defined as the provocative acetylcholine concentration causing a 20% reduction in forced expiratory volume in 1 s (PC20 ). To investigate the pathophysiology using animal models, BALB/c mice aged 6-8 weeks were sensitized and challenged with ovalbumin. Either mouse-adapted A(H1N1)pdm09, seasonal H1N1 virus (1 × 105 pfu/20 μl), or mock treatment as a control was administered intranasally. At 3, 7, and 10 days after infection, each group of mice was evaluated for AHR by methacholine challenge using an animal ventilator, flexiVent. Lung samples were resected and observed using light microscopy to assess the degree of airway inflammation. RESULTS: AHRs in the children with bronchial asthma were temporarily increased, and alleviated by 3 months after discharge. AHR was significantly enhanced in A(H1N1)pdm09-infected asthmatic mice compared to that in seasonal H1N1-infected mice (p < .001), peaking at 7 days postinfection and then becoming similar to control levels by 10 days postinfection. Histopathological examination of lung tissues showed more intense infiltration of inflammatory cells and severe tissue destruction in A(H1N1)pdm09-infected mice at 7 days postinfection than at 10 days postinfection. CONCLUSION: Our results suggest that enhanced AHR could contribute to severe exacerbation in human asthmatic patients with A(H1N1)pdm09 infection. - A case of Epstein-Barr virus-associated lymphoepithelioma-like carcinoma of the colon.
Hiromi Kanno-Okada; Kenta Takahashi; Harutaka Katano; Ai Shimizu; Emi Takakuwa; Shuichi Miyamoto; Satoshi Abiko; Keiko Yamamoto; Tadakazu Shimoda; Tomoko Mitsuhashi; Hideki Hasegawa; Yoshihiro Matsuno
Pathology international, 71, 6, 420, 426, Jun. 2021, [International Magazine]
English, Scientific journal, Lymphoepithelioma-like carcinoma is a poorly differentiated carcinoma with prominent lymphoid infiltration occurring in various organs but is exceedingly rare in the colorectal region. This malignancy is frequently associated with Epstein-Barr virus (EBV). Here we report a case of EBV-associated lymphoepithelioma-like carcinoma of the cecum in an 84-year-old male who presented with occult blood. In situ hybridization for EBV-encoded small RNAs (EBER) in an endoscopic submucosal dissection specimen showed that the tumor consisted of EBER-negative well-differentiated tubular adenocarcinoma and EBER-positive lymphoepithelioma-like carcinoma. Real-time PCR detected 7.16 copies of the EBV genome per cell in a sample microdissected from the latter component. Genotyping analysis demonstrated EBV genotype 1, and viral protein/transcript expression in the tumor showed EBV latency I. Expression of Ephrin receptor A2, a recently reported receptor for EBV, was demonstrated in the tumor cells by immunohistochemistry. To our knowledge, this is the first report of lymphoepithelioma-like carcinoma in the colorectal region showing a definite association with EBV infection. - Highly specific monoclonal antibodies and epitope identification against SARS-CoV-2 nucleocapsid protein for antigen detection tests.
Yutaro Yamaoka; Kei Miyakawa; Sundararaj Stanleyraj Jeremiah; Rikako Funabashi; Koji Okudela; Sayaka Kikuchi; Junichi Katada; Atsuhiko Wada; Toshiki Takei; Mayuko Nishi; Kohei Shimizu; Hiroki Ozawa; Shuzo Usuku; Chiharu Kawakami; Nobuko Tanaka; Takeshi Morita; Hiroyuki Hayashi; Hideaki Mitsui; Keita Suzuki; Daisuke Aizawa; Yukihiro Yoshimura; Tomoyuki Miyazaki; Etsuko Yamazaki; Tadaki Suzuki; Hirokazu Kimura; Hideaki Shimizu; Nobuhiko Okabe; Hideki Hasegawa; Akihide Ryo
Cell reports. Medicine, 2, 6, 100311, 100311, 16 May 2021, [International Magazine]
English, Scientific journal, The ongoing COVID-19 pandemic is a major global public health concern. Although rapid point-of-care testing for detecting viral antigen is important for management of the outbreak, the current antigen tests are less sensitive than nucleic acid testing. In our current study, we produce monoclonal antibodies (mAb) that exclusively react with SARS-CoV-2 and exhibit no cross-reactivity with other human coronaviruses including SARS-CoV. Molecular modeling suggest that the mAbs bind to epitopes present on the exterior surface of the nucleocapsid, making them suitable for detecting SARS-CoV-2 in clinical samples. We further select the optimal pair of anti-SARS-CoV-2 NP mAbs using ELISA, and then use this mAb pair to develop immunochromatographic assay augmented with silver amplification technology. Our mAbs recognize the variants of concern (501Y.V1-V3) that are currently in circulation. Due to their high performance, the mAbs of this study can serve as good candidates for developing antigen detection kits for COVID-19. - Loss of interleukin-10 activates innate immunity to eradicate adult T-cell leukemia-initiating cells.
Hiba El Hajj; Rita Hleihel; Marwan El Sabban; Julie Bruneau; Ghazi Zaatari; Morgane Cheminant; Ambroise Marçais; Abdou Akkouche; Hideki Hasegawa; William Hall; Hugues De Thé; Olivier Hermine; Ali Bazarbachi
Haematologica, 106, 5, 1443, 1456, 01 May 2021, [International Magazine]
English, Scientific journal, Adult T cell leukemia/lymphoma (ATL) is associated to chronic human T cell leukemia virus type 1 (HTLV-1) infection and carries a poor prognosis. Arsenic trioxide (AS) and interferon-alpha (IFNα) together selectively trigger Tax viral oncoprotein degradation and cure Tax-driven murine ATL. AS/IFNα/zidovudine treatment achieves a high response rate in patients with chronic ATL. Interleukin 10 (IL-10) is an immuno-suppressive cytokine whose expression is activated by Tax. Here we show that, in ATL, AS/IFNα-induced abrogation of leukemia initiating cell activity requires IL-10 expression shutoff. Loss of IL-10 secretion drives production of inflammatory cytokines by the microenvironment, followed by innate immunity-mediated clearance of Taxdriven leukemic cells. Accordingly, anti-IL-10 monoclonal antibodies significantly increased the efficiency of AS/IFNα therapy. These results emphasize the sequential targeting of malignant ATL cells and their immune microenvironment in leukemia initiating cell (LIC) eradication and provide a strong rational to test AS/IFNα/anti-IL10 combination in ATL. - Rapid quantitative screening assay for SARS-CoV-2 neutralizing antibodies using HiBiT-tagged virus-like particles.
Kei Miyakawa; Sundararaj Stanleyraj Jeremiah; Norihisa Ohtake; Satoko Matsunaga; Yutaro Yamaoka; Mayuko Nishi; Takeshi Morita; Ryo Saji; Mototsugu Nishii; Hirokazu Kimura; Hideki Hasegawa; Ichiro Takeuchi; Akihide Ryo
Journal of molecular cell biology, 12, 12, 987, 990, 10 Mar. 2021, [International Magazine]
English, Scientific journal - Virus-infected peripheral blood plasmablasts in a patient with severe fever with thrombocytopenia syndrome.
Toru Takahashi; Kaori Sano; Tadaki Suzuki; Takuro Matsumura; Kohei Sakai; Takayuki Tominaga; Yuko Sato; Harutaka Katano; Hideki Hasegawa
International journal of hematology, 113, 3, 436, 440, Mar. 2021, [Domestic magazines]
English, Scientific journal, Severe fever with thrombocytopenia syndrome (SFTS) is a tick-borne viral hemorrhagic disease with a high fatality rate. It is caused by the SFTS virus and is endemic in East Asian countries such as China, South Korea, and Japan. Previous studies have shown that plasmablasts appear transiently in peripheral blood during the acute phase of SFTS, but do not specify the characteristics of these plasmablasts. In this report, we describe the features of peripheral blood plasmablasts in a patient with SFTS. Immunohistochemical and immunofluorescence staining detected a small number of atypical lymphocytes expressing the SFTS virus antigen among peripheral leukocytes in a blood sample. The phenotype of the virus-infected cells was CD27+, CD38+, MUM1+, and CD138+, which is consistent with that of plasmablasts. This novel study demonstrates that plasmablasts in the peripheral blood of patients with SFTS are targets of the SFTS virus. - Accumulation of cellular prion protein within β-amyloid oligomer plaques in aged human brains.
Reisuke H Takahashi; Mayumi Yokotsuka; Minoru Tobiume; Yuko Sato; Hideki Hasegawa; Toshitaka Nagao; Gunnar K Gouras
Brain pathology (Zurich, Switzerland), 31, 5, e12941, 23 Feb. 2021, [International Magazine]
English, Scientific journal, Alzheimer's disease (AD) is the main cause of dementia, and β-amyloid (Aβ) is a central factor in the initiation and progression of the disease. Different forms of Aβ have been identified as monomers, oligomers, and amyloid fibrils. Many proteins have been implicated as putative receptors of respective forms of Aβ. Distinct forms of Aβ oligomers are considered to be neurotoxic species that trigger the pathophysiology of AD. It was reported that cellular prion protein (PrPC ) is one of the most selective and high-affinity binding partners of Aβ oligomers. The interaction of Aβ oligomers with PrPC is important to synaptic dysfunction and loss. The binding of Aβ oligomers to PrPC has mostly been studied with synthetic peptides, cell culture, and murine models of AD by biochemical and biological methods. However, the molecular mechanisms underlying the relationship between Aβ oligomers and PrPC remain unclear, especially in the human brain. We immunohistochemically investigated the relationship between Aβ oligomers and PrPC in human brain tissue with and without amyloid pathology. We histologically demonstrate that PrPC accumulates with aging in human brain tissue even prior to AD mainly within diffuse-type amyloid plaques, which are composed of more soluble Aβ oligomers without stacked β-sheet fibril structures. Our results suggest that PrPC accumulating plaques are associated with more soluble Aβ oligomers, and appear even prior to AD. The investigation of PrPC accumulating plaques may provide new insights into AD. - Corrigendum to: Environmental Sampling for Severe Acute Respiratory Syndrome Coronavirus 2 During a COVID-19 Outbreak on the Diamond Princess Cruise Ship.
Takuya Yamagishi; Makoto Ohnishi; Nobuaki Matsunaga; Kensaku Kakimoto; Hajime Kamiya; Kiyoko Okamoto; Motoi Suzuki; Yoshiaki Gu; Mikiyo Sakaguchi; Taichi Tajima; Saho Takaya; Norio Ohmagari; Makoto Takeda; Shutoku Matsuyama; Kazuya Shirato; Naganori Nao; Hideki Hasegawa; Tsutomu Kageyama; Ikuyo Takayama; Shinji Saito; Koji Wada; Retsu Fujita; Hiroki Saito; Keiji Okinaka; Mathew Griffith; Amy Elizabeth Parry; Brenda Barnetson; James Leonard; Takaji Wakita
The Journal of infectious diseases, 223, 3, 540, 540, 13 Feb. 2021, [International Magazine]
English, Scientific journal - Pathological Characteristics of a Patient with Severe Fever with Thrombocytopenia Syndrome (SFTS) Infected with SFTS Virus through a Sick Cat's Bite.
Masatoshi Tsuru; Tadaki Suzuki; Tomoyuki Murakami; Kumiko Matsui; Yuuji Maeda; Tomoki Yoshikawa; Takeshi Kurosu; Masayuki Shimojima; Tomome Shimada; Hideki Hasegawa; Ken Maeda; Shigeru Morikawa; Masayuki Saijo
Viruses, 13, 2, 29 Jan. 2021, [International Magazine]
English, Scientific journal, A woman in her fifties showed symptoms of fever, loss of appetite, vomiting, and general fatigue 2 days after she was bitten by a sick cat, which had later died, in Yamaguchi prefecture, western Japan, in June 2016. She subsequently died of multiorgan failure, and an autopsy was performed to determine the cause of death. However, the etiological pathogens were not quickly identified. The pathological features of the patient were retrospectively re-examined, and the pathology of the regional lymph node at the site of the cat bite was found to show necrotizing lymphadenitis with hemophagocytosis. The pathological features were noted to be similar to those of patients reported to have severe fever with thrombocytopenia syndrome (SFTS). Therefore, the lymph node section was retrospectively tested immunohistochemically, revealing the presence of the SFTS virus (SFTSV) antigen. The sick cat showed similar symptoms and laboratory findings similar to those shown in human SFTS cases. The patient had no history of tick bites, and did not have skin lesions suggestive of these. She had not undertaken any outdoor activities. It is highly possible that the patient was infected with SFTSV through the sick cat's bite. If a patient gets sick in an SFTS-endemic region after being bitten by a cat, SFTS should be considered in the differential diagnosis. - The peripheral T cell population is associated with pneumonia severity in cynomolgus monkeys experimentally infected with severe acute respiratory syndrome coronavirus 2
Noriyo Nagata; Naoko Iwata-Yoshikawa; Kaori Sano; Akira Ainai; Nozomi Shiwa; Masayuki Shirakura; Noriko Kishida; Tomoko Arita; Yasushi Suzuki; Toshihiko Harada; Yasuhiro Kawai; Yasushi Ami; Shun Iida; Harutaka Katano; Seiichiro Fujisaki; Tsuyoshi Sekizuka; Hiroyuki Shimizu; Tadaki Suzuki; Hideki Hasegawa
07 Jan. 2021 - Next-Generation Sequencing Analysis of the Within-Host Genetic Diversity of Influenza A(H1N1)pdm09 Viruses in the Upper and Lower Respiratory Tracts of Patients with Severe Influenza.
Ikuyo Takayama; Binh Gia Nguyen; Co Xuan Dao; Thach The Pham; Tuan Quoc Dang; Phuong Thai Truong; Thanh Van Do; Thuy Thi Phuong Pham; Seiichiro Fujisaki; Takato Odagiri; Hideki Hasegawa; Noriko Nakajima
mSphere, 6, 1, 06 Jan. 2021, [International Magazine]
English, Scientific journal, The influenza A(H1N1)pdm09 virus emerged in April 2009 with an unusual incidence of severe disease and mortality, and currently circulates as a seasonal influenza virus. Previous studies using consensus viral genome sequencing data have overlooked the viral genomic and phenotypic diversity. Next-generation sequencing (NGS) may instead be used to characterize viral populations in an unbiased manner and to measure within-host genetic diversity. In this study, we used NGS analysis to investigate the within-host genetic diversity of influenza A(H1N1)pdm09 virus in the upper and lower respiratory samples from nine patients who were admitted to the intensive care unit (ICU). A total of 47 amino acid substitution positions were found to differ between the upper and lower respiratory tract samples from all patients. However, the D222G/N substitution in hemagglutinin (HA) protein was the only amino acid substitution common to multiple patients. Furthermore, the substitution was detected only in the six samples from the lower respiratory tract. Therefore, it is important to investigate influenza A(H1N1)pdm09 virus populations using multiple paired samples from the upper and lower respiratory tract to avoid overlooking potentially important substitutions, especially in patients with severe disease.IMPORTANCE The D222G/N substitution in the hemagglutinin (HA) protein of influenza A(H1N1)pdm09 virus has been reported to be associated with disease severity and mortality in numerous previous studies. In the present study, 75% of lower respiratory samples contained heterogeneous influenza populations that carried different amino acids at position 222 of the HA protein, whereas all upper respiratory samples only contained the wild-type 222D. These results suggest the influenza A(H1N1)pdm09 virus has diversified inside the host owing to differences in tissue specificity. In this study, the within-host genetic diversity of influenza A(H1N1)pdm09 virus was investigated for the first time using next-generation sequencing analysis of the viral whole-genome in samples extracted from the upper and lower respiratory tracts of patients with severe disease. - Zika virus protease induces caspase-independent pyroptotic cell death by directly cleaving gasdermin D.
Yutaro Yamaoka; Satoko Matsunaga; Sundararaj S Jeremiah; Mayuko Nishi; Kei Miyakawa; Takeshi Morita; Hajera Khatun; Hideaki Shimizu; Nobuhiko Okabe; Hirokazu Kimura; Hideki Hasegawa; Akihide Ryo
Biochemical and biophysical research communications, 534, 666, 671, 01 Jan. 2021, [International Magazine]
English, Scientific journal, The association of Zika virus (ZIKV) infection with a congenital malformation in fetuses, neurological, and other systemic complications in adults have brought significant global health emergency. ZIKV targets nerve cells in the brain and causes cell death, such as pyroptosis, leading to neuroinflammation. Here we described a novel mechanism of pyroptosis caused by ZIKV protease. We found that ZIKV protease directly cleaved the GSDMD into N-terminal fragment (1-249) leading to pyroptosis in a caspase-independent manner, suggesting a direct mechanism of ZIKV-induced cell death and subsequent inflammation. Our findings might shed new light to explore the pathogenesis of ZIKV infections where ZIKV protease might be a suitable target for the development of antiviral agents. - An influenza HA stalk reactive polymeric IgA antibody exhibits anti-viral function regulated by binary interaction between HA and the antibody.
Kaori Sano; Shinji Saito; Tadaki Suzuki; Osamu Kotani; Akira Ainai; Elly van Riet; Koshiro Tabata; Kumpei Saito; Yoshimasa Takahashi; Masaru Yokoyama; Hironori Sato; Takahiro Maruno; Kaede Usami; Susumu Uchiyama; Kiyoko Ogawa-Goto; Hideki Hasegawa
PloS one, 16, 1, e0245244, 2021, [International Magazine]
English, Scientific journal, IgA antibodies, which are secreted onto the mucosal surface as secretory IgA antibodies (SIgAs), play an important role in preventing influenza virus infection. A recent study reported that anti-hemagglutinin (HA) head-targeting antibodies increase anti-viral functions such as hemagglutination inhibition (HI) and virus neutralization (NT), in addition to HA binding activity (reactivity) via IgA polymerization. However, the functional properties of anti-viral IgA antibodies with mechanisms of action distinct from those of anti-HA head-targeting antibodies remain elusive. Here, we characterized the functional properties of IgG, monomeric IgA, and polymeric IgA anti-HA stalk-binding clones F11 and FI6, and B12 (a low affinity anti-HA stalk clone), as well as Fab-deficient (ΔFab) IgA antibodies. We found that IgA polymerization impacts the functional properties of anti-HA stalk antibodies. Unlike anti-HA head antibodies, the anti-viral functions of anti-HA stalk antibodies were not simply enhanced by IgA polymerization. The data suggest that two modes of binding (Fab paratope-mediated binding to the HA stalk, and IgA Fc glycan-mediated binding to the HA receptor binding site (RBS)) occur during interaction between anti-stalk HA IgA antibodies and HA. In situations where Fab paratope-mediated binding to the HA stalk exceeded IgA Fc glycan-mediated binding to HA RBS, IgA polymerization increased anti-viral functions. By contrast, when IgA Fc glycan-mediated binding to the HA RBS was dominant, anti-viral activity will fall upon IgA polymerization. In summary, the results suggest that coordination between these two independent binding modules determines whether IgA polymerization has a negative or positive effect on the anti-viral functions of anti-HA stalk IgA antibodies. - Suberoyl bis-hydroxamic acid reactivates Kaposi's sarcoma-associated herpesvirus through histone acetylation and induces apoptosis in lymphoma cells.
Shun Iida; Sohtaro Mine; Keiji Ueda; Tadaki Suzuki; Hideki Hasegawa; Harutaka Katano
Journal of virology, 95, 5, 16 Dec. 2020, [International Magazine]
English, Scientific journal, Kaposi's sarcoma-associated herpesvirus (KSHV) is an etiologic agent of Kaposi's sarcoma as well as primary effusion lymphoma (PEL), an aggressive B-cell neoplasm which mostly arises in immunocompromised individuals. Lytic replication of KSHV is also associated with a subset of multicentric Castleman diseases. At present, there is no specific treatment available for PEL and its prognosis is poor. In this study, we found that the histone deacetylase inhibitor suberoyl bis-hydroxamic acid (SBHA) induced KSHV reactivation in PEL cells in a dose-dependent manner. Next-generation sequencing analysis showed that more than 40% of all transcripts expressed in SBHA-treated PEL cells originated from the KSHV genome compared with less than 1% in untreated cells. Chromatin immunoprecipitation assays demonstrated that SBHA induced histone acetylation targeting the promoter region of the KSHV replication and transcription activator gene. However, there was no significant change in methylation status of the promoter region of this gene. In addition to its effect of KSHV reactivation, this study revealed that SBHA induces apoptosis in PEL cells in a dose-dependent manner, inducing acetylation and phosphorylation of p53, cleavage of caspases, and expression of pro-apoptotic factors such as Bim and Bax. These findings suggest that SBHA reactivates KSHV from latency and induces apoptosis through the mitochondrial pathway in PEL cells. Therefore, SBHA can be considered a new tool for induction of KSHV reactivation, and could provide a novel therapeutic strategy against PEL.IMPORTANCE Kaposi's sarcoma and primary effusion lymphoma cells are latently infected with Kaposi's sarcoma-associated herpesvirus (KSHV), whereas KSHV replication is frequently observed in multicentric Castleman disease. Although KSHV replication can be induced by some chemical reagents (e.g. 12-O-tetradecanoylphorbol-13-acetate), the mechanism of KSHV replication is not fully understood. We found that the histone deacetylase inhibitor suberoyl bis-hydroxamic acid (SBHA) induced KSHV reactivation with high efficiency, through histone acetylation in the promoter of the replication and transcription activator gene, compared with 12-O-tetradecanoylphorbol-13-acetate. SBHA also induced apoptosis through the mitochondrial pathway in KSHV-infected cells, with a lower EC50 than measured for viral reactivation. SBHA could be used in a highly efficient replication system for KSHV in vitro, and as a tool to reveal the mechanism of replication and pathogenesis of KSHV. The ability of SBHA to induce apoptosis at lower levels than needed to stimulate KSHV reactivation, indicates its therapeutic potential. - Robust production of IL-33 and TSLP by lung endothelial cells in response to low-dose dsRNA stimulation.
Maiko Emi-Sugie; Tetsuo Shoda; Kyoko Futamura; Tomohiro Takeda; Akira Ainai; Hideki Hasegawa; Hirohisa Saito; Kenji Matsumoto; Akio Matsuda
The Journal of allergy and clinical immunology, 146, 6, 1449, 1452, Dec. 2020, [International Magazine]
English - 2019/20シーズンのインフルエンザ分離株の解析
岸田 典子; 中村 一哉; 藤崎 誠一郎; 白倉 雅之; 佐藤 彩; 秋元 未来; 三浦 秀佳; 高下 恵美; 桑原 朋子; 森田 博子; 永田 志保; 菅原 裕美; 渡邉 真治; 長谷川 秀樹
病原微生物検出情報月報, 41, 11, 195, 200, 国立感染症研究所, Nov. 2020
Japanese - 抗インフルエンザ薬耐性株の検出と性状
高下 恵美; 森田 博子; 永田 志保; 藤崎 誠一郎; 三浦 秀佳; 白倉 雅之; 岸田 典子; 中村 一哉; 桑原 朋子; 佐藤 彩; 秋元 未来; 菅原 裕美; 渡邉 真治; 長谷川 秀樹
病原微生物検出情報月報, 41, 11, 200, 201, 国立感染症研究所, Nov. 2020
Japanese - Listeria monocytogenesの垂直感染による新生児全身性リステリア症の1剖検例
定本 聡太; 三上 哲夫; 鈴木 忠樹; 緒方 公平; 大路 斐子; 片野 晴隆; 与田 仁志; 中田 雅彦; 長谷川 秀樹; 渋谷 和俊
診断病理, 37, 4, 361, 365, (一社)日本病理学会, Oct. 2020
Japanese - Detection of a Peramivir-Resistant Influenza B/Yamagata-Lineage Virus Imported from Indonesia in Aichi, Japan, March 2019.
Emi Takashita; Yoshihiro Yasui; Shiho Nagata; Hiroko Morita; Seiichiro Fujisaki; Hideka Miura; Masayuki Shirakura; Noriko Kishida; Kazuya Nakamura; Tomoko Kuwahara; Hiromi Sugawara; Aya Sato; Miki Akimoto; Tatsuya Kaido; Shinji Watanabe; Hideki Hasegawa
Japanese journal of infectious diseases, 73, 5, 386, 390, 24 Sep. 2020, [Domestic magazines]
English, Scientific journal - Integrating genotypes and phenotypes improves long-term forecasts of seasonal influenza A/H3N2 evolution.
John Huddleston; John R Barnes; Thomas Rowe; Xiyan Xu; Rebecca Kondor; David E Wentworth; Lynne Whittaker; Burcu Ermetal; Rodney Stuart Daniels; John W McCauley; Seiichiro Fujisaki; Kazuya Nakamura; Noriko Kishida; Shinji Watanabe; Hideki Hasegawa; Ian Barr; Kanta Subbarao; Pierre Barrat-Charlaix; Richard A Neher; Trevor Bedford
eLife, 9, 02 Sep. 2020, [International Magazine]
English, Scientific journal, Seasonal influenza virus A/H3N2 is a major cause of death globally. Vaccination remains the most effective preventative. Rapid mutation of hemagglutinin allows viruses to escape adaptive immunity. This antigenic drift necessitates regular vaccine updates. Effective vaccine strains need to represent H3N2 populations circulating one year after strain selection. Experts select strains based on experimental measurements of antigenic drift and predictions made by models from hemagglutinin sequences. We developed a novel influenza forecasting framework that integrates phenotypic measures of antigenic drift and functional constraint with previously published sequence-only fitness estimates. Forecasts informed by phenotypic measures of antigenic drift consistently outperformed previous sequence-only estimates, while sequence-only estimates of functional constraint surpassed more comprehensive experimentally-informed estimates. Importantly, the best models integrated estimates of both functional constraint and either antigenic drift phenotypes or recent population growth. - バロキサビル未投与患者からのバロキサビル耐性PA E23K変異インフルエンザウイルスの検出
高下 恵美; 森田 博子; 永田 志保; 藤崎 誠一郎; 三浦 秀佳; 白倉 雅之; 岸田 典子; 中村 一哉; 桑原 朋子; 秋元 未来; 佐藤 彩; 菅原 裕美; 渡邉 真治; 長谷川 秀樹; 安倍 隆; 三田村 敬子; 市川 正孝; 山崎 雅彦
病原微生物検出情報月報, 41, 9, 169, 170, 国立感染症研究所, Sep. 2020
Japanese - キノロン耐性化を来した血液指向性マイコプラズマ
詫間 隆博; 二木 芳人; 長友 安弘; 時松 一成; 服部 憲路; 荒井 菜々; 中牧 剛; 柳井 亮; 石井 翔; 徳永 剛広; 野村 憲弘; 江口 潤一; 伊藤 敬義; 片野 晴隆; 黒田 誠; 長谷川 秀樹; 関塚 剛史; 脇田 隆字; 塩沢 英輔; 宇賀神 和久; 前田 真之; 石野 敬子; 内藤 結花
日本化学療法学会雑誌, 68, Suppl.A, 289, 289, (公社)日本化学療法学会, Sep. 2020
Japanese - キノロン耐性化を来した血液指向性マイコプラズマ
詫間 隆博; 二木 芳人; 長友 安弘; 時松 一成; 服部 憲路; 荒井 菜々; 中牧 剛; 柳井 亮; 石井 翔; 徳永 剛広; 野村 憲弘; 江口 潤一; 伊藤 敬義; 片野 晴隆; 黒田 誠; 長谷川 秀樹; 関塚 剛史; 脇田 隆字; 塩沢 英輔; 宇賀神 和久; 前田 真之; 石野 敬子; 内藤 結花
日本化学療法学会雑誌, 68, Suppl.A, 289, 289, (公社)日本化学療法学会, Sep. 2020
Japanese - Influenza A(H1N1)pdm09 virus exhibiting reduced susceptibility to baloxavir due to a PA E23K substitution detected from a child without baloxavir treatment.
Emi Takashita; Takashi Abe; Hiroko Morita; Shiho Nagata; Seiichiro Fujisaki; Hideka Miura; Masayuki Shirakura; Noriko Kishida; Kazuya Nakamura; Tomoko Kuwahara; Keiko Mitamura; Masataka Ichikawa; Masahiko Yamazaki; Shinji Watanabe; Hideki Hasegawa
Antiviral research, 180, 104828, 104828, Aug. 2020, [International Magazine]
English, Scientific journal, Human-to-human transmission of PA I38 mutant influenza A(H3N2) viruses with reduced baloxavir susceptibility has been reported in Japan. In December 2019, we detected a PA E23K mutant A(H1N1)pdm09 virus from a child without baloxavir treatment. The PA E23K mutant virus exhibited reduced baloxavir susceptibility but remained susceptible to neuraminidase inhibitors. Epidemiological data suggest possible transmission of this PA E23K mutant virus among humans, although its growth capability relative to that of the wild-type virus was reduced. Therefore, baloxavir susceptibility monitoring of influenza viruses is essential. - Haplotype networks of SARS-CoV-2 infections in the Diamond Princess cruise ship outbreak.
Tsuyoshi Sekizuka; Kentaro Itokawa; Tsutomu Kageyama; Shinji Saito; Ikuyo Takayama; Hideki Asanuma; Naganori Nao; Rina Tanaka; Masanori Hashino; Takuri Takahashi; Hajime Kamiya; Takuya Yamagishi; Kensaku Kakimoto; Motoi Suzuki; Hideki Hasegawa; Takaji Wakita; Makoto Kuroda
Proceedings of the National Academy of Sciences of the United States of America, 117, 33, 20198, 20201, 28 Jul. 2020, [Peer-reviewed], [International Magazine]
English, Scientific journal, The Diamond Princess cruise ship was put under quarantine offshore Yokohama, Japan, after a passenger who disembarked in Hong Kong was confirmed as a coronavirus disease 2019 case. We performed whole-genome sequencing of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directly from PCR+ clinical specimens and conducted a phylogenetic analysis of the outbreak. All tested isolates exhibited a transversion at G11083T, suggesting that SARS-CoV-2 dissemination on the Diamond Princess originated from a single introduction event before the quarantine started. Although further spreading might have been prevented by quarantine, some progeny clusters could be linked to transmission through mass-gathering events in the recreational areas and direct transmission among passengers who shared cabins during the quarantine. This study demonstrates the usefulness of haplotype network/phylogeny analysis in identifying potential infection routes. - Environmental sampling for severe acute respiratory syndrome coronavirus 2 during COVID-19 outbreak in the Diamond Princess cruise ship.
Takuya Yamagishi; Makoto Ohnishi; Nobuaki Matsunaga; Kensaku Kakimoto; Hajime Kamiya; Kiyoko Okamoto; Motoi Suzuki; Yoshiaki Gu; Mikiyo Sakaguchi; Taichi Tajima; Saho Takaya; Norio Ohmagari; Makoto Takeda; Syutoku Matsuyama; Kazuya Shirato; Naganori Nao; Hideki Hasegawa; Tsutomu Kageyama; Ikuyo Takayama; Shinji Saito; Koji Wada; Retsu Fujita; Hiroki Saito; Keiji Okinaka; Mathew Griffith; Amy Elizabeth Parry; Brenda Barnetson; James Leonard; Takaji Wakita
The Journal of infectious diseases, 222, 7, 1098, 1102, 21 Jul. 2020, [Peer-reviewed], [International Magazine]
English, Scientific journal, A COVID-19 outbreak occurred in the Diamond Princess cruise ship and we sampled environmental surfaces after passengers and crews vacated the cabins. SARS-CoV-2 RNA was detected from 58 out of 601 samples (10%) from case-cabins 1-17 days after the cabins were vacated, but not from non-case-cabins. There was no difference in the detection proportion between cabins for symptomatic (15%, 28/189, Cq: 29.79-38.86) and asymptomatic cases (21%, 28/131, Cq: 26.21-38.99). No SARS-CoV-2 virus was isolated from any of the samples. Transmission risk of SARS-CoV-2 from symptomatic and asymptomatic patients may be similar and environmental surfaces could be involved in viral transmission. - Severe Acute Respiratory Syndrome Coronavirus 2 Infection among Returnees to Japan from Wuhan, China, 2020.
Yuzo Arima; Tomoe Shimada; Motoi Suzuki; Tadaki Suzuki; Yusuke Kobayashi; Yuuki Tsuchihashi; Haruna Nakamura; Kaoru Matsumoto; Asuka Takeda; Keisuke Kadokura; Tetsuro Sato; Yuichiro Yahata; Noriko Nakajima; Minoru Tobiume; Ikuyo Takayama; Tsutomu Kageyama; Shinji Saito; Naganori Nao; Tamano Matsui; Tomimasa Sunagawa; Hideki Hasegawa; Makoto Ohnishi; Takaji Wakita
Emerging infectious diseases, 26, 7, 1596, 600, Jul. 2020, [Peer-reviewed], [International Magazine]
English, Scientific journal, In early 2020, Japan repatriated 566 nationals from China. Universal laboratory testing and 14-day monitoring of returnees detected 12 cases of severe acute respiratory syndrome coronavirus 2 infection; initial screening results were negative for 5. Common outcomes were remaining asymptomatic (n = 4) and pneumonia (n = 6). Overall, screening performed poorly. - Double-Stranded Structure of the Polyinosinic-Polycytidylic Acid Molecule to Elicit TLR3 Signaling and Adjuvant Activity in Murine Intranasal A(H1N1)pdm09 Influenza Vaccination
Tetsuo Nakano; Yuki Ohara; Hiroshi Fujita; Akira Ainai; Ei-Tora Yamamura; Tadaki Suzuki; Hideki Hasegawa; Teruo Sone; Kozo Asano
DNA and Cell Biology, Mary Ann Liebert Inc, 22 Jun. 2020, [Peer-reviewed]
Scientific journal - Pathogenesis of influenza A(H7N9) virus in aged non-human primates.
Satoshi Fukuyama; Kiyoko Iwatsuki-Horimoto; Maki Kiso; Noriko Nakajima; Robert W Gregg; Hiroaki Katsura; Yuriko Tomita; Tadashi Maemura; Tiago Jose da Silva Lopes; Tokiko Watanabe; Jason E Shoemaker; Hideki Hasegawa; Seiya Yamayoshi; Yoshihiro Kawaoka
The Journal of infectious diseases, 222, 7, 1155, 1164, 20 May 2020, [Peer-reviewed], [International Magazine]
English, Scientific journal, The avian influenza A(H7N9) virus has caused high mortality in humans, especially in the elderly; however, little is known about the mechanistic basis for this. In this study, we employed non-human primates to evaluate the effect of aging on the pathogenicity of A(H7N9) virus. We observed that A(H7N9) virus infection of aged animals (defined as 20-26 years) caused more severe symptoms than infection of young animals (defined as 2-3 years). In aged animals, lung inflammation was weak and virus infection was sustained. Although cytokine and chemokine expression in the lungs of most aged animals was lower than that in the lungs of young animals, one aged animal showed severe symptoms and dysregulated proinflammatory cytokine and chemokine production. These results suggest that attenuated or dysregulated immune responses in aged animals are responsible for the severe symptoms observed among elderly patients infected with A(H7N9) virus. - An assessment of real-time RT-PCR kits for SARS-CoV-2 detection.
Kiyoko Okamaoto; Kazuya Shirato; NagaNaganori Nao; Shinji Saito; Tsutomu Kageyama; Hideki Hasegawa; Tadaki Suzuki; Shutoku Matsuyama; Makoto Takeda
Japanese journal of infectious diseases, 73, 5, 366, 368, 30 Apr. 2020, [Peer-reviewed], [Domestic magazines]
English, Scientific journal, The COVID-19 outbreak caused by SARS-CoV-2 in Wuhan (China) in December 2019 is currently spreading rapidly and globally. We recently reported a laboratory diagnostic protocol for SARS-CoV-2 based on real-time RT-PCR assays using two primer sets, N and N2. On 30-31 January 2020, the protocol and reagents for these assays were distributed to local public health institutes and quarantine depots in Japan, and nationwide, SARS-CoV-2 diagnostic testing was started. For further validation, the assays were compared with the commercially available kits using SARS CoV-2 viral RNA and the clinical specimens obtained from COVID19-suspected individuals. The LightMix Modular SARS and Wuhan CoV E-gene (LN S&W-E) assay was highly sensitive for SARS-CoV-2, as was the N2 set, and both assays had perfectly consistent results with the clinical specimens. While the LM S&W-E set targets the highly conserved region of the E gene in SARS-CoV and SARS-CoV-2, the N2 set was designed to target the unique region in the SARS-CoV-2 N gene. Thus, the N2 set has high specificity and sensitivity for SARS-CoV-2 detection. These indicate that the protocol using the N and N2 sets is comparable to commercially available kits and is reliable for the laboratory diagnosis of COVID-19. - Human immune responses elicited by an intranasal inactivated H5 influenza vaccine.
Akira Ainai; Elly van Riet; Ryo Ito; Kazuyuki Ikeda; Kyosuke Senchi; Tadaki Suzuki; Shin-Ichi Tamura; Hideki Asanuma; Takato Odagiri; Masato Tashiro; Takeshi Kurata; Pretty Multihartina; Vivi Setiawaty; Krisna Nur Andriana Pangesti; Hideki Hasegawa
Microbiology and immunology, 64, 4, 313, 325, Apr. 2020, [International Magazine]
English, Scientific journal, Intranasally administered influenza vaccines could be more effective than injected vaccines, because intranasal vaccination can induce virus-specific immunoglobulin A (IgA) antibodies in the upper respiratory tract, which is the initial site of infection. In this study, immune responses elicited by an intranasal inactivated vaccine of influenza A(H5N1) virus were evaluated in healthy individuals naive for influenza A(H5N1) virus. Three doses of intranasal inactivated whole-virion H5 influenza vaccine induced strong neutralizing nasal IgA and serum IgG antibodies. In addition, a mucoadhesive excipient, carboxy vinyl polymer, had a notable impact on the induction of nasal IgA antibody responses but not on serum IgG antibody responses. The nasal hemagglutinin (HA)-specific IgA antibody responses clearly correlated with mucosal neutralizing antibody responses, indicating that measurement of nasal HA-specific IgA titers could be used as a surrogate for the mucosal antibody response. Furthermore, increased numbers of plasma cells and vaccine antigen-specific Th cells in the peripheral blood were observed after vaccination, suggesting that peripheral blood biomarkers may also be used to evaluate the intranasal vaccine-induced immune response. However, peripheral blood immune cell responses correlated with neutralizing antibody titers in serum samples but not in nasal wash samples. Thus, analysis of the peripheral blood immune response could be a surrogate for the systemic immune response to intranasal vaccination but not for the mucosal immune response. The current study suggests the clinical potential of intranasal inactivated vaccines against influenza A(H5N1) viruses and highlights the need to develop novel means to evaluate intranasal vaccine-induced mucosal immune responses. - High expression of JC polyomavirus-encoded microRNAs in progressive multifocal leukoencephalopathy tissues and its repressive role in virus replication.
Kenta Takahashi; Yuko Sato; Tsuyoshi Sekizuka; Makoto Kuroda; Tadaki Suzuki; Hideki Hasegawa; Harutaka Katano
PLoS pathogens, 16, 4, e1008523, Apr. 2020, [Peer-reviewed], [International Magazine]
English, Scientific journal, JC polyomavirus (JCPyV, JCV) causes progressive multifocal leukoencephalopathy (PML) in immunocompromised hosts. JCPyV replicates in oligodendrocytes within the brain tissue of patients with PML. The JCPyV genome encodes a microRNA (miRNA) in the region encoding the large T antigen. JCPyV-encoded miRNA (miR-J1) has been detected in the tissue and cerebrospinal fluid samples of patients with PML; however, there are no reports describing the localization of polyomavirus-encoded miRNA in histological samples of patients with virus-associated diseases. In the present study, we detected high miR-J1 expression in the nuclei of JCPyV-infected cells in PML tissue samples via in situ hybridization. Additionally, in situ hybridization also revealed the expression of BK polyomavirus (BKPyV, BKV)-encoded miRNA in lesions of BKPyV-associated nephropathy. In situ hybridization for miR-J1-5p and -3p showed positive signals in 24/25 (96%) of PML tissues that were positive for JCPyV by immunohistochemistry. Higher copy numbers of miR-J1 were detected in PML tissues than in non-PML tissues by real-time reverse transcription PCR. Next generation sequencing showed that miR-J1-5p, a mature miRNA of primary miRNA, was predominant in the lesions compared with miR-J1-3p, another mature miRNA. Deletion or mutation of miR-J1 in recombinant JCPyV promoted the production of JCPyV-encoded proteins in cells transfected with JCPyV DNA, suggesting that polyomavirus-encoded miRNA may have a repressive role in viral replication in PML tissues. In situ hybridization for viral miRNA may be a useful diagnostic tool for PML. - Severe Fever with Thrombocytopenia Syndrome, Japan, 2013-2017.
Yusuke Kobayashi; Hirofumi Kato; Takuya Yamagishi; Tomoe Shimada; Tamano Matsui; Tomoki Yoshikawa; Takeshi Kurosu; Masayuki Shimojima; Shigeru Morikawa; Hideki Hasegawa; Masayuki Saijo; Kazunori Oishi
Emerging infectious diseases, 26, 4, 692, 699, Apr. 2020, [Peer-reviewed], [International Magazine]
English, Scientific journal, We conducted an epidemiologic study of severe fever with thrombocytopenia syndrome (SFTS) in Japan during 2013-2017. Of 303 cases reported during that period, 133 (44%) were included in this study. The median time between onset of illness and diagnosis of SFTS shortened, from 11.5 to 3.0 days, but the case-fatality rate remained high, at 27%. In 64 patients (48%), a close contact with companion animals was reported within 2 weeks of disease onset. Of these 64 patients, 40 were surveyed further, and we confirmed that 3 had direct contact with body fluids of ill companion animals; 2 had direct contact with the saliva of an ill feral cat or pet dog. These patients reported no history of tick bite, suggesting that ill companion animals might be a source of SFTS virus transmission. Direct contact with the body fluids of ill companion animals should be avoided. - Functional Analysis of Trichodysplasia Spinulosa-Associated Polyomavirus-Encoded Large T Antigen.
Toshie Nako; Hitomi Fukumoto; Hideki Hasegawa; Hidehisa Saeki; Harutaka Katano
Japanese journal of infectious diseases, 73, 2, 132, 139, 24 Mar. 2020, [Peer-reviewed], [Domestic magazines]
English, Scientific journal, Trichodysplasia spinulosa-associated polyomavirus (TSPyV or human polyomavirus 8) was identified from patients with trichodysplasia spinulosa, a rare skin disease affecting the faces of immunocompromised patients. Like other polyomaviruses, the TSPyV genome encodes a large T antigen (LT). However, the expression and functions of TSPyV LT in infected cells remain largely unknown. In the present study, we cloned a full-length TSPyV LT cDNA from cells transfected with the full-length of TSPyV LT DNA. Transfection study using green fluorescence protein-tagged LT expression plasmids showed that TSPyV LT was expressed in the nucleus of transfected cells. Analysis of deletion mutants identified a nuclear localization signal in TSPyV LT. Recombinant TSPyV LT exhibited an ATPase activity. TSPyV LT has a chitinase-like domain; however, no chitinase activity was detected. Immunoprecipitation assays revealed that TSPyV LT bound to retinoblastoma 1, but not to p53 in transfected cells. Expression of TSPyV LT in NIH3T3 cells induced colony formation in soft agar, suggesting its transformation activity. These data indicate that TSPyV LT may be associated with the pathogenesis of trichodysplasia spinulosa, which is a hyperplasia of keratinocytes in inner hair follicles. - Severe fever with thrombocytopenia syndrome virus targets B cells in lethal human infections.
Tadaki Suzuki; Yuko Sato; Kaori Sano; Takeshi Arashiro; Harutaka Katano; Noriko Nakajima; Masayuki Shimojima; Michiyo Kataoka; Kenta Takahashi; Yuji Wada; Shigeru Morikawa; Shuetsu Fukushi; Tomoki Yoshikawa; Masayuki Saijo; Hideki Hasegawa
The Journal of clinical investigation, 130, 2, 799, 812, 03 Feb. 2020, [Peer-reviewed], [International Magazine]
English, Scientific journal, Severe fever with thrombocytopenia syndrome (SFTS) is an emerging hemorrhagic fever caused by a tick-borne banyangvirus and is associated with high fatality. Despite increasing incidence of SFTS and serious public health concerns in East Asia, the pathogenesis of lethal SFTS virus (SFTSV) infection in humans is not fully understood. Numbers of postmortem examinations to determine target cells of the viral infection have so far been limited. Here we showed that B cells differentiating into plasmablasts and macrophages in secondary lymphoid organs were targets for SFTSV at the end stage of lethal infection, and the majority of SFTSV-infected cells were B cell-lineage lymphocytes. In affected individuals, B cell-lineage lymphocytes with SFTSV infection were widely distributed in both lymphoid and nonlymphoid organs, and infiltration of these cells into the capillaries of the organs could be observed occasionally. Moreover, a human plasmablastic lymphoma cell line, PBL-1, was susceptible to SFTSV propagation and had a similar immunophenotype to that of target cells of SFTSV in fatal SFTS. PBL-1 can therefore provide a potential in vitro model for human SFTSV infection. These results extend our understanding of the pathogenesis of human lethal SFTSV infection and can facilitate the development of SFTSV countermeasures. - Neuropathology in Neonatal Mice After Experimental Coxsackievirus B2 Infection Using a Prototype Strain, Ohio-1.
Waka Ushioda; Osamu Kotani; Kengo Kawachi; Naoko Iwata-Yoshikawa; Tadaki Suzuki; Hideki Hasegawa; Hiroyuki Shimizu; Kimimasa Takahashi; Noriyo Nagata
Journal of neuropathology and experimental neurology, 79, 2, 209, 225, 01 Feb. 2020, [Peer-reviewed], [International Magazine]
English, Scientific journal, Coxsackievirus B (CVB) causes severe morbidity and mortality in neonates and is sometimes associated with severe brain damage resulting from acute severe viral encephalomyelitis. However, the neuropathology of CVB infection remains unclear. A prototype strain of coxsackievirus B2 (Ohio-1) induces brain lesions in neonatal mice, resulting in dome-shaped heads, ventriculomegaly, and loss of the cerebral cortex. Here, we characterized the glial pathology in this mouse model. Magnetic resonance imaging revealed an absence of the cerebral cortex within 2 weeks after inoculation. Histopathology showed that virus replication triggered activation of microglia and astrocytes, and induced apoptosis in the cortex, with severe necrosis and lateral ventricular dilation. In contrast, the brainstem and cerebellum remained morphologically intact. Immunohistochemistry revealed high expression of the coxsackievirus and adenovirus receptor (a primary receptor for CVB) in mature neurons of the cortex, hippocampus, thalamus, and midbrain, demonstrating CVB2 infection of mature neurons in these areas. However, apoptosis and neuroinflammation from activated microglia and astrocytes differed in thalamic and cortical areas. Viral antigens were retained in the brains of animals in the convalescence phase with seroconversion. This animal model will contribute to a better understanding of the neuropathology of CVB infection. - Inefficient Tax-specific T-cell responses in mice after syngeneic transplantation with tax-transgenic mouse-derived adult T-cell leukemia cells.
Midori Nakamura-Hoshi; Tadaki Suzuki; Akira Ainai; Hideki Hasegawa; Hiroshi Ishii; Tetsuro Matano
Japanese journal of infectious diseases, 73, 3, 221, 225, 31 Jan. 2020, [Peer-reviewed], [Domestic magazines]
English, Scientific journal, Adult T-cell leukemia (ATL) is induced by chronic latent infection of human T-cell leukemia virus type 1 (HTLV-1). HTLV-1 Tax is an oncogenic factor and can be a target for host T-cell responses. However, Tax expression in vivo is little in ATL cells and the impact of Tax-specific T-cell responses on ATL progression remains unclear. In the present study, we examined Tax-specific T-cell responses in C57BL/6 mice after syngeneic transplantation with tax-transgenic mouse-derived ATL (mATL) cells. We first confirmed that cellular tax cDNAs are mostly maintained and detectable in the spleen three weeks after mATL cell transplantation. The mATL cell transplantation did not induce significant Tax-specific T-cell responses. Mice immunized with DNA and adenovirus vectors expressing Tax elicited Tax-specific CD4+ T-cell responses but showed no enhancement of the responses or reduction in cellular tax cDNA levels after mATL cell transplantation. This study provides an animal model for analyzing the interaction between ATL cells and host immune responses and indicates limited impact of Tax-specific T-cell responses on ATL cell proliferation. - Different Starting Dominant Strain of Seasonal Influenza in China and Other Neighboring Asian Countries in 2019-2020 Winter Season.
Jing Yang; Weijuan Huang; Yanhui Cheng; Tao Chen; Minju Tan; Qian Guo; Hejiang Wei; Fei Zhu; Tomoko Kuwahara; Xiyan Li; Xiang Zhao; Hideki Hasegawa; George F Gao; Dayan Wang
China CDC weekly, 2, 4, 57, 60, 24 Jan. 2020, [International Magazine]
English, Scientific journal - Candidatus Mycoplasma haemohominis in Human, Japan.
Norimichi Hattori; Makoto Kuroda; Harutaka Katano; Takahiro Takuma; Takayoshi Ito; Nana Arai; Ryo Yanai; Tsuyoshi Sekizuka; Sho Ishii; Yoko Miura; Takahiro Tokunaga; Hiroyuki Watanabe; Norihiro Nomura; Junichi Eguchi; Hideki Hasegawa; Tsuyoshi Nakamaki; Takaji Wakita; Yoshihito Niki
Emerging infectious diseases, 26, 1, 11, 19, Jan. 2020, [International Magazine]
English, Scientific journal, Hemotropic mycoplasmas are common pathogens in animals, but it remains unclear what role these pathogens play in human infections. We report clinical and biologic characterization of Candidatus Mycoplasma haemohominis infection in a 42-year-old man in Japan. The patient had severe hemophagocytic syndrome 1 month after an accidental needlestick injury. Metagenomic deep sequencing identified Candidatus M. haemohominis and determined its draft genome for an isolate from serum of the patient. A high copy number of the Candidatus M. haemohominis genome was detected in serum and bone marrow samples. Electron microscopy examination showed morphologic characteristics of Candidatus M. haemohominis. Levofloxacin monotherapy induced resistance caused by a gyrase A gene mutation in the quinolone resistance-determining region, but a combination treatment with moxifloxacin and minocycline was effective. We identified Candidatus M. haemohominis in a patient who had life-threatening symptoms related to multiple organ infection. Human infection with this mycoplasma might occur more frequently than has been generally recognized. - Potency of gastrointestinal colonization and virulence of Candida auris in a murine endogenous candidiasis.
Masahiro Abe; Harutaka Katano; Minoru Nagi; Yoshitsugu Higashi; Yuko Sato; Ken Kikuchi; Hideki Hasegawa; Yoshitsugu Miyazaki
PloS one, 15, 12, e0243223, 2020, [International Magazine]
English, Scientific journal, BACKGROUND: Candida auris infections have recently emerged worldwide, and this species is highly capable of colonization and is associated with high levels of mortality. However, strain-dependent differences in colonization capabilities and virulence have not yet been reported. OBJECTIVES: In the present study, we aimed to clarify the differences between clinically isolated invasive and non-invasive strains of C. auris. METHODS: We evaluated colonization, dissemination, and survival rates in wild C57BL/6J mice inoculated with invasive or non-invasive strains of C. auris under cortisone acetate immunosuppression, comparing with those of Candida albicans and Candida glabrata infections. We also evaluated the potency of biofilm formation. RESULTS: Stool fungal burdens were significantly higher in mice inoculated with the invasive strains than in those infected with the non-invasive strain. Along with intestinal colonization, liver and kidney fungal burdens were also significantly higher in mice inoculated with the invasive strains. In addition, histopathological findings revealed greater dissemination and colonization of the invasive strains. Regarding biofilm-forming capability, the invasive strain of C. auris exhibited a significantly higher capacity of producing biofilms. Moreover, inoculation with the invasive strains resulted in significantly greater loss of body weight than that noted following infection with the non-invasive strain. CONCLUSIONS: Invasive strains showed higher colonization capability and rates of dissemination from gastrointestinal tracts under cortisone acetate immunosuppression than non-invasive strains, although the mortality rates caused by C. auris were lower than those caused by C. albicans. - A Novel Gene Delivery Vector of Agonistic Anti-Radioprotective 105 Expressed on Cell Membranes Shows Adjuvant Effect for DNA Immunization Against Influenza.
Tatsuya Yamazaki; Mrityunjoy Biswas; Kouyu Kosugi; Maria Nagashima; Masanori Inui; Susumu Tomono; Hidekazu Takagi; Isao Ichimonji; Fumiaki Nagaoka; Akira Ainai; Hideki Hasegawa; Joe Chiba; Sachiko Akashi-Takamura
Frontiers in immunology, 11, 606518, 606518, 2020, [International Magazine]
English, Scientific journal, Radioprotective 105 (RP105) (also termed CD180) is an orphan and unconventional Toll-like receptor (TLR) that lacks an intracellular signaling domain. The agonistic anti-RP105 monoclonal antibody (mAb) can cross-link RP105 on B cells, resulting in the proliferation and activation of B cells. Anti-RP105 mAb also has a potent adjuvant effect, providing higher levels of antigen-specific antibodies compared to alum. However, adjuvanticity is required for the covalent link between anti-RP105 mAb and the antigen. This is a possible obstacle to immunization due to the link between anti-RP105 mAb and some antigens, especially multi-transmembrane proteins. We have previously succeeded in inducing rapid and potent recombinant mAbs in mice using antibody gene-based delivery. To simplify the covalent link between anti-RP105 mAb and antigens, we generated genetic constructs of recombinant anti-RP105 mAb (αRP105) bound to the transmembrane domain of the IgG-B cell receptor (TM) (αRP105-TM), which could enable the anti-RP105 mAb to link the antigen via the cell membrane. We confirmed the expression of αRP105-TM and the antigen hemagglutinin, which is a membrane protein of the influenza virus, on the same cell. We also found that αRP105-TM could activate splenic B cells, including both mature and immature cells, depending on the cell surface RP105 in vitro. To evaluate the adjuvanticity of αRP105-TM, we conducted DNA immunization in mice with the plasmids encoding αRP105-TM and hemagglutinin, followed by challenge with an infection of a lethal dose of an influenza virus. We then obtained partially but significantly hemagglutinin-specific antibodies and observed protective effects against a lethal dose of influenza virus infection. The current αRP105-TM might provide adjuvanticity for a vaccine via a simple preparation of the expression plasmids encoding αRP105-TM and of that encoding the target antigen. - Influenza A variants with reduced susceptibility to baloxavir isolated from Japanese patients are fit and transmit through respiratory droplets.
Masaki Imai; Makoto Yamashita; Yuko Sakai-Tagawa; Kiyoko Iwatsuki-Horimoto; Maki Kiso; Jurika Murakami; Atsuhiro Yasuhara; Kosuke Takada; Mutsumi Ito; Noriko Nakajima; Kenta Takahashi; Tiago J S Lopes; Jayeeta Dutta; Zenab Khan; Divya Kriti; Harm van Bakel; Akifumi Tokita; Haruhisa Hagiwara; Naomi Izumida; Haruo Kuroki; Tamon Nishino; Noriyuki Wada; Michiko Koga; Eisuke Adachi; Daisuke Jubishi; Hideki Hasegawa; Yoshihiro Kawaoka
Nature microbiology, 5, 1, 27, 33, Jan. 2020, [Peer-reviewed], [International Magazine]
English, Scientific journal, Here we report the isolation of the influenza A/H1N1 2009 pandemic (A/H1N1pdm) and A/H3N2 viruses carrying an I38T mutation in the polymerase acidic protein-a mutation that confers reduced susceptibility to baloxavir marboxil-from patients before and after treatment with baloxavir marboxil in Japan. These variants showed replicative abilities and pathogenicity that is similar to those of wild-type isolates in hamsters; they also transmitted efficiently between ferrets by respiratory droplets. - Gold nanoparticle-adjuvanted S protein induces a strong antigen-specific IgG response against severe acute respiratory syndrome-related coronavirus infection, but fails to induce protective antibodies and limit eosinophilic infiltration in lungs.
Hanako Sekimukai; Naoko Iwata-Yoshikawa; Shuetsu Fukushi; Hideki Tani; Michiyo Kataoka; Tadaki Suzuki; Hideki Hasegawa; Kenichi Niikura; Katsuhiko Arai; Noriyo Nagata
Microbiology and immunology, 64, 1, 33, 51, Jan. 2020, [Peer-reviewed], [International Magazine]
English, Scientific journal, The spike (S) protein of coronavirus, which binds to cellular receptors and mediates membrane fusion for cell entry, is a candidate vaccine target for blocking coronavirus infection. However, some animal studies have suggested that inadequate immunization against severe acute respiratory syndrome coronavirus (SARS-CoV) induces a lung eosinophilic immunopathology upon infection. The present study evaluated two kinds of vaccine adjuvants for use with recombinant S protein: gold nanoparticles (AuNPs), which are expected to function as both an antigen carrier and an adjuvant in immunization; and Toll-like receptor (TLR) agonists, which have previously been shown to be an effective adjuvant in an ultraviolet-inactivated SARS-CoV vaccine. All the mice immunized with more than 0.5 µg S protein without adjuvant escaped from SARS after infection with mouse-adapted SARS-CoV; however, eosinophilic infiltrations were observed in the lungs of almost all the immunized mice. The AuNP-adjuvanted protein induced a strong IgG response but failed to improve vaccine efficacy or to reduce eosinophilic infiltration because of highly allergic inflammatory responses. Whereas similar virus titers were observed in the control animals and the animals immunized with S protein with or without AuNPs, Type 1 interferon and pro-inflammatory responses were moderate in the mice treated with S protein with and without AuNPs. On the other hand, the TLR agonist-adjuvanted vaccine induced highly protective antibodies without eosinophilic infiltrations, as well as Th1/17 cytokine responses. The findings of this study will support the development of vaccines against severe pneumonia-associated coronaviruses. - 2019 meeting of the global virus network.
Ramesh Akkina; Robert Garry; Christian Bréchot; Heinz Ellerbrok; Hideki Hasegawa; Luis Menéndez-Arias; Natalia Mercer; Johan Neyts; Victor Romanowski; Joaquim Segalés; Anders Vahlne
Antiviral research, 172, 104645, 104645, Dec. 2019, [International Magazine]
English, Scientific journal, The Global Virus Network (GVN) was established in 2011 to strengthen research and responses to emerging viral causes of human disease and to prepare against new viral pandemics. There are now 52 GVN Centers of Excellence and 9 Affiliate laboratories in 32 countries. The 11th International GVN meeting was held from June 9-11, 2019 in Barcelona, Spain and was jointly organized with the Spanish Society of Virology. A common theme throughout the meeting was globalization and climate change. This report highlights the recent accomplishments of GVN researchers in several important areas of medical virology, including severe virus epidemics, anticipation and preparedness for changing disease dynamics, host-pathogen interactions, zoonotic virus infections, ethical preparedness for epidemics and pandemics, one health and antivirals. - Human-to-Human Transmission of Influenza A(H3N2) Virus with Reduced Susceptibility to Baloxavir, Japan, February 2019.
Emi Takashita; Masataka Ichikawa; Hiroko Morita; Rie Ogawa; Seiichiro Fujisaki; Masayuki Shirakura; Hideka Miura; Kazuya Nakamura; Noriko Kishida; Tomoko Kuwahara; Hiromi Sugawara; Aya Sato; Miki Akimoto; Keiko Mitamura; Takashi Abe; Masahiko Yamazaki; Shinji Watanabe; Hideki Hasegawa; Takato Odagiri
Emerging infectious diseases, 25, 11, 2108, 2111, Nov. 2019, [International Magazine]
English, Scientific journal, In 2019, influenza A(H3N2) viruses carrying an I38T substitution in the polymerase acidic gene, which confers reduced susceptibility to baloxavir, were detected in Japan in an infant without baloxavir exposure and a baloxavir-treated sibling. These viruses' whole-genome sequences were identical, indicating human-to-human transmission. Influenza virus isolates should be monitored for baloxavir susceptibility. - Intranasal vaccination with HBs and HBc protein combined with carboxyl vinyl polymer induces strong neutralizing antibody, anti-HBs IgA, and IFNG response
Takahiro Sanada; Naoki Yamamoto; Mohammad Enamul Hoque Kayesh; Kyoko Tsukiyama-Kohara; Hideki Hasegawa; Takashi Miyazaki; Jun-ichiro Takano; Yumiko Shiogama; Yasuhiro Yasutomi; Yasumasa Goh; Osamu Yoshida; Yoichi Hiasa; Michinori Kohara
Biochemical and Biophysical Research Communications, 520, 1, 86, 92, Elsevier BV, Nov. 2019
Scientific journal - Serial Section Array Scanning Electron Microscopy Analysis of Cells from Lung Autopsy Specimens following Fatal A/H1N1 2009 Pandemic Influenza Virus Infection.
Michiyo Kataoka; Kinji Ishida; Katsutoshi Ogasawara; Takayuki Nozaki; Yoh-Ichi Satoh; Tetsutaro Sata; Yuko Sato; Hideki Hasegawa; Noriko Nakajima
Journal of virology, 93, 19, 01 Oct. 2019, [International Magazine]
English, Scientific journal, A/H1N1 2009 pandemic influenza virus (A/H1N1/pdm09) was first identified as a novel pandemic influenza A virus (IAV) in 2009. Previously, we reported that many viral antigens were detected in type II alveolar epithelial cells (AEC-IIs) within autopsied lung tissue from a patient with A/H1N1/pdm09 pneumonia. It is important to identify the association between the virus and host cells to elucidate the pathogenesis of IAV pneumonia. To investigate the distribution of virus particles and morphological changes in host cells, the autopsied lung specimens from this patient were examined using transmission electron microscopy (TEM) and a novel scanning electron microscopy (SEM) method. We focused on AEC-IIs as viral antigen-positive cells and on monocytes/macrophages (Ms/Mϕs) and neutrophils (Neus) as innate immune cells. We identified virus particles and intranuclear dense tubules, which are associated with matrix 1 (M1) proteins from IAV. Large-scale two-dimensional observation was enabled by digitally "stitching" together contiguous SEM images. A single whole-cell analysis using a serial section array (SSA)-SEM identified virus particles in vesicles within the cytoplasm and/or around the surfaces of AEC-IIs, Ms/Mϕs, and Neus; however, intranuclear dense tubules were found only in AEC-IIs. Computer-assisted processing of SSA-SEM images from each cell type enabled three-dimensional (3D) modeling of the distribution of virus particles within an ACE-II, a M/Mϕ, and a Neu.IMPORTANCE Generally, it is difficult to observe IAV particles in postmortem samples from patients with seasonal influenza. In fact, only a few viral antigens are detected in bronchial epithelial cells from autopsied lung sections. Previously, we detected many viral antigens in AEC-IIs from the lung. This was because the majority of A/H1N1/pdm09 in the lung tissue harbored an aspartic acid-to-glycine substitution at position 222 (D222G) of the hemagglutinin protein. A/H1N1/pdm09 harboring the D222G substitution has a receptor-binding preference for α-2,3-linked sialic acids expressed on human AECs and infects them in the same way as H5N1 and H7N9 avian IAVs. Here, we report the first successful observation of virus particles, not only in AEC-IIs, but also in Ms/Mϕs and Neus, using electron microscopy. The finding of a M/Mϕ harboring numerous virus particles within vesicles and at the cell surface suggests that Ms/Mϕs are involved in the pathogenesis of IAV primary pneumonia. - Acute Liver Failure Associated with Influenza A Virus Infection: an Autopsy Case Report.
Keisuke Nonaka; Yoko Matsuda; Mototsune Kakizaki; Shoichiro Takakuma; Akihiko Hamamatsu; Yasuhiro Sakashita; Tomoyasu Matsubara; Shigeo Murayama; Toshiyuki Ishiwata; Noriko Yamanaka; Mitsuyo Itabashi; Takashi Takei; Noriko Nakajima; Hideki Hasegawa; Tomio Arai
Japanese journal of infectious diseases, 72, 5, 347, 349, 19 Sep. 2019, [Peer-reviewed], [Domestic magazines]
English, Scientific journal, An 84-year-old man with chronic renal failure, anemia, and diabetes was admitted for hemodialysis initiation. His vital signs were stable until the eighteenth hospital day, before acquiring an influenza A virus infection. Three days later, he died of septic shock with severe liver impairment. His leukocyte count, prothrombin time (PT-INR), and liver enzyme levels such as aspartate transaminase and alanine aminotransferase, were significantly increased. Hypercytokinemia was also observed. Autopsy revealed bilateral diffuse pneumonia with neutrophil infiltration. The liver showed extensive centrilobular hepatocyte necrosis. Immunohistochemistry for influenza A nucleoprotein revealed positivity in the ciliated columnar epithelium of the bronchi and negativity in the trachea, lungs, and liver. Hypoxic hepatitis is characterized by an abrupt and massive increase in aminotransferase levels (> 20 times upper normal limit) due to anoxic centrilobular hepatocyte necrosis. The occurrence of hypoxic hepatitis requires a pre-existing, chronic condition, such as anemia, causing reduced oxygen supply to the liver, followed by an acute decrease in hepatic oxygen supply, such as septic shock. Therefore, this report suggests that hypoxic hepatitis can be an important causative factor for acute liver failure associated with influenza virus infection. - A Glycolipid Adjuvant, 7DW8-5, Enhances the Protective Immune Response to the Current Split Influenza Vaccine in Mice
Huapeng Feng; Noriko Nakajima; Li Wu; Makoto Yamashita; Tiago J. S. Lopes; Moriya Tsuji; Hideki Hasegawa; Tokiko Watanabe; Yoshihiro Kawaoka
Frontiers in Microbiology, 10, Frontiers Media SA, 18 Sep. 2019, [Peer-reviewed]
Scientific journal - Exposure of an occluded hemagglutinin epitope drives selection of a class of cross-protective influenza antibodies.
Yu Adachi; Keisuke Tonouchi; Arnone Nithichanon; Masayuki Kuraoka; Akiko Watanabe; Ryo Shinnakasu; Hideki Asanuma; Akira Ainai; Yusuke Ohmi; Takuya Yamamoto; Ken J Ishii; Hideki Hasegawa; Haruko Takeyama; Ganjana Lertmemongkolchai; Tomohiro Kurosaki; Manabu Ato; Garnett Kelsoe; Yoshimasa Takahashi
Nature communications, 10, 1, 3883, 3883, 28 Aug. 2019, [Peer-reviewed], [International Magazine]
English, Scientific journal, Germinal center (GC) B cells at viral replication sites acquire specificity to poorly immunogenic but conserved influenza hemagglutinin (HA) epitopes. Here, high-throughput epitope mapping of local GC B cells is used to identify conserved HA epitope selecting cross-reactive antibodies that mediate heterosubtypic protection. A distinct feature of this epitope is an occlusion in the naive trimeric HA structure that is exposed in the post-fusion HA structure to occur under low pH conditions during viral replication. Importantly, systemic immunization by the post-fusion HA antigen results in GC B cells targeting the occluded epitope, and induces a class of protective antibodies that have cross-group specificity and afford protection independent of virus neutralization activity. Furthermore, this class of broadly protective antibodies develops at late time points and persists. Our results identify a class of cross-protective antibodies that are selected at the viral replication site, and provide insights into vaccine strategies using the occluded epitope. - CpG ODN G9.1 as a novel nasal ODN adjuvant elicits complete protection from influenza virus infection without causing inflammatory immune responses.
Koichiro Tateishi; Kohtaro Fujihashi; Norio Yamamoto; Hideki Hasegawa; Akira Ainai; Kayoko Sato; Sumiko Iho; Saburo Yamamoto; Jun-Ichi Maeyama; Takato Odagiri; Hideki Asanuma
Vaccine, 37, 36, 5382, 5389, 23 Aug. 2019, [International Magazine]
English, Scientific journal, This study examined the protective efficacy of and immune response to a nasal influenza vaccine combined with a novel mucosal oligodeoxynucleotide (ODN) adjuvant, CpG ODN G9.1 (G9.1), in a model of infection limited to the upper respiratory tract (URT) and a model of infection in the lower respiratory tract (LRT). Mice were nasally primed with an A/California/7/2009 (Cal7) split vaccine (X179A) plus G9.1 and were then nasally given a booster with X179A alone. When mice were challenged with either a large (infection of the LRT) or small (infection limited to the URT) volume of live Cal7 influenza virus, mice nasally given G9.1 combined with X179A had a markedly higher rate of protection against infection limited to the URT. Moreover, this group of mice promptly recovered from an infection of the LRT. When mice were subcutaneously (s.c.) given X179A as a current form of vaccination, they had no protection from an infection limited to the URT but they did recover from an infection of the LRT. The patterns of protection were closely correlated with influenza virus-specific mucosal secretory IgA (SIgA) or serum IgG antibody (Ab) responses. Thus, SIgA Abs responses play an important role in protection from an infection limited to the URT while influenza virus-specific serum IgG Ab responses help to protect from an infection of the LRT. A finding of note is that lungs from mice nasally given G9.1 had low levels of type I IFN-associated protein- and transcription factor-specific mRNA expression. These results suggest that nasal G9.1 can be used as an effective and safe mucosal adjuvant for influenza vaccines since this nasal vaccine system elicits both mucosal SIgA and serum IgG Ab responses that provide complete protection without inducing potent inflammatory responses. - Severe Fever with Thrombocytopenia Syndrome Phlebovirus causes lethal viral hemorrhagic fever in cats.
Eun-Sil Park; Masayuki Shimojima; Noriyo Nagata; Yasushi Ami; Tomoki Yoshikawa; Naoko Iwata-Yoshikawa; Shuetsu Fukushi; Shumpei Watanabe; Takeshi Kurosu; Michiyo Kataoka; Akiko Okutani; Masanobu Kimura; Koichi Imaoka; Kenichi Hanaki; Tadaki Suzuki; Hideki Hasegawa; Masayuki Saijo; Ken Maeda; Shigeru Morikawa
Scientific reports, 9, 1, 11990, 11990, 19 Aug. 2019, [Peer-reviewed], [International Magazine]
English, Scientific journal, Severe fever with thrombocytopenia syndrome (SFTS) is an emerging hemorrhagic fever caused by the SFTS phlebovirus (SFTSV). SFTS patients were first reported in China, followed by Japan and South Korea. In 2017, cats were diagnosed with SFTS for the first time, suggesting that these animals are susceptible to SFTSV. To confirm whether or not cats were indeed susceptible to SFTSV, animal subjects were experimentally infected with SFTSV. Four of the six cats infected with the SPL010 strain of SFTSV died, all showing similar or more severe symptoms than human SFTS patients, such as a fever, leukocytopenia, thrombocytopenia, weight loss, anorexia, jaundice and depression. High levels of SFTSV RNA loads were detected in the serum, eye swab, saliva, rectal swab and urine, indicating a risk of direct human infection from SFTS-infected animals. Histopathologically, acute necrotizing lymphadenitis and hemophagocytosis were prominent in the lymph nodes and spleen. Severe hemorrhaging was observed throughout the gastrointestinal tract. B cell lineage cells with MUM-1 and CD20, but not Pax-5 in the lesions were predominantly infected with SFTSV. The present study demonstrated that cats were highly susceptible to SFTSV. The risk of direct infection from SFTS-infected cats to humans should therefore be considered. - Transient Appearance of Plasmablasts in the Peripheral Blood of Japanese Patients With Severe Fever With Thrombocytopenia Syndrome.
Toru Takahashi; Tadaki Suzuki; Shunsuke Hiroshige; Shota Nouno; Takuro Matsumura; Takayuki Tominaga; Toshiaki Yujiri; Harutaka Katano; Yuko Sato; Hideki Hasegawa
The Journal of infectious diseases, 220, 1, 23, 27, 05 Jun. 2019, [Peer-reviewed], [International Magazine]
English, Scientific journal, Atypical lymphocytes in the peripheral blood in patients with severe fever with thrombocytopenia syndrome (SFTS) have not been well examined. In this study, we analyzed counts and characteristics of atypical lymphocytes in 7 patients with SFTS. Atypical lymphocytes resembled plasma cells morphologically and appeared in the peripheral blood of all patients 4-8 days after onset of disease. Among these lymphocytes flow cytometry showed a CD19+CD38+CD138-/+ phenotype, and immunohistochemical staining revealed a CD79a+CD38+CD138-/+CD27+ phenotype. From our observations, atypical lymphocytes transiently that appeared in the peripheral blood during the acute phase of SFTS were considered to be plasmablasts. - Cutaneous histopathology of the tick-bite region in severe fever with thrombocytopenia syndrome.
Sato T; Nishida H; Goto M; Sho Y; Yamate T; Daa T; Yokoyama S; Kurosawa K; Matsunari O; Sakamoto T; Matsumoto H; Suzuki T; Hasegawa H; Takeo N; Hatano Y
The Journal of dermatology, 46, 5, 409, 412, May 2019, [Peer-reviewed], [International Magazine]
English, Scientific journal, A case of severe fever with thrombocytopenia syndrome (SFTS) in which a skin biopsy from the tick-bite region was analyzed is reported. The patient was a 72-year-old woman who developed fever and thrombocytopenia after a tick bite. SFTS was diagnosed from polymerase chain reaction (PCR) analysis of a blood sample. Histopathological analysis of a skin biopsy specimen from the tick-bite region showed CD20-positive perivascular and interstitial immunoblastic cells, which were positive to anti-SFTS virus (SFTSV) nucleoprotein antibody. In addition, SFTSV RNA was detected by real-time PCR from this biopsy specimen. Moreover, hemophagocytosis was also found in the tick-bite region. To the best of our knowledge, this is the first report to analyze the details of the tick-bite region of skin in SFTS, and the first to detect virus-infected cells in the skin. The present findings may help elucidate the mechanisms of entry of SFTSV. - Disseminated histoplasmosis from a calcified lung nodule after long-term corticosteroid therapy in an elderly Japanese patient: A case report.
Keigo Kobayashi; Takanori Asakura; Ichiro Kawada; Hanako Hasegawa; Shotaro Chubachi; Kentaro Ohara; Junko Kuramoto; Hiroaki Sugiura; Seitaro Fujishima; Satoshi Iwata; Takashi Umeyama; Harutaka Katano; Yoshifumi Uwamino; Yoshitsugu Miyazaki; Katsuhiko Kamei; Naoki Hasegawa; Tomoko Betsuyaku
Medicine, 98, 17, e15264, Medicine, Apr. 2019, [International Magazine]
English, Scientific journal, RATIONALE: Histoplasmosis occurs most commonly in Northern and Central America and Southeast Asia. Increased international travel in Japan has led to a few annual reports of imported histoplasmosis. Healed sites of histoplasmosis lung infection may remain as nodules and are often accompanied by calcification. Previous studies in endemic areas supported the hypothesis that new infection/reinfection, rather than reactivation, is the main etiology of symptomatic histoplasmosis. No previous reports have presented clinical evidence of reactivation. PATIENT CONCERNS: An 83-year-old Japanese man was hospitalized with general fatigue and high fever. He had been treated with prednisolone at 13 mg/d for 7 years because of an eczematous skin disease. He had a history of travel to Los Angeles, Egypt, and Malaysia 10 to 15 years prior to admission. Five years earlier, computed tomography (CT) identified a solitary calcified nodule in the left lingual lung segment. The nodule size remained unchanged throughout a 5-year observation period. Upon admission, his respiratory condition remained stable while breathing room air. CT revealed small, randomly distributed nodular shadows in the bilateral lungs, in addition to the solitary nodule. DIAGNOSIS: Disseminated histoplasmosis, based on fungal staining and cultures of autopsy specimens. INTERVENTIONS: The patient's fever continued despite several days of treatment with meropenem, minocycline, and micafungin. Although he refused bone marrow aspiration, isoniazid, rifampicin, ethambutol, and prednisolone were administered for a tentative diagnosis of miliary tuberculosis. OUTCOMES: His fever persisted, and a laboratory examination indicated severe thrombocytopenia with disseminated intravascular coagulation. He died on day 43 postadmission. During autopsy, the fungal burden was noted to be higher in the calcified nodule than in the disseminated nodules of the lung, suggesting a pathogenesis involving endogenous reactivation of the nodule and subsequent hematogenous and lymphatic spread. LESSONS: Physicians should consider histoplasmosis in patients with calcified nodules because the infection may reactivate during long-term corticosteroid therapy. - Identification of Mouse and Human Antibody Repertoires by Next-Generation Sequencing.
Lin Sun; Naoko Kono; Hiroyuki Toh; Hanbing Xue; Kaori Sano; Tadaki Suzuki; Akira Ainai; Yasuko Orba; Junya Yamagishi; Hideki Hasegawa; Yoshimasa Takahashi; Shigeyuki Itamura; Kazuo Ohnishi
Journal of visualized experiments : JoVE, 145, 15 Mar. 2019, [Peer-reviewed], [International Magazine]
English, Scientific journal, The immense adaptability of antigen recognition by antibodies is the basis of the acquired immune system. Despite our understanding of the molecular mechanisms underlying the production of the vast repertoire of antibodies by the acquired immune systems, it has not yet been possible to arrive at a global view of a complete antibody repertoire. In particular, B cell repertoires have been regarded as a black box because of their astronomical number of antibody clones. However, next-generation sequencing technologies are enabling breakthroughs to increase our understanding of the B cell repertoire. In this report, we describe a simple and efficient method to visualize and analyze whole individual mouse and human antibody repertoires. From the immune organs, representatively from spleen in mice and peripheral blood mononuclear cells in humans, total RNA was prepared, reverse transcribed, and amplified using the 5'-RACE method. Using a universal forward primer and antisense primers for the antibody class-specific constant domains, antibody mRNAs were uniformly amplified in proportions reflecting their frequencies in the antibody populations. The amplicons were sequenced by next-generation sequencing (NGS), yielding more than 105 antibody sequences per immunological sample. We describe the protocols for antibody sequence analyses including V(D)J-gene-segment annotation, a bird's-eye view of the antibody repertoire, and our computational methods. - Acute Respiratory Infection in Human Dipeptidyl Peptidase 4-Transgenic Mice Infected with Middle East Respiratory Syndrome Coronavirus.
Iwata-Yoshikawa N; Okamura T; Shimizu Y; Kotani O; Sato H; Sekimukai H; Fukushi S; Suzuki T; Sato Y; Takeda M; Tashiro M; Hasegawa H; Nagata N
Journal of virology, 93, 6, Mar. 2019, [Peer-reviewed], [International Magazine]
English, Scientific journal, Middle East respiratory syndrome coronavirus (MERS-CoV) infection can manifest as a mild illness, acute respiratory distress, organ failure, or death. Several animal models have been established to study disease pathogenesis and to develop vaccines and therapeutic agents. Here, we developed transgenic (Tg) mice on a C57BL/6 background; these mice expressed human CD26/dipeptidyl peptidase 4 (hDPP4), a functional receptor for MERS-CoV, under the control of an endogenous hDPP4 promoter. We then characterized this mouse model of MERS-CoV. The expression profile of hDPP4 in these mice was almost equivalent to that in human tissues, including kidney and lung; however, hDPP4 was overexpressed in murine CD3-positive cells within peripheral blood and lymphoid tissues. Intranasal inoculation of young and adult Tg mice with MERS-CoV led to infection of the lower respiratory tract and pathological evidence of acute multifocal interstitial pneumonia within 7 days, with only transient loss of body weight. However, the immunopathology in young and adult Tg mice was different. On day 5 or 7 postinoculation, lungs of adult Tg mice contained higher levels of proinflammatory cytokines and chemokines associated with migration of macrophages. These results suggest that the immunopathology of MERS-CoV infection in the Tg mouse is age dependent. The mouse model described here will increase our understanding of disease pathogenesis and host mediators that protect against MERS-CoV infection.IMPORTANCE Middle East respiratory syndrome coronavirus (MERS-CoV) infections are endemic in the Middle East and a threat to public health worldwide. Rodents are not susceptible to the virus because they do not express functional receptors; therefore, we generated a new animal model of MERS-CoV infection based on transgenic mice expressing human DPP4 (hDPP4). The pattern of hDPP4 expression in this model was similar to that in human tissues (except lymphoid tissue). In addition, MERS-CoV was limited to the respiratory tract. Here, we focused on host factors involved in immunopathology in MERS-CoV infection and clarified differences in antiviral immune responses between young and adult transgenic mice. This new small-animal model could contribute to more in-depth study of the pathology of MERS-CoV infection and aid development of suitable treatments. - Unusual manifestation of disseminated herpes simplex virus type 2 infection associated with pharyngotonsilitis, esophagitis, and hemophagocytic lymphohisitocytosis without genital involvement.
Shuhei Kurosawa; Noritaka Sekiya; Kazuaki Fukushima; Kazuhiko Ikeuchi; Akito Fukuda; Hideyuki Takahashi; Fangyi Chen; Hideki Hasegawa; Harutaka Katano; Tsunekazu Hishima; Keigo Setoguchi
BMC infectious diseases, 19, 1, 65, 65, 17 Jan. 2019, [Peer-reviewed], [International Magazine]
English, Scientific journal, BACKGROUND: Herpes simplex virus (HSV) has various presentations, depending on the patient's immune status, age, and the route of transmission. In adults, HSV type 1 is found predominantly in the oral area, and HSV type 2 (HSV-2) is commonly found in the genital area. HSV-2 infection without genital lesions is uncommon. Herein we report a unique case of pharyngotonsillitis as an initial manifestation of disseminated HSV-2 infection without genital involvement. CASE PRESENTATION: A 46-year-old male was admitted to our hospital with a 1-week history of fever and sore throat. His past medical history included hypereosinophilic syndrome diagnosed at age 45 years. Physical examination revealed throat congestion, bilaterally enlarged tonsils with exudates, tender cervical lymphadenopathy in the left posterior triangle, and mild epigastric tenderness. The laboratory data demonstrated bicytopenia, elevated liver enzyme levels, and hyperferritinemia. A bone marrow smear showed hypocellular marrow with histiocytes and hemophagocytosis. The diagnosis of HLH was confirmed, and the patient was treated with methylprednisolone pulse therapy on days 1-3. On day 5, despite initial improvement of the fever and sore throat, multiple, new, small bullae developed on the patient's face, trunk, and extremities. Additional testing showed that he was positive for HSV-specific immunoglobulin M and immunoglobulin G. Disseminated HSV infection was suspected, and intravenous acyclovir (10 mg/kg every 8 h) was begun. A subsequent direct antigen test of a bulla sample was positive for HSV-2. Moreover, tonsillar and esophageal biopsies revealed viral inclusion bodies. Immunohistochemical staining and a quantitative real-time polymerase chain reaction (PCR) assay confirmed the presence of HSV-2. Disseminated HSV-2 infection with multiple bullae, tonsillitis, esophagitis, and suspected hepatic involvement was diagnosed. After a 2-week course of intravenous acyclovir, his hematological status and liver function normalized, and his cutaneous skin lesions resolved. He was discharged on day 22 in good general health and continued taking oral valacyclovir for viral suppression due to his immunosuppressed status. CONCLUSION: Disseminated HSV-2 infection should be considered as one of the differential diagnoses in patients with pharyngotonsillitis and impaired liver function of unknown etiology even if there are no genital lesions. - Immune-focusing properties of virus-like particles improve protective IgA responses
Taishi Onodera; Kana Hashi; Rajni Kant Shukla; Motohiro Miki; Reiko Takai-Todaka; Akira Fujimoto; Masayuki Kuraoka; Tatsuya Miyoshi; Kazuo Kobayashi; Hideki Hasegawa; Manabu Ato; Garnett Kelsoe; Kazuhiko Katayama; Yoshimasa Takahashi
Journal of Immunology, 203, 12, 3282, 3292, 2019, [Peer-reviewed]
Scientific journal - TMPRSS2 contributes to virus spread and immunopathology in the airways of murine models after coronavirus infection.
Iwata-Yoshikawa N; Okamura T; Shimizu Y; Hasegawa H; Takeda M; Nagata N
Journal of virology, 93, 6, Jan. 2019, [Peer-reviewed], [International Magazine]
English, Scientific journal, Transmembrane serine protease TMPRSS2 activates the spike protein of highly pathogenic human coronaviruses such as severe acute respiratory syndrome-related coronavirus (SARS-CoV) and Middle East respiratory syndrome-related coronavirus (MERS-CoV). In vitro, activation induces virus-cell membrane fusion at the cell surface. However, the roles of TMPRSS2 during coronavirus infection in vivo are unclear. Here, we used animal models of SARS-CoV and MERS-CoV infection to investigate the role of TMPRSS2. Th1-prone C57BL/6 mice and TMPRSS2-knockout (KO) mice were used for SARS-CoV infection, and transgenic mice expressing the human MERS-CoV receptor DPP4 (hDPP4-Tg mice) and TMPRSS2-KO hDPP4-Tg mice were used for MERS-CoV infection. After experimental infection, TMPRSS2-deficient mouse strains showed reduced body weight loss and viral kinetics in the lungs. Lack of TMPRSS2 affected the primary sites of infection and virus spread within the airway, accompanied by less severe immunopathology. However, TMPRSS2-KO mice showed weakened inflammatory chemokine and/or cytokine responses to intranasal stimulation with poly(I·C), a Toll-like receptor 3 agonist. In conclusion, TMPRSS2 plays a crucial role in viral spread within the airway of murine models infected by SARS-CoV and MERS-CoV and in the resulting immunopathology.IMPORTANCE Broad-spectrum antiviral drugs against highly pathogenic coronaviruses and other emerging viruses are desirable to enable a rapid response to pandemic threats. Transmembrane protease serine type 2 (TMPRSS2), a protease belonging to the type II transmembrane serine protease family, cleaves the coronavirus spike protein, making it a potential therapeutic target for coronavirus infections. Here, we examined the role of TMPRSS2 using animal models of SARS-CoV and MERS-CoV infection. The results suggest that lack of TMPRSS2 in the airways reduces the severity of lung pathology after infection by SARS-CoV and MERS-CoV. Taken together, the results will facilitate development of novel targets for coronavirus therapy. - IgA tetramerization improves target breadth but not peak potency of functionality of anti-influenza virus broadly neutralizing antibody.
Shinji Saito; Kaori Sano; Tadaki Suzuki; Akira Ainai; Yuki Taga; Tomonori Ueno; Koshiro Tabata; Kumpei Saito; Yuji Wada; Yuki Ohara; Haruko Takeyama; Takato Odagiri; Tsutomu Kageyama; Kiyoko Ogawa-Goto; Pretty Multihartina; Vivi Setiawaty; Krisna Nur Andriana Pangesti; Hideki Hasegawa
PLoS pathogens, 15, 1, e1007427, Jan. 2019, [Peer-reviewed], [International Magazine]
English, Scientific journal, Mucosal immunoglobulins comprise mainly secretory IgA antibodies (SIgAs), which are the major contributor to pathogen-specific immune responses in mucosal tissues. These SIgAs are highly heterogeneous in terms of their quaternary structure. A recent report shows that the polymerization status of SIgA defines their functionality in the human upper respiratory mucosa. Higher order polymerization of SIgA (i.e., tetramers) leads to a marked increase in neutralizing activity against influenza viruses. However, the precise molecular mechanisms underlying the effects of SIgA polymerization remain elusive. Here, we developed a method for generating recombinant tetrameric monoclonal SIgAs. We then compared the anti-viral activities of these tetrameric SIgAs, which possessed variable regions identical to that of a broadly neutralizing anti-influenza antibody F045-092 against influenza A viruses, with that of monomeric IgG or IgA. The tetrameric SIgA showed anti-viral inhibitory activity superior to that of other forms only when the antibody exhibits low-affinity binding to the target. By contrast, SIgA tetramerization did not substantially modify anti-viral activity against targets with high-affinity binding. Taken together, the data suggest that tetramerization of SIgA improved target breadth, but not peak potency of antiviral functions of the broadly neutralizing anti-influenza antibody. This phenomenon presumably represents one of the mechanisms by which SIgAs present in human respiratory mucosa prevent infection by antigen-drifted influenza viruses. Understanding the mechanisms involved in cross neutralization of viruses by SIgAs might facilitate the development of vaccine strategies against viral infection of mucosal tissues. - Mouse LIMR3/CD300f is a negative regulator of the antimicrobial activity of neutrophils.
Ueno K; Urai M; Izawa K; Otani Y; Yanagihara N; Kataoka M; Takatsuka S; Abe M; Hasegawa H; Shimizu K; Kitamura T; Kitaura J; Miyazaki Y; Kinjo Y
Scientific reports, 8, 1, 17406, 17406, Nov. 2018, [Peer-reviewed], [International Magazine]
English, Scientific journal, Leukocyte mono-immunoglobulin-like receptor (LMIR)/CD300 proteins comprise a family of immunoglobulin-like receptors that are widely expressed on the immune cell surface in humans and mice. In general, LMIR3/CD300f suppresses the inflammatory response, but it can occasionally promote it. However, the precise roles of LMIR3 in the function of neutrophils remain to be elucidated. In the present study, we investigated LMIR3 expression in mature and immature neutrophils, and evaluated the effects of LMIR3 deficiency in mouse neutrophils. Our results indicated that bone marrow (BM) neutrophils expressed LMIR3 on their cell surface during cell maturation and that surface LMIR3 expression increased in response to Pseudomonas aeruginosa infection in a TLR4/MyD88-dependent manner. LMIR3-knockout (KO) neutrophils displayed significantly increased hypochlorous acid production, and elastase release, as well as significantly augmented cytotoxic activity against P. aeruginosa and Candida albicans; meanwhile, inhibitors of elastase and myeloperoxidase offset this enhanced antimicrobial activity. Furthermore, LMIR3-KO mice were significantly more resistant to Pseudomonas peritonitis and systemic candidiasis, although this may not be entirely due to the enhanced activity of neutrophils. These results demonstrate that LMIR3/CD300f deficiency augments the antimicrobial activity of mouse neutrophils. - Intranasal inactivated influenza vaccines for the prevention of seasonal influenza epidemics.
Kaori Sano; Akira Ainai; Tadaki Suzuki; Hideki Hasegawa
Expert review of vaccines, 17, 8, 687, 696, Aug. 2018, [Peer-reviewed], [International Magazine]
English, Scientific journal, INTRODUCTION: Intranasal influenza vaccines are expected to confer protection among vaccine recipients by successful induction of mucosal immune response in the upper respiratory tract. Though only live attenuated influenza virus vaccines (LAIVs) are licensed and available for intranasal use in humans today, intranasal inactivated influenza vaccines (IIVs) are currently under reconsideration as a promising intranasal influenza vaccine. AREAS COVERED: This review addresses the history of intranasal IIV research and development, along with a summary of the studies done so far to address the mechanism of action of intranasal IIVs. EXPERT COMMENTARY: From numerous in vitro and in vivo studies, it has been shown that intranasal IIVs can protect hosts from a broad spectrum of influenza virus strains. In-depth studies of the mucosal antibody response following intranasal IIV administration have also elucidated the detailed functions of secretory IgA (immunoglobulin A) antibodies which are responsible for the mechanism of action of intranasal vaccines. Safe and effective intranasal IIVs are expected to be an important tool to combat seasonal influenza. - A Sialylated Voltage-Dependent Ca2+ Channel Binds Hemagglutinin and Mediates Influenza A Virus Entry into Mammalian Cells.
Yoichiro Fujioka; Shinya Nishide; Toyoyuki Ose; Tadaki Suzuki; Izumi Kato; Hideo Fukuhara; Mari Fujioka; Kosui Horiuchi; Aya O Satoh; Prabha Nepal; Sayaka Kashiwagi; Jing Wang; Mika Horiguchi; Yuko Sato; Sarad Paudel; Asuka Nanbo; Tadaaki Miyazaki; Hideki Hasegawa; Katsumi Maenaka; Yusuke Ohba
Cell host & microbe, 23, 6, 809, 818, 13 Jun. 2018, [Peer-reviewed], [International Magazine]
English, Scientific journal, Influenza A virus (IAV) infection is initiated by the attachment of the viral glycoprotein hemagglutinin (HA) to sialic acid on the host cell surface. However, the sialic acid-containing receptor crucial for IAV infection has remained unidentified. Here, we show that HA binds to the voltage-dependent Ca2+ channel Cav1.2 to trigger intracellular Ca2+ oscillations and subsequent IAV entry and replication. IAV entry was inhibited by Ca2+ channel blockers (CCBs) or by knockdown of Cav1.2. The CCB diltiazem also inhibited virus replication in vivo. Reintroduction of wild-type but not the glycosylation-deficient mutants of Cav1.2 restored Ca2+ oscillations and virus infection in Cav1.2-depleted cells, demonstrating the significance of Cav1.2 sialylation. Taken together, we identify Cav1.2 as a sialylated host cell surface receptor that binds HA and is critical for IAV entry. - IgA polymerization contributes to efficient virus neutralization on human upper respiratory mucosa after intranasal inactivated influenza vaccine administration.
Yoshihiko Terauchi; Kaori Sano; Akira Ainai; Shinji Saito; Yuki Taga; Kiyoko Ogawa-Goto; Shin-Ichi Tamura; Takato Odagiri; Masato Tashiro; Mikiya Fujieda; Tadaki Suzuki; Hideki Hasegawa
Human vaccines & immunotherapeutics, 14, 6, 1351, 1361, 03 Jun. 2018, [Peer-reviewed], [International Magazine]
English, Scientific journal, Unlike the current injectable influenza vaccines, intranasally administered influenza vaccines induce influenza virus-specific IgA antibodies in the local respiratory mucosa as well as IgG antibodies in the systemic circulation. Our previous study showed that after five volunteers underwent intranasal administration with inactivated H3N2 or H5N1 vaccines, their IgA antibodies on the upper respiratory tract were present as monomers, dimers, and multimers (trimers and tetramers). Moreover, the multimers associated with the highest virus neutralizing activity. However, it has remained elusive whether a more practical intranasal vaccination strategy could induce the high-performance IgA multimers in the nasal mucosa. In the present study, volunteers were administered with two doses of the intranasal trivalent whole-virus inactivated influenza vaccine and showed that in nasal wash samples the amount of multimeric IgA correlated positively with virus neutralizing titers, indicating that the multimeric IgA antibodies play an important role in the antiviral activity at the nasal mucosa. Surface plasmon resonance analysis of the binding dynamics of nasal wash derived IgA monomers, dimers, and multimers against recombinant trimeric influenza virus HA showed that sample fractions containing IgA multimers dissociated from HA less well than sample fractions without IgA multimers. Thus, IgA multimers may "stick" to the antigen more tightly than the other structures. In summary, intranasal administration of two doses of multivalent inactivated influenza vaccines induced multimeric IgA. Multimerization of mucosal IgA antibodies conferred higher neutralizing activity against viruses in the nasal mucosa, possibly by increasing their cohesion to virus antigens. - The marmoset as an animal model of influenza: Infection with A(H1N1)pdm09 and highly pathogenic a(H5N1) viruses via the conventional or tracheal spray route
Kiyoko Iwatsuki-Horimoto; Noriko Nakajima; Maki Kiso; Kenta Takahashi; Mutsumi Ito; Takashi Inoue; Machiko Horiuchi; Norio Okahara; Erika Sasaki; Hideki Hasegawa; Yoshihiro Kawaoka
Frontiers in Microbiology, 9, MAY, 844, Frontiers Media S.A., 09 May 2018, [Peer-reviewed]
English, Scientific journal - 2017 international meeting of the Global Virus Network
Mike Catton; Glenda Gray; Diane Griffin; Hideki Hasegawa; Stephen J. Kent; Jason Mackenzie; Edward McSweegan; Natalia Mercer; Linfa Wang
Antiviral Research, 153, 60, 69, Elsevier B.V., 01 May 2018, [Peer-reviewed]
English - Application of HTLV-1 tax transgenic mice for therapeutic intervention.
Hideki Hasegawa; Kaori Sano; Akira Ainai; Tadaki Suzuki
Advances in biological regulation, 68, 10, 12, May 2018, [Peer-reviewed], [International Magazine]
English, Scientific journal, Adult T-cell leukemia-lymphoma (ATL) is a refractory T-cell malignancy caused by infection of human T-cell leukemia virus type I (HTLV-I). Although the pathogenesis of ATL remains unclear, HTLV-1 oncoprotein Tax plays an important role in pathogenesis (Matsuoka, 2003; Jeang et al., 2004). Chemotherapy resistance of ATL leads the poor prognosis of this disease. In order to understand the pathogenesis and establish an animal model useful for therapy attempts, we have generated HTLV-1 Tax transgenic mice using the Lck proximal promoter to restrict the Tax expression in T-cells. The HTLV-1 Tax transgenic mice developed diffuse large-cell lymphomas and leukemia with the similar features of a clinical, pathological and immunological characteristic of acute ATL. The fulminant disease also developed rapidly in SCID mice after engraftment of mouse ATL cells derived from the transgenic mice. In this review, we introduce the therapeutic attempts using this animal model and discuss the possible signaling pathway for a therapeutic target. - A patient with severe fever with thrombocytopenia syndrome and hemophagocytic lymphohistiocytosis-associated involvement of the central nervous system
Masahiko Kaneko; Hisaharu Shikata; Shoichi Matsukage; Masaki Maruta; Hiroto Shinomiya; Tadaki Suzuki; Hideki Hasegawa; Masayuki Shimojima; Masayuki Saijo
Journal of Infection and Chemotherapy, 24, 4, 292, 297, Elsevier B.V., 01 Apr. 2018, [Peer-reviewed]
English, Scientific journal - Experimental infection of Cynomolgus Macaques with highly pathogenic H5N1 influenza virus through the aerosol route.
Tokiko Watanabe; Kiyoko Iwatsuki-Horimoto; Maki Kiso; Noriko Nakajima; Kenta Takahashi; Tiago Jose da Silva Lopes; Mutsumi Ito; Satoshi Fukuyama; Hideki Hasegawa; Yoshihiro Kawaoka
Scientific reports, 8, 1, 4801, 4801, 19 Mar. 2018, [Peer-reviewed], [International Magazine]
English, Several animal models are used to study influenza viruses. Intranasal inoculation of animals with a liquid inoculum is one of the main methods used to experimentally infect animals with influenza virus; however, this method does not reflect the natural infection with influenza virus by contact or aerosol route. Aerosol inhalation methods have been established with several influenza viruses for mouse and ferret models, but few studies have evaluated inoculation routes in a nonhuman primates (NHP) model. Here, we performed the experimental infection of NHPs with a highly pathogenic H5N1 influenza virus via the aerosol route and demonstrated that aerosol infection had no effect on clinical outcome, but caused broader infection throughout all of the lobes of the lung compared with a non-aerosolized approach. Aerosol infection therefore represents an option for inoculation of NHPs in future studies. - Combination Therapy With Neuraminidase and Polymerase Inhibitors in Nude Mice Infected With Influenza Virus.
Maki Kiso; Tiago J S Lopes; Seiya Yamayoshi; Mutsumi Ito; Makoto Yamashita; Noriko Nakajima; Hideki Hasegawa; Gabriele Neumann; Yoshihiro Kawaoka
The Journal of infectious diseases, 217, 6, 887, 896, 05 Mar. 2018, [Peer-reviewed], [International Magazine]
English, Scientific journal, Background: Treatment of immunocompromised, influenza virus-infected patients with the viral neuraminidase inhibitor oseltamivir often leads to the emergence of drug-resistant variants. Combination therapy with compounds that target different steps in the viral life cycle may improve treatment outcomes and reduce the emergence of drug-resistant variants. Methods: Here, we infected immunocompromised nude mice with an influenza A virus and treated them with neuraminidase (oseltamivir, laninamivir) or viral polymerase (favipiravir) inhibitors, or combinations thereof. Results: Combination therapy for 28 days increased survival times compared with monotherapy, but the animals died after treatment was terminated. Mono- and combination therapies did not consistently reduce lung virus titers. Prolonged viral replication led to the emergence of neuraminidase inhibitor-resistant variants, although viruses remained sensitive to favipiravir. Overall, favipiravir provided greater benefit than neuraminidase inhibitors. Conclusions: Collectively, our data demonstrate that combination therapy in immunocompromised hosts increases survival times, but does not suppress the emergence of neuraminidase inhibitor-resistant variants. - Syrian Hamster as an Animal Model for the Study of Human Influenza Virus Infection.
Kiyoko Iwatsuki-Horimoto; Noriko Nakajima; Yurie Ichiko; Yuko Sakai-Tagawa; Takeshi Noda; Hideki Hasegawa; Yoshihiro Kawaoka
Journal of virology, 92, 4, 15 Feb. 2018, [Peer-reviewed], [International Magazine]
English, Scientific journal, Ferrets and mice are frequently used as animal models for influenza research. However, ferrets are demanding in terms of housing space and handling, whereas mice are not naturally susceptible to infection with human influenza A or B viruses. Therefore, prior adaptation of human viruses is required for their use in mice. In addition, there are no mouse-adapted variants of the recent H3N2 viruses, because these viruses do not replicate well in mice. In this study, we investigated the susceptibility of Syrian hamsters to influenza viruses with a view to using the hamster model as an alternative to the mouse model. We found that hamsters are sensitive to influenza viruses, including the recent H3N2 viruses, without adaptation. Although the hamsters did not show weight loss or clinical signs of H3N2 virus infection, we observed pathogenic effects in the respiratory tracts of the infected animals. All of the H3N2 viruses tested replicated in the respiratory organs of the hamsters, and some of them were detected in the nasal washes of infected animals. Moreover, a 2009 pandemic (pdm09) virus and a seasonal H1N1 virus, as well as one of the two H3N2 viruses, but not a type B virus, were transmissible by the airborne route in these hamsters. Hamsters thus have the potential to be a small-animal model for the study of influenza virus infection, including studies of the pathogenicity of H3N2 viruses and other strains, as well as for use in H1N1 virus transmission studies.IMPORTANCE We found that Syrian hamsters are susceptible to human influenza viruses, including the recent H3N2 viruses, without adaptation. We also found that a pdm09 virus and a seasonal H1N1 virus, as well as one of the H3N2 viruses, but not a type B virus tested, are transmitted by the airborne route in these hamsters. Syrian hamsters thus have the potential to be used as a small-animal model for the study of human influenza viruses. - Mechanism of Action of the Anti-Influenza Virus Active Kampo (Traditional Japanese Herbal) Medicine, Hochuekkito
Katsuaki Dan; Keita Takanashi; Hiroko Akiyoshi; Kaori Munakata; Hideki Hasegawa; Kaoru Ogawa; Kenji Watanabe
Pharmacology, 101, 3-4, 148, 155, S. Karger AG, 01 Feb. 2018, [Peer-reviewed]
English, Scientific journal - Toll-like receptor 3 in nasal CD103 + dendritic cells is involved in immunoglobulin A production
H. Takaki; S. Kure; H. Oshiumi; Y. Sakoda; T. Suzuki; A. Ainai; H. Hasegawa; M. Matsumoto; T. Seya
Mucosal Immunology, 11, 1, 82, 96, Nature Publishing Group, 01 Jan. 2018, [Peer-reviewed]
English, Scientific journal - Shape-dependent adjuvanticity of nanoparticle-conjugated RNA adjuvants for intranasal inactivated influenza vaccines
Taiyu Tazaki; Koshiro Tabata; Akira Ainai; Yuki Ohara; Shintaro Kobayashi; Takafumi Ninomiya; Yasuko Orba; Hideyuki Mitomo; Tetsuo Nakano; Hideki Hasegawa; Kuniharu Ijiro; Hirofumi Sawa; Tadaki Suzuki; Kenichi Niikura
RSC Advances, 8, 30, 16527, 16536, 2018, [Peer-reviewed]
English, Scientific journal - Characterization of a feline influenza A(H7N2) virus
Masato Hatta; Gongxun Zhong; Yuwei Gao; Noriko Nakajima; Shufang Fan; Shiho Chiba; Kathleen M. Deering; Mutsumi Ito; Masaki Imai; Maki Kiso; Sumiho Nakatsu; Tiago J. Lopes; Andrew J. Thompson; Ryan McBride; David L. Suarez; Catherine A. Macken; Shigeo Sugita; Gabriele Neumann; Hideki Hasegawa; James C. Paulson; Kathy L. Toohey-Kurth; Yoshihiro Kawaoka
Emerging Infectious Diseases, 24, 1, 75, 86, Centers for Disease Control and Prevention (CDC), 01 Jan. 2018, [Peer-reviewed]
English, Scientific journal - Neutralizing Antibodies Induced by Gene-Based Hydrodynamic Injection Have a Therapeutic Effect in Lethal Influenza Infection.
Tatsuya Yamazaki; Maria Nagashima; Daisuke Ninomiya; Akira Ainai; Akira Fujimoto; Isao Ichimonji; Hidekazu Takagi; Naoko Morita; Kenta Murotani; Hideki Hasegawa; Joe Chiba; Sachiko Akashi-Takamura
Frontiers in immunology, 9, 47, 47, 2018, [Peer-reviewed], [International Magazine]
English, Scientific journal, The influenza virus causes annual epidemics and occasional pandemics and is thus a major public health problem. Development of vaccines and antiviral drugs is essential for controlling influenza virus infection. We previously demonstrated the use of vectored immune-prophylaxis against influenza virus infection. We generated a plasmid encoding neutralizing IgG monoclonal antibodies (mAbs) against A/PR/8/34 influenza virus (IAV) hemagglutinin (HA). We then performed electroporation of the plasmid encoding neutralizing mAbs (EP) in mice muscles and succeeded in inducing the expression of neutralizing antibodies in mouse serum. This therapy has a prophylactic effect against lethal IAV infection in mice. In this study, we established a new method of passive immunotherapy after IAV infection. We performed hydrodynamic injection of the plasmid encoding neutralizing mAbs (HD) involving rapid injection of a large volume of plasmid-DNA solution into mice via the tail vein. HD could induce neutralizing antibodies in the serum and in several mucosal tissues more rapidly than in EP. We also showed that a single HD completely protected the mice even after infection with a lethal dose of IAV. We also established other isotypes of anti-HA antibody (IgA, IgM, IgD, and IgE) and showed that like anti-HA IgG, anti-HA IgA was also effective at combating upper respiratory tract IAV infection. Passive immunotherapy with HD could thus provide a new therapeutic strategy targeting influenza virus infection. - Induction of lung CD8(+) T cell responses by consecutive inoculations of a poly(I:C) influenza vaccine
Miyu Moriyama; Haruko Takeyama; Hideki Hasegawa; Takeshi Ichinohe
VACCINE, 35, 48, 6620, 6626, Dec. 2017, [Peer-reviewed]
English, Scientific journal - Alleviation of lipopolysaccharide/d-galactosamine-induced liver injury in leukocyte cell-derived chemotaxin 2 deficient mice.
Akinori Okumura; Takeshi Saito; Minoru Tobiume; Yuki Hashimoto; Yuko Sato; Takashi Umeyama; Minoru Nagi; Koichi Tanabe; Hiroyuki Unoki-Kubota; Yasushi Kaburagi; Hideki Hasegawa; Yoshitsugu Miyazaki; Satoshi Yamagoe
Biochemistry and biophysics reports, 12, 166, 171, Dec. 2017, [Peer-reviewed], [International Magazine]
English, Scientific journal, Leukocyte cell-derived chemotaxin 2 (LECT2) is a secreted pleiotropic protein that is mainly produced by the liver. We have previously shown that LECT2 plays an important role in the pathogenesis of inflammatory liver diseases. Lipopolysaccharide/d-galactosamine (LPS/d-GalN)-induced acute liver injury is a known animal model of fulminant hepatic failure. Here we found that this hepatic injury was alleviated in LECT2-deficient mice. The levels of TNF-α and IFN-γ, which mediate this hepatitis, had significantly decreased in these mice, with the decrease in IFN-γ production notably greater than that in TNF-α. We therefore analyzed IFN-γ-producing cells in liver mononuclear cells. Flow cytometric analysis showed significantly reduced IFN-γ production in hepatic NK and NKT cells in LECT2-deficient mice compared with in wild-type mice. We also demonstrated a decrease in IFN-γ production in LECT2-deficient mice after systemic administration of recombinant IL-12, which is known to induce IFN-γ in NK and NKT cells. These results indicate that a decrease of IFN-γ production in NK and NKT cells was involved in the alleviation of LPS/d-GalN-induced liver injury in LECT2-deficient mice. - cGAMP Promotes Germinal Center Formation and Production of IgA in Nasal-Associated Lymphoid Tissue.
Takaki H; Takashima K; Oshiumi H; Ainai A; Suzuki T; Hasegawa H; Matsumoto M; Seya T
Medical sciences (Basel, Switzerland), 5, 4, Dec. 2017, [Peer-reviewed], [International Magazine]
English, Scientific journal, Induction of immunoglobulin (Ig) A in the mucosa of the upper respiratory tract and the nasal cavity protects against influenza virus infection. Cyclic dinucleotides (CDNs) are used as mucosal adjuvants to enhance the immunogenicity of intranasal influenza hemagglutinin (HA) vaccines. The adjuvant activity of 2'3' cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) on Ig production was investigated in nasal-associated lymphoid tissue (NALT), serum of wild-type C57BL/6J, and stimulator of interferon genes (STING)-deficient mice, which do not recognize cGAMP. Mice were vaccinated intranasally with a HA vaccine with or without the cGAMP adjuvant. IgA and IgG production, T-cell responses, germinal center formation, and cytokine expression in NALT were assayed. cGAMP enhanced IgA and IgG production, and promoted T-cell responses. Intranasal administration of cGAMP activated both NALT and systemic immune cells, induced a favorable cytokine environment for IgA induction, and promoted germinal center formation. The cGAMP effect was STING-dependent. Taken together, cGAMP as an HA vaccine adjuvant promoted a STING-dependent NALT environment suitable for the enhancement of IgA production. - Cytomegalic Inclusion Disease caused by Cytomegalovirus Infection in the Salivary Glands of an African Hedgehog (Atelerix arbiventris)
K. Koyama; N. Horiuchi; H. Hasegawa; H. Katano; E. Oohashi; K. Watanabe; Y. Kobayashi
JOURNAL OF COMPARATIVE PATHOLOGY, 157, 4, 299, 302, Nov. 2017, [Peer-reviewed]
English, Scientific journal - A Highly Pathogenic Avian H7N9 Influenza Virus Isolated from A Human Is Lethal in Some Ferrets Infected via Respiratory Droplets
Masaki Imai; Tokiko Watanabe; Maki Kiso; Noriko Nakajima; Seiya Yamayoshi; Kiyoko Iwatsuki-Horimoto; Masato Hatta; Shinya Yamada; Mutsumi Ito; Yuko Sakai-Tagawa; Masayuki Shirakura; Emi Takashita; Seiichiro Fujisaki; Ryan McBride; Andrew J. Thompson; Kenta Takahashi; Tadashi Maemura; Hiromichi Mitake; Shiho Chiba; Gongxun Zhong; Shufang Fan; Kohei Oishi; Atsuhiro Yasuhara; Kosuke Takada; Tomomi Nakao; Satoshi Fukuyama; Makoto Yamashita; Tiago J. S. Lopes; Gabriele Neumann; Takato Odagiri; Shinji Watanabe; Yuelong Shu; James C. Paulson; Hideki Hasegawa; Yoshihiro Kawaoka
CELL HOST & MICROBE, 22, 5, 615, +, Nov. 2017, [Peer-reviewed]
English, Scientific journal - Functional and structural characteristics of secretory IgA antibodies elicited by mucosal vaccines against influenza virus
Tadaki Suzuki; Akira Ainai; Hideki Hasegawa
VACCINE, 35, 39, 5297, 5302, Sep. 2017, [Peer-reviewed]
English - The road to a more effective influenza vaccine: Up to date studies and future prospects
Kaori Sano; Akira Ainai; Tadaki Suzuki; Hideki Hasegawa
VACCINE, 35, 40, 5388, 5395, Sep. 2017, [Peer-reviewed]
English, Scientific journal - Emergence of Oseltamivir-Resistant H7N9 Influenza Viruses in Immunosuppressed Cynomolgus Macaques
Maki Kiso; Kiyoko Iwatsuki-Horimoto; Seiya Yamayoshi; Ryuta Uraki; Mutsumi Ito; Noriko Nakajima; Shinya Yamada; Masaki Imai; Eiryo Kawakami; Yuriko Tomita; Satoshi Fukuyama; Yasushi Itoh; Kazumasa Ogasawara; Tiago J. S. Lopes; Tokiko Watanabe; Louise H. Moncla; Hideki Hasegawa; Thomas C. Friedrich; Gabriele Neumann; Yoshihiro Kawaoka
JOURNAL OF INFECTIOUS DISEASES, 216, 5, 582, 593, Sep. 2017, [Peer-reviewed]
English, Scientific journal - Pulmonary inflammation and cytokine dynamics of bronchoalveolar lavage fluid from a mouse model of bronchial asthma during A(H1N1)pdm09 influenza infection
Yousuke Fujimoto; Shunji Hasegawa; Takeshi Matsushige; Hiroyuki Wakiguchi; Tamaki Nakamura; Hideki Hasegawa; Noriko Nakajima; Akira Ainai; Atsunori Oga; Hiroshi Itoh; Komei Shirabe; Shoichi Toda; Ryo Atsuta; Tsuneo Morishima; Shouichi Ohga
SCIENTIFIC REPORTS, 7, 1, 9128, Aug. 2017, [Peer-reviewed]
English, Scientific journal - Interleukin-6-dependent growth in a newly established plasmablastic lymphoma cell line and its therapeutic targets
Sohtaro Mine; Tsunekazu Hishima; Akihiko Suganuma; Hitomi Fukumoto; Yuko Sato; Michiyo Kataoka; Tsuyoshi Sekizuka; Makoto Kuroda; Tadaki Suzuki; Hideki Hasegawa; Masashi Fukayama; Harutaka Katano
SCIENTIFIC REPORTS, 7, 1, 10188, Aug. 2017, [Peer-reviewed]
English, Scientific journal - Conserved sequences of BART and BHRF regions encoding viral microRNAs in Epstein-Barr virus-associated lymphoma
Keishin Sunagawa; Tsunekazu Hishima; Hitomi Fukumoto; Hideki Hasegawa; Harutaka Katano
BMC Research Notes, 10, 1, 279, BioMed Central Ltd., 14 Jul. 2017, [Peer-reviewed]
English, Scientific journal - A Single Vaccination of Nonhuman Primates with Highly Attenuated Smallpox Vaccine, LC16m8, Provides Long-term Protection against Monkeypox
Itoe Iizuka; Yasushi Ami; Yuriko Suzaki; Noriyo Nagata; Shuetsu Fukushi; Momoko Ogata; Shigeru Morikawa; Hideki Hasegawa; Masashi Mizuguchi; Ichiro Kurane; Masayuki Saijo
JAPANESE JOURNAL OF INFECTIOUS DISEASES, 70, 4, 408, 415, Jul. 2017, [Peer-reviewed]
English, Scientific journal - Intranasal Administration of Whole Inactivated Influenza Virus Vaccine as a Promising Influenza Vaccine Candidate
Akira Ainai; Tadaki Suzuki; Shin-ichi Tamura; Hideki Hasegawa
VIRAL IMMUNOLOGY, 30, 6, 451, 462, Jul. 2017, [Peer-reviewed]
English, Scientific journal - 2016 International meeting of the Global Virus Network
Ramesh Akkina; Heinz Ellerbrok; William Hall; Hideki Hasegawa; Yasushi Kawaguchi; Harold Kleanthous; Edward McSweegan; Natalia Mercer; Victor Romanowski; Hirofumi Sawa; Anders Vahlne
ANTIVIRAL RESEARCH, 142, 21, 29, Jun. 2017, [Peer-reviewed]
English, Scientific journal - Histopathological Findings of Lung with A/H1N1pdm09 Infection-Associated Acute Respiratory Distress Syndrome in the Post-Pandemic Season
Kentaro Hayashi; Hiroshi Yoshida; Yuko Sato; Minoru Tobiume; Yoshio Suzuki; Koya Ariyoshi; Hideki Hasegawa; Noriko Nakajima
JAPANESE JOURNAL OF INFECTIOUS DISEASES, 70, 2, 197, 200, Mar. 2017, [Peer-reviewed]
English, Scientific journal - Next-generation sequencing of miRNAs in clinical samples of Epstein-Barr virus-associated B-cell lymphomas
Kouta Sakamoto; Tsuyoshi Sekizuka; Taeko Uehara; Tsunekazu Hishima; Sohtaro Mine; Hitomi Fukumoto; Yuko Sato; Hideki Hasegawa; Makoto Kuroda; Harutaka Katano
CANCER MEDICINE, 6, 3, 605, 618, Mar. 2017, [Peer-reviewed]
English, Scientific journal - Unusual presentation of a severely ill patient having severe fever with thrombocytopenia syndrome: A case report
Masahiko Kaneko; Masaki Maruta; Hisaharu Shikata; Kengo Asou; Hiroto Shinomiya; Tadaki Suzuki; Hideki Hasegawa; Masayuki Shimojima; Masayuki Saijo
Journal of Medical Case Reports, 11, 1, 27, BioMed Central Ltd., 03 Feb. 2017, [Peer-reviewed]
English, Scientific journal - Impacts of allergic airway inflammation on lung pathology in a mouse model of influenza A virus infection
Akira Kawaguchi; Tadaki Suzuki; Yuki Ohara; Kenta Takahashi; Yuko Sato; Akira Ainai; Noriyo Nagata; Masato Tashiro; Hideki Hasegawa
PLOS ONE, 12, 2, e0173008, Feb. 2017, [Peer-reviewed]
English, Scientific journal - The Preventive Effect of the Traditional Japanese Herbal Medicine, Hochuekkito, against Influenza A Virus via Autophagy in vitro
Keita Takanashi; Katsuaki Dan; Sho Kanzaki; Hideki Hasegawa; Kenji Watanabe; Kaoru Ogawa
PHARMACOLOGY, 99, 3-4, 99, 105, 2017, [Peer-reviewed]
English, Scientific journal - Deep-Sequence Identification and Role in Virus Replication of a JC Virus Quasispecies in Patients with Progressive Multifocal Leukoencephalopathy
Kenta Takahashi; Tsuyoshi Sekizuka; Hitomi Fukumoto; Kazuo Nakamichi; Tadaki Suzuki; Yuko Sato; Hideki Hasegawa; Makoto Kuroda; Harutaka Katano
JOURNAL OF VIROLOGY, 91, 1, Jan. 2017, [Peer-reviewed]
English, Scientific journal - The Microminipig as an Animal Model for Influenza A Virus Infection
Kiyoko Iwatsuki-Horimoto; Noriko Nakajima; Masatoshi Shibata; Kenta Takahashi; Yuko Sato; Maki Kiso; Seiya Yamayoshi; Mutsumi Ito; Satoko Enya; Masayoshi Otake; Akihisa Kangawa; Tiago Jose da Silva Lopes; Hirotaka Ito; Hideki Hasegawa; Yoshihiro Kawaoka
JOURNAL OF VIROLOGY, 91, 2, Jan. 2017, [Peer-reviewed]
English, Scientific journal - Reducing the global burden of HTLV-1 infection: An agenda for research and action
Luc Willems; Hideki Hasegawa; Roberto Accolla; Charles Bangham; Ali Bazarbachi; Umberto Bertazzoni; Anna Barbara de Freitas Carneiro-Proietti; Hua Cheng; Luigi Chieco-Bianchi; Vincenzo Ciminale; Jordana Coelho-dos-Reis; Jose Esparza; Robert C. Gallo; Antoine Gessain; Eduardo Gotuzzo; William Hall; Joseph Harford; Olivier Hermine; Steven Jacobson; Beatrice Macchi; Calum Macpherson; Renaud Mahieux; Masao Matsuoka; Edward Murphy; Jean-Marie Peloponese; Viviana Simon; Yutaka Tagaya; Graham P. Taylor; Toshiki Watanabe; Yoshihisa Yamano
ANTIVIRAL RESEARCH, 137, 41, 48, Jan. 2017, [Peer-reviewed]
English - Hochuekkito, a Japanese Herbal Medicine, Restores Metabolic Homeostasis between Mitochondrial and Glycolytic Pathways Impaired by Influenza A Virus Infection
Keita Takanashi; Katsuaki Dan; Sho Kanzaki; Hideki Hasegawa; Kenji Watanabe; Kaoru Ogawa
PHARMACOLOGY, 99, 5-6, 240, 249, 2017, [Peer-reviewed]
English, Scientific journal - Risk assessment of recent Egyptian H5N1 influenza viruses
A. -S. Arafa; S. Yamada; M. Imai; T. Watanabe; S. Yamayoshi; K. Iwatsuki-Horimoto; M. Kiso; Y. Sakai-Tagawa; M. Ito; T. Imamura; N. Nakajima; K. Takahashi; D. Zhao; K. Oishi; A. Yasuhara; C. A. Macken; G. Zhong; A. P. Hanson; S. Fan; J. Ping; M. Hatta; T. J. S. Lopes; Y. Suzuki; M. El-Husseiny; A. Selim; N. Hagag; M. Soliman; G. Neumann; H. Hasegawa; Y. Kawaoka
Scientific Reports, 6, 38388, Dec. 2016, [Peer-reviewed]
English, Scientific journal - Protective neutralizing influenza antibody response in the absence of T follicular helper cells
Kosuke Miyauchi; Akiko Sugimoto-Ishige; Yasuyo Harada; Yu Adachi; Yoshiko Usami; Tomohiro Kaji; Kentaro Inoue; Hideki Hasegawa; Takashi Watanabe; Atsushi Hijikata; Satoshi Fukuyama; Tadashi Maemura; Mariko Okada-Hatakeyama; Osamu Ohara; Yoshihiro Kawaoka; Yoshimasa Takahashi; Toshitada Takemori; Masato Kubo
NATURE IMMUNOLOGY, 17, 12, 1447, 1458, Dec. 2016, [Peer-reviewed]
English, Scientific journal - Screening transplant donors for HTLV-1 and-2
Robert C. Gallo; Luc Willems; Hideki Hasegawa
BLOOD, 128, 26, 3029, 3031, Dec. 2016, [Peer-reviewed]
English, Scientific journal - Non Susceptibility of Neonatal and Adult Rats against the Middle East Respiratory Syndrome Coronavirus
Naoko Iwata-Yoshikawa; Shuetsu Fukushi; Aiko Fukuma; Tadaki Suzuki; Makoto Takeda; Masato Tashiro; Hideki Hasegawa; Noriyo Nagata
JAPANESE JOURNAL OF INFECTIOUS DISEASES, 69, 6, 510, 516, Nov. 2016, [Peer-reviewed]
English, Scientific journal - Intracerebral Inoculation of Mouse-Passaged Saffold Virus Type 3 Affects Cerebellar Development in Neonatal Mice
Osamu Kotani; Tadaki Suzuki; Masaru Yokoyama; Naoko Iwata-Yoshikawa; Noriko Nakajima; Hironori Sato; Hideki Hasegawa; Fumihiro Taguchi; Hiroyuki Shimizu; Noriyo Nagata
JOURNAL OF VIROLOGY, 90, 21, 10007, 10021, Nov. 2016, [Peer-reviewed]
English, Scientific journal - Fungus-Derived Neoechinulin B as a Novel Antagonist of Liver X Receptor, Identified by Chemical Genetics Using a Hepatitis C Virus Cell Culture System
Syo Nakajima; Koichi Watashi; Hirofumi Ohashi; Shinji Kamisuki; Jesus Izaguirre-Carbonell; Andrew Tae-Jun Kwon; Harukazu Suzuki; Michiyo Kataoka; Senko Tsukuda; Maiko Okada; Meng Ling Moi; Toshifumi Takeuchi; Minetaro Arita; Ryosuke Suzuki; Hideki Aizaki; Takanobu Kato; Tadaki Suzuki; Hideki Hasegawa; Tomohiko Takasaki; Fumio Sugawara; Takaji Wakita
JOURNAL OF VIROLOGY, 90, 20, 9058, 9074, Oct. 2016, [Peer-reviewed]
English, Scientific journal - Profile of Exosomal and Intracellular microRNA in Gamma-Herpesvirus-Infected Lymphoma Cell Lines
Shiho Hoshina; Tsuyoshi Sekizuka; Michiyo Kataoka; Hideki Hasegawa; Hiromichi Hamada; Makoto Kuroda; Harutaka Katano
PLOS ONE, 11, 9, e0162574, Sep. 2016, [Peer-reviewed]
English, Scientific journal - Assessment of outer membrane vesicles of periodontopathic bacterium Porphyromonas gingivalis as possible mucosal immunogen
Ryoma Nakao; Hideki Hasegawa; Bai Dongying; Makoto Ohnishi; Hidenobu Senpuku
VACCINE, 34, 38, 4626, 4634, Aug. 2016, [Peer-reviewed]
English, Scientific journal - Establishing and characterizing a new primary effusion lymphoma cell line harboring Kaposi's sarcoma-associated herpesvirus
Madori Osawa; Sohtaro Mine; Shinichiro Ota; Kengo Kato; Tsuyoshi Sekizuka; Makoto Kuroda; Michiyo Kataoka; Hitomi Fukumoto; Yuko Sato; Takayuki Kanno; Hideki Hasegawa; Keiji Ueda; Masashi Fukayama; Takuya Maeda; Soichiro Kanoh; Akihiko Kawana; Yuji Fujikura; Harutaka Katano
INFECTIOUS AGENTS AND CANCER, 11, 37, Aug. 2016, [Peer-reviewed]
English, Scientific journal - TMPRSS2 Independency for Haemagglutinin Cleavage In Vivo Differentiates Influenza B Virus from Influenza A Virus
Kouji Sakai; Yasushi Ami; Noriko Nakajima; Katsuhiro Nakajima; Minori Kitazawa; Masaki Anraku; Ikuyo Takayama; Natthanan Sangsriratanakul; Miyuki Komura; Yuko Sato; Hideki Asanuma; Emi Takashita; Katsuhiro Komase; Kazuaki Takehara; Masato Tashiro; Hideki Hasegawa; Takato Odagiri; Makoto Takeda
SCIENTIFIC REPORTS, 6, 29430, Jul. 2016, [Peer-reviewed]
English, Scientific journal - Association of lymph-node antigens with lower Gag-specific central-memory and higher Env-specific effector-memory CD8(+) T-cell frequencies in a macaque AIDS model
Hiroshi Ishii; Saori Matsuoka; Takushi Nomura; Midori Nakamura; Teiichiro Shiino; Yuko Sato; Naoko Iwata-Yoshikawa; Hideki Hasegawa; Kazuta Mizuta; Hiromi Sakawaki; Tomoyuki Miura; Yoshio Koyanagi; Taeko K. Naruse; Akinori Kimura; Tetsuro Matano
SCIENTIFIC REPORTS, 6, 30153, Jul. 2016, [Peer-reviewed]
English, Scientific journal - 動物モデル 抗原非特異的作用、COPD、アジュバントその他 喘息マウスにおけるA(H1N1)pdm09感染によるBAL中サイトカイン動態の検討
長谷川 俊史; 松重 武志; 藤本 洋輔; 大賀 正一; 長谷川 秀樹; 相内 章; 調 恒明; 戸田 昌一; 熱田 了
アレルギー, 65, 4-5, 602, 602, (一社)日本アレルギー学会, May 2016
Japanese - Evaluation of Vero-cell-derived simian endogenous retrovirus infection in humans by detection of viral genome in clinicopathological samples and commercialized vaccines and by serology of Japanese general population
Hitomi Fukumoto; Tsunekazu Hishima; Hideki Hasegawa; Hidehisa Saeki; Makoto Kuroda; Harutaka Katano
VACCINE, 34, 24, 2700, 2706, May 2016, [Peer-reviewed]
English, Scientific journal - Intranasal Inactivated Influenza Vaccines: a Reasonable Approach to Improve the Efficacy of Influenza Vaccine?
Shin-ichi Tamura; Akira Ainai; Tadaki Suzuki; Takeshi Kurata; Hideki Hasegawa
JAPANESE JOURNAL OF INFECTIOUS DISEASES, 69, 3, 165, 179, May 2016, [Peer-reviewed]
English - The RNA- and TRIM25-Binding Domains of Influenza Virus NS1 Protein Are Essential for Suppression of NLRP3 Inflammasome-Mediated Interleukin-1 beta Secretion
Miyu Moriyama; I-Yin Chen; Atsushi Kawaguchi; Takumi Koshiba; Kyosuke Nagata; Haruko Takeyama; Hideki Hasegawa; Takeshi Ichinohe
JOURNAL OF VIROLOGY, 90, 8, 4105, 4114, Apr. 2016, [Peer-reviewed]
English, Scientific journal - Adenovirus Type 7 Pneumonia in Children Who Died from Measles-Associated Pneumonia, Hanoi, Vietnam, 2014
Le Thanh Hai; Hoang Ngoc Thach; Ta Anh Tuan; Dao Huu Nam; Tran Minh Dien; Yuko Sato; Toshio Kumasaka; Tadaki Suzuki; Nozomu Hanaoka; Tsuguto Fujimoto; Harutaka Katano; Hideki Hasegawa; Shoji Kawachi; Noriko Nakajima
EMERGING INFECTIOUS DISEASES, 22, 4, 687, 690, Apr. 2016, [Peer-reviewed]
English, Scientific journal - Severe Fever with Thrombocytopenia Syndrome Virus Antigen Detection Using Monoclonal Antibodies to the Nucleocapsid Protein.
Aiko Fukuma; Shuetsu Fukushi; Tomoki Yoshikawa; Hideki Tani; Satoshi Taniguchi; Takeshi Kurosu; Kazutaka Egawa; Yuto Suda; Harpal Singh; Taro Nomachi; Mutsuyo Gokuden; Katsuyuki Ando; Kouji Kida; Miki Kan; Nobuyuki Kato; Akira Yoshikawa; Hiroaki Kitamoto; Yuko Sato; Tadaki Suzuki; Hideki Hasegawa; Shigeru Morikawa; Masayuki Shimojima; Masayuki Saijo
PLoS neglected tropical diseases, 10, 4, e0004595, Apr. 2016, [Peer-reviewed], [International Magazine]
English, Scientific journal, BACKGROUND: Severe fever with thrombocytopenia syndrome (SFTS) is a tick-borne infectious disease with a high case fatality rate, and is caused by the SFTS virus (SFTSV). SFTS is endemic to China, South Korea, and Japan. The viral RNA level in sera of patients with SFTS is known to be strongly associated with outcomes. Virological SFTS diagnosis with high sensitivity and specificity are required in disease endemic areas. METHODOLOGY/PRINCIPAL FINDINGS: We generated novel monoclonal antibodies (MAbs) against the SFTSV nucleocapsid (N) protein and developed a sandwich antigen (Ag)-capture enzyme-linked immunosorbent assay (ELISA) for the detection of N protein of SFTSV using MAb and polyclonal antibody as capture and detection antibodies, respectively. The Ag-capture system was capable of detecting at least 350-1220 TCID50/100 μl/well from the culture supernatants of various SFTSV strains. The efficacy of the Ag-capture ELISA in SFTS diagnosis was evaluated using serum samples collected from patients suspected of having SFTS in Japan. All 24 serum samples (100%) containing high copy numbers of viral RNA (>105 copies/ml) showed a positive reaction in the Ag-capture ELISA, whereas 12 out of 15 serum samples (80%) containing low copy numbers of viral RNA (<105 copies/ml) showed a negative reaction in the Ag-capture ELISA. Among these Ag-capture ELISA-negative 12 samples, 9 (75%) were positive for IgG antibodies against SFTSV. CONCLUSIONS: The newly developed Ag-capture ELISA is useful for SFTS diagnosis in acute phase patients with high levels of viremia. - The effect of mucoadhesive excipient on the nasal retention time of and the antibody responses induced by an intranasal influenza vaccine
Shinji Saito; Akira Ainai; Tadaki Suzuki; Norihiro Harada; Yasushi Ami; Yoshikazu Yuki; Haruko Takeyama; Hiroshi Kiyono; Hideo Tsukada; Hideki Hasegawa
VACCINE, 34, 9, 1201, 1207, Feb. 2016, [Peer-reviewed]
English, Scientific journal - Neuropathogenicity of Two Saffold Virus Type 3 Isolates in Mouse Models
Osamu Kotani; Asif Naeem; Tadaki Suzuki; Naoko Iwata-Yoshikawa; Yuko Sato; Noriko Nakajima; Takushi Hosomi; Hiroyuki Tsukagoshi; Kunihisa Kozawa; Hideki Hasegawa; Fumihiro Taguchi; Hiroyuki Shimizu; Noriyo Nagata
PLOS ONE, 11, 2, e0148184, Feb. 2016, [Peer-reviewed]
English, Scientific journal - Efficacy of T-705 (Favipiravir) in the Treatment of Infections with Lethal Severe Fever with Thrombocytopenia Syndrome Virus
Hideki Tani; Aiko Fukuma; Shuetsu Fukushi; Satoshi Taniguchi; Tomoki Yoshikawa; Naoko Iwata-Yoshikawa; Yuko Sato; Tadaki Suzuki; Noriyo Nagata; Hideki Hasegawa; Yasuhiro Kawai; Akihiko Uda; Shigeru Morikawa; Masayuki Shimojima; Haruo Watanabe; Masayuki Saijo
MSPHERE, 1, 1, Jan. 2016, [Peer-reviewed]
English, Scientific journal - Knowledge Obtained from an Elderly Case of Japanese Encephalitis
Kyoko Itoh; Kazuhide Iwamoto; Yu Satoh; Tomoaki Fujita; Kenta Takahashi; Harutaka Katano; Hideki Hasegawa; Tomohiko Takasaki; So Tando; Shinji Fushiki
INTERNAL MEDICINE, 55, 17, 2487, 2490, 2016, [Peer-reviewed]
English, Scientific journal - Protective antibody responses against A(H1N1)pdm09 primed by infection and recalled by intranasal vaccination
Kazuyuki Ikeda; Akira Ainai; Hideki Hasegawa
VACCINE, 33, 45, 6066, 6069, Nov. 2015, [Peer-reviewed]
English, Scientific journal - マイクロミニピッグのインフルエンザ感染モデル動物としての有用性
岩附 研子; 中島 典子; 柴田 昌利; 高橋 健太; 佐藤 由子; 木曽 真紀; 山吉 誠也; 伊藤 睦美; 塩谷 聡子; 大竹 正剛; 寒川 彰久; 伊東 祐孝; 長谷川 秀樹; 河岡 義裕
日本獣医学会学術集会講演要旨集, 158回, 331, 331, (公社)日本獣医学会, Aug. 2015
Japanese - Fumagillin, a potent angiogenesis inhibitor, induces Kaposi sarcoma-associated herpesvirus replication in primary effusion lymphoma cells
Takayuki Kanno; Taeko Uehara; Madori Osawa; Hitomi Fukumoto; Sohtaro Mine; Keiji Ueda; Hideki Hasegawa; Harutaka Katano
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 463, 4, 1267, 1272, Aug. 2015, [Peer-reviewed]
English, Scientific journal - Relationship of the quaternary structure of human secretory IgA to neutralization of influenza virus
Tadaki Suzuki; Akira Kawaguchi; Akira Ainai; Shin-ichi Tamura; Ryo Ito; Pretty Multihartina; Vivi Setiawaty; Krisna Nur Andriana Pangesti; Takato Odagiri; Masato Tashiro; Hideki Hasegawa
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 112, 25, 7809, 7814, Jun. 2015, [Peer-reviewed]
English, Scientific journal - Host Adaptation and the Alteration of Viral Properties of the First Influenza A/H1N1pdm09 Virus Isolated in Japan
Akira Ainai; Hideki Hasegawa; Masatsugu Obuchi; Takato Odagiri; Makoto Ujike; Masayuki Shirakura; Eri Nobusawa; Masato Tashiro; Hideki Asanuma
PLOS ONE, 10, 6, e0130208, Jun. 2015, [Peer-reviewed]
English, Scientific journal - A Mutant H3N2 Influenza Virus Uses an Alternative Activation Mechanism in TMPRSS2 Knockout Mice by Loss of an Oligosaccharide in the Hemagglutinin Stalk Region
Kouji Sakai; Tsuyoshi Sekizuka; Yasushi Ami; Noriko Nakajima; Minori Kitazawa; Yuko Sato; Katsuhiro Nakajima; Masaki Anraku; Toru Kubota; Katsuhiro Komase; Kazuaki Takehara; Hideki Hasegawa; Takato Odagiri; Masato Tashiro; Makoto Kuroda; Makoto Takeda
JOURNAL OF VIROLOGY, 89, 9, 5154, 5158, May 2015, [Peer-reviewed]
English, Scientific journal - Establishment of a panel of in-house polyclonal antibodies for the diagnosis of enterovirus infections
Osamu Kotani; Naoko Iwata-Yoshikawa; Tadaki Suzuki; Yuko Sato; Noriko Nakajima; Satoshi Koike; Takuya Iwasaki; Tetsutaro Sata; Teruo Yamashita; Hiroko Minagawa; Fumihiro Taguchi; Hideki Hasegawa; Hiroyuki Shimizu; Noriyo Nagata
NEUROPATHOLOGY, 35, 2, 107, 121, Apr. 2015, [Peer-reviewed]
English, Scientific journal - Seroprevalence of trichodysplasia spinulosa-associated polyomavirus in Japan
Hitomi Fukumoto; Tian-Cheng Li; Michiyo Kataoka; Hideki Hasegawa; Takaji Wakita; Hidehisa Saeki; Tetsuro Suzuki; Harutaka Katano
JOURNAL OF CLINICAL VIROLOGY, 65, 76, 82, Apr. 2015, [Peer-reviewed]
English, Scientific journal - The Pathogenesis of 3 Neurotropic Flaviviruses in a Mouse Model Depends on the Route of Neuroinvasion After Viremia
Noriyo Nagata; Naoko Iwata-Yoshikawa; Daisuke Hayasaka; Yuko Sato; Asato Kojima; Hiroaki Kariwa; Ikuo Takashima; Tomohiko Takasaki; Ichiro Kurane; Tetsutaro Sata; Hideki Hasegawa
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 74, 3, 250, 260, Mar. 2015, [Peer-reviewed]
English, Scientific journal - An autopsy case of Balamuthia mandrillaris amoebic encephalitis, a rare emerging infectious disease, with a brief review of the cases reported in Japan
Kyoko Itoh; Kenji Yagita; Tomoyoshi Nozaki; Harutaka Katano; Hideki Hasegawa; Koushun Matsuo; Youhei Hosokawa; So Tando; Shinji Fushiki
NEUROPATHOLOGY, 35, 1, 64, 69, Feb. 2015, [Peer-reviewed]
English, Scientific journal - Mucosal Immunization and Adjuvants
Hideki Hasegawa; Elly van Reit; Hiroshi Kida
INFLUENZA PATHOGENESIS AND CONTROL - VOL II, 386, 371, 380, 2015, [Peer-reviewed]
English, In book - Development of a new real-time PCR system for simultaneous detection of bacteria and fungi in pathological samples
Hitomi Fukumoto; Yuko Sato; Hideki Hasegawa; Hidehisa Saeki; Harutaka Katano
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 8, 11, 15479, +, 2015, [Peer-reviewed]
English, Scientific journal - HIV感染者の剖検例における日和見感染症と腫瘍の頻度
片野 晴隆; 比島 恒和; 望月 眞; 児玉 良典; 小柳津 直樹; 大田 泰徳; 峰 宗太郎; 猪狩 亨; 味澤 篤; 照屋 勝治; 田沼 順子; 菊池 嘉; 岡 慎一; 上平 朝子; 白阪 琢磨; 鯉渕 智彦; 岩本 愛吉; 長谷川 秀樹; 岡田 誠治; 安岡 彰
日本エイズ学会誌, 16, 4, 477, 477, (一社)日本エイズ学会, Nov. 2014
Japanese - Evidence for human herpesvirus-6B infection of regulatory T-cells in acute systemic lymphadenitis in an immunocompetent adult with the drug reaction with eosinophilia and systemic symptoms syndrome: A case report
Sohtaro Mine; Koyu Suzuki; Yuko Sato; Hitomi Fukumoto; Michiyo Kataoka; Naoki Inoue; Chiho Ohbayashi; Hideki Hasegawa; Tetsutaro Sata; Masashi Fukayama; Harutaka Katano
JOURNAL OF CLINICAL VIROLOGY, 61, 3, 448, 452, Nov. 2014, [Peer-reviewed]
English, Scientific journal - Two autopsy cases of severe fever with thrombocytopenia syndrome (SFTS) in Japan: A pathognomonic histological feature and unique complication of SFTS
Tsubasa Hiraki; Makoto Yoshimitsu; Tadaki Suzuki; Yuko Goto; Michiyo Higashi; Seiya Yokoyama; Tomohisa Tabuchi; Takahiro Futatsuki; Kentaro Nakamura; Hideki Hasegawa; Masayuki Saijo; Yasuyuki Kakihana; Naomichi Arima; Suguru Yonezawa
PATHOLOGY INTERNATIONAL, 64, 11, 569, 575, Nov. 2014, [Peer-reviewed]
English, Scientific journal - Cytokine profile of bronchoalveolar lavage fluid from a mouse model of bronchial asthma during seasonal H1N1 infection
Shunji Hasegawa; Hiroyuki Wakiguchi; Seigo Okada; Yu Gui Kang; Nao Fujii; Masanari Hasegawa; Hideki Hasegawa; Akira Ainai; Ryo Atsuta; Komei Shirabe; Shoichi Toda; Midori Wakabayashi-Takahara; Tsuneo Morishima; Takashi Ichiyama
CYTOKINE, 69, 2, 206, 210, Oct. 2014, [Peer-reviewed]
English, Scientific journal - Preclinical efficacy of the synthetic retinoid ST1926 for treating adult T-cell leukemia/lymphoma
Hiba El Hajj; Bariaa Khalil; Botheina Ghandour; Rihab Nasr; Sharif Shahine; Akram Ghantous; Rana Abdel-Samad; Ansam Sinjab; Hideki Hasegawa; Mark Jabbour; William W. Hall; Ghazi Zaatari; Ghassan Dbaibo; Claudio Pisano; Ali Bazarbachi; Nadine Darwiche
BLOOD, 124, 13, 2072, 2080, Sep. 2014, [Peer-reviewed]
English, Scientific journal - Effects of Toll-Like Receptor Stimulation on Eosinophilic Infiltration in Lungs of BALB/c Mice Immunized with UV-Inactivated Severe Acute Respiratory Syndrome-Related Coronavirus Vaccine
Naoko Iwata-Yoshikawa; Akihiko Uda; Tadaki Suzuki; Yasuko Tsunetsugu-Yokota; Yuko Sato; Shigeru Morikawa; Masato Tashiro; Tetsutaro Sata; Hideki Hasegawa; Noriyo Nagata
JOURNAL OF VIROLOGY, 88, 15, 8597, 8614, Aug. 2014, [Peer-reviewed]
English, Scientific journal - Neutrophil Depletion Suppresses Pulmonary Vascular Hyperpermeability and Occurrence of Pulmonary Edema Caused by Hantavirus Infection in C.B-17 SCID Mice
Takaaki Koma; Kumiko Yoshimatsu; Noriyo Nagata; Yuko Sato; Kenta Shimizu; Shumpei P. Yasuda; Takako Amada; Sanae Nishio; Hideki Hasegawa; Jiro Arikawa
JOURNAL OF VIROLOGY, 88, 13, 7178, 7188, Jul. 2014, [Peer-reviewed]
English, Scientific journal - Combatting infectious diseases; nanotechnology as a platform for rational vaccine design
Elly van Riet; Akira Ainai; Tadaki Suzuki; Gideon Kersten; Hideki Hasegawa
ADVANCED DRUG DELIVERY REVIEWS, 74, 28, 34, Jul. 2014, [Peer-reviewed]
English - Circulating Avian Influenza Viruses Closely Related to the 1918 Virus Have Pandemic Potential
Tokiko Watanabe; Gongxun Zhong; Colin A. Russell; Noriko Nakajima; Masato Hatta; Anthony Hanson; Ryan McBride; David F. Burke; Kenta Takahashi; Satoshi Fukuyama; Yuriko Tomita; Eileen A. Maher; Shinji Watanabe; Masaki Imai; Gabriele Neumann; Hideki Hasegawa; James C. Paulson; Derek J. Smith; Yoshihiro Kawaoka
CELL HOST & MICROBE, 15, 6, 692, 705, Jun. 2014, [Peer-reviewed]
English, Scientific journal - The Host Protease TMPRSS2 Plays a Major Role in In Vivo Replication of Emerging H7N9 and Seasonal Influenza Viruses
Kouji Sakai; Yasushi Ami; Maino Tahara; Toru Kubota; Masaki Anraku; Masako Abe; Noriko Nakajima; Tsuyoshi Sekizuka; Kazuya Shirato; Yuriko Suzaki; Akira Ainai; Yuichiro Nakatsu; Kazuhiko Kanou; Kazuya Nakamura; Tadaki Suzuki; Katsuhiro Komase; Eri Nobusawa; Katsumi Maenaka; Makoto Kuroda; Hideki Hasegawa; Yoshihiro Kawaoka; Masato Tashiro; Makoto Takeda
JOURNAL OF VIROLOGY, 88, 10, 5608, 5616, May 2014, [Peer-reviewed]
English, Scientific journal - The prevalence of opportunistic infections and malignancies in autopsied patients with human immunodeficiency virus infection in Japan
Harutaka Katano; Tsunekazu Hishima; Makoto Mochizuki; Yoshinori Kodama; Naoki Oyaizu; Yasunori Ota; Sohtaro Mine; Toru Igari; Atsushi Ajisawa; Katsuji Teruya; Junko Tanuma; Yoshimi Kikuchi; Tomoko Uehira; Takuma Shirasaka; Tomohiko Koibuchi; Aikichi Iwamoto; Shinichi Oka; Hideki Hasegawa; Seiji Okada; Akira Yasuoka
BMC INFECTIOUS DISEASES, 14, 229, Apr. 2014, [Peer-reviewed]
English, Scientific journal - HIV感染者の剖検例における日和見感染症と腫瘍の実態
片野 晴隆; 比島 恒和; 望月 眞; 児玉 良典; 小柳津 直樹; 大田 泰徳; 峰 宗太郎; 猪狩 亨; 味澤 篤; 照屋 勝治; 田沼 順子; 菊池 嘉; 岡 慎一; 上平 朝子; 白阪 琢磨; 鯉渕 智彦; 岩本 愛吉; 長谷川 秀樹; 岡田 誠治; 安岡 彰
日本病理学会会誌, 103, 1, 207, 207, (一社)日本病理学会, Mar. 2014
Japanese - The First Identification and Retrospective Study of Severe Fever With Thrombocytopenia Syndrome in Japan
Toru Takahashi; Ken Maeda; Tadaki Suzuki; Aki Ishido; Toru Shigeoka; Takayuki Tominaga; Toshiaki Kamei; Masahiro Honda; Daisuke Ninomiya; Takenori Sakai; Takanori Senba; Shozo Kaneyuki; Shota Sakaguchi; Akira Satoh; Takanori Hosokawa; Yojiro Kawabe; Shintaro Kurihara; Koichi Izumikawa; Shigeru Kohno; Taichi Azuma; Koichiro Suemori; Masaki Yasukawa; Tetsuya Mizutani; Tsutomu Omatsu; Yukie Katayama; Masaharu Miyahara; Masahito Ijuin; Kazuko Doi; Masaru Okuda; Kazunori Umeki; Tomoya Saito; Kazuko Fukushima; Kensuke Nakajima; Tomoki Yoshikawa; Hideki Tani; Shuetsu Fukushi; Aiko Fukuma; Momoko Ogata; Masayuki Shimojima; Noriko Nakajima; Noriyo Nagata; Harutaka Katano; Hitomi Fukumoto; Yuko Sato; Hideki Hasegawa; Takuya Yamagishi; Kazunori Oishi; Ichiro Kurane; Shigeru Morikawa; Masayuki Saijo
JOURNAL OF INFECTIOUS DISEASES, 209, 6, 816, 827, Mar. 2014, [Peer-reviewed]
English, Scientific journal - Cytokine Profiles In Bronchoalveolar Lavage In a Mouse Model Of Bronchial Asthma During A(H1N1)pdm09 and Seasonal H1N1 Infection
Shunji Hasegawa; Seigo Okada; Hiroyuki Wakiguchi; Hideki Hasegawa; Akira Ainai; Komei Shirabe; Shoichi Toda; Ryo Atsuta; Akihiro Hasegawa; Takashi Ichiyama
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 133, 2, AB189, AB189, Feb. 2014, [Peer-reviewed]
English - Classification of AIDS-related lymphoma cases between 1987 and 2012 in Japan based on the WHO classification of lymphomas, fourth edition
Yasunori Ota; Tsunekazu Hishima; Makoto Mochizuki; Yoshinori Kodama; Suzuko Moritani; Naoki Oyaizu; Sohtaro Mine; Atsushi Ajisawa; Junko Tanuma; Tomoko Uehira; Shotaro Hagiwara; Keishiro Yajima; Yusuke Koizumi; Takuma Shirasaka; Yuki Kojima; Hirokazu Nagai; Yoshiyuki Yokomaku; Yumiko Shiozawa; Tomohiko Koibuchi; Aikichi Iwamoto; Shinichi Oka; Hideki Hasegawa; Seiji Okada; Harutaka Katano
CANCER MEDICINE, 3, 1, 143, 153, Feb. 2014, [Peer-reviewed]
English, Scientific journal - A novel HSP90 inhibitor, 17-DMAG, induces Tax down-regulation and its oral administration to ATL-model mice intervenes against the infiltration property of the ATL-like lymphocytes and provides extended survival period
Emi Ikebe; Akira Kawaguchi; Kenta Tezuka; Shinya Taguchi; Satoshi Hirose; Takashi Matsumoto; Takahiro Mitsui; Kazuyo Senba; Akira Nishizono; Mitsuo Hori; Hiroo Hasegawa; Yasuaki Yamada; Takaharu Ueno; Yuetsu Tanaka; Hirofumi Sawa; William Hall; Yasuaki Minami; Kuan-Teh Jeang; Masao Ogata; Kazuhiro Morishita; Hideki Hasegawa; Jun-ichi Fujisawa; Hidekatsu Iha
Retrovirology, 11(Suppl 1), P44, 2014, [Peer-reviewed] - P-006 モデルマウスを用いたインフルエンザ感染による喘息発作重症化の病態解析 : 新型と季節性の比較(動物モデル1,口演1,第26回日本アレルギー学会春季臨床大会)
長谷川 俊史; 脇口 宏之; 松重 武志; 市山 高志; 長谷川 秀樹; 相内 章; 調 恒明; 戸田 昌一; 熱田 了
アレルギー, 63, 3, 544, 544, 一般社団法人 日本アレルギー学会, 2014
Japanese - Plasma Antimicrobial Peptide LL-37 Level Is Inversely Associated with HDL Cholesterol Level in Patients with Type 2 Diabetes Mellitus
Shu Meguro; Masuomi Tomita; Takeshi Katsuki; Kiyoe Kato; Henpiru Oh; Akira Ainai; Ryo Ito; Toshihide Kawai; Hiroshi Itoh; Hideki Hasegawa
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2014, 703696, 2014, [Peer-reviewed]
English, Scientific journal - Pathogenesis of fulminant monkeypox with bacterial sepsis after experimental infection with West African monkeypox virus in a cynomolgus monkey
Noriyo Nagata; Masayuki Saijo; Michiyo Kataoka; Yasushi Ami; Yuriko Suzaki; Yuko Sato; Naoko Iwata-Yoshikawa; Momoko Ogata; Ichiro Kurane; Shigeru Morikawa; Tetsutaro Sata; Hideki Hasegawa
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 7, 7, 4359, 4370, 2014, [Peer-reviewed]
English, Scientific journal - Detection of trichodysplasia spinulosa-associated polyomavirus in a fatal case of myocarditis in a seven-month-old girl
Shinya Tsuzuki; Hitomi Fukumoto; Sohtaro Mine; Noriko Sato; Makoto Mochizuki; Hideki Hasegawa; Tsuyoshi Sekizuka; Makoto Kuroda; Takeji Matsushita; Harutaka Katano
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 7, 8, 5308, 5312, 2014, [Peer-reviewed]
English, Scientific journal - Viroporin activity of the JC polyomavirus is regulated by interactions with the adaptor protein complex 3
Tadaki Suzuki; Yasuko Orba; Yoshinori Makino; Yuki Okada; Yuji Sunden; Hideki Hasegawa; William W. Hall; Hirofumi Sawa
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 110, 46, 18668, 18673, Nov. 2013, [Peer-reviewed]
English, Scientific journal - NS1-binding protein abrogates the elevation of cell viability by the influenza A virus NS1 protein in association with CRKL
Masaya Miyazaki; Hiroshi Nishihara; Hideki Hasegawa; Masato Tashiro; Lei Wang; Taichi Kimura; Mishie Tanino; Masumi Tsuda; Shinya Tanaka
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 441, 4, 953, 957, Nov. 2013, [Peer-reviewed]
English, Scientific journal - Development of oligomannose-coated liposome-based nasal vaccine against human parainfluenza virus type 3
Kyosuke Senchi; Satoko Matsunaga; Hideki Hasegawa; Hirokazu Kimura; Akihide Ryo
FRONTIERS IN MICROBIOLOGY, 4, 346, Nov. 2013, [Peer-reviewed]
English, Scientific journal - Characterization of H7N9 influenza A viruses isolated from humans
Tokiko Watanabe; Maki Kiso; Satoshi Fukuyama; Noriko Nakajima; Masaki Imai; Shinya Yamada; Shin Murakami; Seiya Yamayoshi; Kiyoko Iwatsuki-Horimoto; Yoshihiro Sakoda; Emi Takashita; Ryan McBride; Takeshi Noda; Masato Hatta; Hirotaka Imai; Dongming Zhao; Noriko Kishida; Masayuki Shirakura; Robert P. de Vries; Shintaro Shichinohe; Masatoshi Okamatsu; Tomokazu Tamura; Yuriko Tomita; Naomi Fujimoto; Kazue Goto; Hiroaki Katsura; Eiryo Kawakami; Izumi Ishikawa; Shinji Watanabe; Mutsumi Ito; Yuko Sakai-Tagawa; Yukihiko Sugita; Ryuta Uraki; Reina Yamaji; Amie J. Eisfeld; Gongxun Zhong; Shufang Fan; Jihui Ping; Eileen A. Maher; Anthony Hanson; Yuko Uchida; Takehiko Saito; Makoto Ozawa; Gabriele Neumann; Hiroshi Kida; Takato Odagiri; James C. Paulson; Hideki Hasegawa; Masato Tashiro; Yoshihiro Kawaoka
NATURE, 501, 7468, 551, +, Sep. 2013, [Peer-reviewed]
English, Scientific journal - Intranasal vaccination with an inactivated whole influenza virus vaccine induces strong antibody responses in serum and nasal mucus of healthy adults
Akira Ainai; Shin-ichi Tamura; Tadaki Suzuki; Elly van Riet; Ryo Ito; Takato Odagiri; Masato Tashiro; Takeshi Kurata; Hideki Hasegawa
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 9, 9, 1962, 1970, Sep. 2013, [Peer-reviewed]
English, Scientific journal - Oral administration of an HSP90 inhibitor, 17-DMAG, intervenes tumor-cell infiltration into multiple organs and improves survival period for ATL model mice
E. Ikebe; A. Kawaguchi; K. Tezuka; S. Taguchi; S. Hirose; T. Matsumoto; T. Mitsui; K. Senba; A. Nishizono; M. Hori; H. Hasegawa; Y. Yamada; T. Ueno; Y. Tanaka; H. Sawa; W. Hall; Y. Minami; K. T. Jeang; M. Ogata; K. Morishita; H. Hasegawa; J. Fujisawa; H. Iha
Blood Cancer Journal, 3, 8, Aug. 2013
Scientific journal - 成人T細胞白血病マウスモデルを用いた癌幹細胞ニッチ形成における破骨細胞の機能解析と破骨細胞を標的とした治療法の開発
水上 拓郎; 滝澤 和也; 栗林 和華子; 平松 竜司; 倉光 球; 山崎 淳平; Hall William; 長谷川 秀樹; 山口 一成; 浜口 功
日本獣医学会学術集会講演要旨集, 156回, 194, 194, (公社)日本獣医学会, Aug. 2013, [Peer-reviewed]
Japanese - Detection of influenza virus with specific subtype by using localized surface plasmons excited on a flat metal surface
Jun Ning; Kotaro Nagata; Akira Ainai; Hideki Hasegawa; Hiroshi Kano
Japanese Journal of Applied Physics, 52, 8, Aug. 2013, [Peer-reviewed]
English, Scientific journal - Analysis of bronchoalveolar lavage fluid in a mouse model of bronchial asthma and H1N1 2009 infection
Seigo Okada; Shunji Hasegawa; Hideki Hasegawa; Akira Ainai; Ryo Atsuta; Kenzo Ikemoto; Kohsuke Sasaki; Shoichi Toda; Komei Shirabe; Midori Takahara; Sawako Harada; Tsuneo Morishima; Takashi Ichiyama
CYTOKINE, 63, 2, 194, 200, Aug. 2013, [Peer-reviewed]
English, Scientific journal - Excessive Cytokine Response to Rapid Proliferation of Highly Pathogenic Avian Influenza Viruses Leads to Fatal Systemic Capillary Leakage in Chickens
Saya Kuribayashi; Yoshihiro Sakoda; Takeshi Kawasaki; Tomohisa Tanaka; Naoki Yamamoto; Masatoshi Okamatsu; Norikazu Isoda; Yoshimi Tsuda; Yuji Sunden; Takashi Umemura; Noriko Nakajima; Hideki Hasegawa; Hiroshi Kida
PLOS ONE, 8, 7, e68375, Jul. 2013, [Peer-reviewed]
English, Scientific journal - Canine Distemper Virus Associated with a Lethal Outbreak in Monkeys Can Readily Adapt To Use Human Receptors
Kouji Sakai; Tomoki Yoshikawa; Fumio Seki; Shuetsu Fukushi; Maino Tahara; Noriyo Nagata; Yasushi Ami; Tetsuya Mizutani; Ichiro Kurane; Ryoji Yamaguchi; Hideki Hasegawa; Masayuki Saijo; Katsuhiro Komase; Shigeru Morikawa; Makoto Takeda
JOURNAL OF VIROLOGY, 87, 12, 7170, 7175, Jun. 2013, [Peer-reviewed]
English, Scientific journal - Gold Nanoparticles as a Vaccine Platform: Influence of Size and Shape on Immunological Responses in Vitro and in Vivo
Kenichi Niikura; Tatsuya Matsunaga; Tadaki Suzuki; Shintaro Kobayashi; Hiroki Yamaguchi; Yasuko Orba; Akira Kawaguchi; Hideki Hasegawa; Kiichi Kajino; Takafumi Ninomiya; Kuniharu Ijiro; Hirofumi Sawa
ACS NANO, 7, 5, 3926, 3938, May 2013, [Peer-reviewed]
English, Scientific journal - Evaluation of the Effectiveness and Safety of Chitosan Derivatives as Adjuvants for Intranasal Vaccines
Takashi Kobayashi; Kenji Fukushima; Takanori Sannan; Noriko Saito; Yasuyuki Takiguchi; Yuko Sato; Hideki Hasegawa; Koichi Ishikawa
VIRAL IMMUNOLOGY, 26, 2, 133, 142, Apr. 2013, [Peer-reviewed]
English, Scientific journal - Pathological study of archival lung tissues from five fatal cases of avian H5N1 influenza in Vietnam
Noriko Nakajima; Ngo Van Tin; Yuko Sato; Hoang Ngoc Thach; Harutaka Katano; Pho Hong Diep; Toshio Kumasaka; Nguyen Trung Thuy; Hideki Hasegawa; Luong Thi San; Shoji Kawachi; Nguyen Thanh Liem; Kazuo Suzuki; Tetsutaro Sata
MODERN PATHOLOGY, 26, 3, 357, 369, Mar. 2013, [Peer-reviewed]
English, Scientific journal - Frequent detection of Merkel cell polyomavirus DNA in sera of HIV-1-positive patients
Hitomi Fukumoto; Yuko Sato; Hideki Hasegawa; Harutaka Katano
VIROLOGY JOURNAL, 10, 84, Mar. 2013, [Peer-reviewed]
English, Scientific journal - Lethal canine distemper virus outbreak in cynomolgus monkeys in Japan in 2008
Kouji Sakai; Noriyo Nagata; Yasushi Ami; Fumio Seki; Yuriko Suzaki; Naoko Iwata-Yoshikawa; Tadaki Suzuki; Shuetsu Fukushi; Tetsuya Mizutani; Tomoki Yoshikawa; Noriyuki Otsuki; Ichiro Kurane; Katsuhiro Komase; Ryoji Yamaguchi; Hideki Hasegawa; Masayuki Saijo; Makoto Takeda; Shigeru Morikawa
Journal of Virology, 87, 2, 1105, 1114, Jan. 2013, [Peer-reviewed]
English, Scientific journal - A Kampo (Traditional Japanese Herbal) Medicine, Hochuekkito, Pretreatment in Mice Prevented Influenza Virus Replication Accompanied with GM-CSF Expression and Increase in Several Defensin mRNA Levels
Katsuaki Dan; Hiroko Akiyoshi; Kaori Munakata; Hideki Hasegawa; Kenji Watanabe
PHARMACOLOGY, 91, 5-6, 314, 321, 2013, [Peer-reviewed]
English, Scientific journal - Spi-B is critical for plasmacytoid dendritic cell function and development
Izumi Sasaki; Katsuaki Hoshino; Takahiro Sugiyama; Chihiro Yamazaki; Takahiro Yano; Akihiko Iizuka; Hiroaki Hemmi; Takashi Tanaka; Masuyoshi Saito; Masanaka Sugiyama; Yuri Fukuda; Tomokazu Ohta; Katsuaki Sato; Akira Ainai; Tadaki Suzuki; Hideki Hasegawa; Noriko Toyama-Sorimachi; Hiroshi Kohara; Takashi Nagasawa; Tsuneyasu Kaisho
BLOOD, 120, 24, 4733, 4743, Dec. 2012, [Peer-reviewed]
English, Scientific journal - Identification of a Varicella-Zoster Virus Replication Inhibitor That Blocks Capsid Assembly by Interacting with the Floor Domain of the Major Capsid Protein
Naoki Inoue; Misato Matsushita; Yoshiko Fukui; Souichi Yamada; Mihoko Tsuda; Chizuka Higashi; Keiko Kaneko; Hideki Hasegawa; Toyofumi Yamaguchi
JOURNAL OF VIROLOGY, 86, 22, 12198, 12207, Nov. 2012, [Peer-reviewed]
English, Scientific journal - Role of JC virus agnoprotein in virion formation
Tadaki Suzuki; Shingo Semba; Yuji Sunden; Yasuko Orba; Shintaro Kobayashi; Kazuo Nagashima; Takashi Kimura; Hideki Hasegawa; Hirofumi Sawa
MICROBIOLOGY AND IMMUNOLOGY, 56, 9, 639, 646, Sep. 2012, [Peer-reviewed]
English, Scientific journal - マウスモデルを用いたATL癌幹細胞及びそのニッチの解析
水上 拓郎; 滝澤 和也; 山崎 淳平; 倉光 球; 百瀬 暖佳; 益見 厚子; 長谷川 秀樹; 山口 一成; 浜口 功
日本獣医学会学術集会講演要旨集, 154回, 172, 172, (公社)日本獣医学会, Aug. 2012, [Peer-reviewed]
Japanese - Mucosal IgA responses in influenza virus infections; thoughts for vaccine design
Elly van Riet; Akira Ainai; Tadaki Suzuki; Hideki Hasegawa
VACCINE, 30, 40, 5893, 5900, Aug. 2012, [Peer-reviewed]
English - Association of Major Histocompatibility Complex Class I Haplotypes with Disease Progression after Simian Immunodeficiency Virus Challenge in Burmese Rhesus Macaques
Takushi Nomura; Hiroyuki Yamamoto; Teiichiro Shiino; Naofumi Takahashi; Taku Nakane; Nami Iwamoto; Hiroshi Ishii; Tetsuo Tsukamoto; Miki Kawada; Saori Matsuoka; Akiko Takeda; Kazutaka Terahara; Yasuko Tsunetsugu-Yokota; Naoko Iwata-Yoshikawa; Hideki Hasegawa; Tetsutaro Sata; Taeko K. Naruse; Akinori Kimura; Tetsuro Matano
JOURNAL OF VIROLOGY, 86, 12, 6481, 6490, Jun. 2012, [Peer-reviewed]
English, Scientific journal - Herpes Simplex Virus 1 VP22 Regulates Translocation of Multiple Viral and Cellular Proteins and Promotes Neurovirulence
Michiko Tanaka; Akihisa Kato; Yuko Satoh; Takahiro Ide; Ken Sagou; Kayo Kimura; Hideki Hasegawa; Yasushi Kawaguchi
JOURNAL OF VIROLOGY, 86, 9, 5264, 5277, May 2012, [Peer-reviewed]
English, Scientific journal - Erratum: Histopathological and immunohistochemical findings of 20 autopsy cases with 2009 H1N1 virus infection (Modern Pathology (2012) 25 (492) DOI:10.1038/modpathol.2011.180))
Noriko Nakajima; Yuko Sato; Harutaka Katano; Hideki Hasegawa; Toshio Kumasaka; Satoru Hata; Shinya Tanaka; Tomonori Amano; Takahiko Kasai; Ja-Mun Chong; Toshihiko Iiduka; Iwao Nakazato; Yohko Hino; Akihiko Hamamatsu; Hisashi Horiguchi; Tomoyuki Tanaka; Akio Hasagawa; Yoshiaki Kanaya; Reiko Oku; Takeshi Oya; Tetsutaro Sata
Modern Pathology, 25, 3, 492, Mar. 2012, [Peer-reviewed]
English, Scientific journal - Mechanism of Drug Resistance of Hemagglutinin of Influenza Virus and Potent Scaffolds Inhibiting Its Function
Hiroshi Yanagita; Norio Yamamoto; Hideyoshi Fuji; Xinli Liu; Masakazu Ogata; Mizuho Yokota; Hiroshi Takaku; Hideki Hasegawa; Takato Odagiri; Masato Tashiro; Tyuji Hoshino
ACS CHEMICAL BIOLOGY, 7, 3, 552, 562, Mar. 2012, [Peer-reviewed]
English, Scientific journal - Characterization of neutralizing antibodies in adults after intranasal vaccination with an inactivated influenza vaccine
Akira Ainai; Shin-ichi Tamura; Tadaki Suzuki; Ryo Ito; Hideki Asanuma; Takeshi Tanimoto; Yasuyuki Gomi; Sadao Manabe; Toyokazu Ishikawa; Yoshinobu Okuno; Takato Odagiri; Masato Tashiro; Tetsutaro Sata; Takeshi Kurata; Hideki Hasegawa
JOURNAL OF MEDICAL VIROLOGY, 84, 2, 336, 344, Feb. 2012, [Peer-reviewed]
English, Scientific journal - Histopathological and immunohistochemical findings of 20 autopsy cases with 2009 H1N1 virus infection
Noriko Nakajima; Yuko Sato; Harutaka Katano; Hideki Hasegawa; Toshio Kumasaka; Satoru Hata; Shinya Tanaka; Tomonori Amano; Takahiko Kasai; Ja-Mun Chong; Toshihiko Iiduka; Iwao Nakazato; Yohko Hino; Akihiko Hamamatsu; Hisashi Horiguchi; Tomoyuki Tanaka; Akio Hasagawa; Yoshiaki Kanaya; Reiko Oku; Takeshi Oya; Tetsutaro Sata
MODERN PATHOLOGY, 25, 1, 1, 13, Jan. 2012, [Peer-reviewed]
English, Scientific journal - Pathogenic characterization of a cervical lymph node derived from a patient with Kawasaki disease
Harutaka Katano; Seiichi Sato; Tsuyoshi Sekizuka; Akiko Kinumaki; Hitomi Fukumoto; Yuko Sato; Hideki Hasegawa; Shigeru Morikawa; Masayuki Saijo; Tetsuya Mizutani; Makoto Kuroda
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 5, 8, 814, 823, 2012, [Peer-reviewed]
English, Scientific journal - 臓器特異的自己免疫疾患(標的:神経、脈管) マウスにおいてTAX1BP1欠損は炎症症状と心臓系の機能不全の時間・空間的発生を誘発する(TAX1BP1-deficiency evokes spaciotemporal development of inflammatory symptoms and functional failures in the murine cardiac system)
Nakano Satoko; Ikebe Emi; Tsukamoto Yoshiyuki; Yahiro Takaaki; Matsumoto Takashi; Mitsui Takahiro; Hori Mitsuo; Hasegawa Hideki; Kubota Toshiaki; Nishizono Akira; Jeang Kuan-Teh; Iha Hidekatsu
日本免疫学会総会・学術集会記録, 40, 227, 227, (NPO)日本免疫学会, Nov. 2011, [Peer-reviewed]
English - A novel function of the N-terminal domain of PA in assembly of influenza A virus RNA polymerase
Tadaki Suzuki; Akira Ainai; Noriyo Nagata; Tetsutaro Sata; Hirofumi Sawa; Hideki Hasegawa
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 414, 4, 719, 726, Nov. 2011, [Peer-reviewed]
English, Scientific journal - Outer Membrane Vesicles of Porphyromonas gingivalis Elicit a Mucosal Immune Response
Ryoma Nakao; Hideki Hasegawa; Kuniyasu Ochiai; Shogo Takashiba; Akira Ainai; Makoto Ohnishi; Haruo Watanabe; Hidenobu Senpuku
PLOS ONE, 6, 10, e26163, Oct. 2011, [Peer-reviewed]
English, Scientific journal - HTLV-1 Taxトランスジェニックマウスを用いたATL癌幹細胞及びそのニッチの同定
水上 拓郎; 滝沢 和也; 山崎 淳平; 倉光 球; 百瀬 暖佳; 益見 厚子; 長谷川 秀樹; 山口 一成; 浜口 功
日本獣医学会学術集会講演要旨集, 152回, 171, 171, (公社)日本獣医学会, Aug. 2011, [Peer-reviewed]
Japanese - Mobile and Accurate Detection System for Infection by the 2009 Pandemic Influenza A (H1N1) Virus With a Pocket-Warmer Reverse-Transcriptase Loop-Mediated Isothermal Amplification
Ben Hatano; Megumi Goto; Hitomi Fukumoto; Takeyuki Obara; Takayuki Maki; Go Suzuki; Tetsuo Yamamoto; Kohsuke Hagisawa; Yoshitaro Matsushita; Tatsuya Fujii; Toshihiko Imakiire; Yuichi Kikuchi; Ryota Takahashi; Mie Kanai; Kaku Tamura; Tomoko Izumi; Yukihiro Takahashi; Yujiro Iwamoto; Satoshi Mimura; Yasuo Mukai; Kazue Takita; Hiroki Takeo; Ryuichi Kitamura; Eiichi Shimizu; Koji Fukushima; Yukiya Hakozaki; Akimi Uehata; Masao Sakai; Satoshi Ohshima; Toshiki Shirotani; Kunihiro Oba; Hideki Hasegawa; Tetsutaro Sata; Harutaka Katano
JOURNAL OF MEDICAL VIROLOGY, 83, 4, 568, 573, Apr. 2011, [Peer-reviewed]
English, Scientific journal - Identification and molecular characterization of a new nonsegmented double-stranded RNA virus isolated from Culex mosquitoes in Japan
Haruhiko Isawa; Ryusei Kuwata; Keita Hoshino; Yoshio Tsuda; Kouji Sakai; Shumpei Watanabe; Miho Nishimura; Tomomitsu Satho; Michiyo Kataoka; Noriyo Nagata; Hideki Hasegawa; Hisanori Bando; Kazuhiko Yano; Toshinori Sasaki; Mutsuo Kobayashi; Tetsuya Mizutani; Kyoko Sawabe
VIRUS RESEARCH, 155, 1, 147, 155, Jan. 2011, [Peer-reviewed]
English, Scientific journal - Passive Immune-Prophylaxis against Influenza Virus Infection by the Expression of Neutralizing Anti-Hemagglutinin Monoclonal Antibodies from Plasmids
Tatsuya Yamazaki; Maria Nagashima; Daisuke Ninomiya; Yuka Arai; Yasutomo Teshima; Akira Fujimoto; Akira Ainai; Hideki Hasegawa; Joe Chiba
JAPANESE JOURNAL OF INFECTIOUS DISEASES, 64, 1, 40, 49, Jan. 2011, [Peer-reviewed]
English, Scientific journal - Cross-protective immunity against influenza virus infections induced by intranasal vaccination together with a TLR3-mucosal adjuvant
Akira Ainai; Masato Tashiro; Hideki Hasegawa
HUMAN VACCINES, 7, 174, 182, Jan. 2011, [Peer-reviewed]
English, Scientific journal - Plasma 25-Hydroxyvitamin D Is Independently Associated with Hemoglobin Concentration in Male Subjects with Type 2 Diabetes Mellitus
Shu Meguro; Masuomi Tomita; Takeshi Katsuki; Kiyoe Kato; Henpiru Oh; Akira Ainai; Ryo Ito; Shu Takeda; Toshihide Kawai; Yoshihito Atsumi; Hiroshi Itoh; Hideki Hasegawa
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2011, 362981, 2011, [Peer-reviewed]
English, Scientific journal - Pathology of Kaposi's sarcoma-associated herpesvirus infection
Hitomi Fukumoto; Takayuki Kanno; Hideki Hasegawa; Harutaka Katano
FRONTIERS IN MICROBIOLOGY, 2, 175, 2011, [Peer-reviewed]
English - Therapy-induced selective loss of leukemia-initiating activity in murine adult T cell leukemia
Hiba El Hajj; Marwan El-Sabban; Hideki Hasegawa; Ghazi Zaatari; Julien Ablain; Shahrazad T. Saab; Anne Janin; Rami Mahfouz; Rihab Nasr; Youmna Kfoury; Christophe Nicot; Olivier Hermine; William Hall; Hugues de The; Ali Bazarbachi
JOURNAL OF EXPERIMENTAL MEDICINE, 207, 13, 2785, 2792, Dec. 2010, [Peer-reviewed]
English, Scientific journal - Intranasal Administration of Adjuvant-Combined Vaccine Protects Monkeys From Challenge With the Highly Pathogenic Influenza A H5N1 Virus
Takeshi Ichinohe; Akira Ainai; Yasushi Ami; Noriyo Nagata; Naoko Iwata; Akira Kawaguchi; Yuriko Suzaki; Takato Odagiri; Masato Tashiro; Hidehiro Takahashi; David R. Strayer; William A. Carter; Joe Chiba; Shin-ichi Tamura; Tetsutaro Sata; Takeshi Kurata; Hideki Hasegawa
JOURNAL OF MEDICAL VIROLOGY, 82, 10, 1754, 1761, Oct. 2010, [Peer-reviewed]
English, Scientific journal - Functional analysis of an alpha-helical antimicrobial peptide derived from a novel mouse defensin-like gene
Akira Kawaguchi; Tadaki Suzuki; Takashi Kimura; Naoki Sakai; Tokiyoshi Ayabe; Hirofumi Sawa; Hideki Hasegawa
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 398, 4, 778, 784, Aug. 2010, [Peer-reviewed]
English, Scientific journal - Cytokine and Growth Factor Expression by HTLV-1 Lck-tax Transgenic Cells in SCID Mice
Karen M. Watters; Jonathan Dean; Hideki Hasegawa; Hirofumi Sawa; William Hall; Noreen Sheehy
AIDS RESEARCH AND HUMAN RETROVIRUSES, 26, 5, 593, 603, May 2010, [Peer-reviewed]
English, Scientific journal - Early Mortality Following Intracerebral Infection with the Oshima Strain of Tick-Borne Encephalitis Virus in a Mouse Model
Daisuke Hayasaka; Noriyo Nagata; Hideki Hasegawa; Tetsutaro Sata; Ikuo Takashima; Satoshi Koike
JOURNAL OF VETERINARY MEDICAL SCIENCE, 72, 4, 391, 396, Apr. 2010, [Peer-reviewed]
English, Scientific journal - Highly Frequent Mutations in Negative Regulators of Multiple Virulence Genes in Group A Streptococcal Toxic Shock Syndrome Isolates
Tadayoshi Ikebe; Manabu Ato; Takayuki Matsumura; Hideki Hasegawa; Tetsutaro Sata; Kazuo Kobayashi; Haruo Watanabe
PLOS PATHOGENS, 6, 4, e1000832, Apr. 2010, [Peer-reviewed]
English, Scientific journal - Characterization of Quasispecies of Pandemic 2009 Influenza A Virus (A/H1N1/2009) by De Novo Sequencing Using a Next-Generation DNA Sequencer
Makoto Kuroda; Harutaka Katano; Noriko Nakajima; Minoru Tobiume; Akira Ainai; Tsuyoshi Sekizuka; Hideki Hasegawa; Masato Tashiro; Yuko Sasaki; Yoshichika Arakawa; Satoru Hata; Masahide Watanabe; Tetsutaro Sata
PLOS ONE, 5, 4, e10256, Apr. 2010, [Peer-reviewed]
English, Scientific journal - Zymosan Enhances the Mucosal Adjuvant Activity of Poly(I:C) in a Nasal Influenza Vaccine
Akira Ainai; Takeshi Ichinohe; Shin-ichi Tamura; Takeshi Kurata; Tetsutaro Sata; Masato Tashiro; Hideki Hasegawa
JOURNAL OF MEDICAL VIROLOGY, 82, 3, 476, 484, Mar. 2010, [Peer-reviewed]
English, Scientific journal - Induction of Cross-Protective Immunity Against Influenza A Virus H5N1 by an Intranasal Vaccine With Extracts of Mushroom Mycelia
Takeshi Ichinohe; Akira Ainai; Tomoyuki Nakamura; Yukihito Akiyama; Jun-ichi Maeyama; Takato Odagiri; Masato Tashiro; Hidehiro Takahashi; Hirofumi Sawa; Shin-ichi Tamura; Joe Chiba; Takeshi Kurata; Tetsutaro Sata; Hideki Hasegawa
JOURNAL OF MEDICAL VIROLOGY, 82, 1, 128, 137, Jan. 2010, [Peer-reviewed]
English, Scientific journal - Estimation of the Effective Doses of Nasal-Inactivated Influenza Vaccine in Humans from Mouse-Model Experiments
Shin-ichi Tamura; Hideki Hasegawa; Takeshi Kurata
JAPANESE JOURNAL OF INFECTIOUS DISEASES, 63, 1, 8, 15, Jan. 2010, [Peer-reviewed]
English - The First Autopsy Case of Pandemic Influenza (A/H1N1pdm) Virus Infection in Japan: Detection of a High Copy Number of the Virus in Type II Alveolar Epithelial Cells by Pathological and Virological Examination
Noriko Nakajima; Satoru Hata; Yuko Sato; Minoru Tobiume; Harutaka Katano; Keiko Kaneko; Noriyo Nagata; Michiyo Kataoka; Akira Ainai; Hideki Hasegawa; Masato Tashiro; Makoto Kuroda; Tamami Odai; Nobuyuki Urasawa; Tomoyoshi Ogino; Hiroaki Hanaoka; Masahide Watanabe; Tetsutaro Sata
JAPANESE JOURNAL OF INFECTIOUS DISEASES, 63, 1, 67, 71, Jan. 2010, [Peer-reviewed]
English, Scientific journal - Sudden Death of a Patient with Pandemic Influenza (A/H1N1pdm) Virus Infection by Acute Respiratory Distress Syndrome
Akihiro Takiyama; Lei Wang; Mishie Tanino; Taichi Kimura; Naoki Kawagishi; Yasuyuki Kunieda; Harutaka Katano; Noriko Nakajima; Hideki Hasegawa; Tomoyuki Takagi; Hiroshi Nishihara; Tetsutaro Sata; Shinya Tanaka
JAPANESE JOURNAL OF INFECTIOUS DISEASES, 63, 1, 72, 74, Jan. 2010, [Peer-reviewed]
English, Scientific journal - An Outbreak of Histoplasmosis among Healthy Young Japanese Women after Traveling to Southeast Asia
Hideaki Ohno; Yoshiko Ogata; Hajime Suguro; Soichiro Yokota; Akira Watanabe; Katsuhiko Kamei; Satoshi Yamagoe; Akiko Ishida-Okawara; Yukihiro Kaneko; Atsuko Horino; Kunikazu Yamane; Takahiro Tsuji; Noriyo Nagata; Hideki Hasegawa; Yoshichika Arakawa; Tetsutaro Sata; Yoshitsugu Miyazaki
INTERNAL MEDICINE, 49, 5, 491, 495, 2010, [Peer-reviewed]
English, Scientific journal - Effects of the number of amino acid residues in the signal segment upstream or downstream of the NS2B-3 cleavage site on production and secretion of prM/M-E virus-like particles of West Nile virus
Hidehiro Takahashi; Naohiro Ohtaki; Masae Maeda-Sato; Michiko Tanaka; Keiko Tanaka; Hirofumi Sawa; Toyokazu Ishikawa; Akihisa Takamizawa; Tomohiko Takasaki; Hideki Hasegawa; Tetsutaro Sata; William W. Hall; Takeshi Kurata; Asato Kojima
MICROBES AND INFECTION, 11, 13, 1019, 1028, Nov. 2009, [Peer-reviewed]
English, Scientific journal - Covalent bonded Gag multimers in human immunodeficiency virus type-1 particles
Yoshinori Kitagawa; Masae Maeda-Sato; Keiko Tanaka; Minoru Tobiume; Hirofumi Sawa; Hideki Hasegawa; Asato Kojima; William W. Hall; Takeshi Kurata; Tetsutaro Sata; Hidehiro Takahashi
MICROBIOLOGY AND IMMUNOLOGY, 53, 11, 609, 620, Nov. 2009, [Peer-reviewed]
English, Scientific journal - Inhibition of the SDF-1 alpha-CXCR4 axis by the CXCR4 antagonist AMD3100 suppresses the migration of cultured cells from ATL patients and murine lymphoblastoid cells from HTLV-I Tax transgenic mice
Akira Kawaguchi; Yasuko Orba; Takashi Kimura; Hidekatsu Iha; Masao Ogata; Takahiro Tsuji; Akira Ainai; Tetsutaro Sata; Takashi Okamoto; William W. Hall; Hirofumi Sawa; Hideki Hasegawa
BLOOD, 114, 14, 2961, 2968, Oct. 2009, [Peer-reviewed]
English, Scientific journal - PolyI:polyC(12)U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants
Takeshi Ichinohe; Akira Ainai; Masato Tashiro; Tetsutaro Sata; Hideki Hasegawa
VACCINE, 27, 45, 6276, 6279, Oct. 2009, [Peer-reviewed]
English, Scientific journal - Virulence and pathophysiology of the Congo Basin and West African strains of monkeypox virus in non-human primates
Masayuki Saijo; Yasushi Ami; Yuriko Suzaki; Noriyo Nagata; Naoko Iwata; Hideki Hasegawa; Itoe Iizuka; Tomoyuki Shiota; Kouji Sakai; Momoko Ogata; Shuetsu Fukushi; Tetsuya Mizutani; Tetsutaro Sata; Takeshi Kurata; Ichiro Kurane; Shigeru Morikawa
JOURNAL OF GENERAL VIROLOGY, 90, Pt 9, 2266, 2271, Sep. 2009, [Peer-reviewed]
English, Scientific journal - Identification of cancer stem cells in a Tax-transgenic (Tax-Tg) mouse model of adult T-cell leukemia/lymphoma
Jumpei Yamazaki; Takuo Mizukami; Kazuya Takizawa; Madoka Kuramitsu; Haruka Momose; Atsuko Masumi; Yasushi Ami; Hideki Hasegawa; William W. Hall; Hajime Tsujimoto; Isao Hamaguchi; Kazunari Yamaguchi
BLOOD, 114, 13, 2709, 2720, Sep. 2009, [Peer-reviewed]
English, Scientific journal - Rabies virus dissemination in neural tissues of autopsy cases due to rabies imported into Japan from the Philippines: Immunohistochemistry
Minoru Tobiume; Yuko Sato; Harutaka Katano; Noriko Nakajima; Keiko Tanaka; Akira Noguchi; Satoshi Inoue; Hideki Hasegawa; Yoko Iwasa; Junichi Tanaka; Hiroyuki Hayashi; Sachiko Yoshida; Ichiro Kurane; Tetsutaro Sata
PATHOLOGY INTERNATIONAL, 59, 8, 555, 566, Aug. 2009, [Peer-reviewed]
English, Scientific journal - Mortality following peripheral infection with Tick-borne encephalitis virus results from a combination of central nervous system pathology, systemic inflammatory and stress responses
Daisuke Hayasaka; Noriyo Nagata; Yoshiki Fujii; Hideki Hasegawa; Tetsutaro Sata; Ryuji Suzuki; Ernest A. Gould; Ikuo Takashima; Satoshi Koike
VIROLOGY, 390, 1, 139, 150, Jul. 2009, [Peer-reviewed]
English, Scientific journal - Loop-Mediated Isothermal Amplification-Based Diagnostic Assay for Monkeypox Virus Infections
Itoe Iizuka; Masayuki Saijo; Tomoyuki Shiota; Yasushi Ami; Yuriko Suzaki; Noriyo Nagata; Hideki Hasegawa; Kouji Sakai; Shuetsu Fukushi; Tetsuya Mizutani; Momoko Ogata; Mina Nakauchi; Ichiro Kurane; Masashi Mizuguchi; Shigeru Morikawa
JOURNAL OF MEDICAL VIROLOGY, 81, 6, 1102, 1108, Jun. 2009, [Peer-reviewed]
English, Scientific journal - Protective Immunity Afforded by Inactivated H5N1 (NIBRG-14) Vaccine Requires Antibodies against Both Hemagglutinin and Neuraminidase in Mice
Yoshimasa Takahashi; Hideki Hasegawa; Yukari Hara; Manabu Ato; Ai Ninomiya; Hirotaka Takagi; Takato Odagiri; Tetsutaro Sata; Masato Tashiro; Kazuo Kobayashi
JOURNAL OF INFECTIOUS DISEASES, 199, 11, 1629, 1637, Jun. 2009, [Peer-reviewed]
English, Scientific journal - Comparison of acellular pertussis-based combination vaccines by Japanese control tests for toxicities and laboratory models for local reaction
Michiyo Kataoka; Akihiko Yamamoto; Masaki Ochiai; Ayako Harashima; Noriyo Nagata; Hideki Hasegawa; Takeshi Kurata; Yoshinobu Horiuchi
VACCINE, 27, 13, 1881, 1888, Mar. 2009, [Peer-reviewed]
English, Scientific journal - Monoclonal Antibody and siRNAs for Topoisomerase I Suppress Telomerase Activity
Hidehiro Takahashi; Yoshinori Kitagawa; Masae Maeda-Satoh; Hideki Hasegawa; Hirofumi Sawa; Tetsutaro Sata
HYBRIDOMA, 28, 1, 63, 65, Feb. 2009, [Peer-reviewed]
English, Scientific journal - Neutralizing antibody against severe acute respiratory syndrome (SARS)-coronavirus spike is highly effective for the protection of mice in the murine SARS model
Koji Ishii; Hideki Hasegawa; Noriyo Nagata; Yasushi Ami; Shuetsu Fukushi; Fumihiro Taguchi; Yasuko Tsunetsugu-Yokota
MICROBIOLOGY AND IMMUNOLOGY, 53, 2, 75, 82, Feb. 2009, [Peer-reviewed]
English, Scientific journal - Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses.
Hasegawa H; Ichinohe T; Ainai A; Tamura S; Kurata T
Therapeutics and clinical risk management, 5, 1, 125, 132, Feb. 2009, [Peer-reviewed], [International Magazine]
English, Scientific journal, An increasing number of infections of highly pathogenic avian influenza virus (H5N1) in humans has been reported in South-East Asia and other areas of the world. High mortality (>60%) of this viral infection and its pathosis of systemic infection are features of this new human disease. Moreover, there is great concern that this avian H5N1 virus could cause a pandemic of new influenza in humans, once it acquires the ability for human to human transmission. To prevent such highly contagious infectious diseases as influenza, it is essential to prepare effective vaccines. Especially in the case of new influenza virus, we cannot predict the strain which will cause the pandemic. In such a situation, a vaccine that induces cross-protective immunity against variant viruses is extremely important. However currently used parenteral seasonal influenza vaccine is strain-specific, and is less effective against variant viruses. In order to overcome the weakness of current vaccines we need to learn from the immune responses induced by natural infection with influenza viruses. In the case of mucosally acquired acute respiratory infection such as influenza, mucosal immunity induced by natural infection plays important role in protection against the infection, as mucosal secretory IgA antibody plays an important role in cross-protection. In this review we describe the advantages and development of mucosal vaccine against highly pathogenic H5N1 influenza viruses. - Innate sensors of influenza virus: clues to developing better intranasal vaccines
Takeshi Ichinohe; Akiko Iwasaki; Hideki Hasegawa
EXPERT REVIEW OF VACCINES, 7, 9, 1435, 1445, Nov. 2008, [Peer-reviewed]
English - Mouse-passaged severe acute respiratory syndrome-associated coronavirus leads to lethal pulmonary edema and diffuse alveolar damage in adult but not young mice
Noriyo Nagata; Naoko Iwata; Hideki Hasegawa; Shuetsu Fukushi; Ayako Harashima; Yuko Sato; Masayuki Saijo; Fumihiro Taguchi; Shigeru Morikawa; Tetsutaro Sata
AMERICAN JOURNAL OF PATHOLOGY, 172, 6, 1625, 1637, Jun. 2008, [Peer-reviewed]
English, Scientific journal - Diagnosis and assessment of monkeypox virus (MPXV) infection by quantitative PCR assay: Differentiation of Congo Basin and West African MPXV strains
Masayuki Saijo; Yasushi Ami; Yuriko Suzakil; Noriyo Nagata; Naoko Iwata; Hideki Hasegawa; Mornoko Ogata; Shuetsu Fukushi; Tetsuya Mizutani; Itoe Iizuka; Koji Sakai; Tetsutaro Sata; Takeshi Kurata; Ichiro Kurane; Shigeru Morikawa
JAPANESE JOURNAL OF INFECTIOUS DISEASES, 61, 2, 140, 142, Mar. 2008, [Peer-reviewed]
English, Scientific journal - Type 2 diabetes impairs implant osseointegration capacity in rats
Hideki Hasegawa; Shogo Ozawa; Kazuyoshi Hashimoto; Takuro Takeichi; Takahiro Ogawa
INTERNATIONAL JOURNAL OF ORAL & MAXILLOFACIAL IMPLANTS, 23, 2, 237, 246, Mar. 2008, [Peer-reviewed]
English, Scientific journal - Pathology and virus dispersion in cynomolgus monkeys experimentally infected with severe acute respiratory syndrome coronavirus via different inoculation routes
Noriyo Nagata; Naoko Iwata; Hideki Hasegawa; Yuko Sato; Shigeru Morikawa; Masayuki Saijo; Shigeyuki Itamura; Takehiko Saito; Yasushi Ami; Takato Odagiri; Masato Tashiro; Tetsutaro Sata
INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, 88, 6, 403, 414, Dec. 2007, [Peer-reviewed]
English, Scientific journal - Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine
Takeshi Ichinohe; Shin-ichi Tamura; Akira Kawaguchi; Ai Ninomiya; Masaki Imai; Shigeyuki Itamura; Takato Odagiri; Masato Tashiro; Hidehiro Takahashi; Hirofumi Sawa; William M. Mitchell; David R. Strayer; William A. Carter; Joe Chiba; Takeshi Kurata; Tetsutaro Sata; Hideki Hasegawa
JOURNAL OF INFECTIOUS DISEASES, 196, 9, 1313, 1320, Nov. 2007, [Peer-reviewed]
English, Scientific journal - Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma: successful treatment with interferon-alpha
Takashi Ueno; Tsuyoshi Mitsuishi; Yoichi Kimura; Toshihiko Kato; Hideki Hasegawa; Harutaka Katano; Tetsutaro Sata; Shinji Kurane; Seiji Kawana
EUROPEAN JOURNAL OF DERMATOLOGY, 17, 6, 539, 540, Nov. 2007, [Peer-reviewed]
English - High diversity of HHV-8 molecular subtypes in the Amazon region of Brazil: Evidence of an ancient human infection
Marluisa de Oliveira Guimaraes Ishak; Rosimar Neris Martins; Paula Renata Lima Machado; Lia Lobato Batista de Souza; Luiz Fernando Almeida Machado; Vania Nakauth Azevedo; Harutaka Katano; Tetsutaro Sata; Hideki Hasegawa; Antonio Carlos Rosario Vallinoto; Ricardo Ishak
JOURNAL OF MEDICAL VIROLOGY, 79, 10, 1537, 1544, Oct. 2007, [Peer-reviewed]
English, Scientific journal - Intranasal immunization with H5N1 vaccine plus Poly I : Poly C12U, a Toll-like receptor agonist, protects mice against homologous and heterologous virus challenge
Takeshi Ichinohe; Akira Kawaguchi; Shin-ichi Tamura; Hidehiro Takahashi; Hirofumi Sawa; Ai Ninomiya; Masaki Imai; Shigeyuki Itamura; Takato Odagiri; Masato Tashiro; Joe Chiba; Tetsutaro Sata; Takeshi Kurata; Hideki Hasegawa
MICROBES AND INFECTION, 9, 11, 1333, 1340, Sep. 2007, [Peer-reviewed]
English, Scientific journal - Prophylactic effects of chitin microparticles on highly pathogenic H5N1 influenza virus
Takeshi Ichinohe; Noriyo Nagata; Peter Strong; Shin-ichi Tamura; Hidehiro Takahashi; Ai Ninomiya; Masaki Imai; Takato Odagiri; Masato Tashiro; Hirofumi Sawa; Joe Chiba; Takeshi Kurata; Tetsutaro Sata; Hideki Hasegawa
JOURNAL OF MEDICAL VIROLOGY, 79, 6, 811, 819, Jun. 2007, [Peer-reviewed]
English, Scientific journal - Development of a mucosal vaccine for influenza viruses: preparation for a potential influenza pandemic
Hideki Hasegawa; Takeshi Ichinohe; Shin-ichi Tamura; Takeshi Kurata
EXPERT REVIEW OF VACCINES, 6, 2, 193, 201, Apr. 2007, [Peer-reviewed]
English - Participation of both host and virus factors in induction of severe acute respiratory syndrome (SARS) in F344 rats infected with SARS coronavirus
Noriyo Nagata; Naoko Iwata; Hideki Hasegawa; Shuetsu Fukushi; Masaru Yokoyama; Ayako Harashima; Yuko Sato; Masayuki Saijo; Shigeru Morikawa; Tetsutaro Sata
JOURNAL OF VIROLOGY, 81, 4, 1848, 1857, Feb. 2007, [Peer-reviewed]
English, Scientific journal - Intranasal administration of adjuvant-combined recombinant influenza virus HA vaccine protects mice from the lethal H5N1 virus infection
Yasuko Asahi-Ozaki; Shigeyuki Itamura; Takeshi Ichinohe; Peter Strong; Shin-ichi Tamura; Hidehiro Takahashi; Hirofumi Sawa; Masami Moriyama; Masato Tashiro; Tetsutaro Sata; Takeshi Kurata; Hideki Hasegawa
MICROBES AND INFECTION, 8, 12-13, 2706, 2714, Oct. 2006, [Peer-reviewed]
English, Scientific journal - Tristetraprolin inhibits HIV-1 production by binding to genomic RNA
Masae Maeda; Hirofumi Sawa; Minoru Tobiume; Kenzo Tokunaga; Hideki Hasegawa; Takeshi Ichinohe; Tetsutaro Sata; Masami Moriyama; William W. Hall; Takeshi Kurata; Hidehiro Takahashi
MICROBES AND INFECTION, 8, 11, 2647, 2656, Sep. 2006, [Peer-reviewed]
English, Scientific journal - Induction of protective immunity against severe acute respiratory syndrome coronavirus (SARS-CoV) infection using highly attenuated recombinant vaccinia virus DIs
Koji Ishii; Hideki Hasegawa; Noriyo Nagata; Tetsuya Mizutani; Shigeru Morikawa; Tetsuro Suzuki; Fumihiro Taguchi; Masato Tashiro; Toshitada Takemori; Tatsuo Miyamura; Yasuko Tsunetsugu-Yokota
VIROLOGY, 351, 2, 368, 380, Aug. 2006, [Peer-reviewed]
English, Scientific journal - Protection against influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an adjuvant
T Ichinohe; Watanabe, I; E Tao; S Ito; A Kawaguchi; S Tamura; H Takahashi; H Sawa; M Moriyama; J Chiba; K Komase; Y Suzuki; T Kurata; T Sata; H Hasegawa
JOURNAL OF MEDICAL VIROLOGY, 78, 7, 954, 963, Jul. 2006, [Peer-reviewed]
English, Scientific journal - LC16m8, a highly attenuated vaccinia virus vaccine lacking expression of the membrane protein B5R, protects monkeys from monkeypox
M Saijo; Y Ami; Y Suzaki; N Nagata; N Iwata; H Hasegawa; M Ogata; S Fukushi; T Mizutani; T Sata; T Kurata; Kurane, I; S Morikawa
JOURNAL OF VIROLOGY, 80, 11, 5179, 5188, Jun. 2006, [Peer-reviewed]
English, Scientific journal - Thymus-derived leukemia-lymphoma in mice transgenic for the Tax gene of human T-lymphotropic virus type I
H Hasegawa; H Sawa; MJ Lewis; Y Orba; N Sheehy; Y Yamamoto; T Ichinohe; Y Tsunetsugu-Yokota; H Katano; H Takahashi; J Matsuda; T Sata; T Kurata; K Nagashima; WW Hall
NATURE MEDICINE, 12, 4, 466, 472, Apr. 2006, [Peer-reviewed]
English, Scientific journal - Distribution of PrPSc in cattle with bovine spongifonn encephalopathy slaughtered at abattoirs in Japan
N Iwata; Y Sato; Y Higuchi; K Nohtomi; N Nagata; H Hasegawa; M Tobiume; Y Nakamura; K Hagiwara; H Furuoka; M Horiuchi; Y Yamakawa; T Sata
JAPANESE JOURNAL OF INFECTIOUS DISEASES, 59, 2, 100, 107, Apr. 2006, [Peer-reviewed]
English, Scientific journal - Dicer and positive charge of proteins decrease the stability of RNA containing the AU-rich element of GM-CSF
H Takahashi; M Maeda; H Sawa; H Hasegawa; M Moriyama; T Sata; WW Hall; T Kurata
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 340, 3, 807, 814, Feb. 2006, [Peer-reviewed]
English, Scientific journal - Pathological and virological analyses of severe acute respiratory syndrome-associated coronavirus infections in experimental animals
Norlyo Nagata; Naoko Iwata; Hideki Hasegawa; Yasuko Asahi-Ozaki; Yuko Sato; Ayako Harashima; Shigeru Morikawa; Masayuki Saijo; Shigeyuki Itamura; Takehiko Saito; Takato Odagiri; Masato Tashiro; Yasushi Ami; Tetsutaro Sata
NIDOVIRUSES: TOWARD CONTROL OF SARS AND OTHER NIDOVIRUS DISEASES, 581, 515, 518, 2006, [Peer-reviewed]
English, Scientific journal - Highly attenuated vaccinia virus DIs as a potential SARS vaccine
Koji Ishii; Hideki Hasegawa; Noriyo Nagata; Tetsuya Mizutani; Shigeru Morikawa; Masato Tashiro; Tetsuro Suzuki; Fumihiro Taguchi; Toshitada Takemori; Tatsuo Miyamura; Yasuko Tsunetsugu-Yokota
NIDOVIRUSES: TOWARD CONTROL OF SARS AND OTHER NIDOVIRUS DISEASES, 581, 593, 596, 2006, [Peer-reviewed]
English, Scientific journal - An attenuated LC16m8 smallpox vaccine: Analysis of full-genome sequence and induction of immune protection
S Morikawa; T Sakiyama; H Hasegawa; M Saijo; A Maeda; Kurane, I; G Maeno; J Kimura; C Hirama; T Yoshida; Y Asahi-Ozaki; T Sata; T Kurata; A Kojima
JOURNAL OF VIROLOGY, 79, 18, 11873, 11891, Sep. 2005, [Peer-reviewed]
English, Scientific journal - Inhibitory effect of mizoribine and ribavirin on the replication of severe acute respiratory syndrome (SARS)-associated coronavirus
M Saijo; S Morikawa; S Fukushi; T Mizutani; H Hasegawa; N Nagata; N Iwata; Kurane, I
ANTIVIRAL RESEARCH, 66, 2-3, 159, 163, Jun. 2005, [Peer-reviewed]
English, Scientific journal - Synthetic double-stranded RNA poly(I : C) combined with mucosal vaccine protects against influenza virus infection
T Ichinohe; Watanabe, I; S Ito; H Fujii; M Moriyama; S Tamura; H Takahashi; H Sawa; J Chiba; T Kurata; T Sata; H Hasegawa
JOURNAL OF VIROLOGY, 79, 5, 2910, 2919, Mar. 2005, [Peer-reviewed]
English, Scientific journal - Protection against influenza virus infection by intranasal administration of hemagglutinin vaccine with chitin microparticles as an adjuvant
H Hasegawa; T Ichinohe; P Strong; Watanabe, I; S Ito; S Tamura; H Takahashi; H Sawa; J Chiba; T Kurata; T Sata
JOURNAL OF MEDICAL VIROLOGY, 75, 1, 130, 136, Jan. 2005, [Peer-reviewed]
English, Scientific journal - A case of X-linked agammaglobulinemia with progressive encephalitis
N Shiroma; T Omi; H Hasegawa; K Nagashima; T Ohta
PEDIATRIC NEUROLOGY, 31, 5, 371, 373, Nov. 2004, [Peer-reviewed]
English, Scientific journal - BCL-6-positive human herpesvirus 8-associated solid lymphoma arising from liver and spleen as multiple nodular lesions
H Hasegawa; H Katano; M Tanno; S Masuo; T Ae; Y Sato; H Takahashi; T Iwasaki; T Kurata; T Sata
LEUKEMIA & LYMPHOMA, 45, 10, 2169, 2172, Oct. 2004, [Peer-reviewed]
English, Scientific journal - Differential localization of neurons susceptible to enterovirus 71 and pollovirus type 1 in the central nervous system of cynomolgus monkeys after intravenous inoculation
N Nagata; T Iwasaki; Y Ami; Y Tano; A Harashima; Y Suzaki; Y Sato; H Hasegawa; T Sata; T Miyamura; H Shimizu
JOURNAL OF GENERAL VIROLOGY, 85, Pt 10, 2981, 2989, Oct. 2004, [Peer-reviewed]
English, Scientific journal - Topoisomerase I dissociates human immunodeficiency virus type 1 reverse transcriptase from genomic RNAs
H Takahashi; H Sawa; H Hasegawa; K Nagashima; T Sata; T Kurata
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 313, 4, 1073, 1078, Jan. 2004, [Peer-reviewed]
English, Scientific journal - Nucleolin and the packaging signal, psi, promote the budding of human immunodeficiency virus type-1 (HIV-1)
T Ueno; K Tokunaga; H Sawa; M Maeda; J Chiba; A Kojima; H Hasegawa; Y Shoya; T Sata; T Kurata; H Takahashi
MICROBIOLOGY AND IMMUNOLOGY, 48, 2, 111, 118, 2004, [Peer-reviewed]
English, Scientific journal - Protection against influenza virus infection by intranasal administration of C3d-fused hemagglutinin
Watanabe, I; TM Ross; S Tamura; T Ichinohe; S Ito; H Takahashi; H Sawa; J Chiba; T Kurata; T Sata; H Hasegawa
VACCINE, 21, 31, 4532, 4538, Nov. 2003, [Peer-reviewed]
English, Scientific journal - Cross-reactive antigenicity of nucleoproteins of lyssaviruses recognized by a monospecific antirabies virus nucleoprotein antiserum on paraffin sections of formalin-fixed tissues
S Inoue; Y Sato; H Hasegawa; A Noguchi; A Yamada; T Kurata; T Iwasaki
PATHOLOGY INTERNATIONAL, 53, 8, 525, 533, Aug. 2003, [Peer-reviewed]
English, Scientific journal - Human topoisomerase I promotes HIV-1 proviral DNA synthesis: Implications for the species specificity and cellular tropism of HIV-1 infection
Y Shoya; K Tokunaga; H Sawa; M Maeda; T Ueno; T Yoshikawa; H Hasegawa; T Sata; T Kurata; WW Hall; BR Cullen; H Takahashi
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 100, 14, 8442, 8447, Jul. 2003, [Peer-reviewed]
English, Scientific journal - Roles of anti-hemagglutinin IgA and IgG antibodies in different sites of the respiratory tract of vaccinated mice in preventing lethal influenza pneumonia
R Ito; YA Ozaki; T Yoshikawa; H Hasegawa; Y Sato; Y Suzuki; R Inoue; T Morishima; N Kondo; T Sata; T Kurata; S Tamura
VACCINE, 21, 19-20, 2362, 2371, Jun. 2003, [Peer-reviewed]
English, Scientific journal - Rapid tumor formation of human T-cell leukemia virus type 1-infected cell lines in novel NOD-SCID/gamma c(null) mice: Suppression by an inhibitor against NF-kappa B
MZ Dewan; K Terashima; M Taruishi; H Hasegawa; M Ito; Y Tanaka; N Mori; T Sata; Y Koyanagi; M Maeda; Y Kubuki; A Okayama; M Fujii; N Yamamoto
JOURNAL OF VIROLOGY, 77, 9, 5286, 5294, May 2003, [Peer-reviewed]
English, Scientific journal - Processing of the HTLV-II envelope precursor glycoprotein gp63 by furin is essential for cell fusion activity
H Hasegawa; M Tatsumi; K Ogawa-Goto; H Takahashi; A Kojima; T Iwasaki; T Kurata; T Sata; T Takeuchi; N Sheehy; H Sawa; K Nagashima; WW Hall
AIDS RESEARCH AND HUMAN RETROVIRUSES, 18, 17, 1253, 1260, Nov. 2002, [Peer-reviewed]
English, Scientific journal - Binding and dissociation of human topoisomerase I with hairpin-loop RNAs: implications for the regulation of HIV-1 replication
H Takahashi; H Sawa; H Hasegawa; T Sata; WW Hall; T Kurata
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 297, 3, 593, 599, Sep. 2002, [Peer-reviewed]
English, Scientific journal - Topoisomerase I and ATP activate cDNA synthesis of human immunodeficiency virus type 1
H Takahashi; H Sawa; H Hasegawa; Y Shoya; T Sata; WW Hall; K Nagashima; T Kurata
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 294, 2, 509, 517, Jun. 2002, [Peer-reviewed]
English, Scientific journal - Reconstitution of cleavage of human immunodeficiency virus type-1 (HIV-1) RNAs
H Takahashi; H Sawa; H Hasegawa; T Sata; WW Hall; K Nagashima; T Kurata
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 293, 3, 1084, 1091, May 2002, [Peer-reviewed]
English, Scientific journal - An endoplasmic reticulum protein, p180, is highly expressed in human cytomegalovirus-permissive cells and interacts with the tegument protein encoded by UL48
K Ogawa-Goto; S Irie; A Omori; Y Miura; H Katano; H Hasegawa; T Kurata; T Sata; Y Arao
JOURNAL OF VIROLOGY, 76, 5, 2350, 2362, Mar. 2002, [Peer-reviewed]
English, Scientific journal - Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines
Y Asahi; T Yoshikawa; Watanabe, I; T Iwasaki; H Hasegawa; Y Sato; S Shimada; M Nanno; Y Matsuoka; M Ohwaki; Y Iwakura; Y Suzuki; C Aizawa; T Sata; T Kurata; S Tamura
JOURNAL OF IMMUNOLOGY, 168, 6, 2930, 2938, Mar. 2002, [Peer-reviewed]
English, Scientific journal - Persistent infection of influenza virus in irradiated mice and its prevention by intranasal vaccination
H Hasegawa; S Kadowaki; Watanabe, I; H Aizawa; H Takahashi; T Iwasaki; S Tamura; T Kurata; T Sata
VACCINE, 20, 7-8, 1050, 1057, Jan. 2002, [Peer-reviewed]
English, Scientific journal - Human-herpesvirus-8-encoded k8 protein colocalizes with the promyelocytic leukemia protein (PML) bodies and recruits p53 to the PML bodies
H Katano; K Ogawa-Goto; H Hasegawa; T Kurata; T Sata
VIROLOGY, 286, 2, 446, 455, Aug. 2001, [Peer-reviewed]
English, Scientific journal - Transcriptional activation of JC virus by human T-lymphotropic virus type I tax protein in human neuronal cell lines
Y Okada; H Sawa; S Tanaka; A Takada; S Suzuki; H Hasegawa; T Umemura; J Fujisawa; Y Tanaka; WW Hall; K Nagashima
JOURNAL OF BIOLOGICAL CHEMISTRY, 275, 22, 17016, 17023, Jun. 2000, [Peer-reviewed]
English, Scientific journal - Protection against influenza virus infection by nasal vaccination in advance of sublethal irradiation
H Hasegawa; S Kadowaki; H Takahashi; T Iwasaki; S Tamura; T Kurata
VACCINE, 18, 23, 2560, 2565, May 2000, [Peer-reviewed]
English, Scientific journal - Characterization of antibodies raised against bovine-PrP-peptides
H Takahashi; RH Takahashi; H Hasegawa; M Horiuchi; M Shinagawa; T Yokoyama; K Kimura; M Haritani; T Kurata; K Nagashima
JOURNAL OF NEUROVIROLOGY, 5, 3, 300, 307, Jun. 1999, [Peer-reviewed]
English, Scientific journal - High rate of human T lymphotropic virus type IIa infection in HIV type 1-infected intravenous drug abusers in Ireland
JF Egan; B O'Leary; MJ Lewis; F Mulcahy; N Sheehy; H Hasegawa; F Fitzpatrick; JJ O'Connor; J O'Riordan; WW Hall
AIDS RESEARCH AND HUMAN RETROVIRUSES, 15, 8, 699, 705, May 1999, [Peer-reviewed]
English, Scientific journal - Exacerbation of influenzavirus pneumonia by intranasal administration of surfactant in a mouse model
T Iwasaki; S Tamura; T Kumasaka; Y Sato; H Hasegawa; H Asanuma; S Aizawa; R Yanagihara; T Kurata
ARCHIVES OF VIROLOGY, 144, 4, 675, 685, 1999, [Peer-reviewed]
English, Scientific journal - Herpes encephalitis and paraneoplastic limbic encephalitis
Kazuo Nagashima; Yoshiyasu Kobayashi; Hideaki Kojima; Hideki Hasegawa; Takeshi Kurata
Neuropathology, 18, 2, 215, 221, 1998
International conference proceedings - Chromosomal mapping of the gene encoding DOCK180, a major Crk-binding protein, to 10q26.13-q26.3 by fluorescence in situ hybridization
S Takai; H Hasegawa; E Kiyokawa; K Yamada; T Kurata; M Matsuda
GENOMICS, 35, 2, 403, 404, Jul. 1996, [Peer-reviewed]
English, Scientific journal - DOCK180, a major CRK-binding protein, alters cell morphology upon translocation to the cell membrane
H Hasegawa; E Kiyokawa; S Tanaka; K Nagashima; N Gotoh; M Shibuya; T Kurata; M Matsuda
MOLECULAR AND CELLULAR BIOLOGY, 16, 4, 1770, 1776, Apr. 1996, [Peer-reviewed]
English, Scientific journal - Molecular analysis of phosphorylated tyrosine-binding proteins in the transduction of proliferation and differentiation signals
K Nagashima; S Tanaka; S Ota; H Hasegawa; M Matsuda
BRAIN TUMOR, 151, 159, 1996, [Peer-reviewed]
English, International conference proceedings - CRK PROTEIN BINDS TO 2 GUANINE NUCLEOTIDE-RELEASING PROTEINS FOR THE RAS FAMILY AND MODULATES NERVE GROWTH FACTOR-INDUCED ACTIVATION OF RAS IN PC12 CELLS
M MATSUDA; Y HASHIMOTO; K MUROYA; H HASEGAWA; T KURATA; S TANAKA; S NAKAMURA; S HATTORI
MOLECULAR AND CELLULAR BIOLOGY, 14, 8, 5495, 5500, Aug. 1994, [Peer-reviewed]
English, Scientific journal
- ネクロトーシスに着目した経鼻全粒子不活化インフルエンザワクチンの免疫賦活化機構の解明
佐々木永太; 佐々木永太; 浅沼秀樹; 高橋宜聖; 長谷川秀樹, 日本ワクチン学会学術集会プログラム・抄録集, 29th, 2025 - 2025/26シーズン用季節性インフルエンザワクチン製造候補株の性状解析
鈴木康司; 有田知子; 佐々木永太; 杉山隆一; 原田勇一; 高橋仁; 渡邉真治; 長谷川秀樹; 浅沼秀樹, 日本ワクチン学会学術集会プログラム・抄録集, 29th, 2025 - 国家備蓄ワクチン(A/Astrakhan/3212/2020,IDCDC-RG71A)のフェレットを用いた有効性評価
浅沼秀樹; 鈴木康司; 有田知子; 佐々木永太; 白倉雅之; 岸田典子; 佐野芳; 永田典代; 岩田奈織子; 坂井祐介; 志和希; 鈴木忠樹; 乾秀昭; 田辺哲朗; 長谷川秀樹, 日本ワクチン学会学術集会プログラム・抄録集, 29th, 2025 - 重症免疫不全ラットを用いたSARS-CoV-2持続感染モデルの確立:ウイルス変異と長期排出の病態解析
宮崎かや; 宮崎かや; 志和(須藤)希; 岩田(吉河)奈織子; 坂井祐介; 吉見一人; 真下知士; 鈴木忠樹; 長谷川秀樹; 長谷川秀樹; 永田典代, 日本ワクチン学会学術集会プログラム・抄録集, 29th, 2025 - ターゲットキャプチャー法による臨床検体中のA型インフルエンザウイルスゲノム解析
竹前喜洋; 久場由真仁; 大場邦弘; 竹前喜洋; 久場由真仁; 大場邦弘; 白倉雅之; 鈴木康司; 有田知子; 岸田典子; 佐野芳; 渡邉真治; 長谷川秀樹; 影山努; 影山努, 日本獣医学会学術集会講演要旨集, 168th, 2025 - 2023-2024年に和歌山県で捕獲された野生動物における抗A型インフルエンザウイルス抗体保有状況調査
黒田雄大; 相内章; 石嶋慧多; ビルヘスメンドーサ ミラグロス; 井上雄介; 山本つかさ; 西野綾乃; 堀田明豊; 堀田明豊; 鈴木和男; 鈴木康司; 渡邉真治; 宇田晶彦; 長谷川秀樹; 前田健, 日本獣医学会学術集会講演要旨集, 168th, 2025 - 奈良県におけるバロキサビル耐性変異インフルエンザウイルスのcommunity cluster
高下恵美; 藤崎誠一郎; 森田博子; 永田志保; 三浦秀佳; 岸田典子; 中村一哉; 白倉雅之; 菅原裕美; 佐藤彩; 秋元未来; 渡邉真治; 長谷川秀樹; 松浦侑輝; 山本紗也; 千葉翔子; 井上ゆみ子; 美並衣織; 吉川采也加; 山崎聖子, IASR (Web), 45, 2, 2024 - 2023/24シーズンのインフルエンザ分離株の解析
岸田典子; 中村一哉; 藤崎誠一郎; 高下恵美; 佐藤彩; 秋元未来; 三浦秀佳; 森田博子; 永田志保; 白倉雅之; 菅原裕美; 渡邉真治; 長谷川秀樹, IASR (Web), 45, 11, 2024 - 2023/24シーズンにおける抗インフルエンザ薬耐性ウイルスの検出
高下恵美; 藤崎誠一郎; 岸田典子; 白倉雅之; 中村一哉; 安倍隆; 市川正孝; 山崎雅彦; 三田村敬子; 渡邉真治; 長谷川秀樹, 日本小児感染症学会総会・学術集会プログラム・抄録集, 56th, 2024 - IgA tetramerization improves target breadth of functionality of anti-influenza virus broadly neutralizing antibody
齊藤慎二; 佐野芳; 相内章; 田畑耕史郎; 澤洋文; 鈴木忠樹; 長谷川秀樹, 日本生体防御学会学術総会講演抄録集, 35th (Web), 2024 - In vitro characterization of influenza A virus PA-X protein using an endonuclease inhibitor
大石康平; 佐野芳; 長谷川秀樹; 海老原秀喜, 日本ウイルス学会学術集会プログラム・予稿集(Web), 71st, 2024 - COVID-19ワクチン抗原構成の推奨プロセスについて
長谷川秀樹; 高橋宜聖, IASR (Web), 45, 6, 2024 - ゲノミクス技術を駆使した医薬品添加物からのアジュバント活性物質のスクリーニングとその安全性・有効性評価
佐々木永太; 浅沼秀樹; 百瀬暖佳; 前山順一; 水上拓郎; 永田典代; 鈴木忠樹; 長谷川秀樹; 濱口功; 宮崎隆; 高橋宣聖, 日本ワクチン学会学術集会プログラム・抄録集, 27th, 2023 - Characterizations of circulating influenza viruses in the 2022/23 season and selection of vaccine viruses for the 2023/24 season
岸田典子; 藤崎誠一郎; 中村一哉; 白倉雅之; 高下恵美; 秋元未来; 佐藤彩; 三浦秀佳; 森田博子; 永田志保; 菅原裕美; 渡邉真治; 長谷川秀樹, 日本ウイルス学会学術集会プログラム・予稿集(Web), 70th, 2023 - 2022/23シーズンのインフルエンザ分離株の解析
岸田典子; 中村一哉; 藤崎誠一郎; 高下恵美; 佐藤彩; 秋元未来; 三浦秀佳; 森田博子; 永田志保; 白倉雅之; 菅原裕美; 渡邉真治; 長谷川秀樹, IASR (Web), 44, 11, 2023 - 2022/23インフルエンザシーズンにおける薬剤未投与例からのバロキサビル耐性変異ウイルスの検出
高下恵美; 藤崎誠一郎; 岸田典子; 白倉雅之; 中村一哉; 安倍隆; 市川正孝; 山崎雅彦; 三田村敬子; 渡邉真治; 長谷川秀樹, 日本小児感染症学会総会・学術集会プログラム・抄録集, 55th, 2023 - Pathological study of the infection and long-term clinical condition of a rat model using SARS-CoV-2 mouse passaged virus.
宮崎かや; 宮崎かや; 志和(須藤)希; 岩田(吉河)奈織子; 坂井祐介; 鈴木忠樹; 長谷川秀樹; 長谷川秀樹; 永田典代, 日本ウイルス学会学術集会プログラム・予稿集(Web), 70th, 2023 - Analysis of host factors interacting with nonstructural protein 1 of influenza A virus using proximity-dependent biotin identification
中内美名; 井野洋子; 高橋仁; 信澤枝里; 宮川敬; 木村弥生; 梁明秀; 長谷川秀樹, 日本ウイルス学会学術集会プログラム・予稿集(Web), 70th, 2023 - 新興・再興感染症データバンク事業ナショナル・リポジトリの構築 COVID-19患者の生体試料と臨床情報の収集・保管・利活用の現状
栗村 尚子; 泉 和生; 椎野 禎一郎; 松永 展明; 石井 雅通; 平野 勝治; 徳永 勝士; 溝上 雅史; 竹内 潤子[柴田]; 岩元 典子; 山本 圭一郎; 長谷川 秀樹; 黒田 誠; 前田 健; 海老原 秀喜; 花木 賢一; 鈴木 忠樹; 竹下 望; 大曲 貴夫; 杉浦 亙, 日本エイズ学会誌, 24, 4, 479, 479, Nov. 2022
(一社)日本エイズ学会, Japanese - Neutralization of SARS-CoV-2 Omicron BA.2.75 after mRNA-1273 Vaccination
Emi Takashita; Seiya Yamayoshi; Shuetsu Fukushi; Tadaki Suzuki; Ken Maeda; Yuko Sakai-Tagawa; Mutsumi Ito; Ryuta Uraki; Peter Halfmann; Shinji Watanabe; Makoto Takeda; Hideki Hasegawa; Masaki Imai; Yoshihiro Kawaoka, New England Journal of Medicine, 387, 13, 1234, 1236, 29 Sep. 2022
Report scientific journal - Increased risk of rhinovirus infection in children during the COVID-19 pandemic
高下恵美; 川上千春; 百木智子; 七種美和子; 清水耕平; 小澤広規; 熊崎真琴; 宇宿秀三; 田中伸子; 大久保一郎; 森田博子; 永田志保; 渡邉真治; 長谷川秀樹; 河岡義裕; 河岡義裕; 河岡義裕, 日本小児科学会雑誌, 126, 2, 2022 - 2021/22シーズンにおけるインフルエンザ流行株の性状と2022/23シーズンのワクチン株選定について
渡邉真治; 岸田典子; 藤崎誠一郎; 中村一哉; 白倉雅之; 高下恵美; 佐藤彩; 秋元未来; 三浦秀佳; 森田博子; 永田志保; 菅原裕美; 長谷川秀樹, 日本ウイルス学会学術集会プログラム・予稿集(Web), 69th, 2022 - 2021/22シーズンのインフルエンザ分離株の解析
岸田典子; 中村一哉; 藤崎誠一郎; 高下恵美; 佐藤彩; 秋元未来; 三浦秀佳; 森田博子; 永田志保; 白倉雅之; 菅原裕美; 渡邉真治; 長谷川秀樹, IASR (Web), 43, 11, 2022 - ブレイクスルー感染症例に由来するSARS-CoV-2の解析
嶋崎典子; 藤崎誠一郎; 板村繁之; 浜本いつき; 浅沼秀樹; 長谷川秀樹; 竹田誠, 日本ウイルス学会学術集会プログラム・予稿集(Web), 69th, 2022 - 分泌型IgA抗体の四量体形成分子機構の生化学的・構造生物学的解析
田畑耕史郎; 田畑耕史郎; 福原秀雄; 福原秀雄; 安楽佑樹; 多賀祐喜; 佐々木道仁; 板倉友香里; 佐野芳; 上野朗; 相内章; 後藤希代子; 長谷川秀樹; 前仲勝実; 前仲勝実; 澤洋文; 澤洋文; 大場靖子; 鈴木忠樹, 日本ワクチン学会学術集会プログラム・抄録集, 26th, 2022 - 経鼻COVID-19組換えタンパク質ワクチンは広域中和能をもつIgA抗体を誘導できる
逸見拓矢; 逸見拓矢; 相内章; 相内章; 橋口隆生; 橋口隆生; 石川青空; 石川青空; 飛梅実; 菅野隆行; 岩田(吉河)奈織子; 飯田俊; 宮本翔; 上野朗; 上野朗; 佐野芳; 田村浩二; 田村浩二; 鈴木亮介; 鈴木亮介; 長谷川秀樹; 鈴木忠樹, 日本ワクチン学会学術集会プログラム・抄録集, 26th, 2022 - 新型コロナウイルス既感染ハムスターにおけるオミクロン株再感染の可能性
志和(須藤)希; 渡邉真治; 岩田(吉河)奈織子; 坂井祐介; 長谷川秀樹; 鈴木忠樹; 永田典代, 日本ウイルス学会学術集会プログラム・予稿集(Web), 69th, 2022 - ODN2006をアジュバントとする経鼻COVID-19ワクチンは広域中和能を有するIgA抗体を誘導し,ワクチン関連呼吸器疾患増強のリスクを軽減できる
逸見拓矢; 逸見拓矢; 相内章; 相内章; 橋口隆生; 橋口隆生; 飛梅実; 菅野隆行; 岩田(吉河)奈織子; 飯田俊; 宮本翔; 上野朗; 上野朗; 佐野芳; 齋藤慎二; 志和(須藤)希; 永田典代; 田村浩二; 鈴木亮介; 鈴木亮介; 長谷川秀樹; 鈴木忠樹, 日本ウイルス学会学術集会プログラム・予稿集(Web), 69th, 2022 - SARS-CoV-2変異株の猫における病原性比較
朴ウンシル; 黒田雄大; 加来義浩; 奥谷晶子; 立本完吾; 立本完吾; 石嶋慧多; 堀田明豊; 井上雄介; 井上雄介; 原田倫子; 原田倫子; 網康至; 宇田晶彦; 原田俊彦; 志和希; 坂井祐介; 岩田奈緒子; 白倉雅之; 鈴木康司; 永田典代; 鈴木忠樹; 長谷川秀樹; 前田健; 前田健, 日本ウイルス学会学術集会プログラム・予稿集(Web), 69th, 2022 - SARS-CoV-2感染に対するネコの感受性の検証
朴 ウンシル; 黒田 雄大; 宇田 晶彦; 加来 義浩; 立本 完吾; 石嶋 慧多; 網 康至; 白倉 雅之; 鈴木 康司; 原田 俊彦; 志和 希; 岩田 奈織子; 永田 典代; 長谷川 秀樹, 日本獣医学会学術集会講演要旨集, 164回, [DVO, 53], Sep. 2021
(公社)日本獣医学会, Japanese - ワクチン開発を進めるきっかけとなった細菌学・免疫学研究 ウイルス様粒子構造はノロウイルスに対するIgA抗体応答を増強する(Virus-like particle structure enhances protective IgA antibody responses against noroviruses)
小野寺 大志; 橋 香奈; 戸高 玲子; 阿戸 学; 長谷川 秀樹; Gamet Kelsoe; 片山 和彦; 高橋 宜聖, 日本細菌学雑誌, 76, 1, 43, 43, Feb. 2021
日本細菌学会, English - 新型コロナウイルス感染症流行下における小児のライノウイルス感染リスクの上昇
高下恵美; 川上千春; 百木智子; 七種美和子; 清水耕平; 小澤広規; 熊崎真琴; 宇宿秀三; 田中伸子; 大久保一郎; 森田博子; 永田志保; 渡邉真治; 長谷川秀樹; 河岡義裕, 日本小児感染症学会総会・学術集会プログラム・抄録集, 53rd, 2021 - 2020/21シーズンのインフルエンザ分離株の解析
岸田典子; 中村一哉; 藤崎誠一郎; 高下恵美; 佐藤彩; 秋元未来; 三浦秀佳; 森田博子; 永田志保; 桑原朋子; 白倉雅之; 菅原裕美; 渡邉真治; 長谷川秀樹, IASR (Web), 42, 11, 2021 - 経鼻不活化インフルエンザワクチンにより誘導された抗HAストーク抗体の構造情報に基づいた機能予測と中和能の改変
齊藤慎二; 小谷治; 鈴木康司; 相内章; 上野朗; 逸見拓矢; 佐野芳; 田畑耕史郎; 横山勝; 鈴木忠樹; 長谷川秀樹; 佐藤裕徳, 日本ワクチン学会学術集会プログラム・抄録集, 25th, 2021 - Pathological study of the infection and replication sites of SARS-CoV-2 using an animal model
志和希; 岩田(吉河)奈織子; 片岡紀代; 長谷川秀樹; 鈴木忠樹; 永田典代, 日本ウイルス学会学術集会プログラム・予稿集(Web), 68th, 2021 - Establishment of a lethal model using SARS-CoV-2 mouse passaged virus
岩田(吉河)奈織子; 志和希; 関塚剛; 佐野芳; 相内章; 逸見拓矢; 逸見拓矢; 片岡紀代; 黒田誠; 長谷川秀樹; 鈴木忠樹; 永田典代, 日本ウイルス学会学術集会プログラム・予稿集(Web), 68th, 2021 - マスギャザリング時や新興・再興感染症の発生に備えた感染症サーベイランスの強化とリスクアセスメントに関する研究 病原体検査系の開発,症例の情報とりまとめに関する研究
脇田隆字; 大西真; 長谷川秀樹; 影山努; 鈴木忠樹; 片野晴隆; 森川茂, マスギャザリング時や新興・再興感染症の発生に備えた感染症サーベイランスの強化とリスクアセスメントに関する研究 令和2年度及び令和3年度 総括・分担研究報告書(令和2年度繰越分)(Web), 2021 - Risks of cats as sources of SARS-CoV-2
朴ウンシル; 黒田雄大; 黒田雄大; 宇田晶彦; 加来義浩; 奥谷晶子; 立本完吾; 立本完吾; 石嶋彗多; 網康至; 白倉雅之; 鈴木康司; 原田俊彦; 相内章; 志和希; 岩田(吉河)奈緒子; 永田典代; 鈴木忠樹; 長谷川秀樹; 前田健; 前田健, 日本ウイルス学会学術集会プログラム・予稿集(Web), 68th, 2021 - A mechanism of Ig variable region-independent oligomerization of secretory IgA antibody accelerated by polymeric Ig receptor.
田畑耕史郎; 田畑耕史郎; 鈴木忠樹; 佐野芳; 齊藤慎二; 相内章; 佐々木道仁; 長谷川秀樹; 大場靖子; 澤洋文; 澤洋文, 日本分子生物学会年会プログラム・要旨集(Web), 44th, 2021 - 喘息モデルマウスにおけるインフルエンザA(H1N1)pdm09感染による気道過敏性の検討
有吉 平; 安戸 裕貴; 坂田 恭史; 中村 圭李; 松重 武志; 長谷川 秀樹; 伊藤 浩史; 調 恒明; 熱田 了; 大賀 正一; 長谷川 俊史, 日本小児感染症学会総会・学術集会プログラム・抄録集, 52回, 119, 119, Nov. 2020
日本小児感染症学会, Japanese - Mechanisms of asthma(Enhanced airway hyperresponsiveness in a mouse model of asthma with A (H1N1) pdm09 infection)
Yasudo Hiroki; Ariyoshi Taira; Sakata Yasufumi; Nakamura Tamaki; Matsushige Takeshi; Hasegawa Hideki; Nakajima Noriko; Ainai Akira; Oga Atsunori; Itoh Hiroshi; Shirabe Komei; Toda Shoichi; Atsuta Ryo; Ohga Shouichi; Hasegawa Shunji, アレルギー, 69, 臨時増刊号, 82, 82, Oct. 2020
(一社)日本アレルギー学会, English - H1N1 pdm09感染を伴う喘息モデルマウスにおける気道過敏性の亢進(Enhanced airway hyperresponsiveness in a mouse model of asthma with a(H1N1) pdm09 infection)
Yasudo Hiroki; Ariyoshi Taira; Sakata Yasufumi; Nakamura Tamaki; Hasegawa Hideki; Itoh Hiroshi; Shirabe Komei; Atsuta Ryo; Ohga Shouichi; Hasegawa Shunji, 日本小児アレルギー学会誌, 34, 4, 478, 478, Sep. 2020
(一社)日本小児アレルギー学会, English - 抗インフルエンザ薬耐性株の検出と性状
高下恵美; 森田博子; 永田志保; 藤崎誠一郎; 三浦秀佳; 白倉雅之; 岸田典子; 中村一哉; 桑原朋子; 佐藤彩; 秋元未来; 菅原裕美; 渡邉真治; 長谷川秀樹, IASR (Web), 41, 11, 2020 - 2019/20シーズンのインフルエンザ分離株の解析
岸田典子; 中村一哉; 藤崎誠一郎; 白倉雅之; 佐藤彩; 秋元未来; 三浦秀佳; 高下恵美; 桑原朋子; 森田博子; 永田志保; 菅原裕美; 渡邉真治; 長谷川秀樹, IASR (Web), 41, 11, 2020 - バロキサビル未投与患者からのバロキサビル耐性PA E23K変異インフルエンザウイルスの検出
高下恵美; 森田博子; 永田志保; 藤崎誠一郎; 三浦秀佳; 白倉雅之; 岸田典子; 中村一哉; 桑原朋子; 秋元未来; 佐藤彩; 菅原裕美; 渡邉真治; 長谷川秀樹; 安倍隆; 三田村敬子; 市川正孝; 山崎雅彦, IASR (Web), 41, 9, 2020 - A case of severe fever with thrombocytopenia syndrome (SFTS) accompanied by pulmonary aspergillosis
木脇拓道; 福島剛; 赤木真由美; 田中弘之; 岡山昭彦; 鈴木忠樹; 片野晴隆; 佐藤由子; 長谷川秀樹; 片岡寛章, 日本病理学会会誌, 109, 1, 2020 - 血球貪食症候群を呈した血液指向性マイコプラズマの針刺し感染例
詫間 隆博; 長友 安弘; 時松 一成; 片野 晴隆; 黒田 誠; 宇賀神 和久; 二木 芳人; 服部 憲路; 荒井 菜々; 中牧 剛; 柳井 亮; 石井 翔; 徳永 剛広; 江口 潤一; 伊藤 敬義; 長谷川 秀樹; 関塚 剛史, 感染症学雑誌, 93, 臨増, 327, 327, Mar. 2019
(一社)日本感染症学会, Japanese - 【呼吸器感染症と経鼻ワクチン】 経鼻インフルエンザワクチンで誘導される分泌型IgA抗体の役割
長谷川 秀樹, 炎症と免疫, 27, 2, 109, 114, Feb. 2019
(株)先端医学社, Japanese - 宇和島保健所管内のD病院におけるインフルエンザA型の集団発生に伴う抗インフルエンザウイルス薬剤耐性株の検出について
菅美樹; 小玉将慶; 林美紀; 影山康彦; 倉田朋子; 冨田直明; 岩城洋己; 山下まゆみ; 豊嶋千俊; 山下育孝; 四宮博人; 高下恵美; 永田志保; 森田博子; 藤崎誠一郎; 三浦秀佳; 渡邉真治; 砂川富正; 長谷川秀樹, IASR (Web), 40, 12, 2019 - 抗インフルエンザ薬耐性株の検出と性状
高下恵美; 小川理恵; 森田博子; 永田志保; 藤崎誠一郎; 三浦秀佳; 白倉雅之; 岸田典子; 中村一哉; 桑原朋子; 佐藤彩; 秋元未来; 菅原裕美; 渡邉真治; 長谷川秀樹; 小田切孝人, IASR (Web), 40, 11, 2019 - 2018/19シーズンのインフルエンザ分離株の解析
岸田典子; 中村一哉; 藤崎誠一郎; 白倉雅之; 佐藤彩; 秋元未来; 三浦秀佳; 高下恵美; 桑原朋子; 小川理恵; 森田博子; 永田志保; 菅原裕美; 渡邉真治; 長谷川秀樹; 小田切孝人, IASR (Web), 40, 11, 2019 - バロキサビル耐性変異ウイルスのヒトからヒトへの感染伝播
高下恵美; 森田博子; 小川理恵; 藤崎誠一郎; 白倉雅之; 三浦秀佳; 中村一哉; 岸田典子; 桑原朋子; 菅原裕美; 佐藤彩; 秋元未来; 渡邉真治; 小田切孝人; 長谷川秀樹; 市川正孝; 三田村敬子; 安倍隆; 山崎雅彦, IASR (Web), 40, 11, 2019 - マーモセットモデルによるムンプスワクチンの感染防御免疫の評価
木所稔; 加藤文博; 永田典代; 加藤大志; 岩田奈織子; 竹田誠; 長谷川秀樹; 網康至, 日本ワクチン学会学術集会プログラム・抄録集, 23rd, 2019 - 経鼻接種型不活化ワクチンと皮下接種型不活化ワクチンにより誘導された抗インフルエンザ抗体の質についての比較解析
佐野芳; 佐野芳; 黒澤信幸; 齊藤慎二; 相内章; 鈴木忠樹; 磯部正治; 長谷川秀樹; 長谷川秀樹; 長谷川秀樹, 日本ワクチン学会学術集会プログラム・抄録集, 23rd, 2019 - 2018年度感染症流行予測調査におけるインフルエンザ予防接種状況および抗体保有状況
新橋玲子; 多屋馨子; 鈴木基; 渡邉真治; 長谷川秀樹, IASR (Web), 40, 11, 2019 - 2018/2019シーズンにおける新規抗インフルエンザ薬バロキサビル耐性変異ウイルスの検出状況
高下恵美; 藤崎誠一郎; 白倉雅之; 中村一哉; 岸田典子; 桑原朋子; 三田村敬子; 安倍隆; 市川正孝; 山崎雅彦; 渡邉真治; 小田切孝人; 長谷川秀樹, 日本小児感染症学会総会・学術集会プログラム・抄録集, 51st, 2019 - 2018/19シーズンにおけるインフルエンザ流行株の性状と2019/20シーズンのワクチン株選定について
渡邉真治; 中村一哉; 岸田典子; 藤崎誠一郎; 白倉雅之; 高下恵美; 桑原朋子; 佐藤彩; 秋元未来; 三浦秀佳; 小川理恵; 森田博子; 菅原裕美; 小田切孝人; 長谷川秀樹, 日本ウイルス学会学術集会プログラム・予稿集(Web), 67th, 2019 - フォーカス減数試験改良法によるインフルエンザA/H3N2亜型分離株抗原性解析の精度改善
中村一哉; 秋元未来; 藤崎誠一郎; 白倉雅之; 三浦秀佳; 岸田典子; 佐藤彩; 桑原朋子; 高下恵美; 長谷川秀樹; 小田切孝人; 渡邉真治, 日本ウイルス学会学術集会プログラム・予稿集(Web), 67th, 2019 - バロキサビル耐性変異インフルエンザA(H3N2)ウイルスのヒト-ヒト感染
高下恵美; 森田博子; 小川理恵; 藤崎誠一郎; 白倉雅之; 三浦秀佳; 中村一哉; 岸田典子; 桑原朋子; 菅原裕美; 佐藤彩; 秋元未来; 三田村敬子; 安倍隆; 市川正孝; 山崎雅彦; 渡邉真治; 小田切孝人; 長谷川秀樹, 日本ウイルス学会学術集会プログラム・予稿集(Web), 67th, 2019 - A型インフルエンザウイルス感染症に関連した急性肝不全の1剖検例
野中敬介; 松田陽子; 柿崎元恒; 西村優基; 高熊将一朗; 松原知康; 村山繁雄; 中島典子; 長谷川秀樹; 新井冨生, 日本病理学会会誌, 108, 1, 378, 378, 2019
(一社)日本病理学会, Japanese - In vitroにおける四量体分泌型IgA抗体形成機構の解明
田畑耕史郎; 田畑耕史郎; 鈴木忠樹; 佐野芳; 齊藤慎二; 相内章; 大場靖子; 長谷川秀樹; 長谷川秀樹; 澤洋文; 澤洋文, 日本分子生物学会年会プログラム・要旨集(Web), 42nd, 2019 - おたふくかぜウイルスワクチン接種マーモセットにおける細胞性免疫の評価
加藤文博; 網康至; 加藤大志; 村野けい子; 須崎百合子; 永田典代; 岩田奈織子; 長谷川秀樹; 竹田誠; 木所稔, 日本ウイルス学会学術集会プログラム・予稿集(Web), 67th, 2019 - インフルエンザワクチンの現状
長谷川 秀樹; 田村 愼一, 呼吸器内科, 35, 1, 97, 101, Jan. 2019
(有)科学評論社, Japanese - 【インフルエンザワクチン:再考と展望】 不活化経鼻インフルエンザワクチンと粘膜に誘導されるIgA抗体
長谷川 秀樹, 外来小児科, 21, 3, 409, 413, Nov. 2018
(一社)日本外来小児科学会, Japanese - 新興・再興ウイルス感染症の流行状況と対策 先天性ジカ症候群の病理解析
鈴木 忠樹; 飛梅 実; 長谷川 秀樹, 臨床とウイルス, 46, 4, 251, 257, Oct. 2018
日本臨床ウイルス学会, Japanese - One Healthと人獣共通感染症〜臨床医と獣医の連携「新興ウイルス感染症ならびに薬剤耐性菌感染症」 流行地におけるSFTS 臨床と疫学、感染経路、ヒトへの感染リスク
金子 政彦; 四宮 博人; 鈴木 忠樹; 長谷川 秀樹; 下島 昌幸; 西條 政幸, 日本化学療法学会雑誌, 66, Suppl.A, 157, 158, Apr. 2018
(公社)日本化学療法学会, Japanese - 重症熱性血小板減少症候群に合併した二次性血球貪食リンパ組織球増多症に対するHLH94プロトコルによる治療がなされた1例
金子 政彦; 四宮 博人; 下島 昌幸; 西條 政幸; 鈴木 忠樹; 長谷川 秀樹, 日本化学療法学会雑誌, 66, Suppl.A, 360, 360, Apr. 2018
(公社)日本化学療法学会, Japanese - 【感染性疾患の病理】 (第2部)感染性疾患の病理 中枢神経領域 進行性多巣性白質脳症
高橋 健太; 鈴木 忠樹; 片野 晴隆; 長谷川 秀樹, 病理と臨床, 36, 臨増, 116, 119, Apr. 2018
(株)文光堂, Japanese - 【感染性疾患の病理】 (第2部)感染性疾患の病理 新興・再興感染症 重症熱性血小板減少症候群(SFTS)の病理
長谷川 秀樹; 鈴木 忠樹, 病理と臨床, 36, 臨増, 291, 295, Apr. 2018
(株)文光堂, Japanese - 【感染性疾患の病理】 (第2部)感染性疾患の病理 新興・再興感染症 先天性ジカウイルス感染症
鈴木 忠樹; 長谷川 秀樹, 病理と臨床, 36, 臨増, 296, 300, Apr. 2018
(株)文光堂, Japanese - 【近未来のワクチン-開発研究の潮流と課題】 各種ワクチン開発の潮流と課題 新しいインフルエンザワクチン開発
長谷川 秀樹, 医学のあゆみ, 264, 5, 438, 443, Feb. 2018
医歯薬出版(株), Japanese - 経鼻ワクチンにより誘導された抗インフルエンザHAステム抗体のウイルス感染防御機構
佐野芳; 佐野芳; 齊藤慎二; 小谷治; 相内章; VAN RIET Elly; 田畑耕史郎; 高橋宜聖; 横山勝; 佐藤裕徳; 鈴木忠樹; 長谷川秀樹, 日本ワクチン学会学術集会プログラム・抄録集, 22nd, 2018 - CHO細胞由来ウイルス様粒子を用いたデングウイルスワクチンの有効性評価
藤井信; 藤井信; 鈴木忠樹; 佐高明子; 山口喜之; 佐野芳; 小島朝人; 相内章; 佐藤嗣道; 長谷川秀樹, 日本ワクチン学会学術集会プログラム・抄録集, 22nd, 2018 - 経鼻不活化および生ワクチンの有効性評価
長谷川 秀樹, インフルエンザ, 19, 1, 51, 55, Jan. 2018
(株)メディカルレビュー社, Japanese - インフルエンザの重症化と肺炎 (特集 抗インフルエンザ薬物療法update : 最新の診断・治療戦略)
中島 典子; 長谷川 秀樹, 医薬ジャーナル, 53, 10, 91, 96, Oct. 2017
医薬ジャーナル社, Japanese - わが国におけるダニ媒介性細菌感染症研究の現状 新興ボレリア感染症
川端 寛樹; 佐藤 梢; 熊谷 由美; 大西 真; 安藤 秀二; 福士 秀悦; 下島 昌幸; 西條 政孝; 阿戸 学; 長谷川 秀樹; 関塚 剛史; 黒田 誠; 高野 愛; 伊藤 幸枝; 古野 希和; 山野 公明; 伊東 拓也; 今内 覚; 李 景利; Taylor Kyle; 中尾 亮; 中尾 稔; 小山 幸次郎; 兼古 稔; 福島 和子; 齊藤 智也; 中嶋 健介; 榊原 佳子; 増沢 俊幸; 藤田 博己, 日本細菌学雑誌, 72, 1, 34, 34, Feb. 2017
日本細菌学会, Japanese - 2つの感染モデルを用いたCpG‐ODN G9.1添加経鼻インフルエンザワクチンの有効性
立石恒一朗; 山本典生; 山本典生; 佐藤佳代子; 長谷川秀樹; 前山順一; 伊保澄子; 山本三郎; 小田切孝人; 藤橋浩太郎; 浅沼秀樹, 日本ワクチン学会学術集会プログラム・抄録集, 21st, 98, 2017
Japanese - モノクローナル多量体型IgA抗体作製法を用いた分泌型IgA抗体の抗インフルエンザウイルス活性の解析
佐野芳; 佐野芳; 齊藤慎二; 齊藤慎二; 鈴木忠樹; 上野智規; 多賀祐喜; VAN RIET Elly; 相内章; 田畑耕史郎; 藤井信; 高橋宜聖; 後藤希代子; 長谷川秀樹; 長谷川秀樹, 日本ワクチン学会学術集会プログラム・抄録集, 21st, 99, 2017
Japanese - 特発性CD4+リンパ球減少症の関連が示唆され、メフロキンが有効であった小脳・脳幹型進行性多巣性白質脳症の1剖検例
伊崎 祥子; 田中 覚; 田島 孝士; 中道 一生; 西條 政幸; 高橋 健太; 長谷川 秀樹; 野村 恭一, NEUROINFECTION, 21, 2, 200, 200, Sep. 2016
日本神経感染症学会, Japanese - 【感染症"侵入口"で討つ ヒト粘膜免疫と粘膜ワクチン 免疫賦活の独自のシステムは新しいワクチンを生み出すか?】 経鼻粘膜インフルエンザワクチンによる粘膜免疫と感染防御
鈴木 忠樹; 長谷川 秀樹, 実験医学, 34, 13, 2151, 2156, Aug. 2016
(株)羊土社, Japanese - Current status and prospects of influenza vaccine development
長谷川 秀樹, 呼吸器内科 = Respiratory medicine, 29, 5, 384, 388, May 2016
科学評論社, Japanese - 喘息マウスにおけるA(H1N1)pdm09感染によるBAL中サイトカイン動態の検討
藤本 洋輔; 長谷川 俊史; 松重 武; 脇口 宏之; 長谷川 秀樹; 相内 章; 調 恒明; 戸田 昌一; 熱田 了; 大賀 正一, 日本小児科学会雑誌, 120, 2, 274, 274, Feb. 2016
(公社)日本小児科学会, Japanese - CpG‐ODN G9.1併用経鼻インフルエンザVLPワクチンの有効性に関する検討
山本典生; 山本典生; 立石恒一朗; 長谷川秀樹; 前山順一; 伊保澄子; 山本三郎; 藤橋浩太郎; 浅沼秀樹; 浅沼秀樹, 日本ワクチン学会学術集会プログラム・抄録集, 20th, 105, 2016
Japanese - 新規粘膜アジュバントとしてのCpG‐ODN G9.1の経鼻インフルエンザワクチンへの応用
浅沼秀樹; 浅沼秀樹; 立石恒一朗; 藤橋浩太郎; 佐藤佳代子; 長谷川秀樹; 前山順一; 伊保澄子; 山本三郎; 山本典生; 山本典生; 小田切孝人, 日本ワクチン学会学術集会プログラム・抄録集, 20th, 104, 2016
Japanese - 現行ムンプスワクチンを用いた相互補完免疫プログラムのマーモセットモデルによる評価
木所稔; 村野けい子; 加藤大志; 須崎百合子; 永田典代; 岩田奈織子; 安楽正輝; 竹田誠; 長谷川秀樹; 網康至, 日本ワクチン学会学術集会プログラム・抄録集, 20th, 96, 2016
Japanese - Restriction of Injected Vaccines and Development of Mucosal Vaccines for Mucosal Infections
鈴木 忠樹; 相内 章; 長谷川 秀樹, バムサジャーナル = The journal of biomedical science and biosafety, 28, 4, 152, 158, 2016
バイオメディカルサイエンス研究会, Japanese - 髄液JCV-PCR陰性で脳生検で確定診断した進行性多巣性白質脳症2症例の検討
池田 淳司; 松嶋 聡; 小平 農; 石井 亘; 関島 良樹; 高橋 健太; 長谷川 秀樹; 中道 一生; 西條 政幸; 池田 修一, 臨床神経学, 55, Suppl., S394, S394, Dec. 2015
(一社)日本神経学会, Japanese - H3N2インフルエンザAウイルスのHAタンパク質糖鎖欠失によるTMPRSS2非依存的なウイルス増殖
北沢実乃莉; 北沢実乃莉; 酒井宏治; 関塚剛史; 中島勝紘; 中島勝紘; 網康至; 安楽正輝; 中島典子; 久保田耐; 駒瀬勝啓; 竹原一明; 長谷川秀樹; 田代眞人; 黒田誠; 竹田誠, 日本獣医学会学術集会講演要旨集, 158th, 329, 329, 30 Aug. 2015
(公社)日本獣医学会, Japanese - H3N2インフルエンザAウイルスのHAタンパク質糖鎖欠失によるTMPRSS2非依存的なウイルス増殖
北沢 実乃莉; 酒井 宏治; 関塚 剛史; 中島 勝紘; 網 康至; 安楽 正輝; 中島 典子; 久保田 耐; 駒瀬 勝啓; 竹原 一明; 長谷川 秀樹; 田代 眞人; 黒田 誠; 竹田 誠, 日本獣医学会学術集会講演要旨集, 158回, 329, 329, Aug. 2015
(公社)日本獣医学会, Japanese - 【新興・再興感染症と病理】 新興・再興感染症診断の国際比較
高橋 健太; 鈴木 忠樹; 片野 晴隆; 佐藤 由子; 長谷川 秀樹, 病理と臨床, 33, 8, 827, 831, Aug. 2015
(株)文光堂, Japanese - 【新興・再興感染症と病理】 重症熱性血小板減少症候群(SFTS)の病理
鈴木 忠樹; 長谷川 秀樹, 病理と臨床, 33, 8, 839, 846, Aug. 2015
(株)文光堂, Japanese - 【急性発疹症対応マニュアル】 マダニ媒介性ウイルス感染症「重症熱性血小板減少症候群」の診断と発病機構
鈴木 忠樹; 長谷川 秀樹, Derma., 232, 27, 34, Jun. 2015
(株)全日本病院出版会, Japanese - 麻疹に併発した肺炎で死亡した19例の肺組織の分子病理学的解析
中島 典子; 佐藤 由子; 熊坂 利夫; 藤本 嗣人; 花岡 希; 片野 晴隆; 鈴木 忠樹; 長谷川 秀樹, 日本病理学会会誌, 104, 1, 452, 452, Mar. 2015
(一社)日本病理学会, Japanese - Modified In Situ Hybridization AT-Tailing To Visualize the Gene Expression in Formalin-Fixed and Paraffin-Embedded Tissues
Noriko Nakajima; Yuko Sato; Osamu Kotani; Tadaki Suzuki; Toshiaki Kamei; Toru Takahashi; Tetsutaro Sata; Hideki Hasegawa, MODERN PATHOLOGY, 28, 394A, 394A, Feb. 2015
English, Summary international conference - Correlations Among Histopathological Characteristics, Viral Distribution, and Cytokine/Chemokine Expression Level Within an Individual With A/H1N1pdm09 Infection Induced ARDS
Kentaro Hayashi; Noriko Nakajima; Yuko Sato; Takeshi Arashiro; Tadaki Suzuki; Harutaka Katano; Noriyo Nagata; Minoru Tobiume; Hiroshi Yoshida; Yoshio Suzuki; Toshio Kumasaka; Tetsutaro Sata; Koya Ariyoshi; Hideki Hasegawa, MODERN PATHOLOGY, 28, 393A, 393A, Feb. 2015
English, Summary international conference - Correlations Among Histopathological Characteristics, Viral Distribution, and Cytokine/Chemokine Expression Level Within an Individual With A/H1N1pdm09 Infection Induced ARDS
Kentaro Hayashi; Noriko Nakajima; Yuko Sato; Takeshi Arashiro; Tadaki Suzuki; Harutaka Katano; Noriyo Nagata; Minoru Tobiume; Hiroshi Yoshida; Yoshio Suzuki; Toshio Kumasaka; Tetsutaro Sata; Koya Ariyoshi; Hideki Hasegawa, LABORATORY INVESTIGATION, 95, 393A, 393A, Feb. 2015
English, Summary international conference - Modified In Situ Hybridization AT-Tailing To Visualize the Gene Expression in Formalin-Fixed and Paraffin-Embedded Tissues
Noriko Nakajima; Yuko Sato; Osamu Kotani; Tadaki Suzuki; Toshiaki Kamei; Toru Takahashi; Tetsutaro Sata; Hideki Hasegawa, LABORATORY INVESTIGATION, 95, 394A, 394A, Feb. 2015
English, Summary international conference - マウスモデルを用いた経鼻投与型4価季節性インフルエンザワクチンの感染防御効果に関する検討
KITAYAMA HIROTAKA; TAI MAMI; HARIYA MADOKA; TAKAHASHI YASUAKI; AHMAD HAREDY; OGAWA HIRONOBU; TANIMOTO TAKESHI; GOMI YASUYUKI; IKUTA KAZUYOSHI; ISHIKAWA TOYOKAZU; SUZUKI TADAKI; AINAI AKIRA; HASEGAWA HIDEKI; TAMURA SHIN'ICHI; YAMANISHI KOICHI, 日本ワクチン学会学術集会プログラム・抄録集, 19th, 137, 2015
Japanese - コモンマーモセットにおけるムンプスウイルス経鼻感染によるムンプス様感染病態の再現
木所稔; 加藤大志; 村野けい子; 青木なつ子; 永田典代; 須崎百合子; 安楽正輝; 竹田誠; 長谷川秀樹; 網康至, 日本ワクチン学会学術集会プログラム・抄録集, 19th, 98, 2015
Japanese - 動物モデルを用いたムンプスウイルスの神経病原性に関する病理学的検討
永田典代; 岩田奈織子; 鈴木忠樹; 高橋健太; 佐多徹太郎; 長谷川秀樹; 網康至; 久保田耐; 加藤篤; 田代眞人; 竹田誠; 木所稔, 日本ウイルス学会学術集会プログラム・抄録集, 62nd, 361, 31 Oct. 2014
Japanese - 中東呼吸器症候群コロナウイルスに対するマウスおよびラットの感受性について
岩田奈織子; 福士秀悦; 福間藍子; 鈴木忠樹; 竹田誠; 田代眞人; 長谷川秀樹; 永田典代, 日本ウイルス学会学術集会プログラム・抄録集, 62nd, 353, 31 Oct. 2014
Japanese - SFTSウイルスの核蛋白質に対するモノクローナル抗体の作製と抗原検出ELISAへの応用
福間藍子; 福士秀悦; 吉河智城; 谷英樹; 谷口怜; 鈴木忠樹; 佐藤由子; 長谷川秀樹; 下島昌幸; 西條政幸, 日本ウイルス学会学術集会プログラム・抄録集, 62nd, 392, 31 Oct. 2014
Japanese - II型膜貫通型セリンプロテアーゼTMPRSS2は,HA開裂部位にmono‐basicなアミノ酸配列をもつA型インフルエンザウイルスに対する肺内必須活性化酵素である
酒井宏治; 網康至; 田原舞乃; 久保田耐; 安楽正輝; 中島典子; 高下恵美; 関塚剛史; 駒瀬勝啓; 信澤枝里; 小田切孝人; 前仲勝実; 黒田誠; 長谷川秀樹; 河岡義裕; 田代眞人; 竹田誠, 日本ウイルス学会学術集会プログラム・抄録集, 62nd, 155, 31 Oct. 2014
Japanese - 高病原性鳥インフルエンザA(H5N1)ウイルスの経鼻不活化全粒子ワクチンにより誘導されたヒトモノクローナル抗体の特性解析
齊藤慎二; VAN RIET Elly; 相内章; 鈴木忠樹; 池田千将; 伊藤良; 泉池恭輔; 高橋宜聖; 浅沼秀樹; 小田切孝人; 田代眞人; 田村愼一; 竹山春子; 長谷川秀樹, 日本ウイルス学会学術集会プログラム・抄録集, 62nd, 387, 31 Oct. 2014
Japanese - TMPRSS2は、インフルエンザの病原性発現に必須の宿主プロテアーゼである
竹田 誠; 中島 典子; 河岡 義裕; 酒井 宏治; 黒田 誠; 長谷川 秀樹; 田代 眞人, 感染症学雑誌, 88, 5, 750, 750, Sep. 2014
(一社)日本感染症学会, Japanese - 宿主プロテアーゼTMPRSS2はセンダイウイルスの病原性決定因子のひとつである
北沢実乃莉; 酒井宏治; 田原舞乃; 安部昌子; 中島勝紘; 網康至; 中島典子; 安楽正輝; 駒瀬勝啓; 長谷川秀樹; 竹原一明; 田代眞人; 加藤篤; 竹田誠, 日本獣医学会学術集会講演要旨集, 157th, 540, 540, 11 Aug. 2014
(公社)日本獣医学会, Japanese - マウス生体内でのB型インフルエンザウイルス増殖に,宿主プロテアーゼTMPRSS2は必須ではない
中島勝紘; 酒井宏治; 網康至; 中島典子; 北沢実乃莉; 高下恵美; 久保田剛; 安楽正輝; 駒瀬勝啓; 長谷川秀樹; 竹原一明; 小田切孝人; 田代眞人; 竹田誠, 日本獣医学会学術集会講演要旨集, 157th, 410, 410, 11 Aug. 2014
(公社)日本獣医学会, Japanese - 宿主プロテアーゼTMPRSS2は,インフルエンザウイルスの生体内活性化酵素である
酒井宏治; 網康至; 田原舞乃; 久保田耐; 安楽正輝; 中島典子; 関塚剛史; 駒瀬勝啓; 長谷川秀樹; 黒田誠; 河岡義裕; 田代眞人; 竹田誠, 日本獣医学会学術集会講演要旨集, 157th, 419, 419, 11 Aug. 2014
(公社)日本獣医学会, Japanese - CLLの経過中に発症した進行性多巣性白質脳症
高岩 直子; 太田 育代; 吉田 近思; 米野 琢哉; 高橋 健太; 鈴木 忠樹; 佐藤 由子; 片野 晴隆; 長谷川 秀樹; 中道 一生; 西條 政幸, 臨床血液, 55, 7, 826, 826, Jul. 2014
(一社)日本血液学会-東京事務局, Japanese - Critical Issues ans Challenges in Developoment of Inactivated Intranasal Influecza Vaccines
鈴木 忠樹; 相内 章; 長谷川/秀樹, Bio industry, 31, 6, 11, 17, Jun. 2014
シーエムシー出版, Japanese - ダニ媒介性感染症の現状とその対策 日本で流行が確認された重症熱性血小板減少症候群 発見までの経緯と今後の対策
西條 政幸; 高橋 徹; 前田 健; 金行 祥造; 下島 昌幸; 福士 秀悦; 谷 英樹; 吉河 智城; 水谷 哲也; 長谷川 秀樹; 森川 茂, 日本化学療法学会雑誌, 62, Suppl.A, 159, 159, May 2014
(公社)日本化学療法学会, Japanese - 日本人からのTrichodysplasia-spinulosa associated polyomavirusのクローニング
福本 瞳; 都築 慎也; 佐藤 典子; 峰 宗太郎; 望月 眞; 川名 誠司; 長谷川 秀樹; 黒田 誠; 片野 晴隆, 日本皮膚科学会雑誌, 124, 4, 771, 771, Apr. 2014
(公社)日本皮膚科学会, Japanese - Reinhard Kurth Honorary Lecture HTLV-I and Adult T Cell Leukemia/Lymphoma (ATLL) : Cellular and Molecular Basis of Transformation
William W. Hall; Hirofumi Sawa; Hideki Hasegawa, JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 65, 54, 54, Apr. 2014
English, Summary international conference - 日本におけるエイズ関連リンパ腫の病理組織分類
大田 泰徳; 比島 恒和; 望月 眞; 児玉 良典; 森谷 鈴子; 小柳津 直樹; 峰 宗太郎; 塩沢 由美子; 長谷川 秀樹; 片野 晴隆, 日本病理学会会誌, 103, 1, 221, 221, Mar. 2014
(一社)日本病理学会, Japanese - 侵襲性真菌感染症を合併した2例のSFTS剖検例を経験して
平木 翼; 後藤 優子; 北薗 育美; 東 美智代; 吉満 誠; 二木 貴弘; 鈴木 忠樹; 長谷川 秀樹; 谷本 昭英; 米澤 傑, 日本病理学会会誌, 103, 1, 358, 358, Mar. 2014
(一社)日本病理学会, Japanese - 日本国内で発生した重症熱性血小板減少症候群(SFTS)の病理解析
長谷川 秀樹; 亀井 敏昭; 高橋 徹; 鈴木 忠樹; 片野 晴隆; 中島 典子; 森川 茂; 西條 政幸; 倉田 毅, 日本病理学会会誌, 103, 1, 207, 207, Mar. 2014
(一社)日本病理学会, Japanese - 経鼻インフルエンザワクチンにより誘導されたヒトモノクローナル抗体の特性解析
齊藤慎二; VAN RIET Elly; 相内章; 鈴木忠樹; 大原有樹; 池田千将; 伊藤良; 泉池恭輔; 高橋宜聖; 浅沼秀樹; 小田切孝人; 田代眞人; 田村愼一; 竹山春子; 長谷川秀樹, 日本ワクチン学会学術集会プログラム・抄録集, 18th, 94, 2014
Japanese - The Osteoclast Targeting Therapy In Bone Metastasis For a Mouse Model Of Adult T Cell Leukemia
Takuo Mizukami; Kazuya Takizawa; Jumpei Yamazaki; Wakako Kuribayashi; Madoka Kuramitsu; Ryuji Hiramatsu; William W. Hall; Hideki Hasegawa; Kazunari Yamaguchi; Isao Hamaguchi, BLOOD, 122, 21, Nov. 2013
English, Summary international conference - 【感染症症候群(第2版)-症候群から感染性単一疾患までを含めて-[上]】 ウイルス感染症 RNAウイルス感染症 マールブルグウイルス感染症(マールブルグ病/マールブルグ出血熱)
鈴木 忠樹; 長谷川 秀樹; 佐多 徹太郎, 日本臨床, 別冊, 感染症症候群(上), 451, 454, Jul. 2013
(株)日本臨床社, Japanese - 進行性多巣性白質脳症(PML)の病態解明への分子アプローチ
鈴木忠樹; 澤洋文; 大場靖子; 片野晴隆; 佐藤由子; 長谷川秀樹; 長嶋和郎, 日本病理学会会誌, 102, 1, 207, 26 Apr. 2013
Japanese - 【感染症と癌、病理からのメッセージ】 HTLV-1と白血病・リンパ腫
鈴木 忠樹; 長谷川 秀樹, 病理と臨床, 31, 2, 146, 150, Feb. 2013
(株)文光堂, Japanese - In vivoおよびin vitroにおける金ナノ粒子ワクチンの形状依存的な活性
新倉謙一; 松永達也; 鈴木忠樹; 小林進太郎; 小林進太郎; 山口宏樹; 大場靖子; 川口晶; 長谷川秀樹; 梶野喜一; 二宮孝文; 澤洋文; 居城邦治, バイオ・高分子シンポジウム講演要旨集, 23rd, 2013 - ナノ粒子ワクチンのワクチン活性に及ぼす粒子形状およびサイズ効果
新倉謙一; 松永達也; 鈴木忠樹; 小林進太郎; 山口宏樹; 大場靖子; 川口晶; 長谷川秀樹; 梶野喜一; 二宮孝文; 澤洋文; 居城邦治, 高分子学会予稿集(CD-ROM), 62, 2, 2013 - 日本国内で発生した重症熱性血小板減少症候群の1剖検例
長谷川秀樹; 亀井敏昭; 高橋徹; 鈴木忠樹; 片野晴隆; 中島典子; 福士秀悦; 下島昌幸; 前田健; 水谷哲也; 森川茂; 西條政幸, 日本ウイルス学会学術集会プログラム・抄録集, 61st, 2013 - 重症熱性血小板減少症候群(SFTS)の日本における初症例
高橋徹; 前田健; 亀井敏昭; 水谷哲也; 下島昌幸; 福士秀悦; 谷英樹; 吉河智城; 森川茂; 長谷川秀樹; 中島典子; 鈴木忠樹; 永田典代; 片野晴隆; 山岸拓也; 大石和徳; 西條政幸, 日本ウイルス学会学術集会プログラム・抄録集, 61st, 2013 - 後方視的に重症熱性血小板減少症候群と診断された11名のウイルス学的・臨床的・疫学的研究
西條政幸; 高橋徹; 前田健; 水谷哲也; 大松勉; 吉河智城; 谷英樹; 福士秀悦; 下島昌幸; 福間藍子; 緒方もも子; 鈴木忠樹; 中島典子; 片野晴隆; 永田典代; 長谷川秀樹; 山岸拓也; 倉根一郎; 森川茂, 日本ウイルス学会学術集会プログラム・抄録集, 61st, 2013 - 予防 経鼻投与型インフルエンザワクチンの実用化に向けて
相内 章; 浅沼 秀樹; 長谷川 秀樹, インフルエンザ, 13, 3, 199, 204, Oct. 2012
メディカルレビュー社, Japanese - Pathology of influenza virus infection
中島 典子; 長谷川 秀樹, 医学のあゆみ, 241, 1, 37, 43, 07 Apr. 2012
医歯薬出版, Japanese - Histopathological and immunohistochemical findings of 20 autopsy cases with 2009 H1N1 virus infection (vol 25, pg 492, 2012)
Noriko Nakajima; Yuko Sato; Harutaka Katano; Hideki Hasegawa; Toshio Kumasaka; Satoru Hata; Shinya Tanaka; Tomonori Amano; Takahiko Kasai; Ja-Mun Chong; Toshihiko Iizuka; Iwao Nakazato; Yohko Hino; Akihiko Hamamatsu; Hisashi Horiguchi; Tomoyuki Tanaka; Akio Hasegawa; Yoshiaki Kanaya; Reiko Oku; Takeshi Oya; Tetsutaro Sata, MODERN PATHOLOGY, 25, 3, 492, 492, Mar. 2012
English, Others - 細胞培養もしくは鶏卵で製造されたインフルエンザワクチンの品質管理試験および免疫応答への影響
山本典生; 浅沼秀樹; 浅沼秀樹; 佐藤佳代子; 中内美奈; 高橋仁; 許斐奈美; 許斐奈美; 相内章; 相内章; 長谷川秀樹; 田代眞人, 日本ウイルス学会学術集会プログラム・抄録集, 60th, 2012 - 野外株より細胞培養インフルエンザワクチンの種候補株を選定する基準の検討
浅沼秀樹; 相内章; 相内章; 佐藤佳代子; 許斐奈美; 許斐奈美; 岸田典子; 長谷川秀樹; 山本典生; 田代眞人, 日本ワクチン学会学術集会プログラム・抄録集, 16th, 2012 - 肺水腫を呈すハンタウイルス感染SCIDマウスに於ける好中球の役割
駒貴明; 永田典代; 吉松組子; 佐藤由子; 清水健太; 天田貴子; 西尾佐奈恵; 長谷川秀樹; 有川二郎, 日本ウイルス学会学術集会プログラム・抄録集, 60th, 2012 - 2009/10季節性インフルエンザワクチンの経鼻投与によるA/H1N1pdm09ウイルスの感染防御
AIUCHI AKIRA; ASANUMA HIDEKI; TANIMOTO TAKESHI; ODAGIRI TAKAHITO; TAMURA SHIN'ICHI; TASHIRO MASATO; HASEGAWA HIDEKI, 日本ワクチン学会学術集会プログラム・抄録集, 15th, 80, 21 Nov. 2011
Japanese - カニクイザルから分離した新しいサルアデノウイルスの性状解析
酒井 宏治; 永田 典代; 水谷 哲也; 網 康至; 吉河 奈織子; 長谷川 秀樹; 福士 秀悦; 西條 政幸; 竹田 誠; 森川 茂, 日本獣医学会学術集会講演要旨集, 152回, 235, 235, Aug. 2011
(公社)日本獣医学会, Japanese - 慢性炎症病態を形成するTax1bp1‐KOマウスにおけるLPS誘導性急性期炎症反応
中野聡子; 池辺詠美; 塚本善之; 松本昂; 三井孝広; 井上邦光; 八尋隆明; 堀光雄; 守山正胤; 久保田敏昭; 西園晃; 長谷川秀樹; 伊波英克, 生化学, 83回・33回, 4P, 0953, Dec. 2010
(公社)日本生化学会, Japanese - 分子シャペロンCdc37/Hsp90はTaxの細胞内安定性とNF‐κB誘導活性を規定する
池辺詠美; 川口晶; 中野聡子; 八尋隆明; 田村陽介; 松本昂; 三井孝広; 仙波和代; 緒方正男; 堀光雄; 澤洋文; 田中勇悦; 西園晃; 長谷川秀樹; 伊波英克, 生化学, 83回・33回, 3P, 0993, Dec. 2010
(公社)日本生化学会, Japanese - 次世代シークエンサーによるパンデミック・インフルエンザウイルスA/H1N1/2009の多種性解析
黒田 誠; 片野 晴隆; 中島 典子; 飛梅 実; 相内 章; 長谷川 秀樹; 佐々木 裕子; 荒川 宜親; 佐多 徹太郎, 日本生化学会大会・日本分子生物学会年会合同大会講演要旨集, 83回・33回, 1T11, 8, Dec. 2010
(公社)日本生化学会, Japanese - 経鼻粘膜投与型インフルエンザワクチンによる高病原性H5N1ウイルスの感染防御と交叉防御の検討
HASEGAWA HIDEKI; AIUCHI AKIRA; AMI YASUSHI; NAGATA NORIYO; TAMURA SHIN'ICHI; TANIMOTO TAKESHI; MANABE SADAO; ISHIKAWA TOYOKAZU; MIYAZAKI TAKASHI; ODAGIRI TAKATO; TASHIRO MASATO; KURATA TAKESHI; SATA TETSUTARO, 日本ワクチン学会学術集会プログラム・抄録集, 14th, 62, 10 Nov. 2010
Japanese - インフルエンザワクチン経鼻接種による成人での血清および鼻腔洗浄液中のウイルス特異的中和抗体の評価
AIUCHI AKIRA; TAMURA SHIN'ICHI; SUZUKI TADAKI; ITO MAKOTO; ASANUMA HIDEKI; TANIMOTO TAKESHI; GOMI YASUYUKI; OKUNO YOSHINOBU; ODAGIRI TAKATO; TASHIRO MASATO; SATA TETSUTARO; KURATA TAKESHI; HASEGAWA HIDEKI, 日本ワクチン学会学術集会プログラム・抄録集, 14th, 60, 10 Nov. 2010
Japanese - 経鼻粘膜投与型インフルエンザワクチンによるブースター効果と高病原性H5N1ウイルスの感染防御の検討
HASEGAWA HIDEKI; AIUCHI AKIRA; AMI KOJI; NAGATA NORIYO; TAMURA SHIN'ICHI; TANIMOTO TAKESHI; MANABE SADAO; ISHIKAWA TOYOKAZU; MIYAZAKI TAKASHI; ODAGIRI TAKATO; TASHIRO MASATO; KURATA TAKESHI; SATA TETSUTARO, 日本ウイルス学会学術集会プログラム・抄録集, 58th, 297, 15 Oct. 2010
Japanese - 2009/10季節性インフルエンザワクチンの経鼻投与によるA/H1N1 pdmウイルスの感染阻害効果の検討
AIUCHI AKIRA; ITO MAKOTO; ASANUMA HIDEKI; SUZUKI TADAKI; TANIMOTO TAKESHI; ODAGIRI TAKAHITO; TAMURA SHIN'ICHI; SATA TETSUTARO; TASHIRO MASATO; HASEGAWA HIDEKI, 日本ウイルス学会学術集会プログラム・抄録集, 58th, 298, 15 Oct. 2010
Japanese - Disruption of Intracellular Vesicular Trafficking by Agnoprotein is Essential for Viroporin Activity and JC Virus Replication
Tadaki Suzuki; Yasuko Orba; Yoshinori Malcino; Yuki Okada; Yuji Sunden; Takashi Kimura; Hideki Hasegawa; Tetsutaro Sata; William W. Hall; Hirofumi Sawa, JOURNAL OF NEUROVIROLOGY, 16, 84, 84, Oct. 2010
English, Summary international conference - カニクイザルで致死的感染症を起こしたイヌジステンパーウイルスの性状と実験感染サルでの病原性の解析
酒井 宏治; 永田 典代; 網 康至; 岩田 奈織子; 鈴木 忠樹; 水谷 哲也; 福士 秀悦; 須崎 百合子; 緒方 もも子; 西條 政幸; 長谷川 秀樹; 山田 靖子; 倉根 一郎; 森川 茂, 日本獣医学会学術集会講演要旨集, 150回, 230, 230, Sep. 2010
(公社)日本獣医学会, Japanese - 経鼻インフルエンザワクチンによる免疫獲得効果検討
谷本武史; 高野大輔; 森本孝一; 五味康行; 長谷川秀樹; 長谷川秀樹; 田村愼一; 宮崎隆; 真鍋貞夫; 石川豊数; 奥野良信, 日本ワクチン学会学術集会プログラム・抄録集, 14th, 2010 - 分子シャペロン阻害剤によるTaxとTax結合蛋白質の機能相関性に対する抑制的影響
池辺詠美; 川口晶; 川口晶; 田口慎也; 川嶋太郎; 田中勇悦; 堀光雄; 澤洋文; 西園晃; 長谷川秀樹; 伊波英克, 日本ウイルス学会学術集会プログラム・抄録集, 58th, 2010 - 新型インフルエンザウイルス(H1N1pdm)の増殖性に関する検討
浅沼秀樹; 信澤枝里; 白倉雅之; 許斐奈美; 許斐奈美; 山本典生; 中内美名; 網康至; 長谷川秀樹; 相内章; 高下恵美; 小渕正次; 徐紅; 岸田典子; 小田切孝人; 田代眞人, 日本ウイルス学会学術集会プログラム・抄録集, 58th, 2010 - 粘膜投与等の新投与経路ワクチン研究における品質管理に関する研究
ITAMURA SHIGEYUKI; HASEGAWA HIDEKI; YOKOTA YASUKO; KASAI MICHIYUKI; TANIMOTO TAKESHI; SATO KAYOKO, 粘膜投与等の新投与経路ワクチン研究における品質管理に関する研究 平成21年度 総括・分担研究報告書 平成19-21年度 総合研究報告書, HEISEI19-21NENDO,1-13, 2010
Japanese - Inhibition of the SDF-1F?-CXCR4 Axis by the CXCR4 Antagonist AMD3100 Suppresses the Migration of Human ATLL Cells and Murine Lymphoblastoid Cells from HTLV-I Tax Transgenic Mice
A. Kawaguichi; Hidekatsu, I; H. Hasegawa; H. Sawa; M. Ogata; T. Tsuji; T. Kimura; T. Sata; W. W. Hall; Y. Orba, AIDS RESEARCH AND HUMAN RETROVIRUSES, 25, 11, 1212, 1212, Nov. 2009
English, Summary international conference - CXCR4アンタゴニスト(AMD3100)を用いたSCIDマウスにおけるTaxトランスジェニックマウス由来腫瘍細胞の組織浸潤抑制
川口晶; 辻隆裕; 大場靖子; 木村享史; 相内章; 伊波英克; 緒方正男; 佐多徹太郎; 澤洋文; 長谷川秀樹, 日本ウイルス学会学術集会プログラム・抄録集, 57th, 445, 01 Oct. 2009
Japanese - HTLV‐1 Taxトランスジェニックマウスを用いたATL様腫瘍幹細胞の同定と解析
滝澤和也; 水上拓郎; 山崎淳平; 山崎淳平; 倉光球; 百瀬暖佳; 益見厚子; 本嶋藍; 本嶋藍; 鶴野親是; 大隈和; 長谷川秀樹; 浜口功; 山口一成, 臨床血液, 50, 9, 1170, 1170, Sep. 2009
(一社)日本血液学会-東京事務局, Japanese - 急性呼吸器感染症患者からの新型レオウイルス分離とマウス感染モデルの作製
酒井 宏治; 網 康至; 水谷 哲也; 岩切 章; 山本 正悟; 平井 明香; 須崎 百合子; 福士 秀悦; 西條 政幸; 永田 典代; 長谷川 秀樹; 山田 靖子; 倉根 一郎; 森川 茂, 日本獣医学会学術集会講演要旨集, 148回, 302, 302, Sep. 2009
(公社)日本獣医学会, Japanese - 経鼻粘膜投与型インフルエンザワクチンの剤形と効果検討
HASEGAWA HIDEKI; AIUCHI AKIRA; AMI YASUSHI; NAGATA NORIYO; TAMURA SHIN'ICHI; TANIMOTO TAKESHI; MANABE SADAO; ISHIKAWA TOYOKAZU; MIYAZAKI TAKASHI; ODAGIRI TAKATO; TASHIRO MASATO; KURATA TAKESHI; SATA TETSUTARO, 日本ワクチン学会学術集会プログラム・抄録集, 13th, 105, 10 Aug. 2009
Japanese - 免疫抑制剤のSARSコロナウイルス増殖に与える影響についての解析
原崎一浩; 永田典代; 岩田奈織子; 長谷川秀樹; 佐多徹太郎; 山本直樹; 高久洋; 佐藤人美; 山本陽子; 平松啓一; 田代眞人; 山本典生; 山本典生, 日本ウイルス学会学術集会プログラム・抄録集, 57th, 2009 - Structure-based drug design(SBDD)によるSARSコロナウイルス増殖抑制薬剤の同定
山本典生; 山本典生; 永田典代; 岩田奈織子; 長谷川秀樹; 佐多徹太郎; 松本武久; 高久洋; 山本陽子; 佐藤人美; 平松啓一; 田代眞人; 山本直樹, 日本ウイルス学会学術集会プログラム・抄録集, 57th, 2009 - 水様性下痢を呈したカニクイザルから分離したアデノウイルスの分子系統学的解析
酒井宏治; 永田典代; 岩田奈織子; 長谷川秀樹; 松井珠乃; 網康至; 平井明香; 須崎百合子; 水谷哲也; 福士秀悦; 緒方もも子; 西條政幸; 藤本嗣人; 山田靖子; 岡部信彦; 佐多徹太郎; 倉根一郎; 森川茂, 日本ウイルス学会学術集会プログラム・抄録集, 57th, 2009 - 季節性インフルエンザワクチンにより誘導される中和抗体の新型インフルエンザウイルスに対する交差反応性および新型インフルエンザウイルスの性状
岸田典子; 小渕正次; 高下恵美; 徐紅; 氏家誠; 永田典代; 岩田奈織子; 相内章; 長谷川秀樹; 田代眞人; 齋藤玲子; 鈴木宏; 池松秀之; 小田切孝人, 日本ウイルス学会学術集会プログラム・抄録集, 57th, 2009 - 経鼻インフルエンザワクチンの新型インフルエンザウイルスに対する交叉防御能の検討
相内章; 相内章; 伊藤良; 伊藤良; 岸田典子; 小渕正次; 高下恵美; 小田切孝人; 千葉丈; 田村愼一; 倉田毅; 佐多徹太郎; 田代眞人; 長谷川秀樹; 長谷川秀樹, 日本ウイルス学会学術集会プログラム・抄録集, 57th, 2009 - Post-Exposure Vaccination with a Highly Attenuated Vaccinia Vaccine, LC16m8, for Protection of Nonhuman Primates from Monkeypox
M. Saijo; Y. Ami; Y. Suzaki; N. Nagata; H. Hasegawa; M. Ogata; S. Fukushi; T. Mizutani; I. Iizuka; I. Kurane; T. Kurata; S. Morikawa, INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 12, E53, E53, Dec. 2008
English, Summary international conference - The Loop-Mediated Isothermal Amplification-Based Diagnostics for Monkeypox Virus Infection
I. Iizuka; M. Saijo; Y. Ami; Y. Suzaki; N. Nagata; H. Hasegawa; T. Shiota; M. Ogata; K. Sakai; S. Fukushi; T. Mizutani; I. Kurane; S. Morikawa, INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 12, E475, E475, Dec. 2008
English, Summary international conference - H5N1(NIBRG‐14)ワクチンの感染防御効果には,抗ヘマグルチニン抗体と抗ノイラミニダーゼ抗体の両者が関与する
高橋宜聖; 阿戸学; 二宮愛; 長谷川秀樹; 小田切孝人; 佐多徹太郎; 田代眞人; 小林和夫, 日本ワクチン学会学術集会プログラム・抄録集, 12th, 61, 10 Oct. 2008
Japanese - ヒトATL細胞及びTaxトランスジェニックマウス由来腫瘍細胞のSDF‐1αに対する走化性
川口晶; 大場靖子; 木村享史; 伊波英克; 緒方正男; 辻隆裕; 佐多徹太郎; 澤洋文; 長谷川秀樹, 日本ウイルス学会学術集会プログラム・抄録集, 56th, 247, 01 Oct. 2008
Japanese - ATL腫瘍細胞の走化性におけるCXCR4を介したシグナル経路の解析
川口晶; 大場靖子; 木村享史; 伊波英克; 緒方正男; 佐多徹太郎; 澤洋文; 長谷川秀樹, 補体シンポジウム講演集, 45th, 179, Jul. 2008
Japanese - Mouse-passaged severe acute respiratory syndrome-associated coronavirus leads to lethal pulmonary edema and diffuse alveolar damage in adult but not young mice.
Noriyo Nagata; Naoko Iwata; Hideki Hasegawa; Shuetsu Fukushi; Ayako Harashima; Yuko Sato; Masayuki Saijo; Fumihiro Taguchi; Shigeru Morikawa; Tetsutaro Sata, The American journal of pathology, 172, 6, 1625, 1637, 2008, [International Magazine]
Advanced age is a risk factor of severe acute respiratory syndrome (SARS) in humans. To understand its pathogenesis, we developed an animal model using BALB/c mice and the mouse-passaged Frankfurt 1 isolate of SARS coronavirus (SARS-CoV). We examined the immune responses to SARS-CoV in both young and adult mice. SARS-CoV induced severe respiratory illness in all adult, but not young, mice on day 2 after inoculation with a mortality rate of 30 to 50%. Moribund adult mice showed severe pulmonary edema and diffuse alveolar damage accompanied by virus replication. Adult murine lungs, which had significantly higher interleukin (IL)-4 and lower IL-10 and IL-13 levels before infection than young murine lungs, rapidly produced high levels of proinflammatory chemokines and cytokines known to induce macrophage and neutrophil infiltration and activation (eg, tumor necrosis factor-alpha). On day 2 after inoculation, young murine lungs produced not only proinflammatory cytokines but also IL-2, interferon-gamma, IL-10, and IL-13. Adult mice showed early and acute excessive proinflammatory responses (ie, cytokine storm) in the lungs after SARS-CoV infection, which led to severe pulmonary edema and diffuse alveolar damage. Intravenous injection with anti-tumor necrosis factor-alpha antibody 3 hours after infection had no effect on SARS-CoV infection. However, intraperitoneal interferon-gamma injection protected adult mice from the lethal respiratory illness. The experimental model described here may be useful for elucidating the pathophysiology of SARS and for evaluating therapies to treat SARS-CoV infection., English - ドロマイトセラミックによるH5N1高病原性鳥インフルエンザウイルスとSARSコロナウイルスの不活性化
山本典生; 山本典生; 一戸猛志; 長谷川秀樹; 佐藤由子; 永田典代; 市野瀬志津子; 吉仲由之; 若林一夫; 山名英明; 本池紘一; 田中千春; 佐藤人美; 山本陽子; 佐多徹太郎; 小田切孝人; 田代眞人; 伊藤壽啓; 大槻公一; 山本直樹, 日本ウイルス学会学術集会プログラム・抄録集, 55th, 2007 - 新規分子シャペロン阻害剤によるNF-κBシグナルの抑制と抗ガン剤への応用
伊波英克; 川口晶; 田口慎也; 川嶋太郎; 村上真弓; 田中勇悦; 澤洋文; 佐多徹太郎; 堀光雄; 後藤和代; 西園晃; JEANG Kuan-Teh; HALL William W; 長谷川秀樹, 生化学, 2007 - Improving accuracy and speed of SARS coronavirus screening. Analysis on viral kinetics and immune response in SARS-CoV-infected animal model.
長谷川秀樹; 永田典代; 岩田奈織子; 佐藤由子; 原嶋綾子; 佐多徹太郎; 森川茂; 西条政幸; 板村繁之; 西藤岳彦; 網康至, SARSコロナウイルス検査法の精度向上及び迅速化に関する研究 平成17年度 研究報告書, 67, 70, 2006
Japanese - Development of a model of adult T-cell leukemia/lymphoma (Atll)
H Hasegawa; H Sawa; M Lewis; Y Orba; T Sata; T Kurata; K Nagashima; N Sheehy; WW Hall, AIDS RESEARCH AND HUMAN RETROVIRUSES, 21, 5, 454, 455, May 2005
English, Summary international conference - In silico screeningによるSARSコロナウイルス増殖抑制薬剤の同定
山本典生; 松本武久; 森川茂; 長谷川秀樹; 永田典代; 山本直樹, 日本ウイルス学会学術集会プログラム・抄録集, 53rd, 2005 - 経鼻不活化インフルエンザワクチンの開発
TAMURA SHIN'ICHI; OZAKI YASUKO; HASEGAWA HIDEKI; TANIMOTO TAKESHI; SUZUKI YUJIRO; YAMAMOTO SABURO; SATA TETSUTARO; KURATA TAKESHI, 日本ワクチン学会学術集会プログラム・抄録集, 9th, 53, 2005
Japanese - 【SARSへの対応】 SARSウイルスとSARSの病理
佐多 徹太郎; 永田 典代; 中島 典子; 佐藤 由子; 長谷川 秀樹; 熊坂 利夫, 日本胸部臨床, 62, 9, 796, 803, Sep. 2003
現在話題となっている新型肺炎(SARS)の原因ウイルスとその感染病理像について述べた.WHOはSARSの原因ウイルスが,いままで知られていた動物やヒトのコロナウイルスとは異なる新しいコロナウイルスであるとしSARS virusと命名した.現状での病理像としては,SARS患者の剖検肺にはびまん性肺胞傷害(diffuse alveolar damage)がみられることである, 克誠堂出版(株), Japanese - Neural cell specific activation of the JC virus promoter in the presence of HTLV-1 Tax.
Y Okada; H Sawa; S Tanaka; S Suzuki; H Hasegawa; WW Hall; K Nagashima, AIDS RESEARCH AND HUMAN RETROVIRUSES, 17, S56, S56, 2001
English, Summary international conference
■ Research Themes
- Elucidation of pathophysiological mechanism of chronic inflammation and risk stratification of dilated cardiomyopathy.
Grants-in-Aid for Scientific Research
01 Apr. 2019 - 31 Mar. 2022
Imanaka-Yoshida Kyoko
Dilated cardiomyopathy (DCM) is a heterogeneous group of myocardial diseases. Chronic myocarditis has been hypothesized to be one of the causes of DCM. Chronic myocarditis needs to be distinguished from other types of DCM because immunosuppressive agents may control disease progression. At present, endomyocardial biopsy is the only way for diagnosis, however, it needs a clear immunohistological criteria. We have performed a nationwide multicenter study of biopsy prove chronic myocarditis. Our data have suggested CD3+ T-lymphocytes count in the biopsied samples may be a risk-stratifying marker for poor long-term outcome and CD3+ > 24/mm2 could be a threshold for chronic myocarditis. Furthermore, to identify pathophysiological mechanism involved in progression of chronic myocarditis, we have developed a novel mouse model of chronic myocarditis induced by recombinant bacille Calmette-Guerin (rBCG) expressing a CD4+ T-cell epitope of cardiac myosin heavy chain-alpha.
Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (B), Mie University, 19H03442 - Development of pathological diagnostic methods for congenital infections and unexplained illness of possible infectious etiology.
新興・再興感染症に対する革新的医薬品等開発推進研究事業
Apr. 2019 - Mar. 2022
鈴木忠樹; 長谷川秀樹; 有吉紅也; 片野晴隆; 山下和男; 大場靖子
Japan Agency for Medical Research and Development, Competitive research funding, 21fk0108104 - Bronchial asthma induces excessive inflammation and virus replication in pandemic influenza infection.
Grants-in-Aid for Scientific Research Grant-in-Aid for Young Scientists (B)
01 Apr. 2015 - 31 Mar. 2017
MATSUSHIGE Takeshi; HASEGAWA Shunji; FUJIMOTO Yousuke; WAKABAYASHI Midori; WAKIGUCHI Hiroyuki; NAKAMURA Tamaki; HASEGAWA Hideki; AINAI Akira; IKEMOTO Kenzo; OGA Atsunori; ITOH Hiroshi; SHIRABE Komei; TODA Shoichi; ATSUTA Ryo; OHGA Shouichi
Asthmatic patients present more rapid progression of respiratory distress after A(H1N1)pdm09 influenza infection than after seasonal infection. Here, we sought to clarify the pathophysiology of early deterioration in asthmatic patients after A(H1N1)pdm09 infection. In asthma/A(H1N1)pdm09 mice, inflammatory cytokines and virus titres in bronchoalveolar lavage fluid peaked at 3 days post-infection and were higher than those in non-asthmatic or seasonal influenza infection groups. Histopathological examination showed more inflammatory cell infiltration and lung tissue destruction in the asthma/A(H1N1)pdm09 group than in any other groups. Thus, bronchial asthma could be a exacerbating factor for pandemic influenza infection with excessive inflammation and virus replication within a few days after infection. Furthermore, the evaluation of pulmonary function in the treatment intervention group is in progress.
Japan Society for the Promotion of Science, Grant-in-Aid for Young Scientists (B), Yamaguchi University, 15K19619 - Localized surface plasmon sensing for subtype determination of influenza viruses in a specimen with ultra-small volume
Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (B)
01 Apr. 2013 - 31 Mar. 2016
KANO Hiroshi; HASEGAWA Hideki; MORIGAKI Kenichi
Development of a method for quick subtype determination of influenza viruses is important because infectious and pathogenic properties of viruses are different. In this research, we proposed a method in which refractive index change due to antigen-antibody reaction between target viruses with certain subtype and monoclonal antibodies fixed in a micro-channel on a sensing substrate. To realize this concept, we successfully improved stability and sensitivity of a measurement system for virus detection, confirmed a measurement principle for faster data acquisition, and developed a technique to modify chemical property of a substrate surface to locate certain antibodies in a controlled region.
Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (B), Muroran Institute of Technology, 25286062 - Regulation of IgA responses against influenza virus
Grants-in-Aid for Scientific Research Grant-in-Aid for Challenging Exploratory Research
01 Apr. 2012 - 31 Mar. 2015
IRIMURA Tatsuro; HASEGAWA Hideki; AINAI Akira; DENDA Kaori
The aim of this study is to elucidate whether MGL2 is involved in the immune response against influenza virus, particularly IgA responses, in the airway using mice. Mouse-adapted influenza strain, PR8, was administrated into the airways of MGL2-KO and wild-type mice and pathogenesis, cytokine production, and immunoglobulin production were investigated. There was no remarkable differences in MGL2-KO mice. However, in the skin, dendritic cells expressing MGL2 were proven to be responsive for skewing the response toward the Th2-type.
Japan Society for the Promotion of Science, Grant-in-Aid for Challenging Exploratory Research, 24659029 - Identification of retrovirus-like DNA fragments in an AIDS patient
Grants-in-Aid for Scientific Research Grant-in-Aid for Challenging Exploratory Research
01 Apr. 2012 - 31 Mar. 2015
KATANO Harutaka; KURODA Makoto; HASEGAWA Hideki
Genome fragments of unidentified retrovirus were discovered from the spleen tissue of an AIDS autopsy using a next generation sequencer. The whole genome of the retrovirus was 8kb of length containing gag, pol, env and protease genes, and belonged to beta-retrovirus family. A real-time PCR assay revealed that any genome of the virus was not detected in other human pathological samples, suggesting that the virus is rare and uncommon among human.
Japan Society for the Promotion of Science, Grant-in-Aid for Challenging Exploratory Research, National Institute of Infectious Diseases, 24659212 - 普遍的インフルエンザAワクチンの開発
Grants-in-Aid for Scientific Research Grant-in-Aid for JSPS Fellows
2010 - 2012
長谷川 秀樹; VANRIET Petronella Helena; VANRIET PetronellaHelena; VAN RIET Petronella Helena
経鼻インフルエンザワクチンは、現行の皮下に接種されるワクチンと異なり、感染の場となる気道粘膜上に交叉防御能を有する分泌型IgA抗体を誘導し、感染自体を阻止することが明らかになっている。本研究では、ワクチンの経鼻接種により交叉防御能の高い免疫を誘導するワクチンの開発と機序の解明を目指した基盤的研究を目的とする。本年度は、高病原性鳥インフルエンザウイルスA(H5N1)の経鼻ワクチン接種に関する臨床研究(国立感染症研究所ヒトを対象とする医学研究倫理審査委員会承認済み)において、誘導される抗体の特徴を明らかにすることを目的とした。
H5N1ワクチンの経鼻接種で誘導される末梢血中の形質細胞の誘導に関してフローサイトメーターを用いて解析したところ、経鼻ワクチン接種の回数依存的に末梢血中の抗体産生形質細胞数が増加することが明らかになった。免疫学的に無垢な状態にあるH5N1ワクチンを経鼻から接種した場合には、IgA抗体産生形質細胞は、IgG抗体産生形質細胞の二倍程度誘導されることが明らかとなった。次に、抗体の多様性を解析した。抗体を形成する重鎖(H鎖)において、三番目の相補性決定領域(CDR3)は、V(D)J遺伝子再編成による各遺伝子連結部位に相当し多様性に富む。このCDR3に関して、IgG抗体とIgA抗体で比較したところ、IgG抗体と比べてIgA抗体の方でアミノ酸の数が多様であることが明らかになった。抗体は体細胞高頻度突然変異により抗原結合部位である可変領域に変異が導入され抗原への親和性が増すが、この変異はIgA抗体で高頻度に起こる傾向にあった。また抗体の可変領域を形成するV遺伝子座であるVH1-69を使用する抗体に高い交叉防御能が認められるという報告があるが、本研究において同じ遺伝子座から構成される可変領域を有するIgGおよびIgA抗体の存在が明らかになった。
Japan Society for the Promotion of Science, Grant-in-Aid for JSPS Fellows, National Institute of Infectious Diseases, 10F00515 - Localized surface plasmon sensing for detection and diagnosis of influenza viruses
Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (B)
2010 - 2012
KANO Hiroshi; HASEGAWA Hideki; MORIGAKI Kenichi
A method to determine subtype of influenza viruses by using surface plasmons localized in microscopic region on a flat metal surface was developed. In this method, refractive index variation arisen from interactions between viruses and their monoclonal antibodies was measured. Theoretical calculation revealed that measurement region had a size of ~180nm in radius, and could be occupied by ~7 viruses. The detection of influenza viruses with certain subtype was successfully demonstrated.
Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (B), Muroran Institute of Technology, 22360022 - Research for Immunotherapy of Adult T cell Leukemia(ATL)
Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)
2009 - 2011
HASEGAWA Hideki
Adult T-cell Leukemia(ATL) is a refractory disease. It is suggested that the treatment resistant cancer stem cells are present in the leukemic cells population. We have attempted to identify molecules that can be a target for immunotherapy which target the cancer stem cells using a mouse model of ATL. We identified molecules that are specifically expressed on the surface of cancer stem cells of mouse ATL cells by multi TOF MASS analyzer. The molecule can be a therapeutic target of ATL.
Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (C), National Institute of Infectious Diseases, 21590521 - 成人T細胞白血病(ATL)モデル動物を用いた予防法治療法の開発
Grants-in-Aid for Scientific Research Grant-in-Aid for Exploratory Research
2006 - 2007
長谷川 秀樹
(1)NF-κBを標的とした腫瘍の抑制
1)IKK-β阻害剤Bay65-1942によるアポトーシス誘導
Bay65-1942によりNF-κB経路を抑制することで、mATL細胞にアポトーシスを誘導をゲノム断片化の検出及びTUNEL法により調べた。Bay65-1942による濃度依存的なゲノムの断片化を検出した。次にTUNEL法によっても、アポトーシスの初期に生じるDNAの二本鎖切断端の検出を行ったところ、Bay65-1942の濃度依存的にアポトーシス陽性の細胞数が増加していることを確認した。これらの結果から、Bay65-1942はmATL細胞に対してアポトーシスを誘導することが示された。
2)Bay65-1942のin vivoでの腫瘍抑制効果
Bay65-1942のin vivoにおける治療効果をmATL細胞を移植したNOD-SCIDマウスを用いて検討した。その結果、コントロール群では30日目からマウスが死亡を始め、33日目までに全てのマウスが死亡した。一方Bay65-1942を投与した群では濃度依存的な延命効果が認められ、200μg投与群では35日目まで、400μg投与群では40日目まで、800μg投与群に関しては42日目まで生存するマウスが存在し、未投与群と比較して最大で約1.3倍の延命効果を得ることができた。未投与群では末梢血中に白血病細胞を多数認める一方、800μg投与群では、白血病細胞がほとんど認められなかった。また肝臓及び肺組織のHE染色の結果、Bay65-1942未投与群では、いずれの組織でも血管周囲を中心に多数のmATL細胞の浸潤が見られた。一方で、800μg投与群ではいずれの組織でもmATL細胞の浸潤の程度は軽度であった。
Japan Society for the Promotion of Science, Grant-in-Aid for Exploratory Research, National Institute of Infectious Diseases, 18659115 - LIMPII、ユビキチン融合インフルエンザDNAワクチンによる免疫応答と感染防御
Grants-in-Aid for Scientific Research Grant-in-Aid for Young Scientists (B)
2001 - 2002
長谷川 秀樹
1、LIMP II融合インフルエンザHA DNAワクチンの作成
マウス線維芽細胞NIH3T3細胞より得らたcDNAライブラリーを用いマウスLIMP IIの遺伝子の単離を行った。C'末端にLIMP IIのライソゾームターゲットシークエンスを融合させる形でインフルエンザウイルスのHA及びNAのDNAワクチンを作成した。C'末端にLIMP IIのtailを融合させる事により発現されたワクチン抗原はMHC class IIを介する抗体誘導の増強が期待される。
2、ユビキチン融合及びLIMP II融合インフルエンザDNAワクチンの発現と細胞内動態
作成したユビキチン融合及びLIMP II融合インフルエンザDNAワクチンを293T細胞に導入し、ウエスタンブロッティングにて発現を確認、及び蛍光抗体法を用い細胞内での局在を調べた。また、細胞内での動態を調べるためにS35メチオニンラベルした細胞を用いパルスチェース法を用い蛋白発現後の時間的動態を解析した。結果、ウエスタンブロッティングでのワクチン抗原の発現確認ではHAのDNAワクチンでは強い発現が確認されたがHA-LIMP IIでは少量の発現が、Ub-HAではほとんど抗原が見られなかった。しかしパルスチェイス法では3種類のワクチン共に発現がみられ特にHAでの発現が多く又Ub-HAでは発現後速やかに分解されている事がわかった。この結果はユビキチンの融合によりワクチン抗原がプロテオソームに運ばれ速やかに分解されている事が示唆される。
3、HA, Ub-HA, HA, LIMP II DNAワクチンの抗体応答の比較
作成した3種のインフルエンザHAワクチンを用いマウスにエレクトロポレーション法を用いて接種しHA特異的抗体をELISA法を用いて測定した。マウス大腿の筋肉内に1〜10μgのDNAワクチンを接種し100V6回のパルスでエレクトロポレーションを行った。3週間隔で2回免疫しさらに2週後の血清、鼻腔洗浄液を回収しIgA, IgGを測定した。この条件での抗体応答はHA 10μgで行ったものが最も高くそれは抗原の発現量に比例していた。モディファイしたDNAワクチンの発現量を増やす工夫が必要である。
Japan Society for the Promotion of Science, Grant-in-Aid for Young Scientists (B), National Institute of Infectious Diseases, 13770155
- 経鼻インフルエンザワクチン組成物
Patent right, 長谷川 秀樹; 鈴木 忠樹; 相内 章; 上下 泰造; 宮崎 隆, 国立感染症研究所長, 東興薬品工業株式会社
特願2014-554202, 23 Oct. 2013
特許第6247639号
24 Nov. 2017
201803017235428828 - 経鼻投与用ワクチンを用いるインフルエンザの予防方法
Patent right, 長谷川 秀樹; 真鍋 貞夫; 谷本 武史; 宮▲崎▼ 隆; 上下 泰造, 国立感染症研究所長, 一般財団法人阪大微生物病研究会, 東興薬品工業株式会社
特願2014-206998, 08 Oct. 2014
特開2015-028070, 12 Feb. 2015
特許第5921634号
22 Apr. 2016
201603008654579328 - 抗インフルエンザウイルス抗体及びその利用
Patent right, 齊藤 慎二; 鈴木 忠樹; 長谷川 秀樹; 相内 章; 後藤 希代子; 上野 智規, 国立感染症研究所長, 株式会社ニッピ
JP2015070719, 21 Jul. 2015
WO2016-010160, 21 Jan. 2016
201703012848447460 - 多量体IgA型遺伝子組換え抗体及びその利用
Patent right, 齊藤 慎二; 鈴木 忠樹; 長谷川 秀樹; 相内 章; 後藤 希代子; 上野 智規; 多賀 祐喜, 国立感染症研究所長, 株式会社ニッピ
JP2015070742, 21 Jul. 2015
WO2016-010161, 21 Jan. 2016
201703016585837409 - 経鼻投与用ワクチンを用いるインフルエンザの予防方法
Patent right, 長谷川 秀樹; 真鍋 貞夫; 谷本 武史; 宮▲崎▼ 隆; 上下 泰造, 国立感染症研究所長, 一般財団法人阪大微生物病研究会, 東興薬品工業株式会社
特願2011-541970, 31 Mar. 2010
特許第5762307号
19 Jun. 2015
201503014021957636 - 経鼻投与用ワクチンを用いるインフルエンザの予防方法
Patent right, 長谷川 秀樹; 真鍋 貞夫; 谷本 武史; 宮▲崎▼ 隆; 上下 泰造, 国立感染症研究所長, 一般財団法人阪大微生物病研究会, 東興薬品工業株式会社
特願2014-206998, 08 Oct. 2014
特開2015-028070, 12 Feb. 2015
201503069748767510 - 経鼻インフルエンザワクチン組成物
Patent right, 長谷川 秀樹; 鈴木 忠樹; 相内 章; 上下 泰造; 宮崎 隆, 国立感染症研究所長, 東興薬品工業株式会社
JP2013078721, 23 Oct. 2013
WO2014-103488, 03 Jul. 2014
201703003308806640 - 成人T細胞白血病/リンパ腫の発症抑制剤の有効成分をスクリーニングする方法
Patent right, 伊波 英克; 緒方 正男; 長谷川 秀樹, 国立大学法人 大分大学, 公益財団法人ヒューマンサイエンス振興財団
特願2008-087280, 28 Mar. 2008
特開2009-243900, 22 Oct. 2009
特許第5292608号
21 Jun. 2013
201303042881125253 - インフルエンザウイルスの不活化抗原に対するアジュバント、及び分泌型IgA抗体誘導剤
Patent right, 長谷川 秀樹; 中村 友幸; 秋山 幸仁, 秋山 幸仁, 中村 友幸, 国立感染症研究所長
特願2007-115739, 25 Apr. 2007
特開2008-273846, 13 Nov. 2008
特許第5272129号
24 May 2013
201303010601530680 - 混合免疫賦活剤を含む新規ワクチン
Patent right, 長谷川 秀樹; 谷本 武史, 一般財団法人阪大微生物病研究会, 国立感染症研究所長
特願2008-094360, 31 Mar. 2008
特開2009-242367, 22 Oct. 2009
特許第5190628号
08 Feb. 2013
201303072281167609 - 経鼻投与用ワクチンを用いるインフルエンザの予防方法
Patent right, 長谷川 秀樹; 真鍋 貞夫; 谷本 武史; 宮▲崎▼ 隆; 上下 泰造, 国立感染症研究所長, 一般財団法人阪大微生物病研究会, 東興薬品工業株式会社
特願2011-541970, 31 Mar. 2010
特表2012-521965, 20 Sep. 2012
201203098870574720 - 経鼻ワクチン
Patent right, 清野 研一郎; 谷口 克; 田代 卓哉; 冨宿 賢一; 森 謙治; 長谷川 秀樹, 独立行政法人理化学研究所, 国立感染症研究所長
特願2007-511259, 30 Mar. 2006
特許第4909264号
20 Jan. 2012
201303074667973530 - 分泌型IgA及びIgG抗体誘導剤
Patent right, 長谷川 秀樹; 佐多 徹太郎; 倉田 毅; 田中 利明; 森山 雅美, 森山 雅美
特願2005-266881, 14 Sep. 2005
特開2007-077073, 29 Mar. 2007
特許第4828189号
22 Sep. 2011
201303014336897890 - 粘膜免疫誘導アジュバントを含む新規ワクチン
Patent right, 長谷川 秀樹; 倉田 毅; 佐多 徹太郎; 森山 雅美; 田村 慎一; 谷本 武史, 一般財団法人阪大微生物病研究会, 国立感染症研究所長
特願2004-233896, 10 Aug. 2004
特開2005-097267, 14 Apr. 2005
特許第4817625号
09 Sep. 2011
201303027799909654 - インフルエンザウイルス感染予防剤
Patent right, 長谷川 秀樹; 佐多 徹太郎; 倉田 毅; 森山 雅美, 森山 雅美
特願2004-032770, 10 Feb. 2004
特開2004-262924, 24 Sep. 2004
特許第4683844号
18 Feb. 2011
201103031437021950 - 異常プリオン蛋白質の増殖の抑制方法
Patent right, 村山 裕一; 森山 雅美; 長谷川 秀樹; 佐多 徹太郎, 森山 雅美
特願2004-063060, 05 Mar. 2004
特開2004-292437, 21 Oct. 2004
特許第4651078号
24 Dec. 2010
201103074970287962 - 分泌型IgA抗体誘導剤
Patent right, 長谷川 秀樹; 山口 靖男; 森山 雅美, 森山 雅美
特願2004-133268, 28 Apr. 2004
特開2005-314277, 10 Nov. 2005
特許第4554268号
23 Jul. 2010
201103016672587589 - 混合免疫賦活剤を含む新規ワクチン
Patent right, 長谷川 秀樹; 谷本 武史, 財団法人阪大微生物病研究会, 国立感染症研究所長
特願2008-094360, 31 Mar. 2008
特開2009-242367, 22 Oct. 2009
200903009475330440 - 成人T細胞白血病/リンパ腫の発症抑制剤の有効成分をスクリーニングする方法
Patent right, 伊波 英克; 緒方 正男; 長谷川 秀樹, 国立大学法人 大分大学, 長谷川 秀樹
特願2008-087280, 28 Mar. 2008
特開2009-243900, 22 Oct. 2009
200903042792935257 - 粘膜投与型ワクチン
Patent right, 長谷川 秀樹; 森山 雅美, 森山 雅美
特願2008-053334, 04 Mar. 2008
特開2009-209086, 17 Sep. 2009
200903096000919724 - ウイルス又は病原菌由来の不活化抗原に対するアジュバント、及び分泌型IgA抗体誘導剤
Patent right, 長谷川 秀樹; 中村 友幸; 秋山 幸仁, 秋山 幸仁, 中村 友幸, 国立感染症研究所長
特願2007-115739, 25 Apr. 2007
特開2008-273846, 13 Nov. 2008
200903014029440707 - 分泌型IgA及びIgG抗体誘導剤
Patent right, 長谷川 秀樹; 佐多 徹太郎; 倉田 毅; 田中 利明; 森山 雅美, 森山 雅美
特願2005-266881, 14 Sep. 2005
特開2007-077073, 29 Mar. 2007
200903082966558263 - 経鼻ワクチン
Patent right, 清野 研一郎; 谷口 克; 田代 卓哉; 冨宿 賢一; 森 謙治; 長谷川 秀樹, 独立行政法人理化学研究所, 国立感染症研究所長
JP2006307281, 30 Mar. 2006
WO2006-107097, 12 Oct. 2006
200903021561371256 - SARS−コロナウイルスタンパク質をコードするDNAを保有する組換えワクチニアウイルスDIs株、およびその利用
Patent right, 石井 孝司; 宮村 達男; 鈴木 哲朗; 横田 恭子; 大西 和夫; 高須賀 直美; 竹森 利忠; 長谷川 秀樹; 森川 茂; 水谷 哲也; 田口 文広; 小田切 孝人; 田代 真人, 財団法人ヒューマンサイエンス振興財団
JP2005015193, 22 Aug. 2005
WO2006-022215, 02 Mar. 2006
200903085150174881 - 成人T細胞白血病モデルマウス
Patent right, 長谷川 秀樹; 澤 洋文; 長嶋 和郎; ウイリアム・ホール, 森山 雅美
特願2004-204169, 12 Jul. 2004
特開2006-025603, 02 Feb. 2006
200903079604651965 - 分泌型IgA抗体誘導剤
Patent right, 長谷川 秀樹; 山口 靖男; 森山 雅美, 森山 雅美
特願2004-133268, 28 Apr. 2004
特開2005-314277, 10 Nov. 2005
200903035633683011 - 粘膜免疫誘導アジュバントを含む新規ワクチン
Patent right, 長谷川 秀樹; 倉田 毅; 佐多 徹太郎; 森山 雅美; 田村 慎一; 谷本 武史, 財団法人阪大微生物病研究会, 国立感染症研究所長
特願2004-233896, 10 Aug. 2004
特開2005-097267, 14 Apr. 2005
200903060343604627 - 分泌型IgA抗体誘導剤
Patent right, 長谷川 秀樹; 森山 雅美; 田中 利明; 佐多 徹太郎; 倉田 毅, 森山 雅美
特願2003-319861, 11 Sep. 2003
特開2005-082581, 31 Mar. 2005
200903037680747128 - 新規デフェンシン
Patent right, 長谷川 秀樹; 森山 雅美; 佐多 徹太郎; 倉田 毅, 森山 雅美
特願2003-312042, 03 Sep. 2003
特開2005-075819, 24 Mar. 2005
200903039549210065 - 異常プリオン蛋白質の増殖の抑制方法
Patent right, 村山 裕一; 森山 雅美; 長谷川 秀樹; 佐多 徹太郎, 森山 雅美
特願2004-063060, 05 Mar. 2004
特開2004-292437, 21 Oct. 2004
200903070460344330 - インフルエンザウイルス感染予防剤
Patent right, 長谷川 秀樹; 佐多 徹太郎; 倉田 毅; 森山 雅美, 森山 雅美
特願2004-032770, 10 Feb. 2004
特開2004-262924, 24 Sep. 2004
200903046923802326
